key,input
key2c6d8cb1cff92c21a51c55223750ed9a,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM
keybeb4cbdfdf812c8884620c12bbda0eaf,Compound was evaluated for its ability to mobilize calcium in 1321NI cells
key45c83e359ad15eded57acdb8c1e62f87,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680
keye78070d48736d17db9d9826c9f03941e,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
keye78070d48736d17db9d9826c9f03941e,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
keycc3a7b1c12584c9124ec716a652b7674,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells
keyaf59797c030a0803f23f088e5f01e022,In vitro cell cytotoxicity was determined against 143B cell line
keyf50f9f31c06c2dbacae83b4ee51fcc42,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound
key2134aab68606a5ae2c3b483f2b1c9fce,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
key2134aab68606a5ae2c3b483f2b1c9fce,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
keyccabb60aa7214f266e832bf3724983ff,In vitro cell cytotoxicity was determined against 143B-LTK cell line
key2ef804cf1f00ad220582584b75e25013,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
key2ef804cf1f00ad220582584b75e25013,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
key2ef804cf1f00ad220582584b75e25013,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
key2ef804cf1f00ad220582584b75e25013,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
keyad907c8defa09b94d586ee8309f645a6,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase
key5fa2ed5dc8dbd74c7b6e55674ed204f3,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO)
keya369cc1202a78ff8357c11d8a3d31480,Inhibition of partially purified 15-lipoxygenase from human leukocytes
key4505dd60b2dc907c5e184cf4318875fa,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
key0855af4b16cc9fe92bb6d6ddb4475849,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO)
key4505dd60b2dc907c5e184cf4318875fa,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
key04dc1c00baad0c9333fe4692d4eb95ee,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
key04dc1c00baad0c9333fe4692d4eb95ee,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
keya4990d5cf760c58549432adf8fad491a,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M."
key214b5fff5ea96d5d7cf8e6cd79c09844,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase
key461c9f8d55db237f7e9a3bdebed22885,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM)
keyc69d88d3eba7ab0681e81c90cfca0468,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes
key536fa9f2c361194b1f2d8d235b3ccd1f,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean
keye6570cc770721b47d83a93bda743e6d7,Inhibitory activity against soybean 15-lipoxygenase was evaluated
key5a1651a7b0272ff4fcf76cfdb99accd7,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM
key02895fdd05ca8b3093d51ad00ee37db2,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM
key66ee89582e0afaeca7c0661a8ebcb047,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM
key178d4cd5f811a2ee6d7f96f5dd9cac25,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean
key2df6824b3cc646a5d7beb41cdc354a9d,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean
keyb2e65c69f0a6f0148ca41fd379dc65f2,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase
key41af70db6cbc9404265c4709d851c9b5,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay
key09d505af80d58b3c9f4d1f8fb88429de,Dissociation constant with dimeric 16S rRNA RNA construct B
key418e0c9e6b85ab359ea5c09ba7e29dee,Dissociation constant towards 16S rRNA construct A
keya318967ce78857ca1bbd1477b87c2e29,Dissociation constant towards 16S rRNA construct B
key3e4d08facc0dfb45b3704a6de46cf86a,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli
keyf120c2af85e59ded6cea23088f2fbc84,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli
key4d8063f5e5b9ce7e65b4154846b5ba59,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
key4b05a9e2d004e38f18acbc89a4524746,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
key124ebc5022213d16c41081731618901f,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
key124ebc5022213d16c41081731618901f,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
keya10309ae7a567ec1071621baa62a5b0a,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation"
keya10309ae7a567ec1071621baa62a5b0a,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation"
keybf6eb3dd99f30c9c68125a455c5c9412,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM"
keyac3c79261ecf8db94154773ccfd6a2c7,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM"
key4d8063f5e5b9ce7e65b4154846b5ba59,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
key19da41fc466214b94744ef3f33900022,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1)
key0df01f0ec733a9921cb030801c38d54f,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration
keyc674abe63d252b16c6972a57079280af,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration
keyfa92d3c9072d9d8920f039b9f5988951,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes
key39109c2fef640d6f65ef3d62bafce15a,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined
keyedb0a2d1baff6f4ac8ed7ccbc3d41827,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype
key63f019b28c12dbf968395644a7ad2eb1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor
keyf2f1c9685fa7658677339e434476739c,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor
key6b8a65d7fbf27c045f44b40731035d0f,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation
key93578c363fe66e7cba117bf5a08624f5,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation
key53d34717cd4eca5c4395605e92fc0fb2,Cytotoxic activity against human ovarian cancer (1A9) cell line
key6bfd0c1498e7c561cb280123187cc2ae,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined
key7d5a6f09b293bad27b6263f5b8e3bfd3,Effective dose of compound against replication of 1A9 cell line was evaluated
keyc6f988510115beeea2f2a4511dd2a3e7,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line
keyd0e3755edcc934723d6a5c5e7190b675,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line)
key030a4e5d79e4cf2b985aed20a5f84ced,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active
key09371d5a5cb46a6d3e4b7646c30e0ce8,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL
keyd8fe601780d655cb18fdf2841a651821,Inhibitory activity against Taxol resistant 1A9 cell lines
key41a77b52fd92d7745ad0f6b96ece3ac4,Cytotoxicity against human ovarian cancer (1A9) cell lines.
key4e98f0116178f137321146fd6d133231,Percentage inhibition of human ovarian cancer (1A9) cell lines.
key854cd46569be6219e58360619dc373c8,Effective dose required for inhibitory activity against 1A9 human tumor cell line.
key6cd902234e331b039a2ec5267edb26fc,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL
keydd41345340ff1b6a8c18d41c25e376ed,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL
key619274e2e9538fdbeb8e1375a6aa3fe4,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL
keyc79f80ebea08b60948a5364dbdbe8e92,Inhibitory concentration against Jurkat cells
keyba7242d3f6f82294e1149f5adc5009ae,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive
keyc8c44a3c8fffa47bb31ce669a1922478,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase
keybdeeef93527d7acdf395f2808e81374e,"In vitro inhibition of human 2,3-oxidosqualene cyclase."
keybdeeef93527d7acdf395f2808e81374e,"In vitro inhibition of human 2,3-oxidosqualene cyclase."
keyd26ebb105ec84fa4f5ecdabf1054e235,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM."
key682f795aeb5de955ed97bc9db4afd0b9,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes"
key38797342ecb63f050a512be66a59b122,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes"
keyc0a4b31f2468e5822a91a5267e971f04,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes"
keyf8732c0ab6961d3a920587cb7972f0f1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes"
keye83e92ea2c091924ffe67b52851a10d1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes"
keyc2b564004cc8c6ab523922d65796360e,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase"
keye4a4059c3a3a3bedf4c858a4b04f50ab,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)"
key9f9b66074f0ac04f7cd2a2c1cf578c2d,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki"
keyb314a8f89bfadb4c6b3bb74cf81e9ed1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes"
keyda6cbca54173496f7a0f614fee6f951d,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes"
key140517707ca5af6a76e424b3b6220b5a,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes"
keye66981cee3e1e55eb2baf7f872ba08c3,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease)
key0c8704b7212b63a2169e225ff3838581,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex
key225eb18dd032522d8c6d7624e115ba7e,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
keyaf773364ba53f323893fa8f322f460ed,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.
key69399febed2ad6b2a3c4d27d9df119ff,Antiviral activity against Hepatitis B virus in 2.2.15 cell line
key6db58337f75d2ec93ccdd07603c3e44d,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells
key7a2c0c1d452471dad8363d5a11ae77e7,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined
key65317bcb65bc8dbfd599fc013363ea2a,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
key4067fd0aed13e843dac896b651850761,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.
keyd46ff0b9b02047534c7a512508a47762,Concentration required to inhibit 50% of 2.2.15 cell line
keyc95a490759fa227b61c8ac88f72066e7,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).
keyfd8b5ae7c0294294c36eaf0abf2f64c7,Cytotoxic activity of compound against uninfected 2.2.15 cells.
keyad926bedf3333324caa5592694d1dd63,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.
key98902983fcb4b6abe70e8f55f81ecfc2,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay"
key95c379f917fdfd7c136b0de439505a8b,In vitro anti-HBV activity in 2.2.15 cells
key9029cf4b14e26c1b1ef921ffde7a9160,In vitro anti-HBV activity in 2.2.15 cells; Not determined
key34767130010473f39264fbc11f914a5b,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells
keyd5a38112788c5498cb23048421b7a393,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells
keya7a4789f9149c6282c2b844b7a6e8ca6,Cytotoxicity in 2.2.15 cells
keya1b2919068a4ebcea9b22b4932aba64e,Cytotoxicity in 2.2.15 cells; Not determined
key9fb8ea98b6d94e62d3bc954b01d3d7ef,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells
key54c972f6c5fdc0825eff0b17f1479668,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.
keyb925e684f5e907534f32c827574b1af2,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.
key1e9a44f232b47fb0bf5a06f8372ffd3a,Antiviral activity against HBV was determined in 2.215 cell line
key021115d0cb1b2f98ebff9c8113bfe185,Inhibition of 20-HETE synthesis in human renal microsomes
key0f8512c717307b4943b57ea1778d25c1,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.
keyb2dc7d35dc1734b9a4dafc4fd9689bdc,Inhibitory concentration against 2008 (ovarian) cells
key6dd358bc0f255274e590a9c8edddaa00,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.
keya5784bf96e2674fe64a7cea21be6a668,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008)
key648dcc4f5a9f2a39347053a63bfe4060,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells
keybe62eb5463284002a8a061e1df92fe5b,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected
key8704705f8910aa10844df45710c30180,In vitro inhibition of 2008/R ovarian cancer cell line
key8609d1cfbe46c54daf8f28ffb397d198,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable
keya58999dba135fd7099e66de01aeb9740,In vitro inhibition of 2008/S ovarian cancer cell line
key6c28e4408bacd0111ea5f5820d3d8a59,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable
key58388f261c0357e2668c390990b61263,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome
key2f7e2d52db74d322a9e1447ddfa6d638,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain
keyb0792f0242c0ad8ee94d8c8868b90fae,Inhibition of chymotrypsin-like activity of 20S proteasome
key738ba6679875478460ab8900b0ae34b1,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM
key0c3bda2ba05845447015c5ab6381fc3b,Inhibitory activity against 20S proteosome
key280dbf4db8bcd0279bd0e666d6bea7bc,Compound was tested for inhibitory activity against tryptase
key34f8f73857a0cb567b106ac1745f9fe3,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line
key663e5b05ae88c6e25247e980c18a06b9,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line
keyd00056d9934d4c7b4109a7f4e9cdd584,Compound was tested for the inhibition of Alpha-glucosidase
keyca1ddd17bddbe58705305fbfe87bf763,Inhibitory concentration against human neutrophil elastase (HNE)
key62a9530b03d664838b3e2178370acec5,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat
keye6a4773051b57b47eedd0f68986b71f8,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates
keycc2b726c684471d8ab614b70bc2ce70b,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates
keycc2b726c684471d8ab614b70bc2ce70b,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates
keye6a4773051b57b47eedd0f68986b71f8,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates
keyca041c4205827b82b5d6a24f4980a255,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines
key37c5e4ecdb33c21c514ed994ed350c6e,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines
key2dcbddd979995b349a3a74d78344f37b,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).
key7a94708e37184a9f056210db4f436b9a,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells
key862ec5fd3c20eae578fa9feb72f0a1ba,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.
key5baf50a5d65823cddc1a8fe5a28c14db,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C)
keyaef21e569d775ec1b15516b6d1d0680b,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5
key78b39ed3e3b21e4fdd34ee82b21c9d5c,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6
key2c0ed1835cb063233949c709691486d5,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7
key0526622e52d8521e244cdb4d0ece3754,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4
key5dab5319a260e7aee9238d814fb3eb9f,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5
key09a2a3bc14b8eab272b786d12c41cb5a,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6
key6d9c6c498f3ff6a05a0a296b9546997a,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.
keyc8dccda2740b3e44f1fb8efcffc92fa1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4
key9accbd3fd668d4f38ede292fc3fb7b41,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain
key89cb00439083f3292bd5e7d76a0babd9,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse
key258d8ad722078eed4baf64aa1b0790b4,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV)
keyc4bd032c464fe941a2999e58ef2589d3,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.
key404a5ddbee27b357b11a66a6e4089ff4,Antiviral activity against 07/1 strain of VZV; ND: No data
key2d8b8803bc588847e1edf1952e217d97,Antiviral activity against 07/1 strain of VZV; ND=No data
key26b1f0a4b40026ad02aa3684348ac9cc,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)"
keyef9b0fefd24e2e472dda961e6e207850,Ratio of Ki at A2 to Ki at A1 receptors
keyb1e87bd68de64068056917b42ed663c3,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay."
key5658ec7c9189f6e8189aa505fdf69192,"Inhibition of 1,3-beta-glucan synthase"
key75ecc237f21a960d76ab40f6a615e97d,Inhibition of growth of 1-87 human tumor cell line
key651ad69d02854bc9d05eb154bd4162ee,Inhibition of 1-lipoxygenase (LOX)in RBL cells
key07e47462668fbd74d669df51c058c553,Inhibitory activity against soybean 1-lipoxygenase (SLO)
keyc02ad9e05a39114d9323807001c42a88,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect
keyc17e6167ee523f8389169afe5e984d6f,% inhibition against soybean 1-lipoxygenase (SLO)
key3862ca721bbd57c45113e7877536c33f,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition
key21a02677bad7ad1d5ddb46e40a5d3c3b,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90
key67a67c417fd8fac6cad094779ab3302f,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99
key2e5f430a1f9419e248ed4b054d021f1c,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75
keya3f87fff2bd5fe5bac4c7b66eaf85d53,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65
key3a45adfb50cb342cbe3dc259be8c7ebd,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50
keya707ac292d7a4dfaf3f818a6cc796f3b,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24
key226bb29e7aedcc39b45dae7c8c36171f,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13
keyac58ff855ac71989d87d8bd0ec09a7bc,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11
key6491500927a7e0ca86d011cb67db7dc9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5
key1256b2960ef492b8d94d520b36e11c9a,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3
key882db8bde2d435ded3e1a20a3f857dd6,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1
key53bbd5e1196f7d3a06111275ad717608,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM
keyfcc6f5599ec248197e722c0392a179d2,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity)
keybdea1c39298fc348e5c73f9c87dd3c59,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive
key629b0b155ed21b94a7c16ab5bf100336,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA)
keybffe0d864ce95a95fd2c74f13cfadc0f,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA)
keyc90a88ab32d6a1fc149563e8857a74c4,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).
keyed5aadefac0322244c2f14be7815a14b,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2
key107b617c481cab64f620ad2b5986bb8e,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition
keyc453692ca4329d7974d7dcf9d4aadfff,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase
key626866cb35f3fabbe46deb07e5d50d6e,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect
key459efb18754003c5975390011544cada,Inhibition of 11 beta-hydroxylase from rat adrenal gland
keyd0125b29f30b3781d2a68ac58219d609,Inhibition of rat adrenal 11-beta-hydroxylase
keyd0125b29f30b3781d2a68ac58219d609,Inhibition of rat adrenal 11-beta-hydroxylase
key45fadb00ebeeb716d50a74e36ee708d6,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M
key0377fa766d1c3ff20ce3bd8817a430b1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone
key7e773610572c25fab382be8b5e688ddb,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol
key7e773610572c25fab382be8b5e688ddb,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol
key380d3df31a5cfd30405f3988bd0662e7,Compound was tested for the percent of inhibition against 12-LO at 10 uM
key575fe405d74ee5d56b456f2265ac8b00,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
key32ed1247d80cd6b2638c5aa5b1936649,Compound was tested in vitro for inhibition of 12-LO human platelet
key3a89e6fde71ee18081162d738b547ee8,Inhibitory concentration against human platelet 12-lipoxygenase
key9cf4955208fa33c79f2e8a3545b29832,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet
key3a89e6fde71ee18081162d738b547ee8,Inhibitory concentration against human platelet 12-lipoxygenase
key2a95425b10e1e11baf7607f69979dd06,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates
keyf1d6e70591684f5806ffacbd8c7b355c,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase
keyd355cc18bcb3a23a630bbc2e887d1579,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO)
keyf961d1aa920bd353ced77a0621da5325,Inhibitory activity against human platelet 12-lipoxygenase
key58654954006895f8f5ba38ecc2a904ac,Inhibitory activity against human platelet 12-lipoxygenase was evaluated
key59c0a81bbfc10dd9485179525c15a6f4,% inhibition against human platelet 12-lipoxygenase (12-HLO)
key3a1b761b8372a9818dc1f524d48cd2f7,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM
key64dc0865a3ce15a9c76dd074ee275500,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition
keyc40526bee09b15a029e9793884bcac48,Inhibitory activity towards porcine 12-lipoxygenase
key3cd00ba2b79c78c36973dd8e313c7727,Tested for inhibition against porcine 12-LO
keyf1f9a8ca2778a171f20705b42992b1b0,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect
key6d827ebaa90578ff61e46b3b92e87bff,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma
keya2c13fbc33dea897e2664f5793877d3e,In vitro inhibition of rat platelet 12-lipoxygenase
key575fe405d74ee5d56b456f2265ac8b00,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
keye5ebdce5c4ebea41e2ccc6d9a036fa16,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM
key31b3dbbb8116b5353cfa4ffd8bb22c0a,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM
key575fe405d74ee5d56b456f2265ac8b00,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
keya8750e791bbfb01f1da6c872dd625e32,In vitro inhibitory activity against rat platelet 12-lipoxygenase
keya4b3e148837de130aa6daad8ed715571,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM
keyd3af51b4ff3ea4986346c028157dec82,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure
keyac674b47946bda2dc145f20f56030883,In vitro antitumor activity against 41M cell line.
keyb5bd138927b340a275c5c670f15ad326,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.
key2daba167d57cf4d454234bb51de56b54,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure
key16eb4504a1f5acdd3b165d73d62285e9,In vitro antitumor activity against 41McisR cell line.
keyfd995ca42b8b06340739d5e8d10ff01e,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line
key876a6ab495a78b491b5729aab6666eb1,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay
key2735b71c438f5b1f03b1cdb35ba6d398,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I)
key89243a46649545528f0e50fcd0da287b,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II)
keya7675c10348f690021238f1cfbd716f5,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II)
key7c3a9a8230ab5955ade5bf030b635b67,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase
key1aae3a22a33998b25f924e1305f63d11,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined
key4b4aaa44cff82d6baa7415c6a37b7725,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase
key581b24277a4ecd86022b850f9a17ed24,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM"
key0fd0c1c6d023b98b07b64c6972aa7b93,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested"
keye3daa1cb2a75deca3533af655499a287,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested"
key6f4f0f5111e89d955faae4dea36481d3,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested"
key4f76baa92587dd51fea75cd2ebdd0bda,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM"
key1876d2a42d7ca35ca001867efbb6df58,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM"
keyb1031ed0cc8566c34663e33fddbb4e43,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
key47b63f1134e9b572b4fc753ccf486434,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme."
key788b828ecb1b6b8e1bc961c72ae547ba,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration"
key07ec27edb07fcf5238d65877c262ac9d,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration"
keyb1031ed0cc8566c34663e33fddbb4e43,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
key411ec79a45703a787f230b934e4d1b73,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration"
key090b38953d3e758b39c39c35d3504427,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration"
key0a9bd41ed043130d21ac7683cda231d1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration"
keyf48171a460da0b917d3a59dc5cc87ab1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration"
keyb2581f728fec8c2ae2e6a9219dd9a711,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme."
keyb1031ed0cc8566c34663e33fddbb4e43,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
key411ec79a45703a787f230b934e4d1b73,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration"
key1dcc0f65ed50cec20a650d7bf316144a,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate"
key7e6cdd4def31bf8828544506a4ae5184,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration"
key7dc5ff2d9bf58ff8c40fc550b992ddf3,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme."
key1c18d9541b6fb9530f321445f14e5eef,Inhibition of 5-Desaturase involved in ergosterol biosynthesis
key643434c622f6d61bf4f4fc6dc0d7c8fa,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase
key643434c622f6d61bf4f4fc6dc0d7c8fa,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase
key98064af7233a4e5665a84e02cdfbe8bf,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor"
key501ddf8a83b19be903f46672e2f13072,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat"
key203f5a1de106ef86f1481aa4f5565feb,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat"
keyb18330a3bb0c5ed01c2268b28e40e334,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig
keyf1d7b498346b4e547cc322c561d7322c,Stimulatory activity of intragastric pressure was tested in the rat
key21d812b5c0571d89817fc43d4e178627,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.
key3c340c7773b1205314b3d1428211a340,Dose to reduce neuronal firing against 5-HT cells in rats (iv)
key31682734f9768a61de25fba8ccf3e6b2,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor
key90cfb08309ee3659c48bbb11c51c80d5,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine
key7d3f04b0c3c56afded0445de93cccad9,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data
keyc5aba697ea837ac9b9e9e5ba792bc688,Inhibition of high affinity 5-HT uptake at concentration of 1 uM
key401ad7ffb82c226e9d11142b3f6d5e28,Inhibition constant of high-affinity 5-HT uptake
key32987d1d7d5593d5542b815d1b88c19f,Michaelis-Menten constant was reported for high affinity transport of 5-HT
key6a6429d0d1f4fda2f16e3488954d3a5b,Maximum rate was determined for high affinity transport of 5-HT
keybb7842d0e4f69cb1ea2a2831c5ce722f,Compound was tested for agonistic activity against 5-HT uptake
key8cfe36fdfa035ed23630af162398a6c5,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay
keyc69bc6d9646ab1c3af2b6e8e80fbdc0e,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay
keyf71feb2801eba7d3aef338b989ba7179,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand
key42810a35a77634af05e67915fbd02dde,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand
key4e74e5e519a1911361f55b9434404f88,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M
keya5f8cc640dda8cdfb08d30c2f23d765a,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.
key91a4b0c850002fcf2da47f3b34999133,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
keya8f6c21067b13664cff9a0edc49e50eb,Dose required to reduce neuronal firing of 5-HT1A cells by 50%
keyf9d3f179d35947ce987c19c87162164e,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
key3d670290283640539884d11c58913883,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
key383fc1f23b2890db4782f2873d9b4d0c,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
keyfb551739873cd224a44b2cb6c4706467,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52)
key57d79f0cfe8db4b0b382d711d0385441,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.
keyb9ff0513569e2b740da0f4f97b66fdf2,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
keyda450a22e39ffafb28c50d8adb56b38e,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor
keya6c3adacd0bdd69ed5751cebc82f4ff5,Efficacy against 5-hydroxytryptamine 2A receptor
keyfc8f6505f7b10e58ea2d880b12efc27a,Intrinsic activity towards 5-HT2A receptor of rat tail artery
keyaf6de46ba44d9a02722bda80e7b49dee,Relative potency towards 5-HT2A receptor of rat tail artery
keyeb65a0fef8fc3bfb3827d10f411e9688,Blocking 5-HT2A receptor-mediated contractions of rat tail artery
key098b6097387c41ab40bb2d24b9a392e7,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery
key4e022fc1260ca147cae8b1289bd74c7d,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.
key08afd701c4282c793865d43d0a3f2a85,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery
key74d37e3db9ecccdbe840ef53f227453a,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.
key82a63ec6a3bc1299ecf1fe3042dcc9c1,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI)
keyaae8c8da21bed2ec168cf723aafde8b7,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.
keycec224ddd3d13c5ed3c17d67a28acbd6,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.
keyd4f5642d7dc39007a7068b6dc4ed516c,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae
key3517b611fed5d2d1803fe109a041593d,Binding affinity against 5-hydroxytryptamine 4 receptor
keyc796bc4ace70b9c9c8237303c2ee7844,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine
key2db16e88740d38b10295dd2cd5353801,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity
key7ae95118f4791ca7711e250094a352aa,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control
keyf02df726ae99068615f3a08af0d664a8,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells
key19d5eeca6ae921f14ca448917cecb636,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity
key26ebb9c42b75e6d8cbbfa71ec4e7573f,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control
key21ebda534be25a3e3f9a8529e70719ec,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes
key77eaa3aaa64f1c9ad64f140ab0feedc4,Chymotryptic inhibitory activity against 26S proteasome
key3c03d5d19029a06a62c9a02938dc5eec,Inhibitory activity against 26S proteasome degradation of IkB
key3f1bdd49352e6b5273e11ced430a04ec,In vitro inhibition of 2780/DOX ovarian cancer cell line
keybac8178d0368fdf81ac9e65628097433,In vitro inhibition of 2780/S ovarian cancer cell line
key3e987c5ae04542fb2e57276304384240,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells
keye325ab50b696ddb92366518d480ea8ed,Association constant for binding to AATT 28-mer AATT hairpin
key87b190370b2b6ff7400854d69cba7728,Kinetically Defined Association Constant for 28-mer AATT hairpin.
key7514a897868bf915d795b0ecf5170d5a,Reaction Rate Parameter for 28-mer AATT hairpin
key7514a897868bf915d795b0ecf5170d5a,Reaction Rate Parameter for 28-mer AATT hairpin
key3c68d6c51970f8e3b4e8ec5a5e0d4eb0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1)
key83f57a08bbe1818ca7afd5fe86458ce4,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2)
keyab0bc3eb7d08ebf557dfb9c19276ad91,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1
keye8827f8175001885d2eed1a8caacef86,Cytotoxicity against cell line 2SC/20 determined by MTT test
keyf6b0e72f11ec9580e17fc6e544aeeea1,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test
keyf1e7c9b2e9cff26d7ce4da66593bf4d4,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test
key5b98e0d961f640cdf67a828d2e0e54c9,Binding affinity on 3 beta-hydroxysteroid dehydrogenase
key29f689e146fb443499dfa6f5871a5957,Binding affinity for 3-beta-hydroxysteroid dehydrogenase
key17034d30bb98638f5f59e5c57576bb23,Selectivity ratio of ID50 in liver and heart
key29cd360c367074389e13bca7815d03c2,"Selectivity, ratio of relative ID50 in liver and heart"
key60adbea066cd5bb9d434948439018407,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3
key8e74f52634fc67f33c4d8cf1753bd066,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
key64417bc947024c35cebac84eb8d0ff76,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
keyb591c92ba2dfebdfed9cc9ef8e70f7fa,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
keyb591c92ba2dfebdfed9cc9ef8e70f7fa,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
keyc67c7cc42b4c791b6bdb40a0c293b458,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine"
key5e752dcf068292ff28d5b5d8ed6ebbec,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3
key868812cc2d8db0b0d8e8cb5b8d218f32,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart"
keyb4ccb6714d4a13b99421610b09886135,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3
keyb4ccb6714d4a13b99421610b09886135,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3
key9448250cb5bd5d8dfa6c325df3de5eaf,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor"
key309f7ab056c5c334613ff9f14d969c55,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration"
key3906e92382c500dafb46a44496b18a67,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3
key64417bc947024c35cebac84eb8d0ff76,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
keyd60e91a5a8006c469e874176d27fedc2,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration"
key553ea682d67375049af5ff3e2171176f,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor"
key553ea682d67375049af5ff3e2171176f,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor"
key08b6e7610e80e87db1e0b12502efdfd4,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor"
key2e64a9bff82a45a6f7783ea0d5b4ff52,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli
key4586985b07a36df44628b448ef370e89,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli
keyf16b450f304f572f6f72f0f81ef5b406,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli
key3689865bbf36440179bc5d676c637fe4,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli
key288cfc5dc46b7fd4f31e289203ca63c0,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible
key2fe868744c4633640476dfcbcaf4bc4b,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase
keyc81b79f00060a90669e371943aeb1afd,Inhibition constant against 3-dehydroquinate synthase
key515ac780a225df17f8285163d700709e,Association rate constant against 3-dehydroquinate synthase
key69a9125807020003b41dc35e537ec58a,Rate constant against 3-dehydroquinate synthase
keye5eea1b53c4398013df3e332c2a0df82,Inhibitory activity against fuc-TVII
key293a3b0308dc28c3b5f4572ea860e86b,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
key2b776036a4749335fd65a2bf22f28d03,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
key139070b739958e3e691792ab650ae421,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
keyb990fec49479e4697187d9a0c47c36af,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
key1839cbe245e10b6fd9682fef637562fb,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
key536ace18cc19f51b747ab3298757276f,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes
key8da0e134c383825c9ac9ea10ecdf65e4,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM
key9820f183c27098b9eb340d69a1e6d047,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM
key3240f2fdbf38c398dc724ba16ba7920a,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM
key8780dc1cf3e24f2a250438bc96d298ab,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM
keyfa72afab4341415d957133f8e518ff2d,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM
keyaf0f1135416325311c08f928511e3e01,Inhibitory activity against 3-phosphoglycerate kinase.
key5784fbb2b4e6ff0215c6a94ca1aa221c,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1
keybe0c656fc3183f8ed5e8bd9ea697e17a,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase"
key8fd580c1eff3d905096ef292de1a10df,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM
key3deb7c2a7cae774c4d005473381398a2,Cytotoxicity on 3677 melanoma cells
key457d77b5a7d2401ce403a7e061bce865,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL
keydfd23be272ebb6f535841298a10b77cc,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay
key5527eac917631fb3cdf90d12fae45495,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines
key17f92c3c19de1a31455d1c155e130fef,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested
key6ff0afd5b41f0329c67896f8c3b79dfb,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.
keyb07791c9f04c15b3ec668889fa9bb315,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease
key68fab349ac26e17f77d380797292911e,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM
key89b62fd27b9d8108a515d3dd526439db,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI
keyc537d040d7cdbdc1299ecfbf1e5d324f,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact
key105ffed1be3d4b2f720bda7b81e1fe01,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
key105ffed1be3d4b2f720bda7b81e1fe01,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
key105ffed1be3d4b2f720bda7b81e1fe01,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
key4b210dbbba85c6570b86fbee0906077d,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive
key7163580fb187245b00fbc52378da1c0c,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease
key7cc8af7e4f644f585b18dd98dcfe9dea,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease
key0ded88dcb832047bddd330173740fbef,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease
keyf071cdb7bd61835fc29fb1dfbdd036c5,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease
keyd60bc2113421a5f14a7e97f9c251e4dc,Inhibition of human rhinovirus 3C protease
key6e86949feef7cbe56676150b0e7d284f,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited
keybc8d9a8b7766a8704fd72bc85be77f3b,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5)
keybd4b7f64f1af5707574b35ee2c234e9c,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16)
key10ccf3850abe9f39c11ba1fe82575509,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10)
key63a8b17521f453488c5e66e18e86be14,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6)
key1ba814aba659c3fbcf5ac4c6093109a4,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg
key11506a42ae34f8d9ee50e1794a68a33b,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg
keya2c4875c96c2bde6487c7e8b75c49b70,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor
key09f0dd02a81d8ce803d75b3b392a447f,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor
keya952585c8402f949cd466ed0dbce7720,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.
keyf8522a3b43ea194f855f7dd0780efb12,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose
key62f7583ec1abc02cbcf6c6072bbfec85,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose
key252fab080887d9e4fe3f90d1e09503cd,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose
keyaeaf47d4b8eb263f31629db9bbb7459b,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose
key3faa8c0d2703a6baf07f085a4d9a2cbd,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose
key821589ee9bf911fe461e124c3065d898,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose
key48295fbe5be39fa5541fec848f5beee8,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose
keya507752080ec95d4d2217ebc89042521,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose
key0dc0396e0de8d420b0229e214f232ef4,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose
key2e65ba5bb12cb04d5427fe817c35889f,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose
key04104e4265d1db6878dccf9f420d1935,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation
keya953b4a8e8ca876aef7ee46fdc2c4940,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation
key35a357945eb5f9997f27f29397ed10d0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation
key0dc0396e0de8d420b0229e214f232ef4,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose
key5b8801317ace5aa4df8184018cad3698,putrescine levels in 3LL cells after the treatment of 1 uM of Compound
key4b57b62d02b81cfd1bfd6ccc96dad629,putrescine levels in 3LL cells after the treatment of 10 uM of Compound
keyac88288afeb408d747cf3cea60b87a06,putrescine levels in 3LL cells after the treatment of 250 uM of Compound
keyf52f3b5d8f46eb73a671173d4fe5160a,putrescine levels in 3LL cells after the treatment of 50 uM of Compound
key66232776abf943c070acafe720fb5300,spermidine levels in 3LL cells after the treatment of 1 uM of Compound
key4ca0b44e0fcc6dcd467454497c9f9a2a,spermidine levels in 3LL cells after the treatment of 10 uM of Compound
keya3b8a5029aa0c7b615d193bb040f2396,spermidine levels in 3LL cells after the treatment of 250 uM of Compound
key2e8c8882eb14f5ecaa8d5d093c3d2a80,spermidine levels in 3LL cells after the treatment of 50 uM of Compound
key21b0efd54f34a0196599b33f6536a5f7,spermine levels in 3LL cells after the treatment of 1 uM of Compound
key2b59445ba4b7de5dae3b79448829de41,spermine levels in 3LL cells after the treatment of 10 uM of Compound
key7bfff38c4705f9cc63405ea963713e3e,spermine levels in 3LL cells after the treatment of 250 uM of Compound
keya24f4be2a92f3d67762a6bb6563c646a,spermine levels in 3LL cells after the treatment of 50 uM of Compound
key02bd2930adce863716636f01bf36eaa0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%
key7ea499e18c04b6bbfd1bad431e41f320,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity
keya1ff5c47a3d1d24fd1b18bf5295cc247,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.
key98612e6420de249ce50852ccbfa47049,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested
key5addc7a240ebdec5d26b116b670d295d,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.
key4a9ee847d6c144aa29c360e2b95d4006,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts
key4a9ee847d6c144aa29c360e2b95d4006,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts
key82c8621f6ddabfa9e5ea735a0d979ee8,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay
key7ac29d4b249c832ca3adfc48ac601ae2,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active
key6bfbbd1b541201fd3a6128617fd4ce09,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested
key17cb957058598899209a67286c7514b9,Effective dose against murine 3T3 fibroblasts cells
keya140c1093788dd0409431519f142276c,Dose required against murine 3T3 fibroblasts cells; 1-10 uM
key7219cccb9f5cab92ccbc700fcd6a05e7,Cytotoxic effect on 3T3 cells
key7219cccb9f5cab92ccbc700fcd6a05e7,Cytotoxic effect on 3T3 cells
keybfcf6629abeac3408e756f2b8e264216,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.
keyf02c21de0d598876210d933f3c4c5d7e,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration
key8c1a99e1f7616c531bc8e81d877ddf9a,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data
keye9a531bb43d6a74b32f352398963ab1d,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration
key59fdf8fb090a1ae011e4e30151b6a08c,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data
key83f7d8f367d72bc628c6b5ff907473e1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested
keyeacd241c4fcf111aa47dc124b98558b8,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration
key9f2022518537501e148d5decf39ec4e1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data
key96502b8c7e0314f9943b671bef5087c6,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested
keya9d57c72a0dc1a3f8734a8655273a003,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models
key96d8f991591f1b68110fb153e27b47f2,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells
key8921381bbaeadab307e70a484192b206,Inhibition of Swiss 3T3 Mouse fibroblast proliferation
key3e0fe2ecfbcfdac1b842b3a7a03767de,Inhibitory activity against 3T3 cell line
keye2fd9e45256570bcd1fc84cc92dcf2ba,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured
key2e4f5976d7b8189e897509899d345f4e,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.
key9d3a781e3fe76071b84c4a15edec08ed,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested
keye24ea8ded093a1db0675ea43e171fa7b,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured
key11ae7c6c4dc9acf086855b1f8c8f48bd,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells
key12e09e20c84a810e6a1ea65291e91f36,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested
keyf02c21de0d598876210d933f3c4c5d7e,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration
key2c56b03f6021ad424243f5ec3cd66aff,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data
keyc6be31aa61943517ae49d1149cf5d9de,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells
keyb52ddf2deae5dbe7d7a91c3905b8f8af,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested)
keyf75c07de7a2a6c61560fea87ef307ef7,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells
key58484fa2c6aa8abf466de6f2347a697b,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested)
key3defe4189fd8ab4844e45d513208e672,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation
key6c2cc1a972b6ccc4da3f6b9bb02263e7,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation
keyd5b303e0e3e42515a1fed406287de6db,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay
keyaeea2cabba6471ecc253c7aa98fa1d23,Inhibitory concentration was calculated on 3T3 cells by using growth assay
keyd1aba31e370d667a8a1ea5701cd92c06,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells
keycb5b264df0a516522e3b653544557385,Inhibition of Swiss 3T3 mouse fibroblast proliferation
key7643bd6209f37c715fb86b0a50883d41,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.
keye624ab5cbdd9be5d8b402b85a65028fa,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts
keyaf1949665c98602a646c45c339911985,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested
key295f37f196ace2b2ebcc4c41621c2478,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
keyfcb20340ab2b58d7448ef4ae6152561b,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
key41725f26aa16fa92cb121e29b12da444,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
keyfcb20340ab2b58d7448ef4ae6152561b,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
key295f37f196ace2b2ebcc4c41621c2478,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
key4ac4907236e60d2b977d7541a4e071c3,Inhibition of swiss 3T3 mouse fibroblast proliferation
keye713c766390211cc41d29a00c4e01cd2,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.
key349673cf774a6c4104f3f70d2e09a425,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
keyd96c23aee5a61bfbdcddf5976718011d,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation
key1b522cd71e3e4e8661b4731a009f1462,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM
key83bebe1f43100edd7662d5def1bb9bb0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM
key5582e218d28bf6ce580eed788b212dff,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM
key46f01931676b06123514e80cb6a9dd25,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr"
keyf0b33664c9d0b2a8523cb1806c5847b9,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr"
key3a0bcab3682a35cafaa712fe832ffd1b,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes
key19213a7f0e225cf1ac93f896051b166b,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M
keyd9ed9f006dcef3d0f038dd40733e37c7,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
key62ed5b1b8c765aa8bcdad86a996bdcf0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M
keyd9ed9f006dcef3d0f038dd40733e37c7,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
keya5f8ef65e5271a8db1f37c180ea84451,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.
key882d9d5afd9accf9865cbe1f7b28befa,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.
key8ff7efaba34441e3cdc497692e2b66c6,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.
key1bd9e0a66d446a30f4577567c3f46baf,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
keyeb88b928b0c0cc0db5d12b29157aee7a,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.
keydeb02d847db6f10010388f9f17ec7615,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
key8ff7efaba34441e3cdc497692e2b66c6,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.
keyce5324033612f3f27073cf0fcb7b03c5,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
key2d60fdc3a26b9f28db48d880bda74694,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.
keyab2984dfc50a99aa98a59f5a0c6b0675,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
keye7c461b3df70c82c7a903df1e851583c,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
key7b9a379de8aec1abdb0835ff3b8c5068,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.
key19213a7f0e225cf1ac93f896051b166b,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M
keyd9ed9f006dcef3d0f038dd40733e37c7,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
key62ed5b1b8c765aa8bcdad86a996bdcf0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M
key5e401a995c58c21f4d0ab960bce90384,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.
key1bd9e0a66d446a30f4577567c3f46baf,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
key349673cf774a6c4104f3f70d2e09a425,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
keyce5324033612f3f27073cf0fcb7b03c5,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
key452942c49a32e959e9c90d6e1ff3c5a2,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.
key163a6f2a4ba6373e450ee97d5b22511f,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells
key4a8b97630e7a9f8134b7fa70c9af3903,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data
key02359a55f052fcbe64c037863632d8f3,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active
keyde4ee42b497eb92e95fa3f62c3da6894,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone
keyaa99177f1e25954e2c608cf5378ca57f,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone
keyaaaf0f570e65dc37ba61f4bc116d67d4,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone
key0adca6d9d85148f31de5b828d8d0426e,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
key516db20f44778f2254e0735b4c4894a2,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
keyb720f9cce630b0013e65386f22216252,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells
keyad9a0e073aeae1be554e8077dba7a6a9,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.
key7aa5b2dcd570457d357aca671fcbc3a3,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.
key41d3e27b31614b1b00fb661a4d025eac,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.
keyef24774d28d0f456c78f6ff96ade1190,Inhibitory activity against rat fibroblast (3Y1) cell line
keye4a3c9d987e996d57b0abdad1e9ca24b,Mean concentration causing inhibition of cell growth in 3Y1 cells.
keybf09c49c567308e4609b28a7502e3540,Cytotoxicity in 3Y1 cells.
key652b15eaf48b8d7670817c6a29c0bee7,Cytostatic effect in 3Y1 cells.
key3f2640becb764364eb6107fb3c07261e,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect"
keyd336656d3da48128ae1e40c9a0be979c,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure
key40aee3d5a390ac06ed55818940fac3bf,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase
keya15a9bc270b596f4838fdd4fedc4e3d0,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase
key48a8d784ee5e52aa691f5709a9081236,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase
keyb6f15ca32335f814cfa464b5269ea779,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method
key95e2aa103b4dc683d1fded06847c070d,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver
key856df10d10a67386f6d217177eeed476,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme
keya4c55f9a82ddf082e8544561a8b23aa5,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver
key93c7ddf889664590dd453275f7f3355c,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value)
keyf84a05d29aa695725b97f1b1e0f54fd5,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method
keyd880357cc4b695428eabb2f9561348df,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD)
key67e7a00bcf08961fc48a838e48b9fca4,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method
keya737fea2523d2194c5e23f89f1051288,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated
key01994b28e7d1f359f353f3b94e427f6b,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method
keycb64b39724774e26c39c58928a4d6485,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.
key2260ad42e0127f33afc37d6e10390428,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM)
keyd360b3f2cb818ffaecc48cf948e2149d,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver
keyb970b53101c55486ff3242dbdb379663,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value)
key122f2506f7027f2cbe993a3c4de449d6,Binding affinity against melatonin (MT1) receptor (pC1)
key382e1e803dd92abde982022fa51e2494,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor
key87195ff704ff67db9bc9bdb1387034da,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M
key3b8a328dad4e4db8160c102849d38f77,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system
key4375e7aac2ea0d7713fce177684a948e,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration
key7dc0bbe2c1c8f1d3c55cbd1c10f49487,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand
keya22997618c0afc04b79f68a7e3d2eddd,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT
keye12439c539122932423faa67382015a2,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand
key4129eedc046cba005a91b0fb540e9973,Binding affinity for 5-hydroxytryptamine 1A receptor
keya9c4593a7843c7f9dee2c9c3c210cfa7,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT
keyda41b0613d2aecd0ee894ad1a4ec86f1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
keyda41b0613d2aecd0ee894ad1a4ec86f1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
key7c9c6dd4831cab318dad9ca88d6cb266,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus
keyf9d3f179d35947ce987c19c87162164e,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
key8fb1f93850f395e2ce083c6acdafa2ee,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus
key47d33134d4d75672f96e01627ed82d56,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus
key374aea5ea0c84023c8a2522d2a7979d5,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
keyc053558d1a07beae4b2faeb27bc7d4c2,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
key9fdbfce26129a155fd3f25dc96fdb072,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand"
key51c3e4a0e217efd73ad9bb0188c03087,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes
key0eb24ca81ef20973cf4cf4366424912b,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.
key487d559fc7c97efda7c5e8ac4f111e82,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined
key7a156715f8311f637d1e6837f70a6d07,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus
key7d0554c572f189b65fb457d3e4dc9744,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.
key8dbc6f4c7390cc17b5679314fd5bdae2,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus
keyefc3b2cc6ba1cab6a1627f84cac392d8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells
keya0b946fa4985a7729d1608a07bf223cf,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
keya0b946fa4985a7729d1608a07bf223cf,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
keyf98d28c24f67f4a5b9e1b46830bf3f61,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
keyd0f132431872ad496ba59ea3d44eb893,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand"
key7e1aecaef5d4f12c862353f97283d5e3,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand
key7c9c6dd4831cab318dad9ca88d6cb266,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus
keyf9d3f179d35947ce987c19c87162164e,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
key3d670290283640539884d11c58913883,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
key383fc1f23b2890db4782f2873d9b4d0c,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
key3d670290283640539884d11c58913883,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
keyf2032468229325f81e35d87400e23ec2,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.
keye27ffc516f57d5602900017dce1acbcd,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus
key08f19a1afd07f4f4a08a6fc6feddd309,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells."
keyd3186594c8017c11f936ca8a02ce296f,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig
key16ca342f7b45cbd8d4c922920bb26863,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested
key4a1c676634940b3570980e2ae49194d0,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.
keybdd61c66c746372b275b681dd71f9637,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.
key44791baef372bb071716cd8ec280edad,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
key31041291ee34d54ba985164adcea908e,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.
key3b58f67956998454db179cccc457f408,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
key3b58f67956998454db179cccc457f408,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
key87b45e19af285d430f88c45637418b00,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM
key9cadd406ed9f98d3b21b7e225f401047,Binding affinity against 5-hydroxytryptamine 1A receptor
key833baae9be9115561c3b11edfe7d4af0,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor
keyf63b236a6ce05944fbe45dbe4f15690b,Binding affinity was determined against 5-hydroxytryptamine 1A receptor
key4da23c836516bfc430c4abf423a3d73b,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus
key4da23c836516bfc430c4abf423a3d73b,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus
keyff4add60dd5c528df820c2319e9adcec,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)
keycc91cd1f04fd1d5c19ab0b0dc8590ee5,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor
keyb4de55e904764d1373ade237f165420e,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370
key85841661847ac384300cbd88174d1d9d,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320
key777ade518511a1508b4205ba0351db52,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor
key8264a1b38addb14937fe8dc750fb9d99,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor
key8264a1b38addb14937fe8dc750fb9d99,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor
keyc169f1df2be54a8284430e7a3cb7bd77,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined
keye2e5c4a2b21e96a760b3442eacd19c3b,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined
key06ae1eaa9b9537199dc91295bdacad26,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
key06ae1eaa9b9537199dc91295bdacad26,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
key5ed6f35c9c0a9c3e73ae6683c80d97df,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined
key6b30fbb190fbd92532b9d1beba2c30c5,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP
key699ef3b5aa3859fed4933a85d3adeee0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells
keybfbccb2d05c2e0c6affedc28d719c842,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse
keyda616cf7503f08848a1db1b79ce58baa,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor
key1417453d90ee2b91b25e71648253de5b,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined
keye49f4d1772073cfe0398ae57c989e881,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor
key3d7b5dad0d30a412a290b005abdba1ee,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor
keyac1642b7f07ce8394c6621f5eddb1b38,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
keya7ed3d61266e4161d5a9283029c5f90d,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
keyc3ecab63dcbbda76385b15efe80206d7,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1)
keyf8be9662aff97a02ce2b3030639196a2,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2)
keyf245c442556ba132297460eb8bb6d273,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2)
key28c7d1991c283dbdd1e53e9f4409185c,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
key3c06f6b5822b0ac6869a88b18a611e47,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1)
key15e9356d4755eed3cf4347bb416ec45c,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1)
keydd199088ba8822779253e694d730aaca,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2)
keyd61a39bca5a0087cc3e833036c45f800,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2)
keyc1d0ed0a101aaa89970b0de70eb03837,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response
key4ad20e474b6b6b256d5b3a240efed68c,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
keyb678b83cd94ce726295b2f12d81a62cb,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data"
keyced4554e02f5cd5d45283c61c4247d8d,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,"
key7d583e649aad605f8439a86b960ef089,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
keyde9879d7e0196b995c1b82153efc9acb,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
key565eadde0a1aaa7b77b1917ab6d171d5,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined
keyde9879d7e0196b995c1b82153efc9acb,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
key565eadde0a1aaa7b77b1917ab6d171d5,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined
key5b90342686efd733bb03c17d2ae82f23,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined
key43562c502ff589b088aa02df83441143,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
key1e7693a25674495fafe6ef1831ee32fc,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined
keyf5f6b792731345a8b5f7947972a17b67,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
keye608095cbea9aad6f096f991190a1076,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined
keyf5f6b792731345a8b5f7947972a17b67,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
key4a79c9a95cee422bf702aebb16684ae3,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined
key2c733b603f77e369a485f0ea590ce000,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
key2c733b603f77e369a485f0ea590ce000,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
key5b0f01f3a1a1cacf721051286663be81,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay
keyea103f95df2f379d1a36cf9e28a7becf,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
key8a95336214798867fa56ef5305a2e2d0,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine"
key24bc57a3320ed1f26a5d10ab7da1bd37,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined"
key7f777f89f93688a3cd5cb13d4f100d09,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor
key08170348073eb0c2ddd08d9c13c2e6c1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data
key36505ef775174a3870641001f67a13ca,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
key0563f5d2c8307408c0ae6860424712b8,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding"
key354d97b45e40d6d224604e6d0a0ad065,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
key354d97b45e40d6d224604e6d0a0ad065,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
keyd86a1f819ffcf621e6873f7041d16d08,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding"
key1927c88622c865e228569f617ff26894,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined"
key845d35851203f02e6a4ec9f61d30977d,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined"
key3590ca930f6b55f634c1fa90815b9a21,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor"
key863daabfe27874adfac1a34bd857b515,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors."
keybc0a319f5bf1378f99f808e3de23838c,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined"
keyda5c3837321f36b087eb127006bd0c2b,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay
key5666a53f67b477df686010c0129fbe60,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.
keyd794e9e3cd2fec0905dab9c8f0972b15,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
keyd794e9e3cd2fec0905dab9c8f0972b15,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
key2c733b603f77e369a485f0ea590ce000,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
keyd58ce4c76f3ce73bf642f2f9d12283c3,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available"
key5b0f01f3a1a1cacf721051286663be81,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay
keybc1696c9db36a77f613287c9bda4cc45,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor
key2c733b603f77e369a485f0ea590ce000,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
key0742e9175e8f9e1d1cc473647c03a780,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro
keybc845cd3890be037d6870a88b727bd98,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
keyd980da4f552350c5e6f6f6ebbe320af6,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data"
key745e0945a87a00ec92520c3c5544d8bc,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data
keybda7f697d84a4a05514d703501384120,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro
key928fdb36ae6bc84a6bd46400bd5c81d7,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
keyd980da4f552350c5e6f6f6ebbe320af6,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data"
keyc3c0c2968502fd2f4e3dbe7e8acf523f,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data
key3b11b7f7808851edcf67d44cd2f96244,Inhibition of human 5-hydroxytryptamine 1A receptor
key9fc6b457a772ff8f78e330be592b6964,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
key14e27551a96b74f38b0180616038825c,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells
key9c5cb119859ff0a3de6fd7e67f99815a,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells
keyee82901d8d21c4ab10118686d7b0d5d2,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
key97bc0018f59f65bcf83565a55561d7be,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay
key7c939549a698d242423379ce89011858,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor
keyf2a9d8f747acd150416bfbb015fc5f67,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells
key28571309a4fba986c89827772ceff08e,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
key942630f74358397ffc0418b2f4d9fd1f,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration
key4b963fb2750ed982b77d64ef50abbfd8,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive
key227c7ebc063c1d8e01bd61379f651c8e,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration
key65be9e7c69a8ac3b8fc3f1a8d79b1a55,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive
key4a345a0a8d31a5b57491a75502125e81,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested
key65be9e7c69a8ac3b8fc3f1a8d79b1a55,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive
key3180246c97882c881b1d1d31a16f0149,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration
keya51935cd0c3d15307dba5eb13ade1ca4,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive
key1aea3470ad2c7355cb668c03d28dffb9,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration
key5fa43c98dee2a8a38d39596b215c725d,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive
keydf40b1ba885d8b0e9a68aaf2f307a6e3,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested
key8646abb80b998b4a981ee85e2ba8e243,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration
key8acb399f560703a1b09c0a40cf111121,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive
key3e0df34c53e04c39d61dcf507ad08069,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested
key3806756ac08a79deada3ee1bf60cc990,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration
key19e29d47d967b5761c72db118da4ae8f,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive
key7f6954e05358da77903375134a20e44c,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested
key7bae4125f2bbd9424eb9d6ac9d648c39,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested
key942630f74358397ffc0418b2f4d9fd1f,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration
key891e0607a8b7d393cb37e644b64b974e,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.
keydd61942c43152d725161d8aa9213812d,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand
key7a99ca9271b4fd5979a6b7d56a8be187,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data
keydcd6b912919600167f59ddc74d734cb7,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.
keyd6b26655658824e564e10de161288aa2,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.
key7a7516eb04bd7c83bda69128bebe4e22,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated"
key3b3d1aa74c571dc7199e2bbcff7e14a6,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated"
keydfaafac787f393c556dfe3c69a932db6,Compound was evaluated for the inhibition of 5-LO (lipoxygenase)
key133f343bcdce60e0e111e133837c4e97,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
key133f343bcdce60e0e111e133837c4e97,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
key133f343bcdce60e0e111e133837c4e97,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
keyeb4a5fc1877e49b04f650cfc7ae7fafa,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN
keycd7ba81b46203dc6ce07ee870e87389f,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity
key4b32944df7688b519bdc06c1a0178bac,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes
key452b438eb54baab0f2fec84909cd7904,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM
key1a2c4822fe9d074263501dae2e1bba6f,Inhibitory concentration against 5-lipoxygenase from human whole blood
key394d49bbfb27f862e15c0b1fa8c01e97,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS]
key67a6aa11ebcb1cdc2064f4b1b6e52c15,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg
key60640aa9dc751e139df0aa2480c5375d,Inhibitory concentration against 5-lipoxygenase from mouse macrophage
key67a6aa11ebcb1cdc2064f4b1b6e52c15,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg
key69ad350a28bf33ee38c4f661bfb93948,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.
key787ad2e1b1f5e0c46587a5410ebfc98a,In vitro inhibition of rat 5-Lipoxygenase
keyfc6f8bd9af6ce173134599ea952075f5,Inhibitory activity against 5-Lipoxygenase
keyffadadc8acce7af8cf738bb1b470537c,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells
key788df1e22aa24b32037aa5414c466430,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
key7bb20c37b3f4cc4ea0a563b49ec46fea,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1
keycdb00c66df5cd2e90b8c05eaac049821,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood
key647ce8234ba4d6d8f3e1e00d5d0ab806,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS]
key68303ddc90bd8cdad4b6680af402fa49,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM
keydfdc35ae944bb6903416d922727a7fb0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM
keyb888f2021f8e3ad6a30f73eccd1c0072,The compound was tested for inhibition of isolated 5-Lipoxygenase
keyd73bf9897698cfacfe78fe0b8be4d4e7,Ratio of IC50 against 5-LO and COX
key68303ddc90bd8cdad4b6680af402fa49,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM
key7a997bd2b0806d2fbad82b4355f621e2,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%
key8ac24a0e4a80f6e67f8628d1e6ebf1e4,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration
key62e53f5a24b8a34379f650028e28cd94,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo
key5812d219879f86066bfabbd2971fe558,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates
key8a346266f43b2a8e9b4cae76b8589f91,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration
keydc287cf5de00f418fcd31b94d1fbfa7f,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration
key0d2490c0b05fe43d2c5aa2d17f24daae,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.
keyf8441428bdd8751d7f4f7c67d339616b,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM
key91926ffe8b1517034317b58ba79e959f,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested
key62e13484f86fbac22541f39623e1d51b,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT)
key62e13484f86fbac22541f39623e1d51b,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT)
keyd5d616e7238bcb030e0cf0a9b2d6ff71,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus
key1c5d7fbe398e53cc30040be93851160e,Binding affinity towards human 5-hydroxytryptamine 1 receptor
key2b72b8139402fbc0a07a9a1d397d0f0f,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
key93c804a805864d3b72ed68f4ed9d9184,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
key8c3e14ad116fdc91311e5cade415f657,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.
keya792bb54b951f4bea6a75d2ca692d13f,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.
key587caa3b8a1085dbd6978cbfed46fb32,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
key587caa3b8a1085dbd6978cbfed46fb32,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
key63dc00424b15c821cb9671b3bd1c41a7,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
key6817b96ccc61d94760746cac949918ab,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes
keya1969226600dff1cadaaaf81aae27883,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat
key9e361ef4ca2dcc439c1dced9f4f4c4b5,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand
keyd2f49b1186672229ac42ef458b75c5af,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates
key34e6d1b5457e3b96520bf5fe689fc077,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay
key01adaf44f66a4744d48361785ba5e935,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT
key614a07bf71361ac8a5df3160c8d7f9d4,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus
keycca94aeefd4399a7cf35e7f051fe8204,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.
key061402c3efa6a0a1c9018b743496d649,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat
key9242b361fb70304f6fdd6ab3a8afe8a9,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.
key300db51daafdcad6324da78a99b64238,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
key300db51daafdcad6324da78a99b64238,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
keybb1166086aaf0a7259ae9cac23ab1e22,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
keybb1166086aaf0a7259ae9cac23ab1e22,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
key2940418bdc3de851de27e73c6b1fd16d,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM
key186455aec00366eb56a857bb375efcc7,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor
keyf1fd99d9d02faa58639a89de6d930bc1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor
key0d15f829502b025f5611bd1d68001a65,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
key793a09cb4dddff7d05d8c8d9dcd16bca,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
key793a09cb4dddff7d05d8c8d9dcd16bca,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
key07ec3be739a97d08674570d72335757b,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand
key944d9013c80c1f84702b914a7fc530ca,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand
key9b4700d0befa1338de459c63d5e3a431,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined
key4d90684b0cef402708a2739172b1c4d9,Affinity for 5-hydroxytryptamine 1 receptor
key901fdef6dddaa9f71b14051165301a79,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex
keybb1166086aaf0a7259ae9cac23ab1e22,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
key397f2ccc2518a4591f3f3606b85b8400,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding
key82bc2c12778bc849a78ffdbfebd139f3,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay
key44538d403acabf9f91adcad142597c46,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
key0bd3ad545b591dda516fa403130d3479,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex
key0513d0ce2ee3be99e8a22ff3cc740136,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.
key5d579c4bb151269c7d909d9997b74cf0,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex
keye30fefe651883c7bb64189880684a4a3,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates
keyd00c85542fdf60cc1132323706f59c39,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex
key8a0b537e56d464caf87643ecb1cbd36d,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue
keyb9c68a602bdfd0575faac043b5a7f088,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex
keyb083a513131c1e02dabc3141432fb6cb,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes
key47aea3e723c87c90d375dee3a8c36303,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.
key2a30f379638d6804168af4f492ca5e09,Compound was tested for binding affinity against 5-HT1 receptor
key47f92095e1296f9fef9cf98c0e76905b,Inhibitory concentration against 5-hydroxytryptamine 1 receptor
key723124393852b136ceffdc391c05b490,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM
keyb326c3e1f42eff111c016cb3f28dfd32,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor"
keyf8dd5746b7c1d3880911eeed8f281253,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration
key308d220cb98a725d9888e02f91d75570,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration
key3714f57c852579085ecce0fa82d3a685,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor
keyf8dd5746b7c1d3880911eeed8f281253,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration
key308d220cb98a725d9888e02f91d75570,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration
key95ff115ce8c9cd3fabac026685c2bbc8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats
key85085070192da59a39cc9a248ba8fa81,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration
keyafed06d58613c05d6281f4ab0fa00992,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT
key1755d0dbcc070862247cb9f9b6f38e73,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect
keyda4da7f9c5216b7764d28e7a09856a52,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values
keyc01a0a3ae3d5d0fb50dcf901949a406f,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT
keyd531e9a6e5c04a4177c22aa5d6f72be7,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT
key9a3eed334319be0d234d7a9076b6e530,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes
keye76b3d2cd2267b516ae939e24c37e958,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT
keya745ea85fe5dc06a65387dfa51a8ed34,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT
key9849b34e68c9053cf4a2897e9ef18cf6,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand
key16b301c94d3a1267a0f74076e901a0aa,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive
keya745ea85fe5dc06a65387dfa51a8ed34,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT
keye7a397925fb19e3f7fdff978c659b3c9,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand
key18c5f977dacf161cffec8d7a88e72ce2,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand
key1cae39e2a6bae1ac0ca5396f73fa251d,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand
key81882fdd7f6e057bf41264978600d469,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
key1a1e4a1528f461d6611ae6a78f93611a,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand
key2af64a706232334fe4a64fbe063840a0,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand
keye91dc91fbcb895a49caa08a02de61933,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor
key4a2ce63a27f43d4338afc2b41c0c21e2,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand
keya693af9187362a596ab35ccdac5cd3a3,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand
keyc9ad9b31fc1818c1e859170940a8ca07,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes
keyf1de8828a4ad98e585b382f0887a3fc7,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.
keya35908a9c6c3df561dccb6dc5e312602,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.
keyee42ad0a6b30487e200b3d6ba8c0c55f,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined
key7afb64c0ce67b521cba85c8ec4fef6b7,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)"
key340aeb76a5062b05ff66823a5cfbb71c,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand
key66684fb711fd2ddb864150b422cc922a,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes
key46c3fe2b545201db0becce316f040187,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
key9c7c70e8b892d9a1ab706e0a8abb1914,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
keyc1edb2cebf2d12b5d2bbd644640838cc,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue
keyc0708bfeb47fee97e03055f8ddf96353,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.
key3398863dbceb9a7ca8404a10cdbf3907,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.
keye0764ef2a78bf4af780c98c6d8341e0b,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue
key1c2431ddf7a2797b72bfb56a90509e4b,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM
key723124393852b136ceffdc391c05b490,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM
key09894863250afb658dfbfe70392b10b2,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat
key09894863250afb658dfbfe70392b10b2,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat
keydb0fc04efa165ddbf386cfdbe6ab00bb,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex
keyc6b566613b70df09b775b83eb1bd425f,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus
key633fbed8c7e75357cb38864334d63428,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand"
key01f678acab4fe3a5a646792e96dce073,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand."
key3da64567804ffc9c30c1ed754ac2419b,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand"
key90232d555b253e404ac39b4555bb6d14,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand
key1dc97cc7d0b2d368470ab3fd1ead9942,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
keye70b7fa353b930c70b9c6a05682765d9,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate
keyc5cac59d6a3520e2a559c6070ba5d658,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated
keyf616fd9f465f2d494753b77ec35ac88d,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin
keycbb33ac8afba992027327ddf544753b2,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
keydfbb720290bb2e32d731dc7f727eadac,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.
key1d8a75779ef00703eaa1c216334733a3,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
keyaeb184401a81ce34d884bc43f85ad44a,Inhibition concentration against 5-hydroxytryptamine 1A receptor
keye568f1ed87413cc539cd6f4598744b35,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration)
key2e6d0ea3848bd10e5427c4c825e31e6f,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes"
key5b80740e4851609d0ff839e9c0456ef9,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%"
key03f13b96967e2cf982c7c95401dc3418,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus
key03f13b96967e2cf982c7c95401dc3418,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus
keyce9c9ca0102689f7bbf6e64d61652a83,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor
keyd7f82d20780a4e340479ead798eaaa30,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor
key5615dcc5208749043a14722045a1a526,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
key7d8a990e16a1cfe4f7d644bab55f6c10,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype
keyec0d4062c2edb23dca1dbe4ef7e5f9ff,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus
key28571309a4fba986c89827772ceff08e,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
key40e3315ff481db171f451532a8469f8e,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
key40e3315ff481db171f451532a8469f8e,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
keydd30f2ec3d9b6949931f5bb1bafc5f3b,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor
keyb03932b30488854e1a592c37fe46b893,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested
key2c733b603f77e369a485f0ea590ce000,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
key3c00c223dde85ac9e4d54e85229ac541,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM
key0e6cdcdce65f71f76b0c2ea9e53dbe91,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor
key9cd8ecccfdce337e62a39de8350c24ab,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM)
keyc6141b6a727b8f2dfcccc9719a1e9365,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
key0f312c7aa26637f95fee9b19280f2d5c,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration
key4adfb5aadfc537cf17bbb1fc5136227f,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration
key32cd56e07df7658fc865294c24d88ef5,Percent binding affinity against 5-hydroxytryptamine 1A receptor
key5e8e2867e66f0543a51cfe208bc6d94a,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
key388bc3bb60386dcb15d07e11aa7e1da2,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium
key5c585bb8b11b89c0eee8bb2b37d8db17,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor
key863daabfe27874adfac1a34bd857b515,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors."
key40a6cc2004bc68249e34080641a69661,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined"
key8b2b993b75c99238f06e0e91dcd6e022,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor
key850e62d161f4bae68d3e6436f2b22502,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor
key86ed2aa2951718a656fe21cfa67d7f86,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor
keybfc300f581393b57b5a59c9340b09560,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand
key9cadd406ed9f98d3b21b7e225f401047,Binding affinity against 5-hydroxytryptamine 1A receptor
key98b72524e33b26482132e6296bc087ef,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT
keyecd0baa171138e883671c0d03f4f93dc,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
keyc537b823f98bd4745b0a6f203f6199af,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells
keydaecf292d437eaaf8fa97d306a34498a,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
keyfa7ad6bfe9fd20666395204fc37ba74d,Binding affinity against human 5-hydroxytryptamine 1A receptor
key4fa50a71bd7cd93829fd7d223782240f,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand
key3956962c055a0581f622c95ce4edc672,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined
key1b321c52498678e9d1aea015ed231032,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor
keyace68eb210effdd514ae34bc740459b4,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells
key78477e3fc18a5d83e51d12ad7f38dfc5,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand
keyabc2f8fb7f84819ab3d77aeed15455c0,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined
key78e6ae5b85fce0ec96a3969fe3b0fa0d,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.
key35775a5e4e77ac7c892ba2111d251b8b,Binding affinity towards human 5-hydroxytryptamine 1A receptor
keyecc0a0c02a9addc9016fa4870ee75f65,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells
keyd1333222075cb5ab4335af19662fcdd0,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand
key253e549f919ee93cb9c0c3000577f43d,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
key35613fd9828f6a5ee22acbcd0d4cf1d7,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
key33032e9b73e5b943e63446c315ede6f0,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.
key6aed4bf01c3b23a0296e03a40628a476,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La)
key90e47e995b36e6b1b48ebc4e67350d94,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La)
key3563e13f73b7fb1869becc6b9baa2225,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand
key2082bf8c90d45c2a13d5f789650c4c92,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
keyab4ec0c5dca4925c3921d1c91befa8dd,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
keyb739bfca81d789991ae01508315f0756,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT
key541f8a615f0b6551b81e85c7eb6aa361,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
keyfe9f316c4e0aedde349f899970fe085e,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand
key077b30123c2e28513f56a16684c202a5,Binding affinity towards 5-hydroxytryptamine 1A receptor
key926ccb81332f7f5b412019bc7753a591,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand
keyab4ec0c5dca4925c3921d1c91befa8dd,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
keyabc2f8fb7f84819ab3d77aeed15455c0,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined
key40a28eeaa7c9fd14a87a54c1f64a4cf7,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
key66efe28f9f646268b7925440c1ac2a1c,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT
key89c0b06da26c52f16d218cb094f31fa3,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
key642769fbcdb012c56f4e68bc6596bb73,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
key8a170fecae56ed38bac4fe2bbac2ca39,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor
key19cc179b3b14ef624b46a57dcf44166e,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor
key1d8b24eecb0ff50acfcf925b742c4e50,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.
keyf67498d88468380be650e1f6d7dc8469,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells
key50f1349b08912f02e72752bb3e18a1f2,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor
key9c7e1b402a5b4b7c73fe4b68b605479d,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1)
key9cd297cba2208ff03615f8fc88154f4a,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2)
key4ab19a8bef9be5d14f7ddc43f7816912,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay
key9fc0f73d457c8436169101fdd89e5793,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells
key79947116cc766487f0a6e3588869f3c6,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor
key3eec3ec5544fcfe44080bf1d948765d8,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor
key29127d0c0be2946c17e8e50cb64c9c37,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor
key7237a2a389c47773bdcb2d47d3d6b8ae,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor
keyb272e28b48144b438db3bc54d4284552,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.
key5c2defea1717c9aee06c4822c9916ad3,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT
key6e56be0e106d0c525657ff70acbbb476,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand
key27b4847b4be6b5f71869da487e93f162,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor
key0d50bbb62cfdb007c0655f4e24bb3d0d,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand
key8f10a6b8a8c7f3b9cece1d5b52ae7cda,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor
key4bacffd17d8f97b3433da9a962a17ccb,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant
keyfb2bf2f7422170d4ecadb203cce6d9e7,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells
key01853ede0d420a8de272f307a49bb6e2,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells
keyb8efa79935049a7312322a525a903cb3,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
key16439edcabe6efaaad3f61de7ba70649,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT
keyefd9fad973ebe8e1f09d2b46ef13fb57,Affinity for 5-hydroxytryptamine 1A receptor subtype
keydbfe9429ab78629a9ea3d99432cdf67e,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes
key06a08c86d40d73786ec2b6e7a15d21fc,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.
keycb0b0b1e3218ea32b7c5b3f5d70e16d5,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor
keyf4f78befb9753363df749aad0b9ca615,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor
key1df799aaf8fab77a8151dd45309528e7,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active"
keydf2a03e65af4c36f4abbe706cffc6624,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined
keyb8efa79935049a7312322a525a903cb3,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
key7419beedbdb6d7b91ab3f598c5928ee6,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined
key3bceb7d1ea26e9947fb18ac4a95f88a3,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
keycf08d7be0f78d4c827b07e764b8a6f70,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested
key3bceb7d1ea26e9947fb18ac4a95f88a3,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
key3bceb7d1ea26e9947fb18ac4a95f88a3,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
key94826570b3c7db30d48f4b2b14a9d6cc,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
key94826570b3c7db30d48f4b2b14a9d6cc,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
key94826570b3c7db30d48f4b2b14a9d6cc,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
key764114775538d07b0e4d5a4d3910c1cc,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested
keybb524dfc30679154b5213128e917616b,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested
keya71765599fea4cb435820b1a1b790fab,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested
key0274a0dccd8e41df4f658392ea9a996e,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested
key79947116cc766487f0a6e3588869f3c6,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor
keyea103f95df2f379d1a36cf9e28a7becf,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
key28e83d1714858e688b13d59dd2d72798,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM."
key7f4284051f7e9ae527f24274d90063a9,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined"
key98798c59d6cb46de9d40179be828a9da,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined"
key9ac894126e742f8034f4d9aae3731aa3,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined"
key28c7d1991c283dbdd1e53e9f4409185c,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
keyb1b224412b26772e124d165e3baa5d1d,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT"
keyf85f7de2cee237e0841c5ba115b9401a,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT"
keyff9e3eb2f891d08949c4843f9b4fb464,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response
key76c59c2f00284239cd92e794379a712b,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT
keyd025be8b82a19ce397b85106c66dfe02,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.
key3b8b444963987e32f0abc2c2f50eafad,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype
key3b8b444963987e32f0abc2c2f50eafad,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype
keyc920060a594da65c842e9827579dccef,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
keyc920060a594da65c842e9827579dccef,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
keyefcca81870e7bba2c96e6b02bdaf9423,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor
key426957f8e7540f653c0fb05212158035,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
key426957f8e7540f653c0fb05212158035,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
key426957f8e7540f653c0fb05212158035,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
key4b91178e4d15f301340b337cd931d0ab,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor
key5c306cc7698f86d97707eac1e5b7d8e8,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
key392e81f670377aaef54c8873138a32f0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
key392e81f670377aaef54c8873138a32f0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
key8bf89cf0e99c5e07da3ccfc6307e1c34,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor"
key94837e1f092bdaf97df7d92288da05db,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
keyea103f95df2f379d1a36cf9e28a7becf,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
keyca571ea8cf360b23ac909d89f1faeb8c,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2)
key71876bb815775540c01aa9e265da4b03,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells
key80853164bcc745199f8e15702388a302,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1)
keyc2c617947aed93ab36b1aa5dc93d539e,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2)
keyf259d9ecca9e18da22c8ad155d7285d5,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor
key13c8e2ee3b858c920e6be55d8e524f71,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested
keyb757640769cf68e10d5e6442ddb74c17,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
key19fa1d85f0531194df1b28a0a1a999f1,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells
key107df5feb34c4657e2d7eb4b3b17ecb9,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
keyf61cd4dd5379b9d1d4c5aa9917deffc6,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
key83427caa3d76f7f03b20dc1741fe4709,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor
key83427caa3d76f7f03b20dc1741fe4709,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor
key777be7775d6449a918aac81cd36436c9,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor
keyff4ab7abf699b0bd0db6be2b94e6bf1a,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor
key24270487b11dcc05c9c0040eb6846b70,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor
keyed3076a9593bd963e38a5f368446b7c3,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A
keyf83d51790a2ab7fffc55b852eae785f9,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor
keyf48e30844f85c74a793e638836f64618,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined
keya72a7cb3b8cbbd5e58ec0908ab417570,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line
key0461e26c9d82d18600a64d18557c7525,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand
keydce03beec8701e7b910c2f5acebe262a,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells
key639f2ee334c4099e2ca9f5e61bf42636,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand
key9e64d727379e7292b2ab0554ddd47194,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;
keyc9a2edd34c7bf570a29a2fc971cb7ce7,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data
key01c546b8953f6a10def1441b3caf284f,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.
key926ccb81332f7f5b412019bc7753a591,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand
key9e64d727379e7292b2ab0554ddd47194,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;
key390220325218c5855fd607228012333c,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand
key2cbefc9f747b41f529f66615db359b91,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells
key6656cad2816c76b407655d9934eaea52,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor
key7be763a8b91db3e3908986780ea7e82a,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.
key81f25d473b6844c5cca843b73cdac5d8,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.
keyf41512600465d68c0750f332d8366495,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT
keyed4be9da24f06811ec8a479fc30abdff,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand
key61ec943c6febaa51b723a6d72ad75ffe,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand
key2d78daf64c061de6dc4b75961433940c,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.
key054a0b18a6a72c749cca2e831046dfd3,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.
key9c3a96c91a42bd7d3a75d202e20d6848,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand"
key7c939549a698d242423379ce89011858,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor
keyf33d685aa0f2d54bce9b453ed4777247,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor
key4f9b2de6e29e7c1ee37936b36d43f56e,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell
keyf1fad0d30a8a11e83c85d4ef24c16b37,Binding affinity against 5-HT1D receptor
key9cadd406ed9f98d3b21b7e225f401047,Binding affinity against 5-hydroxytryptamine 1A receptor
keyd794e9e3cd2fec0905dab9c8f0972b15,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
key822f224ea1e78acabac120770cc866e1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay
keydd30f2ec3d9b6949931f5bb1bafc5f3b,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor
keycb5b23bf5436a7ae476ac96c9cd39fba,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound
key7b71fded1f36ab13ef294c8fc8fb2905,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound
keye727a4f33bb3cfca71925f402054e217,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound
keyc67ee7906cf0dbc416d7924685f569d5,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min
key95a7019158931624d547975161437d17,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min
key7ed90ed737933f527d4c2869acf1d00b,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min
key4a5c7a35d10bcab0d769c9f8c3de34ae,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min
key8caa3a059508073d5181255aac55b969,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min
key2510ec5d1e0d88144a00bb5d5d2e6aec,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min
keybabc0b101031807ca6ae5c579f7328ba,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus
key3b8f014aae51a1d4fa5423f63c478f73,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.
keyba18db97675d1a6bf8aac2cb103e6162,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus
key1e74493db1904343eeacd0d0ffc9459d,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined
key27b267e234425c3c5dc900b27d8abb61,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus
key1e74493db1904343eeacd0d0ffc9459d,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined
key48819b96114b1bf1b2bcaa0597edfe15,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand
keybabc0b101031807ca6ae5c579f7328ba,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus
key85b251d18f59c4d7272540cd93cb09bf,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor
keycfce885234f0e635adfa487a4526304f,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined
key40efe28d5531866f3055753e849948e3,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates
key504bbc2fc03b2f38655298dfb22b3cb0,Compound was evaluated for the binding affinity at 5- HT1A receptor
key5e3419c4f0e6c9950c368983781a80f3,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate
keyba2f7c1e117987e86f0b29680b578536,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate
keydc5a7d024db46beadcd841fc3e15052b,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex
key5ae1cd3342c186d0d5c8abbd9fca6595,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
keyf5ee147e85a3f260e0d3ef5b517001d5,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.
keyf5ee147e85a3f260e0d3ef5b517001d5,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.
key576400f75057eade61124f42d1186435,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex
key0f13a4949913be1907ff088578e2adc4,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor
keye54ee45044832e9241d1abddf4a9a8f4,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT
keya165330f755cdd971149a74909c09dff,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT
key4bdfea653f914b6237f0c9767abe99f9,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT
keybb83b3e4954ef8f2b2622ca2104aff55,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT
keyead30253fe989f7510f9da9c79962c6f,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium
key8fd5fb2300e9fc7547c8538baf6440f7,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays
keydecc6153238d5ec3f6d3fc2b597b67d6,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active"
key0ca37ef35632874fa03d8c979b2fd7f4,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity
keyb329bfbd40246433e3306aa50415082e,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes"
keybc90a208d6b3050e5c081eb1f18c9509,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes"
key9bf663333b79aed5006af84d4d450b3a,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
keye8d238760c1b4d5a17da70ed7d5e53ab,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding
key5961be0f631b1fbbfe02c26f1363a718,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.
keyca12b923e51468c05473d08f68fe4c35,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.
keyeefc11f1bce7631cd861db21121516d5,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay
key73a22a1f73fa2c199394664043b39d12,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
key07fee5e0676308a559d36f6315c32361,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT
key6c7e59fbbdadf557b07a1399d097fd91,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes
key6c7e59fbbdadf557b07a1399d097fd91,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes
key1be3cd2462a7eb905154d42e6760f33c,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.
keyf7d2992690bf9d485be827d8c79aeb9a,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT
keyfdfe0a1ec97d5959acdcac66b50aff2c,Binding affinity to the rat 5-hydroxytryptamine 1A receptor
key2d823164ea10d23a731823ed7a60cfb4,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.
keyb75de77bcfef0acd77c220daf8804d05,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.
key46bb58b3f07cc790487d317b5cfaa970,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.
keyf08ad03bc490937fbfc09d2976d76d99,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
keyd2c7494bceeb06879e7db24eb43a8b6c,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor
keyabf60362ca78a1d44d246dc7736f78c1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor
key7688940a9fb1d283e4c99afff7715cc1,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand
key077b30123c2e28513f56a16684c202a5,Binding affinity towards 5-hydroxytryptamine 1A receptor
key4ac1f6d4b4526e85e687d4ef14d4620f,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay
key15d5fdd9c171c721390b1f0e6dbe2f38,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes
keyd575917b9d7bd197bf49152f55f36265,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
keyd575917b9d7bd197bf49152f55f36265,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
key1a45e60fc1eb43a6aec8847e8dcb2473,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand
key2fe0b510001a152305b08ca5490a516b,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT
key6f365ac247a58127b65a890c4b02a269,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand
key33d8162b32475274215e01a4031ed72f,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand
keye25e780b6f3d35dddddd5e19a624ab13,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand"
key0ca97347c8706ef2bbe60c361a85e704,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes
key6c4db9f8dff35c42ec7c58230b4a5602,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes
key0e39bd69b14962c390f67b311fb6dcdd,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
key88a7d746f45cea9c8ec69fcbd7309c55,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested
keyae4e14ea16d662fa2f7798e23319dd92,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand
key2d6872cae22cdf5b0d06c897c210e1a6,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
key8d96d6824821a68d33e3159585ca905d,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand
keyeeed8fb828f594558b4086a2548db246,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.
key45867b9d4a5ace372411ae09e6aea3f8,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined
key3db9f0dab10d59a0dd4ca31e861a29ff,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined
key3a1096b90731437f4dd5a2ed2346d28c,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.
key98a1bdc8f7730aa96c32a90433f07ebe,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor
keyc677e280ba6c4c0d33a70839fe10341f,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined
key878ad7dc496f6ca1ccf6a7a0a1b08d52,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes
key4a8043311c53199ecf1a1fd85b61cd3e,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined
key913e5a4cca6806456b571ac528c5afea,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells
key077b30123c2e28513f56a16684c202a5,Binding affinity towards 5-hydroxytryptamine 1A receptor
key24bf7230245105610a1120e257b223aa,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain
key5ed77394babc769be6a151cfad6d1cd7,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain
key5a376d216d2806df455f298f97dad36c,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex
key7e27ac17c60da73257be0c90a082f93f,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates
keyfe540d0b1f7459125c743671d9ede73a,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT
key5d49a3c2f75b4668f5425b4f6b1aa106,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate"
key223ce4df2e7291ccc37bd95b0bf87d34,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101
key7d47f679041ac36dc67fcbdedda845a8,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.
keyeb402d38f4544602fdc7623e9409134a,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides
key09bd9cde07023b337250b2edf967d79e,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
keyf5ea9002be5f7cabd53fc908e73ec596,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand"
keyb8906f80b212d494571a997828b77a3f,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro)
keyed680d0bf7ad8cceb1ca978d79c4ca62,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo)
keya0df546067ab777846caa5fa32c1da95,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex
key4b208a340a72250ccc9af6cdc89279dc,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
keye9949e711114c959418517b6785b0c38,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes
key4a7e1d687e245bc177c03800200ada55,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes
keyfe85e0bb218f491e74786617bd8a8fd9,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand
keya583bf533552802c5dfe6dee59614ac6,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand
key71698d4aa0536911fba1f94632500c45,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor
keyfd480963c7cccd505219a8bb556bd6ee,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.
key69edf8e624632d921b461ea3af902630,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor
key2ac1d475c6be90cb34cb593523900df4,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex
key492116a74c459f4c61e486b2703bab4b,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand"
key8fe90966bcb346ab809b09c57e6f30de,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor
key4eddd9308913624bed09489f864bbdfa,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex
key2b4ec5800e33906c99fe6e17eeb9dbbf,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.
keyce27e4fdd25c6271768e1c1c3bf11a31,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
keycfccfa04fed71ca7979fd3a9f006539b,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.
key0e24fbd68f7692bc79051b5ddd0bb5e5,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.
key0234d7c696a01898959d6a7781e592b6,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand
key9a3c3b1cc537775b6b7a58138b76d0d2,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.
key961224a673350621d0aeca1cd11381b8,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor
key961224a673350621d0aeca1cd11381b8,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor
key89e462cf85699ef260f43f6273e28ba7,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor
key6954d4eabedb0a2e666e68b96d1dbd6a,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand
keyefe941828f3a70ce0bc914dc030eecf5,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
keyb4ac19902b615dc4152a14fff3b68fbd,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.
keya01fa5ca843f8951a0e880ec1aac88aa,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.
key169240814be7695f50e19dbb7cf02b2e,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12
key6d1b09aa8d461f1c80e25b707b3a7fb3,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus
keyfaabed4d550e489baa9eed4d6e7b2346,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17
keyf4d70403433e98ba11f5ed1eb3293221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841
key7e9f586ed71603e0fab72fa428593b9a,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.
keyc41514dce9cbe9e5219bb31586d04408,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.
key902772a7dde4be0640e2b02e58cde76f,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736
key44047e36c12ff9b2f83e89d476f87db3,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84
key20a2b080dd6a027750a84ca39fbdfad8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59
keyae594722eacfce09e8dd1a061a1469bf,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5
key76d87c5953ac0a657acee5233b95a3a9,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31
keyc5b95c1bf6cfc3e2d3161faaf21aecca,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42
key4952515e6d1038e344ff6b39bd020f77,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13
key265ca3a6ba7587716e2b20aac6664f6c,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus
key77fc29e48265dfcb6ee1ebc0c77d0dbe,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.
key2030c67e030bbb0a54351f438a71f7e9,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27
keyb7f3cba724c20cda077df5483a711bcf,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.
key627f958777e4e1113608b96283df2c5f,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate
key95156d89174aab748e2ec6a447eee0ba,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1)
keyc9af0bd14530b31df8bfdc61fe0c4f33,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2)
key17bd819510139615bfcb1f13a91b4782,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
key7985354fde556ddb670af1dc5687e67f,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.
key629ff1d132ee6dabd3fa16385a7975b8,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.
keydb12301aff03b3f49c2ed4311f73e984,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data
key324701d2e9a0cc588338fec4a29fa5c3,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells
keyc3a62228876672717cc033997940f3a3,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes
key3b0a1c76b83810cba749c6a8be1a7886,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.
keyff4add60dd5c528df820c2319e9adcec,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)
key720a31f9ed9484bd4be6499bcacedd48,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc)
key70ed9ad4b368fb09c9b883ff73be436e,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT
key9aa85a511a50910ec29de12d39479993,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
key3ac0428936134071faaebeef8ca8d707,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex
keyef9818fcfe49af030c04089b2c0a6e63,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex
keyace68eb210effdd514ae34bc740459b4,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells
key694585a4033a3e0a4cb0351170bd0651,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.
key314baffab7fab1a3c2b544a291887f7b,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus
keya39634cea23ef93c4098729dc07621a7,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
key00be5e19a97c7593cec34e56642224dd,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230
key05d5c2a7aaba6b713e0b7e5907896f0b,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14
keye9c6a962cb885f449fbd79b89c8db7d9,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20
key2c85a78c85100efbf380823a14ece74e,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430
key947736d5576cfdb75a2098370bda94bc,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224
key7f7607c7edd7c173659c351178627a70,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503
key845d5187ec4da9b4eb40e08eae157c90,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23
keyb4a12caec666c042b1552262d69141fb,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2
key81601618dd55b8a736fc0d6ed07f6ff5,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6
key13c5123189753d08af7197ea71fb1557,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23
key723cf364d1cbcb882b33d0bd3a5fae04,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28
keyc86c41e98b5d17e01cb894da39e8ff97,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760
key76720d988cd710ce1af1f16561fa0d3b,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87
key4566974b1e40f7e03434ac9ae03beca0,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2
key292e08b4ec2d7eface8c4150dd206841,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat
key26ae5e81aee62eec61168aa0bacb3e99,Inhibitory concentration against 5-hydroxytryptamine 1A receptor
key943649630f48f568e6f6f218b9e6b265,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT
keyd4e4c7e9a6a211c36e47f15747267e73,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat
keyf6a7b7b96ac36f80d65dd9d921c5049a,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
key243fef667108ac7701e39f0b1218bca1,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe
key7f5b467dca583a9bf00429bc7d35a025,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells
key9b32e36f8144c3944528a0720c5286e7,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand
key36ce66b7da03861185e6e9725de204dc,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested
key410274889f971ba3eefaa1deac03f6c0,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats)
key26f6a0834f3009be76463336dc2797a5,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. 
keyb7ef05ada03ce8b951632c42a1dfef86,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay
keyaa8e887ca40f86771592935f4c5840d4,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand"
keyb520222fed535ee61b33699924966d3b,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand"
keycde3c4e6bc48b601e8ed85feb221a207,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat
key8cb7ae8c289c86b77b8245ab7b9206cf,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20)
keybd33d3c85f1843806a5420e8845544ff,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60)
key9927e7b67d1d54ca73f34f96a24339f5,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80)
key05e29298e7aada10729a381c9a44fe96,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27)
keyfc28c027f62fe4570c2cb26db14e14cf,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70)
key9d4382327c58bced5c28352b85e84900,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4)
key3b65ad135b06233eb80ac2ad6adf88f5,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51)
key200ca53c213611db23d977d297be78ea,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30)
keyb680661ef99cf7acb10bf02590e88c39,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60)
keye38c88f8fbd19319a14fa888ddf44d3f,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87)
key3d05761938e85b47a6ddd64c6eba8887,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80)
keyf6536bae5400148d50cf36d78f6e58f3,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5)
keyaf39ff7f70537741883c68699bf5cf90,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5)
keyea8f7a2a34ba69e351764c212925fcec,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable
key111edcaa76efc30652b9fe56833528e7,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes"
key65ed108c6b50805c2b9b08a83be333cb,% inhibition towards 5-HT1A receptor from rat hippocampal membranes
keyb95b355c8a33f317f9620736fdaf1c7b,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes
keyc9c942a28c9e713a6684002b732499ac,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.
keyb326c3e1f42eff111c016cb3f28dfd32,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor"
key5d04c25359300ebac2d38d1518483a76,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
key1b8ddb1f4814b7d6b6318bea38566461,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane
key61f901c2e3b0970485afdf764f3fc2e1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM
keyed66783f427fd24839437ad5645d4550,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.
key21838241c2238a94e4e1fcd6b22af238,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.
key76024a9d2138a80e4466d318ef007124,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.
key1d19aad93edb0dedd5ba927ff8ebf4bc,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM
key1d19aad93edb0dedd5ba927ff8ebf4bc,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM
key0c277b6fde717bd7e03787a12646a36d,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.
key14d0acd2d49040663d0cce025b050c5f,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose
keyed66783f427fd24839437ad5645d4550,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.
key952672ec02aa5114acd6e0fedf9b4810,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.
key9cee4b2bd6a3aab79bc18fbf450f8be5,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.
key31cab2f2de67e7fc82f39145dd26ff35,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM
key064552df10945935a2fda93e59e57e2e,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.
keycbe9a00707d5f099929965339f188831,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM
key868ac43d2520692ca6ef35428cdca8ed,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.
keya1e8a549edd8c370cb9085c1eab51d0c,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.
key98d25b9fecff00ea67e991a0327b79de,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.
key8205e22cc7bda7f643bacefc093e6fee,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.
key5855ad15cfde2297216454ab6064d2e7,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.
keyc03e12f9e420938900362dd6eab07961,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM
key616f1340f9f97d93b87fe55fda6757bd,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM
key04f946e283029e753896de8fe5c4287d,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.
keyfc89745d125606429d851347c9ffa384,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM
keye396f53f100bdaea7cd0c3f472b53d66,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.
keycbe9a00707d5f099929965339f188831,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM
key0f91c202496bd88e9637d96b10cb5bcc,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue
key4a719f4bff164dc351c8e2460f1d8268,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM
keybf5f3f3082982ca710f1c5c6e1237ad8,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M
key09bc3b4feba5eba66e4c6934aabe378f,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM
keyb9f8f184575432ba83a24912f7ca0672,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration
key00fccc3fa9fbae4571dcee4ac8c754d2,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration
keyb3c0ba3e51730ce0eb6cf0cdfcc42f46,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes"
key548500a7fb5f4e7c57dc8f6602f18c79,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor
key9bcab390046d5f332df0c24d69332608,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.
key5b85c2d8b7f77aea6f1cda226252a243,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.
key7003356303c00c9e58f4ba759494fb77,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT
keyded0c7f6e405b6b89a2e0f1f2771dfe5,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations
keye96e3b493940fdf5505eeb196dfa9da9,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
key9bf663333b79aed5006af84d4d450b3a,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
keyc3f24a47ae18f5b5c2fc580efff80142,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
key85b946bd623f7705ff8d60b9308271bd,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand
key34904f9f8a493747783417733c59598e,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus
keyff7c71bbce61d539bc0b185b15b6de9d,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus
key3fa2313794bd7dda38537c58a4d17615,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
keyd9088bb9880f0ce65e9db82f03d42131,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor
keyce6e401b8a8cb6852c38666877116a71,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested
key5e333d9e2c3a24c09c9a190690d1aa64,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined
keye341d728c82b56bffa83a5713221e947,Affinity for 5-hydroxytryptamine 1A receptor site
keye341d728c82b56bffa83a5713221e947,Affinity for 5-hydroxytryptamine 1A receptor site
keyb5c9c10714e792291e9827706f960446,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.
key6c2081752ff98b06afcb2ebec52bafa5,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT
key348a058400e8c8313afade9d4813e109,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand
key00f86704a2dbd2d739cc17a209fb4388,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes
keyc19679024bbcf88b6df27d215e846aee,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane
key54307244808f33bb6408a09ed97dd9e5,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand"
keyd589042427b3d75d3d2ab9a6cf33ed21,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue
key10a3b47178d0c8a5ee854865958bd9f6,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay
key34037e4e0fda3b5447e41d32079c8031,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand
keyf2d3ca2ccbe7becd9e4de530b9e82362,Binding affinity against rat 5-hydroxytryptamine 1A receptor
key64b79e99702f82223a3d75c8b22885ee,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor
key9e2d1a465fb34fd5424b179b8b707e75,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates
key822f224ea1e78acabac120770cc866e1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay
key1cd55079333d3c911a1f657e9cdd8ed6,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
key1cd55079333d3c911a1f657e9cdd8ed6,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
key88a0de3074db7a9c36495b8d9ef5ec66,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.
key5e777362a3416118a592ec3e224781c3,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat
keya6631988f526f0569cceda49e0f19364,GTPgammaS radioligand binding assay
keyed0939641c7c5a93a58dab52b4da033a,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined
key0b90eec2590d7c14f825d5a70a3ba900,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist
keyc6611d99533c9bed836c676f9b6c7fd6,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist
key1b12bf21ef1663fe69d0152cfeb355e3,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor
keyed0939641c7c5a93a58dab52b4da033a,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined
key6aef4e2ae4f66a1768f15bac53b580be,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist
keye83bca7abbcd39ab1097d4153c6c3a67,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor
keye4dcf3dd0c6d278c76fe03751c57e57d,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor
key517d110005b32df363a4f9e343eca711,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor
keya22696ab35b1a28959e2840ab44685d4,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand
keyce6eb231598153d528dd17ed15a9cb81,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand
keyd5581be81747945a99dd80656a9e812c,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand
keydd8b369f72349203280970f49d48696b,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor
keycca7879a087edf44a9b98bcd5ceadb35,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand
key6fb35f8d82c8b7e15abaf10ffba3f691,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
keyf1c74d85da74a435ced94e461e697ae0,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand
key80c294da15615cbf8ef2fc61d75d4314,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor
key80c294da15615cbf8ef2fc61d75d4314,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor
key8a7c6b7a4d183bac2d0e93232a71a00a,Binding affinity towards 5-hydroxytryptamine 1B receptor
keya800faebb746f17dc6a4218fd15376e9,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor
key2d4532dc7fe82c30c0a0e1bbf14129e3,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand
key499958060f3188797e1e17a8b8a04903,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand
key095671bf96c2d30f5700509bd96b5416,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor
key9283759d87deada29e2a13b0464722b4,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells
key3c796f5e15b94af8a16728bf025f269d,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor
key493c90dc9e1c478e9b43c5426b905caf,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor
key9f84fdec892c3d804914d511730353a4,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand
keyfbeb7960be5d7bfd4b4d7b55d6490c99,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor
key87ebb80d2dd964491c18ad4236a5a198,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells
keya800faebb746f17dc6a4218fd15376e9,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor
key343abfc192afd53a2e981e8d7642b476,Affinity for 5-hydroxytryptamine 1B receptor subtype
keyd086ea69eba2d10e7dd68c3352f0eac9,Binding affinity for human 5-hydroxytryptamine 1B receptor
key5b030717dbe9ea545a2db3cfdbf00281,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined
key108eeec97d386107b3c3d47b26cff15e,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined
key2ebc2f72cd6d302d1121001ccb9c2027,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested
key47d2fcebd7386de48bd3256be42326d7,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested
key757cc5ef8f34ea3ad174a4fa6a087e23,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested
key61c31cd0459ed337889a183ca0abdf5c,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested
key5500b6720281212ac75c7b2110f0054e,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested
key19cea040a49651dd1d47c78cd8b3f4c4,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor
key3a1579ac715f3b1ea6183aeed4d1ee3d,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor
keyb02665755256318bc5841121e5553210,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor
keyd293b6d75f5b122ea4b5b442d3c89484,Binding activity against human 5-hydroxytryptamine 1B receptor
keyd293b6d75f5b122ea4b5b442d3c89484,Binding activity against human 5-hydroxytryptamine 1B receptor
keyd1b86b7c0c50212b10a8c7c6834ab76d,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand
key08d87014eaabda94c38482ec727f5a4c,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined
key2f93bf30b9a20d2c707bd8c8da5059d7,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand
keydd77986de18ee657ce70bbddbfe8982c,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells
keyede601a130af4777c798df62b2b04794,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand
key0ba7c58b898696703e180089ce8c4558,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
key986968658b8e03827c90005c23bdd20f,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
key2246cd3bd2b143563b374cd987aa7051,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.
key27cece887000f090063d9d4f26a0fa49,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand
keyd086ea69eba2d10e7dd68c3352f0eac9,Binding affinity for human 5-hydroxytryptamine 1B receptor
keyf8f9ff3f7c48d32100421b07569a2eee,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT
key76e1dc6cfed334c0020cfba7c146c9bb,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand
key99b36da849a7d754d9564d99ec970919,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT
keyd9b054cac7c9ddbfae54060bf571cfb4,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand"
key5cc30d2524266d5be60b3d26422390e5,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM
keyb9a077ea379dd9f9d04fb3d92532c8f2,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM
key1ed788648e0bf6a57ad490cc6c4788cb,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor"
keye190fb2005a49a888528bd9d32acd1b2,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor"
key7a9f19c03948db59838f520d52d5f16d,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT."
keye5057cca3f79c330d9b2e5cdb01cc346,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.
key6989c9aeea6facd0a474baf68809fdb4,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor
keyc1289e322d9bdea718263427fbfd4bb0,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model
keye52bc524f056d129de78507b101d85d2,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).
keyf164cefdf9006b9815452a0225372c8c,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)"
key62bc701d661425b10c6dc076e752b43f,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).
key21ffc97086d37b2a0fdc861e9d3a36fb,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand
key0a327b57e497e99c2b5987612ed75edb,Binding affinity for 5-hydroxytryptamine 1B receptor
key79ba320085d826de7d3042a0c8807e5e,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active
keyaf1500a34f40afd69fd8c0854d6412b3,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM
key6513048a9f6287369a82c5d325949705,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77
key0776e7fc7014307e87a93761a63ce9aa,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95
key1d17b57cd38f09891773ea8f746f5914,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980
key5df39e30bdc28946b788299b44b04d60,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140
key1b4c0c00baab417a80d30fd024320a1e,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130
key185ea13497466065c595406c436c1a66,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280
keye096d6d349936e502e666345cbec25ea,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.
keyc6e1b99ec55b08d3df0002324d6e69bf,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand
keye70b7fa353b930c70b9c6a05682765d9,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate
key3b7385bf6a64862c9d61776062415c66,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.
key1d4129f44925c4b13bbaa66dbf5040ca,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
key09218226fb6383bedfa341d97dfcbbbc,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates
keyfe621a2467bb7615a95f8efdd0abc446,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates
key3d6f5347e2296b72d37fd9620b3b46bb,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined
keya4373c4f4118862b169a39c03a0e22bc,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined
key91b0d625454dbd522106adebd81629ec,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined
key16e612bbb40b8a36562dea3c213d5410,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes
key30f41e879c960dd28ca69ce9c164ffa1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes
keyc86074bf8e0af0df46a232ca3a47de76,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive
keya97cddfbfd3d96c72994a85d9e676777,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT
key503285bd60e16f562c095178b4a7af3c,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.
keybc2b0460eafb331f39f96c5dcbfdc4d5,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested
key838ad34a7da9809a08dad6100acebf5a,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor
key5b3d5473d7ccf4d4c50b28be7ee205a3,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor
key14df035c68fd36773e00f0808fff0a31,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
keyd47d45b94f562abe9ca61b20f723b196,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin
key9e7d8f007fc61819960905df13554246,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand
key4bfc240890eb4e6a07536fef662738fb,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue
key1f4cfecb553c04c3983fd1a6ba7ceff5,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
key0d89e138073857fd947ffa2b0376ec5d,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor
key79231f959b85ab2a9a237695611fd7dc,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor
key6b3f508319f972af1ad56f54a5ef7e49,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus
key0f5caa49094cb0cef3c2a3a4cdd21591,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.
key528257e68a9917867cd15583bd06b360,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain
keyfb64e3b0d71e2130a5bac811a95e69a3,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue
keyaf44295a459724a04ce846d31d722f43,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells
key770d933ba560f8a124fbaf2e078bf32c,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand
key66c67f2ac304dda9f54b58e7966e8d8a,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined
key838ad34a7da9809a08dad6100acebf5a,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor
key2cb569a90141a85b95427280af65f495,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus
keyd5ff80a14c3ec5dd2d23607e4d659c95,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active
key671c2cdc546db65928f53ccbb038099f,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined
key4bea9f139de164725753a601c8d68bd1,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates
keye49c3d4908c27cfb2d0d6f4cb28dfc19,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.
keya47b2c903bf110900d0b738f0f609d67,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT
key37dc261793b309d37a4bc789f360c180,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal
key42e265133ec1a12233c731603248ce0b,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.
key78dc8a724f478ff49571fb972532a2bd,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT
key02867e26d7bbfb12bffa955273a5002e,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation
keyb0d3e1d0d1b9006ecfe2e09f55039e17,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined
keyfa9e089fb43a4a7c93c8941f9112a378,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.
keyed2b7502f9c0d267c5babf1e1353ad7f,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2
keyfee206a51b45ebb73c8ddda266ba7b19,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S
keye2a1ae56fc8ed70e3aca0817400cf3c6,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.
keyde2782d5c06e470a868fed81da19afe2,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations
key9bcab390046d5f332df0c24d69332608,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.
key347a3f8b1662cbbadfb92b7c9c2df815,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus
key347a3f8b1662cbbadfb92b7c9c2df815,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus
key30247d7f098ccbceb6370df96d2e0757,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT
key077b30123c2e28513f56a16684c202a5,Binding affinity towards 5-hydroxytryptamine 1A receptor
keydf4c09e409ad495ff38e2faa205e81df,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus
key17bfd013154e8b2670a9e8a87c802cd0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus
key7662424870b0a0e9d16ed117917077c3,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand
key429ca8bcf4427cae26631bab62ed01c2,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.
key88ac4c41ff820c687cd4a5e6833505d9,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand
key211767b7848bec49524ab45d5773338a,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand."
keyb2c9ba2174c755e84f4605870ed13856,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
key2dc4181bdf972f33518e47d455931777,The inhibition activity of 5-HT1A at 1 uM
key110e7a2ab9528de937375af1640c6861,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand."
keyf796f66b3fa1f64298613fc062a0d99f,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane
key8ec491d8a8d56ba4e521fd81a69affda,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.
key1143071f76f862f6380b2fa3f5be5f42,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
key96d893f8e0e5cb2c58c5240e06cc7e3a,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
keyb180f7a76384634cd55205e398410d53,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes
keybc90a208d6b3050e5c081eb1f18c9509,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes"
key93dd2f21eec8a17d01b6327416c566bc,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.
keyf0a99e11ce1e1d931d2ce725463ca9e2,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.
key07c4cdcb6f089dab02c602fa239f0d2d,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.
key69949ac5bbf379098b9b0c05af4af947,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.
key87a061002aaeda243ff32e2e0668815c,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data
key0f583b2d0322737cb4be7e369ae7ca1a,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined
keyffd63de560e22b90b131b58aa351d815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data
keyf1d025cc5cf88cb6a9cfa092d27024d0,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes
key629267d95bbe8cbbcf162adcbada43db,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested
key9ff2ece0901ba708e3fa55522262605f,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested
key77fab401c28ab466223176d7791bde8d,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested
key749dc1dfbce36cc6e314f16b684f1f37,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested
key56b541507f7650b5ad8a56a4d305a1f3,Ratio of binding affinity to 5-HT 1A and D2 receptor
keyf089f8dfe625319751b7fef3ecd1bddb,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM
keyfdddaaf3c9e3fb1a6424401f36beacd3,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM
keyc9614008c4bb990feb386bcfb6b650e6,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.
keyebd608564b82c9f3c9c963994ea31a86,Percentage inhibition against 5-hydroxytryptamine 1A receptor
key41880bc283cc3e37456ce9baf2d706f7,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1)
key41880bc283cc3e37456ce9baf2d706f7,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1)
keycd69cfb9abaf81a8ecb85995ec5f5ccd,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2)
keycd69cfb9abaf81a8ecb85995ec5f5ccd,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2)
key321b301457c95752e9574c618829cce9,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.
key7bf118fb8f4a001024d495d8399548ce,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
key8835a35ed49657ee5d3b783fc583852b,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand
key901549ce04322468bbd6c26424ba40b5,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.
keyaa38d231d29aecefa6ee9ea27dc87aea,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
keyd7b756520da4d155651ac8cf073602e8,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.
keyd9d9bc0a5f7d760188f4147cbcc7c6a7,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.
keyab4eeb20f4a513173f664c4d5f6da6ec,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.
keye499109bc6ed34e7e7f2cad4410faa10,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydroxy-2-(di-n-propylamino)tetraline) binding assay
keyadae7dbade534b215f29f6c9749b0f5c,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay
key96cb70139921a59d2913e214ff4433dc,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined
keyf2d3ca2ccbe7becd9e4de530b9e82362,Binding affinity against rat 5-hydroxytryptamine 1A receptor
keyba65aa1f506d1ae2c6a08ae6402cc9dd,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates
key2f4e2f12d62495417cfa3741e77dbd26,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement
keyca69854f75287bf7e22d2b7498dede5c,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
keyc9f02f2b10d101a75fc43feecff5ca0f,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand
key4c492eb8f9bf2bdb8dad6e22cf5e2cd9,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
key4aab439115baf21ce1bef635e8d1e94f,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane
key5484768c8b1d4d290d7b636c5e694dc7,Binding affinity at 5-hydroxytryptamine 1A receptor
key4b23a22b08a42628282e88cb35fbc7fc,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes
key05e75edfc85505d343ab5dd53d472f65,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.
key25c04754e8b7f415de2f9f2d6edc3406,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand"
keydb0fc04efa165ddbf386cfdbe6ab00bb,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex
key28f8a74fbf1efc0eabf3687feb1d36f5,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT
key0c3ec3391b75c14d8b8fa39e86e90c23,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT
key79570a9d4c98c707a2b3775283e943d7,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand
keye7fe0a2733521a4b4e0b22d235e3c82c,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
key06eb091de2c2bcdcd4b6c0ead62148b4,pKi value against rat 5-hydroxytryptamine 1A receptor.
keyb9812539f851de6c72ec3e6c219d83aa,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.
key77fab401c28ab466223176d7791bde8d,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested
key149d3135ea213a8d6a2e50d98c576c43,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides
key68cec648a4dbe8ef466a6d3ef50c6c7c,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
key5958a99dc267e383f0a44231472ea512,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated
key801aa1c91e706f3d0ddb07fdb83e7304,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker
key5855ad15cfde2297216454ab6064d2e7,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.
key1cd55079333d3c911a1f657e9cdd8ed6,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
key54307244808f33bb6408a09ed97dd9e5,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand"
keyf61f8cb079f9f810921756dc62ccd6f4,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor
key072ead9f5f252db502abd81ae4a269de,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT
key077b30123c2e28513f56a16684c202a5,Binding affinity towards 5-hydroxytryptamine 1A receptor
keydbf97c3fa144c7da2f76f5d9f414d97a,Tested for binding affinity for 5-hydroxytryptamine 1A receptor
key91b5ffd648986d54569bd6ba8df753f4,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes
key50d43c3be2b8f2dfe57838283a384876,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration
key65d867c5bc00bf490d68dfeff1f190e9,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor
key5e45a5b36d1e02f55378aaacb5666278,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand
key077b30123c2e28513f56a16684c202a5,Binding affinity towards 5-hydroxytryptamine 1A receptor
key5bad2eee247a7345f8ba98b572148abe,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM
key9cadd406ed9f98d3b21b7e225f401047,Binding affinity against 5-hydroxytryptamine 1A receptor
key1f91f20e093141599d6888d49ee3c915,Binding affinity to 5-hydroxytryptamine 1A receptor was determined
keye5c5d042582c3ff69597e2e926ab09cc,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.
keyd767830483188f5fb836ad57802fbfe6,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive
keyf98d28c24f67f4a5b9e1b46830bf3f61,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
key2771c8a31093494a0354587c034f8e90,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes
keyc61133faaf0ffd0ae84ec73845c6e647,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
keye27ffc516f57d5602900017dce1acbcd,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus
key870e7c7e1d52e7a086af9fbacb658b8f,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined
key1677425a502f22eec3d9aec0d75dc6bb,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.
key5d66ad3c98f018ec904265a831c433f2,Binding affinity for 5-hydroxytryptamine 1A receptor was determined
key5d66ad3c98f018ec904265a831c433f2,Binding affinity for 5-hydroxytryptamine 1A receptor was determined
key8af55a429fb293e4a558486693fa29d9,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor
keyc3f24a47ae18f5b5c2fc580efff80142,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
key746eea45aaddeaa70ea58fc578d7e06e,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand
keye401c95c73be3da65e16971e308fc066,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor
key1fdb8690d17a574a9c039d3784eba715,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand
key051813bc9cb2f9333be8e646534b7a1b,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells
key924344a0b29fdd7f9aa95d6842ea0e1d,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
key7ece7d67a588f251f3c9c5070dc18521,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration
key9cadd406ed9f98d3b21b7e225f401047,Binding affinity against 5-hydroxytryptamine 1A receptor
key9d7142b8489caacdf0ed975d0a273aee,Binding affinity against serotonergic 5-HT1a receptor
keyec20c1ed4b7d0fc137440e90fca9cbd8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand
key4129eedc046cba005a91b0fb540e9973,Binding affinity for 5-hydroxytryptamine 1A receptor
key5484768c8b1d4d290d7b636c5e694dc7,Binding affinity at 5-hydroxytryptamine 1A receptor
key1599eeeb394bc3976422533ac12ec120,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand."
keyf98d28c24f67f4a5b9e1b46830bf3f61,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
keyf98d28c24f67f4a5b9e1b46830bf3f61,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
keyb3744b3324fb6b8bb862b7f3d1df5fde,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor
key77a6b4044a0e33dac6d215a4154ee730,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand
keyc4cb7bf6bf48e26555b8e1826fca1bce,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor
key578636f6cb4b3a4d7ccadf30bb230fb5,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity
key65747c999ec6988a31aa26ca9549f0cc,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor
key9cadd406ed9f98d3b21b7e225f401047,Binding affinity against 5-hydroxytryptamine 1A receptor
key7cc664f6aff4e706b2a244039f9781f4,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay
keyfb3eb81c73a8bc513d0f30ec08a06d91,Tested against 5-hydroxytryptamine 1A receptor
key4e8ef2964db9e765662fbd7eb5dae6fb,The compound's binding affinity against 5-hydroxytryptamine 1A receptor
keyb7ebe722899059d309c0ff85e3b857a1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein
key1bfdd0707f1e6ceebb5559d76a6f5464,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable
keydcbd1bcdbe44ef11ed467d533a6c0e5a,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells
key735ce59ae8f1f447e890f091ed916f73,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration
key06a52626c44e2012a63370e0174fa49b,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration
key4600c2475467cbaba57ce738d59869c8,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery
key88388ca15a2845835198c50b266d8f74,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined
key398fe62f3342f97a063d4b4fd2b66559,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig
keye3e3ded3dedccc84b1a7d8ec4958e4d8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done
keyd71b9d183fb3cf792df8f5040d8f2710,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding
keyc7d815499f598c3c878185ff3b1d54e7,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT)
keyfef714a5f3d72a3b0710e9659f39d1fe,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT)
keye7af70830accade10167ecd78b8a3098,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation
key682dd32bd2d6316519d8dfe7e0411903,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells
key8b669338698d44197d0f1b5a6677ad9d,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines
key1b12bf21ef1663fe69d0152cfeb355e3,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor
key9c67e20032aa6c356656fa3490f2fd84,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist
keyf2c52a87af06ffd1cd1c828ede43fed4,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor"
keyd809dbcaaac09a254337842db4dcde05,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line
keyfbf4d1ad1e125e295ba981a5cd9c4329,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist
keyc74393b24bde58292436fffe2172d07a,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist
keyd21dc9917f9d30ce21d3089c34b018dc,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist
keyf215f127a3bcfa1145f4855cda7b7ae1,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand"
key092c3840694c0444dff8bab32f426da3,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand"
key7b6c3d74938fd3d844e6c9015dc1094c,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor
key753c652f7cda9892cc9c9b2c634ba1c0,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro
keyd14b919c5cdf95a878dea34479746b41,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique
keya505dcefe8536369eb4f71b1477c219e,Binding affinity against 5-hydroxytryptamine 1B receptor
keye855673ed96d4171c0098a3dcb685b3b,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells
key498f4c4bdb2df60f7909cd54fd1272e1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.
key73633ebd5ef8423dafebec58e14d8a8a,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor
keyc8efb470c233aaa44693f9dc9e267670,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells
key40a8defa1da15de595af5b634f22b335,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.
key537543ae5967ab3a62dc5f438a23ff0f,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells
key8c008e05772b8067d4d57df11193c3b8,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.
key2e8bb2ed42f9082763b42890cf8e2ded,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells
key568d89d1345c7baf7e62bc517b51f189,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM)
keya5dfcb59b2cf5be72b8eee1c70f9a526,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response
key050d1ea1a464e2155e46f8cc9a724a12,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
key6e40e56cb921499c1de3c4b8f47125b0,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
key342fc7ec05555934d045d900fb06988e,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9)
key4db588ad9a3bc04c95c312c83313a1af,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9)
keyc72e50aad305cbaca551e694232a96f2,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor
key7d914b192581f69afac9309ee487172a,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype
keyb50520eaa1ccc57f6f36b2ae73369e86,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT
keya391ff3b84c0856371f074ac575e8a7e,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate
keyee4439d3e188d767a0f2c4247ccc79fd,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra
keyef5de8f2b8d3b8e7780579aea0dce59b,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.
key574b7df7be0a0a75f48269e67f8d752c,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand
key574b7df7be0a0a75f48269e67f8d752c,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand
keyb15dce741215162548824366b25c79a7,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand
keyc6caa8fb408c704f647e8f3842e80157,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand
key21cba29066223a4ba73b1d174f593813,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand
keyb0ef7fd54caa8dc58511aedea6717a12,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested
key129616c165f6344ac5b489780e338c9c,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested
keya239c4df00927df92d160ac8231b6f07,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand
keya391ff3b84c0856371f074ac575e8a7e,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate
key37bcf58f482416fb05f84bfd78ab34b0,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate
keyd4a4b22315f4e37905a18200521691e9,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT
key129616c165f6344ac5b489780e338c9c,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested
key08b09db1bb237c329a896e74be9e87c4,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP
key39b152eceae53203842cedc7395d500c,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined
keyd306b138e66b1ad57237fb704de9dfa3,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
keydf1e37d0da10780c9d00b332f4929730,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate
keyd306b138e66b1ad57237fb704de9dfa3,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
keyd306b138e66b1ad57237fb704de9dfa3,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
keyd306b138e66b1ad57237fb704de9dfa3,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
key09e4b08a5e971593120c19c07e953a5c,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells
keya37c1ddbfbb6adc442e1d44bf8a88aa4,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra
keyc00b7f28449c20297a1936c1aae78242,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested
key234fac2d297e7bae3e7ce636b3c0615a,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611
keyefff43ae95aa79498d22db9e6ca96f0a,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
key5aa0907c531cbbad9b71e28739b2c688,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9
keyc29ce0a9d619c6c3d37ce685a0c42d96,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4
key601c82768eb5046bff2482fbaec2d782,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2
keyd048af33806db3af886eecbcd92066a5,Binding affinity against 5-hydroxytryptamine 1D receptor
key2e370a7c94def7ede57e460a17c19bda,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined
keybdd6112d3e06be732dd21cda7958e7ca,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
keye2050bb1daf42a4b3a74b7fbe279fe4b,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
keyf643465d67a8d0f3bfeb58521254a632,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
keyf50cefde28c6876feb6fbcad62f502f3,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig
keybd9834ca976eef5284ba153514e424af,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex
key0c0c21c06b3d816b306067ad95909b9d,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor
keyb2d2ce0f2a95d95cb86551b5c144457e,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes
key6e8cbbe598aa2459bc3aa613c7e8043f,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine
keyf7d6f5752aa8f7e3867f4445e1912b5f,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra
keyd048af33806db3af886eecbcd92066a5,Binding affinity against 5-hydroxytryptamine 1D receptor
keye78332f549cfec68716f0928d437f2d9,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta
keya362be322630e8859381516ede61dc17,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor
key3f48d12c92cc147c922c19c92d2580df,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor
key23d754d934dd807b2a33c374acc5336c,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor
keyd5b6d26b4b6f51a84b966e5f43cfbf5c,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor"
keyb5e716d101f2cf763658e3c2ba44598b,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor."
key22a054b109867aab1bca439a54b0b4f4,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor
key53cd68a27eec24d3eff1e7353328a36d,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor
keye2713ffdbee40dcb334ee746c3cd3997,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor"
keye2713ffdbee40dcb334ee746c3cd3997,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor"
key0663768cd2a464f62cae1f7486437ed0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor."
keyd213fa3a46248afb014a0acae07cf5ad,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor"
keybae8a74f3077c0de98756b93a378d6b0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor."
key369bb9c7db63ca91b562bbd022126431,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor"
key4d33f22019fd43d35c356df3f338a3cb,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor
key435fa7a16afb7d702296b02765a685a6,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor
keyfe292c6e6d554456e45ca68a0966186c,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT"
keyfe292c6e6d554456e45ca68a0966186c,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT"
key01ce4e19d200f9cc8c7afbcb90d1cdc7,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand"
key4e0017f2f3c35874459bb770fe6d0793,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor."
key24ef65ac1e6e15b26cfa5fd860f6a450,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT"
key5d22b036b523a78bdde0f2ec91f0e0bf,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor
key892e146bbdb02801bc1bc340a2d673d2,Intrinsic activity for 5-hydroxytryptamine 1D receptor
keyf07e6697f720d7ed9af97dc907f4e05c,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells)
key8ffacc42aa0cf43163f8c0b3112272c9,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro
key3502ffd70ae01eaedfeef078e6915380,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique
keya99d35b47945e961a992d26a03a70e4c,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
key5ff360823438a6492354d98508e2a7df,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.
key6d0d04ce01ca1e9131e6ba31cc5309bc,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor
key2f12ea35af132333e9bb4ef3aa83416f,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.
key15b8de90fa747bb3c07e155538fe3739,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
key8200a4abb614771a92d10365ef792771,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
keyb27e16cd6c2c48473b7b4d0e639ee72e,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
keya99d35b47945e961a992d26a03a70e4c,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
keyb623fc152be3110e63a9a09d79627c46,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
key80f790cfffd81550fcec349b449a2672,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells
keyfd706ef076d53c5b1bf138c4f6037eef,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM)
key3cfc5aa66b3a132577158be6e8def0d7,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM
keyab96b159fd6d5b6d0abdb1059490e272,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand
key603b19c663563f3f8c0c8c91d6ed9430,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand
key55d3d9617cab8d695b97c2c9a81830e2,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor
key997ddd8ac75d631e3eb4b1e52d76f9b5,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand."
key2f269ea6d2e8e5f0f240f9c123e084a1,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand
key990b46718fcb1ebde44ae259368c6e13,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand
key3f4be889c18a129cb0f81d0e9b6b7663,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.
key2a22c2c71687d59af76b877c524db840,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand
key391bbe29ba5b73333659d282b765d5e5,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor
key42304e44226c5e4dd996a3c3d93bdbfe,Binding affinity towards 5-hydroxytryptamine 1D receptor
key54350392aeb2c06fc5f208366d7b03e8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor
key86e6023c946a1302af35c2edf3e3c736,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand
key46087baa76e5597c9a6cfde22bd7fdb1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined
key4437d8ed59b828b363ab3a96e64f7a14,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined
key326f2c242c1528ed3fbbbc0511b6f90e,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor
keyef979141b245e6a194ac47a950e675d4,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells
key44f749b8cec7cf205b6b6fdc92e87dda,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells)
key4b60264d1242cf2c72e716605aefe622,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor
key6e4f000f764bb1f51298d5b082684594,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor
key4f967841f588ea9f775931a281bf8481,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand
keyf52ef73708a864a44f61703f65bda371,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor
keyad444c44ea7947ea194a2579f19d5488,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells
key0c7525c1823b4fbe298588e040fad514,Binding affinity for human 5-hydroxytryptamine 1D receptor
keyfbc55fb7090c31b55246b21a58df1b2d,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity
key8c725da949405fc905ecc9457f499250,Affinity for 5-hydroxytryptamine 1D receptor subtype
key0c7525c1823b4fbe298588e040fad514,Binding affinity for human 5-hydroxytryptamine 1D receptor
key6e4f000f764bb1f51298d5b082684594,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor
keyb3d67d47e8bc935215a8daac28f7b841,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined
keyd66f23002321d000054a5811b1d7fea5,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested
key5c11cf7bd1ff1fb0fa3fa27949723dd6,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested
keycdef19c6c2e3b3e11e7941da95c60e06,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested
key21a04251aebb23f6b8fdf6db96b7688f,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells
keyfe7154ffb893ceb5a94322b9328669bf,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT"
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
keyf61cd4dd5379b9d1d4c5aa9917deffc6,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
key66f70193b03f1eb6c62685c25c3e4bfe,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor
keyc8e4ae67f94961b0333732dcdd8fbe9e,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor
keyc8e4ae67f94961b0333732dcdd8fbe9e,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor
key4c130d37a81bea267e55242c49978e56,The ionization constant (pKa) for the compound measured potentiometrically
key7319fa4f4df9733aca2237ad2b8c23c9,Binding activity against human 5-hydroxytryptamine 1D receptor
keya688b630058e400f90bc55c015dab232,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand
keyb6d11665cdabdf941aba0555a4ced389,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.
key7506f0bea28de4b65897f7a62bb8d9ac,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
key54350392aeb2c06fc5f208366d7b03e8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor
key6bc9c34ca15bc627c332ad07d2c1de58,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.
keyca6a6ba14ca3520db14d4041da7a6cba,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.
keyb42c53e54db1672fa891365d68cdd52d,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand
keyb42c53e54db1672fa891365d68cdd52d,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand
key05703d0fd3b761b26490af1cb886efb1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined
key984c821a5da82367e698ad23e8a3b25a,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand
key0c7525c1823b4fbe298588e040fad514,Binding affinity for human 5-hydroxytryptamine 1D receptor
key3eb237ee9cefb92fa7e20875c39f01f5,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT
key50b7a534496455bdc437a3cd1671fb14,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand
keye57faf702204bdc1ad221f2c5cbc575c,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.
keyb8e4a954ce1a48ec3c60a3bad9e04f29,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand"
key1f119c5f65b9bb4b161b97e51e8b9985,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM
key974a56eb2b137f43bdc3c7888f13b67c,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM
keye411960917ca43ac7c578de857b8083f,Binding affinity against 5-HT2C receptor
keyd048af33806db3af886eecbcd92066a5,Binding affinity against 5-hydroxytryptamine 1D receptor
key601bfd11df44e5c06d7f1c3cd48f034a,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra
key601bfd11df44e5c06d7f1c3cd48f034a,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra
keyb9c573e2ac8ff7dae5791215c91fd67d,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus"
keyb4a07c2a49b68d5410d906d2ae76228c,Binding affinity towards 5-HT1B was determined
keya5aa4506a153f80537298848937427b7,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT
keyd221851e58a8407cc546fd66f2e10b6e,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB"
key6bff23ee8885fd99d153757eae4aa950,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB."
keyb3f89159457251ae6d9cacb30bc55632,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
key7618f59a54995495622a322d31ad73df,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT
keyaf1500a34f40afd69fd8c0854d6412b3,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM
key0940dd0a3681da3d897bdd1ab4c89d59,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM"
keyd5b14f6f026a5ca74fecf927dd70eec1,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane
key6b159a7bd3f09528864ee99406ccda8d,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%
key8e1dcc84ff90a720edfad175ec39fd8b,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor
key58eee23c0fee2167a1175903d525d510,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.
keyafa0a309fdd601f0cf789e6349d3953e,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum
key0b26d68801604f6ecd19555724a6ec90,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT
keyf8416e5c5bd73c0c8eadd7f628a1fed0,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue
keyd8b85841dd00361a9ad5e92268d86ece,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane
keya9aef1374332a769413d1048c179a4bc,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M
key789b9264a168b1c10a12921da0f96ead,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum
keyb4d98f0bc342517902f3d0c0f78d6103,Binding affinity against 5-HT1B serotonin receptor in rat striatum
keye9eab53f63fca195bd50979b66dc1c36,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex
key23ed97f613160d4a3d5c0638d0ab6d42,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.
keyc17ff3dada1654ef5a8d81ebe7719c8d,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor
keyc35dad9216f67ff1a3a7375e03d3d177,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor
key10631625a17558c4ea6ddb817d430dfe,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum
keyd2140845bb44e95ea4d68fe1859823f6,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.
key9e326a137e5249ca6281abb04b7fac6c,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor
key47040eacd77926064ba57495d7b30b4b,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand
keya9855b7497c4d65170176812559755bd,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay
key0a3857854b94cc2bfe603cdb5e8f7f80,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.
keyc746b21b379bd1a04b28225de6ee6731,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT
keybc0d28c699e685c81261fdf0f2b6b0c6,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.
keya29bfcea4d0355fff8953c7c6b6c83f1,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.
key0d1cad80548e1c28820b12f99c85eaa0,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor
key00ce41dabc1b598c2cf409fc20a8933f,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand
key1c18d43c28af83540169def5538f3bf5,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.
keya8fe60493f7a9e3cc21836888d881f83,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity
key79389664e80d5c78ab077a5971dffd07,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand
key8a7c6b7a4d183bac2d0e93232a71a00a,Binding affinity towards 5-hydroxytryptamine 1B receptor
key20628154ddee258518d7274e649846b3,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex
key59baca7e70b6be4a74fd0ce595a7a8a1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand
key8e6bd730d837c0b30fdd75b24ae19f56,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.
key4d4519a291ae1372dcf311a44f010468,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand
key9eb50f107ceffdcd2ecd9e1485a240ab,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM
keya6e105a0cdaa860dcda2751d8fc59a61,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
key78ea616f584ccd95b5f4c3508283bfe1,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand
keydb91c4a8a98bc7bacbae2c4b8d16ab9f,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
key9873b1d49c5d0432be23985ab398bd80,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine
key982434435ed9f0851d0ae0d184956e4d,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor
keyb1dd727b75552c2a4528094b9cb3b237,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate
key43a0bc2a2ee9a744b554c3b3c6da0777,Binding affinity at 5-hydroxytryptamine 1B receptor
keye0b7054b507b558a614d60cb27a8676d,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand
key57e6939338291f126edea7eec2b82ee2,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol
keycd0e394177e21b259ab628e10f308492,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand
keyf45b3a04c424bdfd88e39f70fe96531c,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
keyed2339e538dc9ffc14fba32ae6c44387,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex
key6cb7fe452529a1b494da4ccaf5bdca31,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor
key6e0249ded8dbe9e56a323b579c4ca10f,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes
key76f687fb1cfdb3cd3d44d8086fd6f4b2,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand
key2496e3bccd5f8a4cb053411efa7c412f,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration
keyd3aae1148ed67b95132fdf898b0103d4,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor
key53f45d39f9e2993ac0f65fe6c21ca016,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM
keyb7451ffa6f0fee672552fbe7c84eb0c2,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined
keyded7dca571491a72a59a0fb714d83f9f,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.
key6c0fc87a10034f7e6522467feb2a6f39,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.
key1a90ab3375d9fcd438ddb583fabeba31,Binding affinity for 5-hydroxytryptamine 1B receptor was determined
keyd35a06daeaa60cb79241bded45fbe4d0,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor
keya505dcefe8536369eb4f71b1477c219e,Binding affinity against 5-hydroxytryptamine 1B receptor
key1935b3f95fac268046fdb4714c58913a,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand
key139a8d452b2afe9fb4e54fbaed6e8737,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
key0e73768695f27d73cb0c962a1055db42,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand
key4ea90c1218dd3b25a0344ab10419fdd6,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.
keyd9062375ade38c6ed29516a51ca532fa,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine
key23d55a068a79f559656dca4ebc950290,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand
key08cf93ef5e43a726f280266f17301458,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand
key4041229dafca979bc39a4c0281ff76d9,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand
key221961796220b0d8e1c1ae9d59cd3d30,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand
keyfffff73d9c96a9a63333ba4ee0189574,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined
key58e45ca1f857e946e80672fb273ff555,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor
keydbcc8982ca73a2d10d070acfd9a2cb5f,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.
key7545f287709a7435230136c7f118ef0a,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus
key0724e4b497cb019e68e3b6bdcb3189c8,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor
key02557d1cf50d40a472b9d2c186f254ec,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT
key45558b8a6618b325fe40efa6bcf1ab29,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.
key92d38c8c256d5d9c2317dd3334fe0d2b,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity
key5e746590dd8247d3213f72eca3281379,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M
key5e746590dd8247d3213f72eca3281379,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M
key46b21c666dcc3d240d9f128ffeadba10,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand
keyf9275473fae4a496429677e1ac1df28e,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay
key23d55a068a79f559656dca4ebc950290,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand
key56bdee5f218913d0876859cf5ddaab71,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.
key2923fdbd94646bf7636f03d8a670905b,Binding affinity against 5-hydroxytryptamine 1C receptor
keyd6e49c56b09666c544288a22cc661a4c,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
keyf92590d49b2893f8130d14beb225be03,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
keyb25285214a5afc5e24dc9ec287ecfaec,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
keyf92590d49b2893f8130d14beb225be03,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
keyd1820ba9fb4948d7ceafc1f82f91cd74,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.
key41e21bcfbb2777f00846afa707a107d0,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand
keya8f4033b5bb3b1c2cc87c651b881ca08,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand
keyab2ccf4e0e218de78259aac9230854e4,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.
key6bbe86bbe0de69dc8d1cf24de0499dda,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex
key15c9e9b97ce4ff4447d33cc952aead8e,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells
key8672c69736643a9e5af61895240129d5,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor
key591282848633b3f42e6ca8df86c67ebf,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand
key591282848633b3f42e6ca8df86c67ebf,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand
key2923fdbd94646bf7636f03d8a670905b,Binding affinity against 5-hydroxytryptamine 1C receptor
key8672c69736643a9e5af61895240129d5,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor
key2923fdbd94646bf7636f03d8a670905b,Binding affinity against 5-hydroxytryptamine 1C receptor
key59b9997de0055b9d81d47ac58961ae39,Binding affinity against serotonergic 5-HT1c receptor
keyb0637716dc910cff9cdaf2dfdce545dc,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand
key30e88980d25580f2f35c181d044efe89,Binding affinity for 5-hydroxytryptamine 1C receptor was determined
key050d1ea1a464e2155e46f8cc9a724a12,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
key87431cc851decd428e48db6abe22fb4f,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.
key02085179e96faff24dd5c14bb6a3e8b0,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.
keyd5cfeb7a949e87f0f274d5e8608b1523,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand
key345c14750d56bb1c4b1b8630637ae35b,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein
key2e12773aa094ad881985e2a20baa0bd1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes
keyd0423b0906c12da3390e9ac8b7f7314c,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol
key060ccfbcb09a77c6a3d7eb05e287087e,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay
key2037b2c6b2ee2fd7f04f649a11ea0b33,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol
keyb6ff20c2377bcb381ba93ef7d6a67751,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.
key3bf1357ddfde8678c9cca37a02d9050e,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
key6b4ae66d3b7439c875285c3da429385a,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay
key382932c42811614362f0aae17063dd81,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.
key6df452517bea8c955900baedc479d3b5,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
key6df452517bea8c955900baedc479d3b5,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
keyf5fcc7188b484308e9820aaa48e64cc2,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined
key18b0a6367e171a8eb3218ee4d1516600,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined
key6df452517bea8c955900baedc479d3b5,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
key53f5ebca6a56722dc371a9581f35e1e5,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand
key1d1dfb9778119dae46b21a798d3226a4,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand
key8df3da0ba92298422d71d58bedc7b613,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex
key21777173092f7410a92f69ef8b145ae9,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
key21777173092f7410a92f69ef8b145ae9,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
key884a8d700e7a4e22b981ce5df5dfaee1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand
key82885b9fb46f503356995c7c113cac17,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.
key8e5b489c0b262811cf385baa0e35dd3e,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol
keya29279a6c0a291b5600543c01e7c2565,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.
key44f2f8c37ce34eab7ba690df51517f32,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.
keye2f7de28bc69bd0ea0ba6e8e3b6cad6d,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes
key3b301870de6bb66feab41cb8f62ebec6,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor
key968689802e5e91a162e08aacdfcd8e67,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.
key3a2303bb6666c9dc2856cb614018a845,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.
keya39e02700dd7a7caad19b3cad41d778e,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested
key4a65382cb30703368839ff0dc0450e63,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor
key3301131956a2d826a9fea82fb427209b,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested
key3ce035b6bd5ef8c31610bfc5e25ceaa6,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.
keydc908d47a550923e0fa3dd84e5d9464e,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor
key8f665295d0a46bda00acdfe046b42557,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM
keybb837cc2b944caeab1859d319c910b8b,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM"
keyeffdfac7a6dacf912f52bec0f9c2c443,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone
keyb1d45db0e3b68997add0c49d87bc60ae,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive
keyee1679e67c08642f3b4a22d9349f76e0,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.
key0889d02aa9f86b8b28c3fae47ef8711e,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex
keye0b3bd2382b6568753c3e004b642774a,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.
keyd6eed4a8a1cb7bf1bc10600818435d1c,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M
key708d2d69661cf19c98cf77e608ea0255,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin
keya8602ea646035b93e980e17772bfe8f3,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor
keyd915e7c6ec85649c15386cbc6bd39ce3,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes
key026cb339808382497af1ca8754ad9ea9,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested
key791f8ea3b4384088a555479aef08b578,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.
key116583e69c9fcce4b80d75db638e5cab,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex
keye3135043e0506a2ef0031782f77f2277,Inhibitory activity against 5-hydroxytryptamine 2 receptor
keyb0698475f1bd8b02e434444a377ea174,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin
key3e01261e3ac97ee1b5c6b658e6753cca,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin
keyfdda16b324991abe71f5c8b44050eb01,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat
keyf858ed1dcc1f2fe3b67bdeca0cb598f1,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex
keyd7722bdfad8a0fe4518cc264524d42a5,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone
key0084ab5f3bb10338592497278a891e77,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
keye2f7de28bc69bd0ea0ba6e8e3b6cad6d,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes
keyc24131985a8a58d2ec499223131d5c15,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats)
keyab8c0f5cb981a712496ea15b518c2345,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro)
key567c37c46e8644193243e3a34069df54,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
key9c0e729353b47bc9fb34242280247ab3,Binding affinity towards 5-hydroxytryptamine 2 receptor
key204ad6ea58c483e8b7846ba742c01e66,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration
keyd6eed4a8a1cb7bf1bc10600818435d1c,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M
key687465101cdca706d41b708da638959a,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M
key575ffac92a1deeb544e7fa4f8ac0b8f5,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.
key881abac3253bde131b5bc5af199f61fe,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta
key81c9be6b86fbb4257945a1caa49e365c,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor
key1f2477ea07a5eb65f41030d74cf441e4,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis
keyb2cec3a56b76bbdd7386328764919bb3,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand
key0d52739d6f706195080f3dfb7023d076,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand
keycd6d23cc7e00a3eae2aaaedf40b36023,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand
keyf6ec5af328c37507928ba38e068efd33,Binding affinity for 5-hydroxytryptamine 1D receptor
key3cb0c06ff2ee8ab8bef4df6b33d72d7a,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
keyd5aa11674b467c1878626daeee6eb4e3,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
key250d2ffe5b24c944703591fdcda9d1ca,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex
keyb4d75173803bca4ab0f7730b49a299bc,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor
key98741012279c8df68af9e3f51d9b7c5c,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
key5618c975abf90b75607cac27b24da730,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
keyf61cd4dd5379b9d1d4c5aa9917deffc6,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
key0b18349223a5de53cd5a25bac958f1c1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available
key90a5e36f3a1d1e20f01f0e38d1d8a6ea,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
keyf5ade9290502230add67b473221e152a,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane
key44f7d7bc2f586ae0bda2073e3ae09ddf,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane
key1b4e94a3d8da9b294fcd99eadb503d3d,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT
key060018d29fc564c7b084a1aa67867977,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate
key2fa6a8c70569fd8e622d9310d58a89b6,The compound was tested for intrinsic activity against 5-HT1D receptor
key2b72b8139402fbc0a07a9a1d397d0f0f,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
key577ae9bbb46c4a18333f978fa8097ec1,The compound was tested for binding affinity against 5-HT1D receptor
key85188f8ca4505fca75a3bdf666522986,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity
key48bffbb1ad830d989f825f0394b193f8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra
keyef209a8b7b8cdd98de64b5566bdc27d1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor
keyf4c0edead17d64f834b64bd0f2003161,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor
keyc818a33f06618866371c2d89fb25de33,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
key5766ef5e835078aaa325413b2a4c78f1,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand
key347a4564ca8aea4f4820eab1bbe67a06,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.
key1fa0c6e0b8d971a860b2ed80c5272281,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.
key70b798fd620120fdf5ad6abcb4880722,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration
key5556904505876647b27b40496a104ca3,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor
key617f9b91d4dfef0d73ee0102fd47f752,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand
keyddf611ba5a8cad577726cb1b3e858b9f,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor
key26791b6948073d4c680db5dccf1be391,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM
key1d6e81fb6b20e7b4503bb7d3ab6ca6ab,Binding affinity for 5-hydroxytryptamine 1D receptor was determined
keyb6ff748525066beaccec6dc91dab895b,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor
keycaf060ac0fccf97288a5d18bdb58787e,Tested against 5-hydroxytryptamine 1D receptor
key57881bdf13548b851e2c1c2be811f80a,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand
key343c7165ee36aa7bc895ccba57a629e7,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand
key4d3e7f1831f5ce38f8fec8f1145889fb,Binding affinity against 5-Hydroxytryptamine 1D receptor
key6229ac61fd162486561924db7473546c,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
key6229ac61fd162486561924db7473546c,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
key98fadea2c1988240848171d5c6cb8c44,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.
keya32f8203a7a22175b69bb0c7bbb45661,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested
keyf79595f11c1f6d05c00349e608646aa9,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.
key79096941995b2cfec6b96abbf8c8dc2d,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human
keyccbe39a2965e1a3e227afa41f508be60,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.
key57aaa608ce0fd8fbfe1eb147b9e6de94,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined
key4e1518d02dd51b0dd7ad245a8fa4aada,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand."
key6229ac61fd162486561924db7473546c,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
key5b0349cecac6896a7dc334763aa92182,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.
key6282f9d1ad0d61e0f50773717f2fe605,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
key131890e4ec8a01267e86b58ae244aaa8,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
key47e264d65097b588645373d2cecf7d24,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
key47e264d65097b588645373d2cecf7d24,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
key81ed06d92f93baf8acdf83d0588b5f24,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand
key5036757dc4bb4fa641b17bd347bfecfc,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand
key809c7da4641ec4dd682ad31fb1835a1f,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha
key4513559369d2ed953466bb4a44421eaa,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha
keyf17013b40f328915bc02ad61950842b2,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand"
keye7ccd1a7784dd5e5b512b78a67a19559,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT
key51785e74dec87ed0f3a178db62843b9f,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay
keya792bb54b951f4bea6a75d2ca692d13f,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.
keye262dd5d7fee6a880eae9b32475bf27d,Binding affinities against 5-hydroxytryptamine 1D receptor alpha
key1ccabcc8077bdf25947efe8fa0625f0b,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha
key1ccabcc8077bdf25947efe8fa0625f0b,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha
keyc1d64d88403e070609f1bf9495abb7dd,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand
key3924ffbdb83418dd2a95df5a0038bd44,Affinity against 5-hydroxytryptamine 1D receptor alpha
keya4a649068b0bd69ba46fa495e9769428,Binding affinity against 5-hydroxytryptamine 1D receptor alpha
key6282f9d1ad0d61e0f50773717f2fe605,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
keya3155cab8985c1e7df43e50c0813b658,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.
key9582939f2c2d4466b3b85e45440f66bc,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested
key7942d4774b6075fa4ffdf9939c5a6bf4,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand"
keyf79595f11c1f6d05c00349e608646aa9,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.
key579870166bce6fb4abc0b5a3df3f61c0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
key579870166bce6fb4abc0b5a3df3f61c0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
key579870166bce6fb4abc0b5a3df3f61c0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
key47de3215557a8b31fd47333f18885eb3,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand
keydeec66b1eefd5a8465f114acd0e470b4,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand
key10f063cb3fee449fa316af63b375dacb,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT
key7f5681de49704ff8fafbb03639e91515,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.
keyd2a4abfa718e887cb5c61c6adb252fde,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.
key6282f9d1ad0d61e0f50773717f2fe605,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
key787bdf350be2d20e3a054924ae7bfa40,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand."
key6c4ecc7afa17bd57f2f19a4e911d79e6,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta
key4eb2e41cb92019a94cfeaf356c028561,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand"
key09443dc8c98fd76826df8113813f3d20,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55
key014b9eac844ef1abff73cea59ae2b39d,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0
keyccc8480faeb99f7d5ff65b8bf618d219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5
key17d0fb38582d2e66702ff9524c5c9928,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70
keyd5cce176560f43810a20098d95b22d4c,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined
keya0c0b4bcf0b8d4fb3358121bf907318e,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.
key29fe716b7c61fbd8ebecc00e29691b16,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand
key14b85cb818d84b9c6e08250530dcfd34,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand
keye501636374e555edaa95f16b34bd4dc5,Binding affinity against 5-hydroxytryptamine 1D receptor beta
key0c6670b5802a626b762fe7473564ae24,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells
keye330262f1aa3f6ea259f3557973e9bb5,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype
key10ef132e18f1b1af3c00c958488aad22,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available
keyb1e68c00cae9f32150e62bfb2872abbd,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor
key5613c49d22cb016045d99756ff3aa82a,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand
key9aa7f0921c1c4e14f33a6fbac28d22b6,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate
keyf874ffbc28225aea43040c22ce0861b9,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor
keyae558fe82aa9e4840712ae86958d2f4e,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor
keyd04d9f8b73f8b09bf8b32ebc4cd23430,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor
key5ec9e6d1d880ca05b43ae4e08b1bcaf2,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells
key1276abf582100d91ca9ed08744437d5d,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined
keyb83cdc59a034e739988a37baeab30522,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
key2a21b2ac412516a3618f0b37ea787820,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.
key7e56f90c86954f85e36bdb623b0e2bc0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.
key2bc5de07cf0fb2a42ab6dce793b6b4c3,Binding affinity was determined against 5-hydroxytryptamine 1D receptor
key56f3cbe3a2ad496c6c1b2a0fe5371585,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand
key2eea784586eb19edc911c6a59539d82c,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor
key0a2ad4dd8aa54691d5d903b2a5e8fc6c,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT
keyeace8c78e29b705f4ac7fffa0a9714b1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand
key51ac3a21d5505ae4e6bdcb1ade9c90ea,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand
keyca967da0b49142ddaa6039719f854980,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand
key6cf0c5a2e9f7368a73eb752fa23f73d0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.
key556eedd30949d74aa1694c0286081c8d,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand"
key64b178f3d66ec5cbb6bcde8808e95e6a,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined
key008e14bcd88b2db8b30a079f0b4a5f02,Binding affinity for 5-hydroxytryptamine 1E receptor was determined
key45f6616afd239bf8ae0c8b09f29e3d0c,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor
keycf373953f911bc583b9a85d2fb5f47b3,Binding affinity towards 5-hydroxytryptamine 1E receptor
keyb8bfd498ed620692bd9b0e7e17951429,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor"
key0c6264740af842d1edcb31388bc47ccc,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor"
keyaf3113fab4335c55fdd2c5166fc1933f,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor
keybbccd8735f814d1e02dbe3537ada1447,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor
key20b7854c1a2be55d4782e76553554362,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor"
key3a8dcae2cf45ffa811913b5f0498e1a8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor
key4e45799d7a9648229c2c7f27e168ed77,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells
key661be7cc373469e9b24bb4966455a0ff,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM)
keyf54a079039babe6decccf18ceb9b7c91,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand
keyb2a5d502b1106f71d0c61445a8ef8b0c,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand
keyec1266f0887c1701db01c8ad12a85e61,Binding affinity towards human 5-hydroxytryptamine 1F receptor
key46db65d5b783802b757416a05a5194e6,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined
keye4104ebaafeee1cedd1ba2d4e7569373,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand
keyb3ef6e88e8229a20b9b3e0e9ae0ae8d6,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor
keyabb38a59723503442a6b521b0e68aae4,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor
key59f6992c65db1959cd5b2e98f353df26,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor
key05bfd2a8ec6dd9361663d4c73387d0fc,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined
key5cec5afcafd90db785a34c901e99f7e9,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
key254dc96768cf5db6173ba9a1d6d37995,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand
key48c26aac435e25dfa2b51eaa0b232587,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor
keye2faa1a5457e907e922ee89183d85de4,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT
key9558c99921a012d68db8ca1681e40a7c,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand
key5859222bd43163aed2446ac667f0d4e4,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.
keyb24d820fd74f943f2d2444044c866c3f,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand"
keyb24d820fd74f943f2d2444044c866c3f,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand"
key0eef7142623b6336e6c110be88e85ad2,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined
keyca29c4e8606a3387cd94e248b31e1db5,Binding affinity for 5-hydroxytryptamine 1F receptor was determined
key0d8f60ea35767d421c02947ea6f86198,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor
keyf664be2d304a2c85908d6633c3c2faf5,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand"
key2d990c32effe69cd20c9ae49a903d216,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand"
key6bb75912f6965ada5159194f0bc09120,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
key8ce505f7d6478acd2c1b2b6829fd2eb7,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor
keyad4b17d2f3e4245c76ea3cd2a0f7b828,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration"
key0acd69fc1f39e992ecb4622c2bd5a6d3,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
key98f103b049f4ed7c32f6353f011617b2,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex
key2b2f7918543a7a51cfe9201f2afea76d,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB"
key193c2b5159db91f75bf462bcb5aa4b05,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M
key4015ad6349afefad45c586e1f5a914df,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex
key18b8e90a92dcfe7271ebb3f736819628,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined
key3166bf8f08a3cb9c2ffb6d0478d1abc8,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex
keye3143bfb5170a5a619ec2fe0d5601d2b,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes
keycbb17ad946b49be130bd42b853b22a5c,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex
key983a9add4d6b2050a801ee0f7bda9559,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined
key3bf1357ddfde8678c9cca37a02d9050e,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
key171bd13a44b8114acf03ea0f237f5605,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor
keyc36913e8116f72184bba5ad2b22d6b03,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell
keye53fb223ed1646ffff082cfe83b90bdb,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin
key6a7625c1dd86606908c4b72920bf7c1e,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex
key547e935181eee762fdbc3b7daa9b4744,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.
key55f2f1654bd62976cf4d80ce29dde5fc,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex
keye53fb223ed1646ffff082cfe83b90bdb,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin
keye1100fe7bd82ab6c1091e452ee172933,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex
keyf11871cd8d76d9f1b22aef0f4a39e25b,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor
key0b9d82eb8b80ffabac0c66dc02e2d497,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors
keye613a28b5244a5427b6cf28d592cf7bb,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data
key6a7625c1dd86606908c4b72920bf7c1e,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex
keye2c0d80725ea96fe72939414cd836966,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin
key1328c157c0da679abfeee27c9b085949,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin
keya2b0a676fcccf1c17618cea5a6ca9584,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate
key5c57fdb42ed07f4d6352f03a85e2ee74,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate
key148a3bf8afcaaaba0972a997fdbe42cf,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor
key17992e712989ab4b24fc7c6b82da8bc5,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor
key17992e712989ab4b24fc7c6b82da8bc5,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor
key476f509659c792397df03e1598c800d0,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.
key585c0e34a7b5fb06020395e5c8b903b6,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor
key97e11b626cefa2398e5d91d864312a49,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data
key154bf062f5dfa090b2cdb366ef3c3341,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.
key8a51e6e1046b8ba55762e2d6a7017698,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity
key9ab43dc48c0328d27c7de878b2f7bfdd,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein
keycd6ec29dd5b98471d658d10419c580d9,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein
key61878932ff54df51b1a7e0cad218eaba,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor
key089158a09642c347dbdb162945e2b779,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin
keycdf4e24656e2af4a66238064700513d8,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity
keybe41fa2cdb1d3483cc0153d115bfa52b,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.
keyc45aeae067a0b063f3fa5df3ff4626ee,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.
key1f2477ea07a5eb65f41030d74cf441e4,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis
key8f665295d0a46bda00acdfe046b42557,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM
keybb837cc2b944caeab1859d319c910b8b,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM"
key569a8f8c7247eef644740b3be70df801,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor
key9ddd5e070ac0a703591a06207d5ceb0a,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor
key32e05b291e7a61fcc59a8d9bfa5d08ca,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested
key76ee85d93178fb69071d6b8857c06828,Compound was tested for the inhibition of quipazine induced head twitches in rats
key8ff77d19c2a030ee97b81c3621df2d9a,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested
key36ce6e967e0ed81e3fac1fcd8bd42efb,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone
key7a20ddf37e260731c287d3a956095451,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone
key13d920e3a28cf83a36c96c1e0d8ac79d,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain
keyeaf1a4fa1d14eb0bd8195cc698d89c5b,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex
keya5a2c925fd8823c97799715ef3c56c67,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes
keyc9b0376318e2d8d0f3497f65920c9610,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes
keyc3b927219ddb0c9f41dcd45e83322ed7,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.
key27108ca79e715fef192064ba213cc7e1,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.
key8e5b489c0b262811cf385baa0e35dd3e,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol
key2ed075c4d06dbf86fd02fc286b59ee5d,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes
keyd57030fd8774d35c32a8b99e67126c6d,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand
keye6280b3fe5bbb517c17294c93a977c56,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.
keyc331063dc84be40d391697cc82fa839b,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips
key8a2eaa64f0ddd7bff66a7e9bce19386e,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
keybdc0eb08d073e521edf0a1c2f3cd63ca,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism
keybdc0eb08d073e521edf0a1c2f3cd63ca,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism
key0acd69fc1f39e992ecb4622c2bd5a6d3,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
keydb99a4259099b160194c88960095442f,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes
keyad8318819ac55f83f21242059820f78e,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand
key68d65e4605c20891c3761540675967ba,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
keyd75427cdafff10707b9ebd9f80c25c99,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex
keyad8318819ac55f83f21242059820f78e,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand
keybef6c5814ef42811b0e763db21b1ddb5,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor
key9f77bed73712e90bc56d83ab5599543c,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex
key4a1fd9b1de4063956148a9f396ea86a6,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex
keyaf1320046081d329208d920462314db5,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery."
key9141c10060e39a2ba191fbe27c44b243,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin
key1a75b3cb7c3381f0e0c519f92a0d1677,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta
keyce6b0ec041b1752633711c516f8b02f3,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor
keyce6b0ec041b1752633711c516f8b02f3,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor
key9db588e82643719bf87467938a0cdfc0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate
key1e53fb15eda2f6b9bdb11864ac7afd6f,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.
key69889b5ed1a0613f1c904b3a6c208aa8,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane
keyba2fb1e99317737c59421eeed759a654,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor
key8e815a18b706c8c4c127952c6e8e7186,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand
key32ca44ca990f14d6b2b6433702e4f283,pKi value for 5-hydroxytryptamine 2 receptor binding site
key8102bd0436cd0687e7b12338dc4901cd,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.
keye6280b3fe5bbb517c17294c93a977c56,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.
key5c4353dde6162425b9d4da686d04b130,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
key630d974bf1df0618fd7aa13df71e1213,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
key755f8b1fa50e0b43e3e86cf326a0a1d5,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
keybd059d47f9f5777fcb39fedef5ccd2d7,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
keyc0dc7ed29422226a899d436f9c809f2a,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
key87bdb2a45255138d22cef8bebc2af616,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
key8acc98a870ebc9d239ad08c1230041be,Hill coefficient of compound was determined
key17914d15a4982c8e29ea85e38f618e00,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor
key1b5832764c4248dc717e69b2fd37e865,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane
key34bf0a7ffc2113d8c3d20535b7a4f522,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand
keye8b0f0b54fd0e55bea85e367a6db75c8,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive
keyad52b21e0e63e561673c10aa1039ec2e,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09)
key41668ab1f13714b647cf00e15f34f740,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09)
keydae1bb802a7643fb7d3a98dda64475bb,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand
keyc9685503300f1111b88ce9db7593c877,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin
key57db10335a8dabd12199a74b08413ecc,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand"
keyb92a64944b5cf3c22cf4ead86da03f6d,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand
keycc73548e36e95184e3017e729ccb49cf,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
key761c56727c33d7da4e93586a753082ba,Inhibitory concentration against 5-hydroxytryptamine 2 receptor
keyc68314692ed294050a39f1a78a0c7b4a,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand
key6b56f2927ff4db58e0b5f8abfc6d6e00,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)"
keye9cf81f2261c4b538c9c8db8e0b53e3b,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor
keyfa7cd5811091816be5e01f33b34ef175,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor
keyacbc915122d701c9748dce4cc69b56ce,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor
key98a89833285330f673a365f62d95a082,Tested for binding affinity for 5-hydroxytryptamine 2 receptor
key0ab3d32eb28866459b1cffdbeeff6640,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes
keyd06c9eb2d2fec8b34c44d7f13a7ecb93,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand
keye12867728889381df89ad66c2199932b,Binding affinity towards 5-HT2 receptor
key3e0c5b630e26df43b9521973b04b6619,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor
keyb799afa22fb22c3e2baa28188d8a9fec,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding
key0ebc3a444a4451345f3ff00420051f06,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.
keyf7ad411330b1a81850d519b979d0d735,In vitro binding affinity for 5-hydroxytryptamine 2 receptor
keydf2b83baf8e3592b1635656fa228a61c,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand
key39b02031de35bef954946c7e3c348d23,Binding affinity for 5-hydroxytryptamine 2 receptor was determined
keyf7ad411330b1a81850d519b979d0d735,In vitro binding affinity for 5-hydroxytryptamine 2 receptor
keybf1f4434a25f0264b47a6e7867fb1d5a,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor
key518534b911a7d5970e509599384ef757,5-hydroxytryptamine 2 receptor binding affinity
keyfe226fb3444ccc20b7e8beaad16b3876,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand
key4a002571f9e5c370fe1aa5dcadcad7d5,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand
key1241c693754e2c78ec4b8313fa743a8c,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M
key9f4a74ab96700f1db2d736761653587a,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system
keyccc665407e2b0ca6a91579d9b39d5a5e,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M
key4f1a4beb331e8eb16cf7a322757677e0,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration
key5869c232a6ddef8337829b4fa351bfca,Binding affinity against 5-hydroxytryptamine 2 receptor
key5869c232a6ddef8337829b4fa351bfca,Binding affinity against 5-hydroxytryptamine 2 receptor
key61dbde6cb242ce1a700694cc873eb188,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand
key4bc14d034573119edaf9db48eda30f10,Binding affinity against serotonergic 5-HT2 receptor
keyd5a1337b7207306affe7fdf75268d685,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand
key5af33d23e0336bef0dc298adbbe662d6,Compound was evaluated for the binding affinity at 5- HT2 receptor
key46c7d86411b11bded2aece3c000587d8,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor
key1ad61bedbf51fce31d61e51a29211460,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor
key5589b52f69d0ab8732e4d6bf20ea27e1,Inhibitory activity against cloned human 5-HT2 receptor
key199affe48546052a1175a849b999c715,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells"
key9ccaf864ae2db4e613f0c0bd2624b78d,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells."
key4a1ac1fe98bc7de282a986152f1ce778,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive"
key6224a479ef5356a8467e986e2caef85a,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested"
key9c0e729353b47bc9fb34242280247ab3,Binding affinity towards 5-hydroxytryptamine 2 receptor
key089158a09642c347dbdb162945e2b779,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin
key9c0e729353b47bc9fb34242280247ab3,Binding affinity towards 5-hydroxytryptamine 2 receptor
keyc49c0a3fd0d515137a896b63d73cde51,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay
key0fe3d83553db038b15dbbdacc65873d4,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand
key55b22eaa4cb15771a677cccd39229d10,Binding affinity towards 5-hydroxytryptamine 2A receptor
keyf434ebf9e8f797499c69e06ad19dee9e,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin
keyed3d58a10c43dd2baef26ab71591f620,Binding affinity was determined against 5-hydroxytryptamine 2A receptor
key5b52456ed2729d21eb8b113706d7e7ad,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
key5b52456ed2729d21eb8b113706d7e7ad,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
key5b52456ed2729d21eb8b113706d7e7ad,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
keyd7620dbbd937518b293cc2798741f5a7,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand
key1a8393e1bf947fd1f20f915179fea0bf,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand
key3dd2823499730c50355eee221b2a157f,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader
keybde0643eec10153fb5dee9492af08de9,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line
keyfd45c3eb6c0a57a34703865f211eb6a5,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data
key8f0a1dfd1bb6e52be8e2d00bc2d823af,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line
key4897ab516c5044b1c554ff90706ec07b,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax"
key7ae22d00abcd5f5ecc674969fa2d6a8f,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax"
key46d976e676490f607ae77ccf5a4da435,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique
key8abfad270b6c99bfcf570553706b2aec,Inhibition of human 5-hydroxytryptamine 2A receptor
key95b53b383ff7d728a04e547140b455e1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
key35fa85f926a8e67580153534e77c0a0a,Inhibitory concentration against human 5-HT2A receptor in BEK cells
keyfbf381b902659b5e64b62a6bf9a61321,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM)
key680319dcfcb6d91a1bb881736b32fdab,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined
keye3e21014b4b75a5fb82e63f881409119,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.
key9f2e94867e98193e82f6124e4929cb41,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells
key2004ae271de20c711857ced6fb9d8873,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
keyb1b83a14bba0697e72851f1d1a2d651c,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand
key8a9719a746755cd210ae08b3dd782b97,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
key102870cef0540bc9242e1acae1813891,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand
key114e713cd6494fa920c28fcdbb5603a1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done
keye490789d8fc9143fc99b62d32b44432e,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand
key5392a01e8ca4cd066a7cd7a95b4ba6f5,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested
key67ece7985132c8e6c05c942569b4e2cc,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
keye92ae70b1f618b63950a1018d76921a9,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand
key9ad74fb592c276da7a63a0fc0352b22c,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
keybf62b3218babc9e0800b798a5af3bca2,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.
key237d785ec2a36c77133c97fd42e76239,Binding affinity against 5-hydroxytryptamine 2A receptor in humans
key1e1105a375c7d83e885d3ef3b07c53a7,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand
key1af25cce7c3627e688e03be66a0b2a25,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
key51fc7fa5229be13d949ac99fba49c3f6,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor
key382185af477d82dd3c3aee77744adcc5,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line
keyaa8d5b8b7cb98d29960f27176bacb19f,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.
key47058e881669d04ed6f5e12c3a428645,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor
keyb09e1caa85b18f3793afa57fd03cf0fb,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.
key0f9f8e4a6e4f8a6d6acf2f64797290dd,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells
key8bb59d64ab68412ff623c7fc4ec6aee0,Binding affinity towards human 5-HT2A receptor in BEK cells
key4e860aa97162c720b3dee0ddf2768cbb,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor
key7ca9477c72d2ca9121ac29349cc0d7eb,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.
key06a2be28a1779ad21e8ca073d6a95c63,Binding affinity for human 5-hydroxytryptamine 2A receptor
key58557711543693c6214332492e53b66d,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
key0689083e588ce2150adcc230d359e286,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin
key1262e102a03ec7adb289da88b81f9256,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor
key028891a54a0d897f98d9a96c2d3b435f,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor
key37ed4ce2d7dc73c130ec03204e6bcc17,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand"
keyc9eb32e1c8b7e0b42fba9270e59703fe,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand
key382ff6ad07994703f5e157ca727abb49,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand
keyddfdcb5ec7cdf1853e45578469fe6d7b,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor
key5b52456ed2729d21eb8b113706d7e7ad,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
keydf9c3883c55564af6e0447fcbf49a7ae,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
keyeb808052d41bd705ac82b38787b6b1ec,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells
keyd2c8e2c94063faf3294026816f972810,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor
keya16378fe61319bdab55a3ef60a771865,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor
keyb2ea3d09804c28e4a3321150f86de177,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained
keycd3eb7d0c38b30db38f3135927d71ef7,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor
key9158f810756ae4bd7b94b2aa71487e6b,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand
keyf0fd252633886c696fef60f95a9f1a73,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
key965114384805becbee7cf99bb3c16a10,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate
keyd99337a0e1b1c60e1ca091f784570818,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat
keyabf3602472a416e8402b97f4e9e55868,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI
keyf532e68a443f73c94d43cdc88921553d,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates
key982425da90ef7b8eca1d6ae58a0ee990,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates
key03700614576c4f8b4823b653d6a5f288,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.
key5e4e338dba8ea4da1860831e279c0ce6,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand
key6f36478099b92e2d1c4b78e6aa123f34,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand
key8d1095ff6b284e18c8cda0f709e8db2d,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand
key5e4e338dba8ea4da1860831e279c0ce6,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand
key61dbde6cb242ce1a700694cc873eb188,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand
key5980238838f13277e970b115c1056e42,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.
keyd1f6281ea0749d418f9f02a7db40578d,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor
keyd1f6281ea0749d418f9f02a7db40578d,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor
key567c37c46e8644193243e3a34069df54,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
key3e0c5b630e26df43b9521973b04b6619,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor
key0baa5b4a4b3d58b912d9b8e0a61c5da8,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin
keyf9a0b427d56f98b91db89368d03c46c4,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor
key3c336e67e50aa1a3d08a1a3202c96cb2,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as
key9e2068653c6cb3a39ff069640384f43d,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
key9e2068653c6cb3a39ff069640384f43d,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
keyeb14e10241763c86c1a633765aa39865,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand
key953e9f294c9b6e66ba5cd460e155a57a,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.
key2d6580ace3686ac8be133c41d8c57706,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.
key9c0e729353b47bc9fb34242280247ab3,Binding affinity towards 5-hydroxytryptamine 2 receptor
key204ad6ea58c483e8b7846ba742c01e66,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration
key4184647c993f77d1825a25f11a3f819c,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex"
keyf46ea8597cc06ec1c565ebfad995a81b,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex
key3bf1357ddfde8678c9cca37a02d9050e,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
key6f8d7524ffde8eaac84e105edff5f213,Affinity for 5-hydroxytryptamine 2 receptor
key824110acb2512d1c322ae7fc1826ccb0,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay
key8af7b9afdbbbc0e2c73cb2fe25d500e5,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.
key560bde96a59eac38af0982b5b7557141,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate
keycc440384a1ac3bbf5839c213aeb50fa3,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate
keyfcb6b57066889bb3149158ac5f59f761,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro)
key453cae59218bb3d5bf575e2ac0c0d153,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo)
key561bbf3335edee2f03d5419063398d48,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain
keycfdb460c37a633f6077032eac36c73d9,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat
key70b4ec500fdd8f03fc3f467d3bce8b98,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand
key7f120e42d9ef51cb139678a37fdd5175,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand
key4cfa2132d6ec7b87df19f95d7ab717d4,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.
keyac08c0b65daea17c10c6354e8ef92dde,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor
key92995432bd9b206202f660ca919423a8,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor
keyd32f21b7834e6beda4d7499182ea9f8b,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor
key4b2686385e5f2b654425e87114f6fe46,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay
keyc54e10f7fad619de531fdd707093a2ad,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203
key3d0ea9eeb805c88c4b9a0ce3161f08c1,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand"
keycc73548e36e95184e3017e729ccb49cf,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
key3551e93fc81018b9eb28542c31f50d74,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor
key585c0e34a7b5fb06020395e5c8b903b6,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor
key8665fde10bf980305f90f14ffb283ff7,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates
keya02935a332eafe6a63c581b0b1ca604a,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex
key0cb00927c4e61eda632fabdcb5857884,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.
key6a8f9b7a118763d3d5210bb4fdc6f9b6,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
key0cb00927c4e61eda632fabdcb5857884,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.
key628a18783e85e03f504d0fe739ae229e,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.
keyc29136e890a3ffa5711f9ec6ed5b4cb6,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.
key45735b00f78728d84722d1e6b02d83d8,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined
key600ca5122a8ed60efb322a683ee1ca94,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data
keyc3daf4337a8d934a010a9ef4c189b565,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.
key527b063bc1132fcc122ea07ac2e717a3,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263
key2c41ff336bdaabf4313cdf8b461ea415,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3
key9e726deb4a7aeb618d79c360adbb07ed,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.
key8e5f2fd4dd2437b6013d0c23cc218a5e,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980
key67c3862f3bdcf8dc6437b3d2800193ac,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299
keyc93fdc7d20345517790eae5c628dee52,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66
key41cb4cfe3c25a3d71e3d309a943c0518,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220
keya2a087f51e8e60508526c9a4f09ba6e4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341
key17f84dc6bef94a35f42404bdf7d31aa7,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187
keyef98cc5901c2c56e25a01466af939c1c,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132
keyb2aaec29fc1058dbae770f40459e51ef,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75
key58c5a9b3160b706a1ac4b32023178ab4,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells
keye08369d5b77da53148c8c2d82c56488c,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.
key69d5795a4d11afc96dc5aa9f64125e3d,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand
key2670995d4a7598bf71bb795d75ef410d,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor
keycabca8ae6e5c0e84110f34d944bcf7e2,Inhibitory constant against 5-hydroxytryptamine 2 receptor
keye65f19d8993290ef0fe7c6052dfd71de,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor
key0369856e48683176e9d335eabf2ad5cd,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum
key5a08d07a1b738c1dc878c50ed27dfdec,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand
keye807e6dbb61dc2b406d5a77f4a9ca85c,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex
key1d74753be093618fe2587317b7440df5,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active
key558e4bcc3a2ff2fe712dd3a0e39ec122,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined
keyca2d256912ee7f339dd35515a3c4b217,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor
key403a03ed4343766f62d1965deeba6a91,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.
key889e635ef39f114dd45c18e680a6bd17,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay
key27f58f79e668d970bf2ed5ed785b51ea,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain
keyc0e917acd80a739b3e3379f70ad7b064,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue
keyeff54f72a6674718b43ccd2d650d46fc,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.
key137132e5508b36389cb06f7d64b6b6ce,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.
key9c0e729353b47bc9fb34242280247ab3,Binding affinity towards 5-hydroxytryptamine 2 receptor
key8dfc9d2ae76fbf1ea94398e90ec29bfa,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex
key108dd01b7746020f4c5403c5f0a44f06,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand
key86ee2ee9402279d25746c2fcc043ceb2,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor
key0acd69fc1f39e992ecb4622c2bd5a6d3,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
key0acd69fc1f39e992ecb4622c2bd5a6d3,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
key3bbe8c3ca8b812881d8e2889ba9749f0,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration"
key54c328bd245e70afe75f249619152979,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration"
keyd8718489801f295169090afdda2d8bc0,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration"
key30f8fe609b5cb0522dbdb2894f966dd0,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration"
keybc207e129aa571a490c8cbf6a40f75f8,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin
keyea08ffe2ca020e90bf20219d8d00ec34,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
keyfd3025311ccfc2788aa71a922a4a476d,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates
key6d735e2163f7f8fd2d12cc18142e5005,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined
keye4de7443d09374b1de49617c2fc65d78,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex
key79a865adbf4772157eab9a5fc4eb6609,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin
keyc40ac07c75e4dc503a05c941f042c2be,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane
key6b2a2c49f0b1cbd8755517fe5a61346c,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor
keyc6cd3e3a3743d1ca37f54014e79423a7,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor
key87b8a2e4bce7071baec8b26e636dd140,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand
keyf1890ec872f0665c836d9a7e18f28740,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate
key8ec8cb0c97b4e2931275f9f499d2595d,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate
key2dc2b890c93f315a4979ab9b2704831f,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor
key222462f5ac4378048e91b3bc3362357b,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor
keyb872295d95bc4b2c874914e3765f74a7,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane
key2bb59ac63b06e894d6f49cffc37c7d74,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex
key2b6cc2a40f79a495322b8dca9195b42a,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells
key2f986f65199ddc46cac7f1f546128052,Kinetic inhibition constant evaluated by measuring serotonergic activity
key121ed14efcd4e5f9baaf1908c7ad6973,Serotonergic activity of the compound.
key165868cba108327734c960a4efde3943,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes
keycd50c985c3c85f7146bbbce3506319f6,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.
keyff9b5e6595cd38e2ab189f00ed44b153,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.
keya8ee11a7fc0e0585d6b42e31a4d33d15,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
keya8ee11a7fc0e0585d6b42e31a4d33d15,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
keya8ee11a7fc0e0585d6b42e31a4d33d15,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
keyfcf30f009d129e3ab772172617a1f292,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
keyf6186e43055d3215e29942bbf6c37a2d,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.
key55b22eaa4cb15771a677cccd39229d10,Binding affinity towards 5-hydroxytryptamine 2A receptor
key074df408ee5e4180f49547e1118c9844,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin
key7ace8e1a86031b0a0e6affbce33a12e4,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L
key16c1cb757acc539cb140009cb0cadead,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L
keyc417e0664a258d30bb08dd65b5f3ac4d,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration
key8f191524e2c6b2fab975278f82b24121,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM
keyaeeb82cc754b501fc0130cda099060fa,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor
key55b22eaa4cb15771a677cccd39229d10,Binding affinity towards 5-hydroxytryptamine 2A receptor
key9c72c5805868181caa7c9dd6cc1b2b30,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM
keyf55fcdcb1a87458790ccfa16f1cb0368,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor
key39048a6261bf1baa97eb134b7f806d4b,Affinity for 5-hydroxytryptamine 2A receptor
keyd6634ed3297223b81202380b3cd3e443,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).
key79a865adbf4772157eab9a5fc4eb6609,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin
key62cd669876efdb937b5c6e04bc09e885,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.
key6dadb2b62bd1a9d16417b124a35c735d,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor
keyde1cffe6cdab1c9ffded4db2473bea8e,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined
keyca0082ee3598a7f50473b31e7b706b7c,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined
keyf4eda2efdcef5360c24cd772fa845ef2,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor
key3adcac8ff19af06d6abbdf69de5ff9ef,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin
keydcfca23578218949e11a02ff1e77013a,Binding affinity for 5-hydroxytryptamine 2A receptor was determined
key7ef9a1200d6e4bd1b4b5cc2b7b3549e1,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor
keyc96a5b0b17de97fd303c3875359eee7a,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor
keyeb1a0ed445a497d02b52145c5a0847ec,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor
key8f9c09839c13733b4c476dac6196e49f,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor
keycb765b83d0b5b6221d3a4f9408fa52de,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells
keyf4b0d3ea1040d595e32178c92e841e32,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor
key42625b2154bd50bcf62dd0cf5b506722,Binding affinity at 5-hydroxytryptamine 2A receptor
keyd9327dea0449a4cd944ac259f9c9922c,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor
key66a9f786a940014dd72530f2bf4e2dd4,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined
keyeaecaf2066107d6b9ce2910a41375237,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity
keyb0ff2836bbb09ad1477c31bc1465423b,Affinity against 5-hydroxytryptamine 2A receptor
key0a10310fc762a74b805b606c9597b7c3,Binding affinity against 5-Hydroxytryptamine 2A receptor
key8889b31bdfce245b25ca140463535a0f,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay
keydfa30ab52594ec45b217d73a22f1c62e,Tested against 5-hydroxytryptamine 2A receptor
key59f867abadaa1fd5fe43f3be53d4076a,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin
key9393b8a97acb977d95a70ef6bdd420f5,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin
keya588544a9fb3b3634dacde073c6ceaa1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI
keyf1398186f6c291707c1f39fd83774210,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin
key9259e38bb76b82006c17d1473caff600,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 )
key73f1f732cc54e2affebb3be2af80ed44,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data
keyb1194a9a74c1d91094244215f50b6f92,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader
keye9346d6f12c521a68df740b2aabac6f4,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM)
key2fd57173c7b65b462e1c6fa795910557,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor
keyd7da81e6029209f1d0499e3f04bb1305,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand
key00890afdebfa05a4502feeab91df5c06,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand
key2eebe636a3002b2e3813adfc48e5ba0f,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand
keyb9cfd884b060e3736e60212967f64932,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested
key0305f86b77c432db8342d08278af204a,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand
key1dc2d0a316cef06bd7371b35f8ac1845,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand
key80e6f92591d610946c1cadea3a6d0f1d,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand
keyf3d7559dc96630cc41b20def975297b0,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand
keyd614334c491b3469e25c5b1b1604836e,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand
keyb9c1d754f14d9e2564c469ec449bd501,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor
keya0cfcec4a87044e2ae00b1cea2357ce6,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.
key0852b0e09453671af6ad59f8dab7d7ae,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.
key23e085ed3a01dba40decd7bacea0b28b,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes
key207196a0fb45be8f66a0e9db461bcd12,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.
keyae5c3c42e93599fc154f07e6aaf7a2fb,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
key411c13183aa15d85af4452c137a5d662,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
key411c13183aa15d85af4452c137a5d662,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
key420e029e525c3c35bd399edbb4e8a53f,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
key5618c975abf90b75607cac27b24da730,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
key24da605e29eb70951727e7c8ca7b2976,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand
key7bf310a7961712dc3964395b3299d97d,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand
key5843b11e6e221691bc44dd37fc851fbe,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.
keyba9ca6bd1410bd9af997e9050bec1882,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested
key62e8677f903607080e35e8e08cce62b0,Binding affinity against 5-HT2A receptor
keyed4e3166b32ee289ffba029e8ddfdaa9,Binding affinity against 5-hydroxytryptamine 2A receptor
key343c7165ee36aa7bc895ccba57a629e7,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand
key810e707f6c791d010598a313f38ac174,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand
key19142e68d876cb6247646c96c72887a7,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells
key9d7ff42e21a39b83057cf69b13058b58,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
key9c2731417ee46acbb562fa63a1a37ec3,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT
key9d7ff42e21a39b83057cf69b13058b58,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
key9d7ff42e21a39b83057cf69b13058b58,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
key2cf92cf9dacd7f95ca079527d40ab637,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand
key11e22d9fb9827a92172f2decc2478ca1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.
key57e61a3401f2ac05f0ce92d5349947ff,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand
key57e61a3401f2ac05f0ce92d5349947ff,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand
keye6dc746fb030665fb0be0bc0a322c93c,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand
keya560249bfae733281cf896f982d40532,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.
keyf7b5f32cbabdd29676bebacaf69fbd78,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand
key290fc41c167132da999863ca982e7c4b,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand."
key3ae766db659dfaf48c8e08d3e4f32148,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble
key51b6daab125eea0acc357af6428153e2,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin
keyf58239c1649af6d0f4cdabecad170203,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.
key9d7ff42e21a39b83057cf69b13058b58,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
keyf9e136a889e96794b9ca921f2623bef4,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand
keyae5c3c42e93599fc154f07e6aaf7a2fb,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
keyae5c3c42e93599fc154f07e6aaf7a2fb,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
key4195863eff2540b697a98f680ee6226d,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand
keyeadd551578650fd0d44ad531307f0a78,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells
key3a031471883bf09277bd40fa29a0d9e4,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.
key06a2be28a1779ad21e8ca073d6a95c63,Binding affinity for human 5-hydroxytryptamine 2A receptor
key9618d1eff3248f13d024eda88c287db9,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin
key54871027ba48c8dc70b0ad3af5d60798,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand
key8a25aa11646f53cba63c196078611673,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells
key5980275733fa4d3d3f3e7037f821f83c,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.
key4eab7255bd6d7cfcde1387665fe9d7a8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand"
keydf976a87821b6e84d530818657e07bcd,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells
key8ea777a3793e5249e986ef340cdda43e,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells
key1f2fee4a46a3f94c6297092a91903f61,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor
key3357e9338b7b25cff478c9936deaecd1,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor
key4477ff17234367440c04845d84b065e2,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined
key6862307f019c17d84333ab9414275b4c,Binding affinity against rabbit aorta 5-HT2A receptor
keyb779fc56d5fb3130752c9ae3ced9d958,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations
key8ad125dab0c4872d8163be42e571eca1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta
key45558b8a6618b325fe40efa6bcf1ab29,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.
keya103f76b41f3730f3a96eb71a0ea0a91,The compound was tested for binding affinity against 5-HT2A receptor
key7cd1a52209074f7edb57437df36c8fad,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.
key9e95939867ebaf480eb5f4fd2951a773,Binding affinity analysed towards 5-HT 2A in rat jugular vein
keyda5652035eac1d953ac1d07b5367d679,Binding affinity analysed towards 5-HT 2A in rat jugular vein.
key655417a6b8a15b096d58ccd8fae905c5,Binding affinity analysed on 5-HT 2A in rat stomach fundus.
key5927f8fb7712068be1558add2496bd27,Binding affinity for 5-HT 2A in rat stomach fundus
keyda5652035eac1d953ac1d07b5367d679,Binding affinity analysed towards 5-HT 2A in rat jugular vein.
key6eb21948b3b932c7e9212b34686823e4,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor
key8271441f601b99a50182362a05d8ce1f,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor
key6c61a5731796fab2afa834cd4bfefe2f,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor
key5375a22023d10f40c3bc58bb1720c05f,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor
key8e730c63b29593fe7ad53441cf676a24,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation
key7450e88aef57d8da45f2dd365e605e6f,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells
keyda13223956db8fd8c627b62d86220a26,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
keyda13223956db8fd8c627b62d86220a26,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
key2b311d63fb71b7acf94de909c46eeb6b,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
key83bd4a071a399544ac3dcadd752fcbd8,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
key9878be476a72d2a5b783c5b6a4811d51,Efficacy at 5-hydroxytryptamine 2A receptor
keyd2110e3a72bbeb1f5b83edaacd5d2c0e,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax)
keyd2110e3a72bbeb1f5b83edaacd5d2c0e,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax)
key0986a8a99a9e4c42535febd84fe23f91,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax)
key83bd4a071a399544ac3dcadd752fcbd8,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
key3cffd3fbebd9cfe8e0e9699983a910b0,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
keyd39f3242aed8d331dc5d8e7e42aed852,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor
key6cd0676f19b17d027f5c4eddb4e8e890,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes
key9bcec67462256853b2a372ec317629ef,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes
keybe39101688c443db5963d0827e579576,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand
keyfb9c7fcfb88565ffeb8038cab48a7224,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex
key2fa49701514c7a7728a7a66b72ee1585,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor
key14440440fbfe40b3db6d5d62c027bbb6,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates
key3f28dcaab9e2c04d6a4aa2d5733460be,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor
key11ceccd2f428c09e2b46662d102eeea9,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand
keya6e05282c978fd2ed2dab57ccacc49cc,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand
key0a007b1819044b8bf68a779f5ea380a9,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor
key3c115cce2f8555e76e7e15ad7a069230,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane
key62a41669aeb2415d18897bf56bb446f6,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex
keyd51b8ec16e513d509e21ab5f4bcd5faa,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration)
keyae69ff94b5c02984618b3a8037073e67,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor
keyb78c8654b61de1322d4b1ad094e5de4a,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain
key54237b5fc36b1ebee3b88a7a4a5df0d6,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. 
keybcf82dca96e34fd3374b41ede26d5817,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values."
keyb408b5a11b902a5fde72ab8c306680fa,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M
key10d7cb958ddb08cad5cfc37a494c9021,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.
key879533a44139b7ac317576109864b915,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI)."
key4cc14c05b85cd89102caa584914c13ea,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate."
key9a76c29dae22226054928b242be676cd,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand
key3bac37668673981b647fa1855d2f16d1,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex
keyd5d1da128d8c7c14abea9f9c25edc08c,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors
key76b2ca12aef0542b13cc760756fd8cac,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex
key8ce505f7d6478acd2c1b2b6829fd2eb7,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor
key4090a876c0f6ab093a01094233c4fb13,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested
key7cf418538043ff1ad37575c9f1dbbc70,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes
key7d377d07407801caffcde978a116a2dd,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.
key336e8c23d1734030c1c28f9069b8c00c,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
keyea08ffe2ca020e90bf20219d8d00ec34,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
keyec29a18f06f2417829b0fefa21fdf82e,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined
key3b1d22b034b1d7653684e4f20d31b522,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor
key1d1d7395012505af83985f94b9098dd9,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor
keya7c89ac83107d0e1cd9af236431ea7a8,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates."
keye3da165af1b029560fbe99e2521aac58,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand
keyed4e3166b32ee289ffba029e8ddfdaa9,Binding affinity against 5-hydroxytryptamine 2A receptor
keybe413fc355a1cece1e334fd0f4bad3a6,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes
keyd2b9b8b258dc9857e761e6212cab652c,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand
key2b78b35ce9ec7ce57dd7d2b682018bd1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
key8093f320b65e17d9cd0957f2c3e4d7f8,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin
key3c7cec93f989fc0369785774ee9da8f8,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
keyad8fb81a63ca4d56ada8e8ba0e35fff2,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
key12fc5741ac62b607489ed44d0ab365a0,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor
keye922a056d06c6296f9aa3d73bed81cfb,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
keyabac7afe8609131451ea6c292e6f3a4a,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
key5eb3b6732d6bfc2a6c30224c862fd37b,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.
keyefcfe1bc254c58b8dd353340201090de,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay
key9d3cbd7c5412242a38ff8c2a611b78bb,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor
keyd1491325292bcbd7870beb4469dc3644,Binding affinity for 5-hydroxytryptamine 2A receptor
key55f7f54da3f74abf1b2688afc1c25498,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.
key808416c7f1f601a8f4803b98c066a0c6,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex
key329647f9f4ebd93189500cd15b68bfbd,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.
key4e206f003cf156e1962ed7e22f997337,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand
keyf64712a4e0c78054787f2de58f3a4e3a,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.
keyb6280a9eeaf7816c7b9d03e6aa906cc8,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand
key63dfa4a09ca5cda8cececf4726219006,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor
keye81af475d4a2ee2f2ff49dc00a141980,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
key4b19fe8b79344c5b54acefa6dea0ab6d,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested
key6c09eb56a42423fdae0c2010627e977f,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor
key55b22eaa4cb15771a677cccd39229d10,Binding affinity towards 5-hydroxytryptamine 2A receptor
keybe8c99a7b437c0cee516d0cf3a4b0dd7,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
keyee92882c77c1f4f3d93a3e958dcb3f72,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand
key83e1256901c8509e849e1a719c57bf92,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB
key7d9f540d08fbaf43903ef1cbde8f0cf3,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data
key445da4a1bd51465f2529cff73dd5400f,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.
keye3d55cbc7bda699e31c322cb6ab05dca,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand
keyfc2c50f35be47155c530c3ea4ad77db0,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand
keyf69f49de74b2b473879bb5531fc94d6c,Binding affinity towards rat 5-hydroxytryptamine 2A receptor
key5d7b567b9a5d90852f17b85d1f2b96ca,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand
key149d3135ea213a8d6a2e50d98c576c43,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides
key81bec4ee81b6dfac0d6025991e19ec0f,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain
key35e26d2ea89fe9141c1957743db4ffc9,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand
keyfe634da644e4bd7597fcfded7f04199d,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined
key7be974f5fd6f92bc382f3f3c0729bb31,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture
key1e2e87c4238a0451592a42b2eaec879f,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate
key3562848fcb3f1965300ff4c8df038f14,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor
key806324d9c441a893a9a05f10c6ae1ad2,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor
keyfbe288ab10575c13f8d42ff5a3583d0a,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor
key57ab30082104444acaaa7342bd7ba9e4,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.
key837a441f354f2c455a52b8c31f92a559,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.
keyac13dcbba7613610946f1c3e931d0e12,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.
key524c612665ced91a7ad4b6ea80c161f9,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.
key442f7f5c72df1e6c2e0f252a2a663f85,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor
key0591bc3468c8325f6189d07e8bee5799,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate
keyf703d1809c8eac4b8bc66d8dac7153b1,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.
keyaffdcc842dfd5caed5e5e560f11cdbdc,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
keyaffdcc842dfd5caed5e5e560f11cdbdc,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
key7c267034ac59564b55394148d738b5e0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex
keyaffdcc842dfd5caed5e5e560f11cdbdc,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
keyaffdcc842dfd5caed5e5e560f11cdbdc,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
key839f543e6457f7f20a0c1ab012612ce7,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane
key64c000d1a7f81d38230ead43680ccc36,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor
keya17a74389048426904952600423d2bde,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand
key0f448d7995254676c6144c4d6f06aff5,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M
key6236f44595303b0f291044ed6d4aa986,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex
keyfafcd2fe8a70e2c57e44c2b1fc979638,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex
key93ce65df3477e871a644fdcff5ea4856,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki"
key4b42fbef4bd10d21ff0fa94c2e87bfa9,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
key14dcc3de10f28d0a066c4820d747f439,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
key20d82b4f37d917541de47295519d24ee,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand
key5c3b23aaa82e240476e4d5a3c394e217,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI
key1e96ceff818ab7bac12d0253da9b7f92,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin
key6d57e622f35ced665548948575c79668,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor
keyefc839dd9c01bb46d76d7aa49bcbab49,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
key09099b1556878e465f7d8d66d20474b0,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.
keya26970039d67695daf700f6196100c76,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM
key074b73a6216174ec537e067b487d7e4f,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM
key99a223db072ac179c45cbcfa50f6018c,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data
key1d033bfb2bf935e7291d850252bbec32,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data
key55f3f6f9b7637d79e91e561ab483af2d,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data
keycd490e8adb78d58a7f9d33e8ba2fedd4,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined
key20a7f8a4b333f1bf8963452180459a06,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested
keyf73ea6e64fa516f4463987a4c1b470da,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested
keyec986aa13de7f85fe47ee0f3bd7c2080,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63
keyebefc90ea5422eb35e0ebb77ff81e1b0,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg
key7b6c90f01a55b4db41bb5c91954d0575,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg
key54d0136ec465d625f3c0715a4ce30b29,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor
key1d679c1818ab9a0cdb817d4715b263bc,Ratio of pKi of 5-HT2A to that of D2 receptor
key6c6534ac70e7d58377fdecbefeea7a7d,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor
key6c6534ac70e7d58377fdecbefeea7a7d,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor
key6af24e24f275b56311b2f586e83454cf,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor
key9b05df0b407e4b6116c7556e188685dc,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data
key163088b6bb751a2e644daf3f2fe1d549,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM
key6c1d1db81810bada97b3924b374d4c80,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat
keyc2912685630c98530e0ba93ff05fc462,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done
key7e26cc78834674cc51df4af94ea1a145,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery
key99bd92a49870cbcb7c057c2fcf3576fa,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta
key760f14c1248841ececce93826b13b9bc,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta
keye123a6391ec84efffd7fe35bedb23abb,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
keyf38fb2f847b8b82a3988664cc0a23a9a,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
keycb72b7af515cabec2dd30967d2d7c7ea,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available
key392d5d7725a8e831f0e9b02d24058cda,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate
key3d5892592d05f1f66930806d751c4efa,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930
keye43c1b04b58ac21032111b2993c51a1c,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined
key55d4ffea04c0303f2b1efac11c41ab71,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin
key17c8368e741df4a46874fbd5218c57b1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin
key3c3f2b200a17e24a8844a894468a71f0,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor
keye7a5df0a910a001d4a348a0a3b6eeea6,Binding affinity towards 5-hydroxytryptamine 2C receptor
keyea5ab73b7181b93085a0572e8f3f0d0b,Binding affinity towards human 5-hydroxytryptamine 2C receptor
key2d9544a605299b5fa1e32907b0b5248e,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor
key63dbb88050129036b4813d53821982c9,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined
key5dc4714458b1f92d63a099f3199a4793,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor
key661e76e6b73052ffe2001f32b3963e47,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor
key661e76e6b73052ffe2001f32b3963e47,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor
key86bcae98550afb9bcdf097ca72b1e9f0,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine
key517060dd0b4e40a3b97ea846af9e5828,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.
key21fe875511a0dfa3fcab3345c041d2eb,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand
keyc219f2536d68368dda643e7ac8dc6ad1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor
keyfed2d415c20712f06ccbb3cf1ee14110,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand
key62b523e8b7e032285d9fd67ec53e32c4,Binding affinity towards human 5-hydroxytryptamine 2C receptor.
key14741c2c062a103bcdd7e67449edd7c9,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand
key5acbcc81d82d9fe1f9598d69111a9e7b,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
key5bc3dad82dd57c3e90261629ba947cdd,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand
key2083c8cac03adec211d8494024c932dd,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
key8d267b6a88790b0a224713c7c2853c62,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data
keya841a7ed6715a90895e82306ee0d2f15,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
key36a5a425d639de32d33a048d0c13cdd6,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
keya051c5036043b562469d1042c0cfed02,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
key5618c975abf90b75607cac27b24da730,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
key180ed7914f810dee554008b6b0a72d4a,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand
key439a480068c8a3bac690a25ee0bdc7fc,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.
keyd9b9e3a031448fab46e289ccc7f4c67e,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested
keye411960917ca43ac7c578de857b8083f,Binding affinity against 5-HT2C receptor
key810e707f6c791d010598a313f38ac174,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand
keyb3b8bd4a6f8d873d0f60b691cb9ce15d,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells
key789d2a7dda96af422988823057d3c5bd,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine
keyc4138416b5c9e80907950d02ecd0180a,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB
key789d2a7dda96af422988823057d3c5bd,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine
key9bd960fbc52e04df10302de1ba276a38,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand
keydf38149389f17abd58cc695cf5e0929f,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined
key0873c08d565e75031cb4629836af7b86,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined
keye899bdfe992ab553d641d333e4f62583,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand
key88720d19b617c3c3ed1133cdecd37cb2,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand
key5e367c50389e41dc98bd2260524296f2,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
key0bc3cd1a542407af02b78e3282262513,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
key2682db2cb22ffc9e97aaa2f9fe3bc86e,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand
key8d338f65f8a39b294ca9999f38ad4c88,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand"
keyf3962bd93290e88da2ed4e594d8f15e1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand."
key3421340008820093499bc9a935219104,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble
keyd0c5e57b5b55a4f7c9e09e0bacd72dc3,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data"
keyf432825af3aea922350796ba05e4a972,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine
key36d0c268c76c2692ee99d0c41306eeb1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.
key9bc958b5747568f8795caa70adc7b505,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand
keyf83b2c0e5d51a27d801dddef9e807ce0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand
keyb77a7d2f7817fdcc0aec9c4acd377c06,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells
key86f6a6a266cda7d425185826a3ce2e1f,Binding affinity against 5-hydroxytryptamine 2C receptor
key97ba25e810b02d8c0de4a34d125b97c2,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor
key86ba2fd6a6434654da88a4be4fc81e79,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine
key8e86afef41431bc208542a7b23c82f35,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand
key88fd2274a2916a102c3492f3dbcb8ff5,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells
keyad8609f107ef103932c9212c37d7a60d,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor
key0bd8aaf38d5a962559439f939ca30b18,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand
key5616902eb1c9b29bf462643388b1138e,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.
keyadb62b06318c3f165acd15b5de838208,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand"
key9413aad7d12ed6593667a557c3c3d268,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand
keyc47f540676520c1680ecb2002e057b56,Binding affinity analysed on 5-HT 2C in rat stomach fundus
key3d5f8818d2757454bbe3f4be4c999c30,Binding affinity analysed towards 5-HT 2C in rat stomach fundus
keyc011e64b084a265194291c4ad4a63e79,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells
keyf00c79a546b2ea6730f33069d8bb1de5,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells
key9e951f1c88686d727280b10cc081e3bc,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells
keyf00c79a546b2ea6730f33069d8bb1de5,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells
key23fd50804860c25a70b20a6d3ebc7500,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor
key17c186a48944113f2f9f360f15121b64,Binding affinity analysed on 5-HT 2C in rat stomach fundus.
key8defe098ec92626980f84c6ba99519c7,Binding affinity towards 5-HT 2C receptor in rat stomach fundus
keya2ba55635ea8bad27fe724512741b613,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand
keydf4dda7ef93ba292286e192b2b9023cc,Binding affinity for 5-hydroxytryptamine 2C receptor
keye7a5df0a910a001d4a348a0a3b6eeea6,Binding affinity towards 5-hydroxytryptamine 2C receptor
key9389dbb45583adbf49a10ca379763eae,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine
keyd536303ddf356f1f5a627a88c4100c78,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex
key52b07336b61ff8085c9a3127258619ae,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane
keydfd592aaeb221bce534aea7cbfc3a607,Binding affinity towards pig 5-hydroxytryptamine 2C receptor
keyf0d9fddd7dd27c0fe8d0d10c8479bb1d,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
keyf38fb2f847b8b82a3988664cc0a23a9a,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
key9a31207dfecbe936f72702c33913c052,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available
keyb27a18051bf57ccda5eaee5c1c2f1465,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT
keyf4a26f2ea69f3054429fb3eb66d54010,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined
key914cba55964e926f295d45d321084cb6,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine
key914cba55964e926f295d45d321084cb6,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine
keye290d3871cb07a4df8cc4c6fa533f95d,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand
key8e5ef0cb68414e2a8cafec79c5d98f59,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex
key1149b97f801f86413c877b2e7d01eaec,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor
keyf38fb2f847b8b82a3988664cc0a23a9a,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
keye9c570c35c5e30f26a1410f660f71556,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor
keyc93002a3762339178bcea78fe15b0e8a,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand
keyabb8082d07f3116b395af0fdfbd1bd2c,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand
keyd4afff3d0c3f2bbf3c944c7139a1a84f,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested
key04a192ccef912c70c76980d479a50eec,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor
key475265c6a365472de449f83dcd986595,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor
keya2cf3a4306af70a4e3f845939274083c,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes
key1bb22fa18836da56798294b630121209,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested
key55f9f99cd81bdbad5c4c0c74154e0823,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex
key87d7930b941bf658420c84d62feb28ab,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor
key46df1c032a5ab539ea655f8660cf7586,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells
key8f9d9093214e1007597c5d116fafb134,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes
key122759e4c0115b4bf8ccfe154f529bd5,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.
key11fe8b84a43c0cb01986dad963176188,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor
keyf7b6038f819f34621484bc41d75c4d19,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor
key38f53ef194bb0eb7e57a9f208305af6f,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand
key86f6a6a266cda7d425185826a3ce2e1f,Binding affinity against 5-hydroxytryptamine 2C receptor
keyd6a700cf40434d12decff67a2e4c1f05,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
keyea7758b5f3621579767dfa8ecb376e51,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
keya1a90856ce44c1598bd0e7b3a634effe,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand
key1885f55535577fa6530ccddb7b540095,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.
keyf83c1877802cadfc9e2c1391ff9f4fd2,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex
key617f1518e34b68b318c85db36845461c,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.
key306916ae2d7adeab6d40b67c8e667f47,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor
key1ee002e7eee1b1776c26f30528a73db9,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
keya7cbbb7d1a5ff55118426bac5fdb0d8f,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.
key23463bfec1d69d33efb040d539f4362b,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand
key1d011fbd90e4607c44d539235759f9c1,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine
key2b64c6785f93ec2b7b903dca2db3c772,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain
keya2608ed499ba8c14e11da428ebeb10c3,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture
key882f8929fa1c4a174e4a2d37a27f6016,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data
keybe53e96c09252b7860a3070d87ff5822,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor
keyc3e11663208550522e8c88137edf95f1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor
key1a75c54720a4eb3bb3d3da91a831070b,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor
key7cf8f89963a74522ae3c70ecc48eb94f,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.
key283decbcfbea6692b811db5d05f82561,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor
key3610fff3fb1eb4c4f847adf5a14c4bda,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI
keye3e87cdbada70af443eabd932d2485b8,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine
keyaee9bd5bd5c7f2f46bed2546131b12de,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor
keyeb9b4ce5bf56a90dad6a10432838edfd,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.
keybfb71939fcbcdedb54cd3ec908458a39,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine
key6501791b94688472159a5ee9bf0f69be,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor
key3297e9efc11bbc0c391413379aa08e97,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM
keyb706873a70575e8b2081ec15df2f3717,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM
keydf4dda7ef93ba292286e192b2b9023cc,Binding affinity for 5-hydroxytryptamine 2C receptor
keyb82201663a4dab698452a33306f65709,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined
keyf8938c2bbfd536aa59018a4abf5357e6,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested
keye6e93bda4db0b9f31891d69ce4c5787c,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested
key25d3f7140ab85e7785c90c082d134912,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.
key90ce4a5caff39b764d4f3bda4879fdf4,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.
key4eb2da89b50a40e77c7e4602e6995fae,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined
keycb943ff9602fc5327383422d05c69bc9,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293
key965d35cf2378e686f4602153d9bf6b0c,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand
key6fd8d4ca3f475c500048a24c5f5cc559,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.
keyf1b22619626e09c5238dd62305a6657e,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
key6a4bb232f8dba3c2cfb8af031a853b1c,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.
key909528de6a2efe175048f27549a77de5,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor
keyba06f5ce655e38b27ce62c3fd3a13402,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor
keye7a5df0a910a001d4a348a0a3b6eeea6,Binding affinity towards 5-hydroxytryptamine 2C receptor
key890579a242e4beb1e82299f4e10b9ebf,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested
keya91513545c8aa671bbf69bf8fff0235a,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.
keyc5f89a155b6742a03424fefbff210f25,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand
keyfee24b864b0729aab0e03274ac060c1e,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line
key3996b698692e4f76b489cdaceaac1965,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand
keyc8461af0d5982ee42c1cc48a6ae8d745,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor
keyc8461af0d5982ee42c1cc48a6ae8d745,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor
key394ae5b09c3888e1b6bbca8a5a908180,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor
key41279d13c0ccd5330bed2821160f424d,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor
key0fdbbbba1ee4cca03210af8ace6a7b3c,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand
key4270abc0fb347124efa18f29f7841f45,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data
key149023dda15b8a1ee45252101ba90658,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data
key36a5a425d639de32d33a048d0c13cdd6,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
key85290d032e6095ae608549254c2363a2,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
keyf0d0c567c98729df26763af16ae36b8b,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
key825de05e6cf967573822691084a9760b,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.
keycbb4f6418b92a6502801a61810556ffa,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data"
key3a882dd6db3788cb8cdef276a527091f,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells
key1288c85f2e64635a4ff8db17046074c6,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand
key3fb8d0f3ea01fc8f783467f3f466d849,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined
key43934ffab1b844e71add27c67dc2e4b7,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.
key8d67a32b6ad4f0bd810fdce5006ffbda,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand
key233256694c843e2fc10fb2881d49e362,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT
key629c49fec2834e64383c2de00b81edec,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.
keyb4eab94ff2b6ca74c0eab382d3167860,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells
key722eed437a5d06c6a947050df6afe337,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble
keyd6ce08bdf8dc97796e8db7f4c24dbfa1,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand
key6f25077b184eb6a06051bba596e8b986,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells
keye2a0baa81915f8e7fe7d30c5888d8be9,Binding affinity against 5-hydroxytryptamine 2B receptor
keydfdfbd371178f9284bd10695576d0947,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT
key7d055f91199037e1a8d976539f4b3ee0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand
key8cc24ee2a859cb90c9563ddb5f2193c7,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.
key1983f5502ab4cd8f72e23afea59b6776,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
key1983f5502ab4cd8f72e23afea59b6776,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
keybbc919550fe36f9d31ffcff07e939bd8,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.
key0f40460730124058c29feb2abd348d5d,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus
keyc283a8f221596f97e23716b618b423c3,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus
keyfaf5a0bf528cec76ee550802ba1acf33,Affinity against serotonergic receptor in the isolated rat stomach fundus
keyabf0e9a9fc23c76976f2902543fcc181,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation
keya54f3a1c78a88a3043c75b4b0ac0b6ba,Antagonistic against 5-hydroxytryptamine 2B receptor
key730a29eb53257acce5d2936e02a98c7b,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus
key51df8e3c3909740957b3cf25274d9b59,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus
keybbd8a242cb06d21cbce7e2712facdc9f,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor
key668b30d061752236001240c7bb51d511,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data
key91e9bfca3f5d0394d332a88e92a1cf69,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor
key258f68dfa8ce635f931c349558cfb349,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
key258f68dfa8ce635f931c349558cfb349,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
key258f68dfa8ce635f931c349558cfb349,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
key258f68dfa8ce635f931c349558cfb349,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
key7d1a1a9b7ab6e19c473f92a360beec61,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
key9e73cf809312ebbc53b19582cfcf57ae,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
key1cbbe85a70fa602ae7175970463071e1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.
key04999186799376e9711227b9482112c2,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.
key721f0f5e2a28555704486d37910dc93b,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined
keyfeeae5198ba6b8f7c4c33966830542db,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined
key5fd130d017d60ff801a09e89115cf713,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot
keya07a6f9eb658fd9ac327848bbf833e71,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus
keyd4ca4dd5d518f547779decd1f4f65e1d,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot
key57c2781a3c8fbfaef4739712ed3842a2,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot
key7d1a1a9b7ab6e19c473f92a360beec61,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
key9cadd406ed9f98d3b21b7e225f401047,Binding affinity against 5-hydroxytryptamine 1A receptor
key4086247fd7c8291b882ee5c7ccc74538,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined
keyd33f245dcd370323f9bbc162feb34daf,Binding affinity for 5-hydroxytryptamine 2B receptor was determined
keyd031c4a82db299f3496e30bf5bd9fa8b,Evaluated for the binding affinity to 5-HT 2B receptor
key79e2ca554d72d31dd7d454d79aa94ff7,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor
key6bf7e492e0c2434954391c916680043e,Binding affinities against 5-hydroxytryptamine 2B receptor
key0112972e0a488f5de88b741d1d1bcaa2,Binding affinities towards 5-hydroxytryptamine 2B receptor
keya859a9edd6dad03d1cfe647bc56fb4fc,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand
key117a724e5be13804178e14ca46238aa9,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.
key18f58e95f5c58c7cda8db7baf87204ab,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor
key198fe70db379265b10a412f93b31cad3,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M
keycc98491f692bdbc326826f2e5d9f0b80,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M
key930c4eaaf02b3d5099909a2c4e095197,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M
key910f4b3cb0404d25f3a6bc3e63919918,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus
key117a724e5be13804178e14ca46238aa9,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.
key18f58e95f5c58c7cda8db7baf87204ab,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor
key311596fa30a98f995a0049c0736b2bce,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine
key5940e34e119df0082e5280404230b96d,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum
key292c7583b1f794253c4bbfc9ad9fc20a,Binding affinity against 5-HT1A receptor
keyc19ae62a15d8fa05b784f214fb6474d8,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed
key165503e135c8d3443f2d9c394979e9eb,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader
key2621ab559d7e998d690a5d678a4b33f6,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line
key264f88405c98ca317f1cdb105c7c7c8f,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand
key5dc0d39653a9cbd3fed1c09822d06767,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax"
keyc7717a298f1adae75713c541e66d7763,Inhibition of human 5-hydroxytryptamine 2C receptor
key4b7addf57d9931ecd05e057e0c65ae7b,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM)
keya051c5036043b562469d1042c0cfed02,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM
key3daf0d7f5b0e775a212834c0d910ddb7,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor
key69f6fc7090ec699c7cac61940a2029d7,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined
key95904da2fa2268cb7131baddb55215c6,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined
key4e825e7f3ded9b8d4fc886dbaab2750f,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.
keye5dcd2655577120b805a2a95120411bf,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells
keyc5c060aea07717cb982b6617f03f1c50,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
keyadbad98dc4c36c3eef94e3b648d5aa50,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor
keyf5d81e196f23fef4058d91888c14f29b,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor
keya6bfeb73fed71716ace49debc1a915a1,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand
keyc2cf35e09e39d09d0c5da38eb8cc13a4,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
keyd00b2767bde7d741c4f3beb7d744d006,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI 
key9fdae75b4f3da615e4e4e0a09544d1d1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand
key2a3495d00a813e055b0c26dcc036c561,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested
keydbca08df249b3522ff58f20235fa6893,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
keya5845157a1a16dd683df567aa214e0b4,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand
keyd9f5354fc3e735bb7be02de899106ce8,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand
key2202d8627b72b27bf0ef1b70913d76dd,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested
key47c0dd83c5419e0cbe947afc042cd739,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.
keyfd26761d4d8ec902e430e2f2873417eb,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand
key2083c8cac03adec211d8494024c932dd,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
key0545c76dde2a9b8a02b425bcf9592814,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line
key3110db156f8a66279afc69ff74436aa7,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.
key82f287690e5c2a53344e55a7e8049e54,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor
key029c50d3a9dd9909c1303a67a4cd3ce6,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand
key92bcc544898305965028384e5eddca0d,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes
key9a5795f6b321db9be5ffa528729c9ad1,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated
key3b3e8d0d2d8e989ea0b788b7f5399c74,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex
keyf7f316b9887ff66a0f9d9b91d3254b0d,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex
keydda523c8c3e5ab69b0c0876cc45f902f,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested
key81ea924940bafcbf16dca8d77e495fce,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630
key0c4db6c11af39faa4baed19caa7e7451,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex
keya5eea46b59d54f498dc71605346727ce,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.
key25d3ecd39f7cbe7eff5b830b15470a71,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT
key9ca84aed3a0ab286e63497c541200c31,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630
key8de82443f64ccdcb213723a8481f8244,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin
key2e43127cfbfbdef6fe1cf1cc4dded841,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes."
key39616c44a8a10ef2886bdfdfa5e6c735,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes."
key9b5c2b3bdac75932c3389eb362118b97,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.
key5b1f298b3fad1cc17f853a8d317c08d5,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor
keydeb5c04725fbc47ba23931b3438ea943,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.
keyff274c1bbe91d76106a3935a85466e24,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.
keye09c588dceafea4cfd1e3db67ecebf86,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. 
key77cb90038aecb28f1c6f4c7b9f7ded2c,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex
keyff75c4b6ab206e9409f1e2875c3e0f9f,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor
key471febb55b7d516371665ce99504489d,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane
key556909270f6871dca3ee609d04b34bdb,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor
key3a3210b3f240cb5e215b303a4f3ca9dd,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex
key5582d02a275a0be48e3812dc91f22d9b,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex
key93fa66dd9f13de412295b0a7e0ba5b2d,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.
keyf0dd21b4fa8e46feac8963ed4d4454ce,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand
keyf46f0d502657a0ba9d674be58af95d19,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand
key677e1c654c897d90ce5ae84d999ce051,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand
keydeb5c04725fbc47ba23931b3438ea943,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.
keycc59c5833f3c1125d472c39676a91c1c,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes
key9eb44e3c0c16bd68a8ed0fb450feae27,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor
key837e1e82b531e07e4b7b9c5db2f80877,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices
keyac00169a6e514959ea7bec06a2fcbfe0,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.
key3c1e8ce3c83fcde62cd01b49f1ae5bd7,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584
key5ac07cdd14c94f921e1621846c45a0be,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested
keyb3c0948b51991df9c04ed008cdeb8dff,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.
key4389659360d1620ccb2722ee3ef0fbdc,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630
key9d5ced470584003a3cb92251db592e16,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.
keyaf5015b18d5ef87a38db44251510fe07,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand
key682cf24fd7557887977c9144afcbc086,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active
key708e11df758c1add64971d4df76fa633,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM
key0b18349223a5de53cd5a25bac958f1c1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available
key18277f3def8a8c80d049d0886644a1d7,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats
keyf074345f4dc3007a16d04a9ec7097059,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats
key883dc0e1d95ed7ca3f8f3bf301ece8de,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats
key75ea598590c0817f9747784508d80c1e,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats
keyce02e8584927524f1e74e2e44021dd05,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats
keycf71197a8787b8d19ed6c17c408bb7ef,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats
key078c49935b9a48d3649bc28903436a8f,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats
key75ca63f088d06fa5d1c1add8125791b2,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats
keyd0152b5e254ae94a67a8f58c8db2e4be,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats
key95ae49bbf2067ede39104b0f7db6040c,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats
keybedf5d8565f56bfd3e9abb32a17bb174,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats
key3cf779ad127b39b27cf4e85b05972b5b,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats
key7ae9e36a1eb3101b5e00f334b7372661,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats
keyaba6414156fc7bc1baa0b549d2a17778,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats
key7a8fe1dbe0b6acc9eff5468aa947c0f7,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats
keycb9a44f19f2ae94b704fc2fb97af6247,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats
key6a9e2367a8fa45aecfcb48c1f72f6166,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats
key5e16cd46477189445ffc65a6af6908e5,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats
key5ad99a6c02da6495132b5fc3a3d28e08,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart
keyff19fa454e4a8cd7d020bfdca0e0c6e1,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.
keyc88c1caf9276fc0a80bb181e769b4d90,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
keya4026ea4ab8d08bda3bd65d2de238cf4,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes
key7c0b3ebffc20990ca8a5497d5173e3fc,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.
key1649a297fe78e488878b0c22f85f0eaa,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L
keye3fbd2ccdeee9fe9b8a73ed66a5a4991,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L
key2591125da40a1de2811ecdc7b59357b9,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration
key4871c16b62ec9dd50f0416c9aad2e8bf,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor
keyb56b7fef562bc33ba0250f352391ad89,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor
key4f8d79ad8bcbffa33c271cb4b390d885,Affinity for 5-hydroxytryptamine 2C receptor
key2b0225f26cf413142dd2ce4ffd60b844,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
key8ce9f6b51345e7927e1cc9d2d3504423,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.
key88f1b6a8400e654d15543d41c3bdadb8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined
keye279122f76e90b233d130fd62e7d77f7,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin
keyfa75be50ac22e070a57c65275e9ab7e9,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine
key31d0e94211003e0c0339a22720ff23b9,Binding affinity for 5-hydroxytryptamine 2C receptor was determined
key82b5cdf8bde47ed074841122b14bc619,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor
keye2f148f630315a88babe217732209597,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor
keyddef4e40afd989b71227ee713981efff,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1
key602e26db719b1be47beeb82a5cc03065,Tested against 5-hydroxytryptamine 2C receptor in experiment 2
key705157a4b89131b7abfb0cd40e4848f1,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor
key768d09280de860f20b3c1a32a04dddf3,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor
key04fb6d2b6162e5b2a5f0baf007dca6b1,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity
key6d6921696ce5d23e118e3adde84baeaa,Affinity against 5-hydroxytryptamine 2C receptor
key86f6a6a266cda7d425185826a3ce2e1f,Binding affinity against 5-hydroxytryptamine 2C receptor
key3711563d373aeede4b082aa9f9205ac6,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay
key3242f9a79bdbf01b4c6f5c4eee310ebc,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630
key6158d25b9856ddb692305ac077503f27,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand
keyacd4d32d92d908b834a9e634789b76af,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay
keyc3f720ea71f48420e93cee827915572b,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum
key60effbfe16777c7a4374023affcf6198,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig
key7dcb902b177c4b14ea11d20040011957,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done
keye0641bb100551c95fcb311c092cd4af2,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum
keybe958ff6724bb603c27aeec1b1452a19,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.
keybfba04d188ff7f1f50acba7eccf35d9c,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM
key9172c3b003f43a31d702c4827b34c69f,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM
key64b69d2a7b46a93ef1bedfdfe0f3133a,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM
key1f964f220eb26913f04e10de78f48170,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222
keya9466a18e6643e380a0fe482e158ccac,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM
key5b3d4c2f7b3f774444d3d22ea6813174,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM
keya1f5cbca0d0471a468e71978a07d15ca,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum"
keya1ade0c37730ec89dff4433255b19425,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum."
key2418003f4a0d8d238564d264e33088c2,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum
key4a5e285189907418f6bcb9a46e49ba36,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum
key7341d4238f0db8261fe7c6382d0b4ddb,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested
key8efcd76bb327c707886eb18ee96048bd,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15
key97d376ce11d6e1cd1247e20954dc4e64,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
keya8fc5f632c14c690dc4125ccccb9d5d3,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
key43decdaf9c3f22fde3d7f11c758e948a,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI)
keya217b010364619d9c95a986031067cb9,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum
keyc58c77a5e9622a40fa0c34714e4a508d,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay
key141dd651b829531e8684d38ac199c45a,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay
key97d376ce11d6e1cd1247e20954dc4e64,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
key788ac3eb5e93db49c90ba1f9ccc7cf8b,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
key97d376ce11d6e1cd1247e20954dc4e64,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
key4d34e150fbefcbbcb08ffcc375a63e55,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined
keyc50dd30135b127fb162e03ddae6237f3,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined
keyf36f6f234eca50e615f0e82442bbfb4d,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.
keyed3d58a10c43dd2baef26ab71591f620,Binding affinity was determined against 5-hydroxytryptamine 2A receptor
key895636ddd8877a8fca7d3e81eecc40ab,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell
key38250fc10c4c288d3a6e5f0836aa6ff4,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor
keyaa4834665c66a1096a8ceb24c3a62cb6,Binding affinity towards 5-HT3 receptor
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
key454bf5727fd37b467a3ab5853c3d8974,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.
key69cfafbc0c9a01aeac712d4ebb682c89,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor
key69cfafbc0c9a01aeac712d4ebb682c89,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor
key0526188b6bcf836696f2da741cba74ab,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested
key587ab18d3d8a158b564cf4b7e5c02b2e,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor
key6e6b0681d881d97285eb61b223461f12,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells
key7778971be70a7c4f1fe1b8a5b03a284f,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)"
keydadbbef580c77fff2c796eb1f6756e73,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)
key1e58c80dcba5945ea7556eaf7068e663,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype
key6bd340d4bb69641c8a52ba2bda1b4870,Compound was evaluated for the binding affinity at 5- HT3 receptor
keydadbbef580c77fff2c796eb1f6756e73,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)
key19ba54f68c196db88798b70f44547afa,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates
key7d06990e56a84dbd8503f642a741dbbf,5-hydroxytryptamine 3 receptor agonism in mouse
key5a4a5ebceae87953bb5fd33b681aa509,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells
keyafd2e86a814b96da0c097074690bbbee,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin
keyafd2e86a814b96da0c097074690bbbee,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin
keyb5671b13ebfaa4dd5d3404f99b06290b,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron
key8bc74cbdc56882fc914417333c3fd8b0,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand
key949814c0b086309f2b44685dcfaf7b29,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand
key079bc3b3a50904258323b6ecdc9bf670,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart
key5c46c4eb9cbed091b186642dae96aa11,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells
keya4e43b05d39d0a2abbd969f6e4d2f989,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand
key90e6f0e5e2fc5678200b479685b63e54,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells
key9a51845d263072c9810a23c04181ce1f,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15
key57a23662d6386016615b279438d0fb1b,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.
keyf61cd4dd5379b9d1d4c5aa9917deffc6,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
key594259b51434a1e46c7bc56e8b7ea3ed,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor
keyb2bf879d4c5f91519ca20e5d6ab40429,Binding activity radioligand.
keyfad56369a35947caeb3cf56c84dca36f,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus
key079bc3b3a50904258323b6ecdc9bf670,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart
key392faeee1db56fd36bc117a32c7d306f,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart
keya6a096fe6bda14c43512cd0136294ad6,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex
key422a26b6ebf77485f1244c8f73df1028,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
key8727bb859378d8a63c44cf8cfc7bf9a6,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
key788ac3eb5e93db49c90ba1f9ccc7cf8b,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
key6401e9a6b371f147c649ba03d3946d61,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
key6b788972da872d22c366c3c57db88075,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
key6401e9a6b371f147c649ba03d3946d61,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
key48bdd8d09c7f07627f2bae2a8eadffcf,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
keyd89eade084ff6308115917c0d96e1f4f,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand
key368aa82cd43f8281e3eb416fbb0f2c97,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor
keyead09c65a6c645c84bdf4ec90d092d31,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01)
key90f8b394b3c66ade933f22c7589a7356,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01)
keyc1be068f95404c81ddccdef618471c2c,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells
key7a145866e1759472e14c51308ef87109,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630"
keyd1a317a3b2b138b8c4038999072c58e7,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate"
key97178e4fd3a10778acdcec42cc44ea18,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate"
key8ccb39e748e27067b434c32bf680c5b3,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate"
key9620e32449736198ea6508bc6fb0bfd1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate"
keyd533708c8d90514d1e5d4ebdc42d791a,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate"
keye0a6e85e0e4eaa0e39b058c6b541f0f4,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia"
key691729614003b7d19d2620750c645310,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia"
key60d51e272d2636ab01f39f9cc751ddce,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia"
key0fa15c5a23a8c51e1a93fa3cb7337f5f,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia"
key88add1aea8e322fb29bd47d6000e5819,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism)
key363582ec2571c765808a1ea47a9240ba,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor)
keyb306746167ce836c58345cfb823605e0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats
key653457cb5db23c86befc0add99c692ef,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+
key6f4fa24a9ece1bdfc01736d0a2299460,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration
keyf6c1950be9c5e97765624000fbfa0b70,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism)
keye5c10b0cc9b2729fc4182ddf652740ba,Binding affinity towards 5-HT3 receptor in rat was evaluated
key4f55a0cbccc47976d2deb369c361636d,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor
key0e8d0342a3903866878a297f947dc9d8,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor
key2456f1d80440c066f87e2df9e8ed7350,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.
key1459dcb14778a8c96512b75065c4fd36,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex
key9605695332c2b9537568998390fe3a2e,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand
key99790c3ab8d55aeab93a169ccdfcc7bc,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates
key64a7d0ca1241a666c93e4f74d9992857,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane
keyacb7f42a78c9847c9716535183618029,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane
key37920d3758b9053778ee4e9921532563,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane
key4ef47d7a1b629713a470f74478a8271f,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane
keyaa0f26521ae1c6bf606ce4f08f03bde7,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.
key434f024a7a127a89e65a6c3dd19cc6bf,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm
key233f32214aa782bfcd7e2df9b340a9f0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM
key8964d8793040df29deb73a216b302ef9,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor
key677e1c654c897d90ce5ae84d999ce051,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand
keybd0437110124fc1ea25f8c6afc32d52c,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50"
keyabc9d67c7da9cb79a5f299f93d3776f1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor
key5ac07cdd14c94f921e1621846c45a0be,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested
key78fadef6bf85bcdffc3ffe7ad1227fae,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor
keyf270b5e5a7e544750ffcf195bf20861e,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand)
keyb60264b6a6f38dec4304f271312f1da7,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand
key181ee8e53bc5914e8c8c8f543821be7a,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand
key84b5173cc5694a4ca1c4ee25d01eb305,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active
keyfc2f5197ba2b4155298ec2f153254b85,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active
key51386cc297d839d25a604ab7af15e1bd,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active
key9b19fd60e798bd302df1923313ecb691,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats
key2f60d8a71d6029d3e7f7019a1e0eb43d,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat
key3b9be93d0410117535aa319c6062648a,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously"
keye8b751b7ba67d60b48158a90b51de7c4,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats
key50026336c2351c5bd422e3e7fa23d5b3,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats
key0dc18a4d116d4a6362d0e2bde81dc0a1,Inhibition of 5-HT evoked reflex bradycardia in rat.
key46305dcdc40454038f67488d1f0d308f,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
key1f5bcd42e06051be29ec4895497d5935,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats
keyea7c4ec9e9f2205440c1912a41367c76,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats)
key76bcb76183630cacf6c289ca38e71a94,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats
keyea1847d98ad3767620e03476c54fb36a,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
key79bee0278ce121dcad1b9f4a878c5b2d,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats
key02131db07e255f16177cc498ec2c0e1b,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats
key42c4fcad39ef5acf04174afdf8e53438,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats
keya091d6322ac0f8fdeca7d49e55326019,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats
keyd117e9b679a53932174ce8ded67f3de0,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats
keyff32039d6fa2faa856ce1e3b0ad07949,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats
key9771d9278db4c54f432dab2ab11b9506,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats
key8f8c2d712e389f2572bfec123935483a,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats
key54dbf209d19e4baa4fbf56ac55952af2,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
key023baba36da66eafd9259d6c8aac5993,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats
key1499177b45f3e09c0c2f2285f67b3c59,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats
keyf26c43192d05a1ed81cabb0a616d0b7c,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats
key6bed2dcfd39f1629b81039bb616f53c6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour
key9cb0e9ed47659af457883537ee0bbe9f,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour
key77373ea62670742f6fa3fac8ecd9c05d,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour
key69fe557680a1bb202488f57cb990c6cf,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour
key1ecf7133324deaa3f4fdba00ebd82a2e,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour
key5d8359bed990c27289e52208696030e8,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats
key4fcc8ec3ccec338695cade84aee1518d,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats
keyb306746167ce836c58345cfb823605e0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats
key5d8359bed990c27289e52208696030e8,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats
key222f1b8c5d98b9ed783dcaad1a070d2d,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats
key615cb64a5231e5dd9cb0c45a13a2cccf,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats
key3628d48257391f9768813ad4d1a6b94d,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats
keyeff162c88931c3267cbb2d19d9abd11c,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)"
keyadbfcc15f76caceb5c44a83e7cf46836,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested"
key2cea821ab62ade07673f669cedad1e28,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg
key47ee505a41fc2c0bd4eb1188e43acc8e,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg
key32e86914f9bfd756786c7655de4a0186,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg
key9e8dd42105c943ab3c01e56c2ca8fc17,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg
key959f81525aac57ffca1c4970d091e90c,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg
keyec05ec611c6381034b446df7edf76457,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg)
key089a7c0de5592f07d9b4b0371187f93d,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist
key089a7c0de5592f07d9b4b0371187f93d,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist
key2365ec7cd51be416ceceddbe4a8961c5,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor
keye6b6ae6916f5b40171fd40ec4dab7304,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist
key92a0cb0d4464d6bc1ee9bf1ba38f4422,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue
keyd808f00cb4eb4d41277fae12d1a0d5b7,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane
keya7c780d804572dc28439d220ba645c78,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor
key20b79146a95ef30297846103c441defb,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor
keye9c9632512912565fa2b8656a8669212,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor
keybd961d50cdd70500ddfe58827485099f,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.
key6eb00c706ed4f31ab152e94a3cbfcfd9,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices
key9fd62e5424ede88393db9d1aae890ef6,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand
keye5c10b0cc9b2729fc4182ddf652740ba,Binding affinity towards 5-HT3 receptor in rat was evaluated
key979bd4ad968b333d713bab67c74fef61,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum
keye09443c616e7f40dc186f9e298ab0819,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested
keycef1db5d877ccfa7347ddd33bd7363e4,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum"
key8c2e3cf23cacc682e30fea5d86652ffc,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M"
key21a60a1f7ecdefa7da8b1907e7f2a198,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested"
key21a60a1f7ecdefa7da8b1907e7f2a198,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested"
key1e4d5c2fae101609dfd05c7a5ec177f5,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation"
key3c0cc6c5ee106f4d7021db03fe64fb1b,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.
key9b476dcbf30c9dc6b5f0bf743a3f456f,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.
key7dc54af38f6c4b3d3223e451c0bd07c7,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum
key931767c0bcdcb64503c08cc6909df14c,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable
key82df565e585d5fe6e59c4ddb33d34ef1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested
key033cdf4bb122e5953fda2f223dfaea08,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum"
key92a4cd794edf488977ffa1df2924d4cf,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M"
key16b62671cf60fbec16f333564a920d06,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M"
keybd53d32e9d7a4183c0075ff47e2e219e,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.
key29598bfe9ba0b57e82afd1bd9ab20198,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested"
key29598bfe9ba0b57e82afd1bd9ab20198,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested"
keye8622917ede1408abf680b02b4b45d18,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum
key9187ebc0df4ead635a9529d3d47ccead,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated
key2c6fbce5a37260bc9a1f160abf3bfd64,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated
key656d12020cc8c16ad32bbf9bdf3c3b3a,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand
key355588f2941f7cda53701e8f17fa0879,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum
key7adca3442c84a08b5d775a688d1cc673,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum
key371456760193f422693490c352221f2d,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum
keyf91addfffd37b8fc433f55a514ccfa84,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.
key1cc8581704d4be060870e353fc4f637b,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.
key6d87649f6da161550c12296c04097b2d,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.
keycd1680ab07a289e3642cc871742ed826,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig
keye5143bb9fdbc08052e673d9eb576c669,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig
keyfcf90b471a46c7e27ad111d70cc8abe8,Agonistic activity against 5-hydroxytryptamine 4 receptor
key9f17595c54e626e5a7d5af50303c7acd,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested
keyd89d47df59dd2d2942b9c2f95ee04d4d,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor
keydcfecc4ee6626f37e3c375d4fade6fe5,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor
keydc1db44dd70d9949ad64814070e3e285,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor
key7705bd81e06e3b61fde1360dea71c459,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand
key9187ebc0df4ead635a9529d3d47ccead,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated
key2c6fbce5a37260bc9a1f160abf3bfd64,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated
key4a33e87efbe197c7ad7d8959a8647871,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.
keya284a22acf58115f27fd70b731a436d0,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum
key59b36ccc4261d4434047e1bea0c54dde,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM
key53ab3d3f5820f00b48b252b9a14702b7,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.
key77530456fa154ed3624b72fc3e9b64a5,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM
key8844409801a3153d3b95c060b5f1dc09,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.
key13ee67e515ff343309f5093a36ceb36f,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay
key404a238ee57f61fc1bd8b762e78864a6,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation
keyb794f5887f385eaa0652b8b6747a69e4,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).
key4a50730807c0453ee64da624065502c1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.
key2633104f338360833115b1b42880b905,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP
key910abf9e4be9bbab9066289cbd05a105,Binding affinity was determined against 5-hydroxytryptamine 3 receptor
key59e1f71a3cf94365ad5f8ccf75a5ccc0,Antagonistic activity against 5-hydroxytryptamine 4 receptor
key26d4a282199630523d1a5887a4de1080,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor
key3fa52951a704e296de54fa6302c750d5,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.
keye118caef5787dd86c1421e9722af163b,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine
key28b20d2fd55d02ce5e6ace29a50abda3,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane
key1d301fa73b2bae47b765288bf897893f,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand
key23aed7a672f65e84b9ed2f92e593c62c,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.
keyf0e75e23b97062949f949e38988cd6e8,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand
key403a2ccfdc04b9889005257dcc3253e1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.
keya300979c2b13242587e4f67fa252b3d9,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand
keya06fa6daf618ef82d88476a64f242620,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.
key6d87649f6da161550c12296c04097b2d,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.
key9fd84a98053c2a1c2c0b85caeda3f4b5,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell
keyc75d7bea525cafd9715bce412a1823ed,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand
key7b4459be359f08a0ae7c0699dd3d72eb,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor
keyb1f061d60677f569b51f97a976d3a206,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand
key9c5eaa811e241c688d788d98427c7d22,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor
key159a49a2eaac266835950904a8d70793,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor
key761a0c3e393a9c56329003d2420f5320,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand"
keyaa9139d7f18d0f8f518b7ea5e2b4efb6,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons
key37a74d696e35d21751caebce2d17a97c,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive
keyd85d95bd683ec2ee0b6acf37c3474aca,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells
key842a2ef50f37ea1a53904bbdfa5d01c9,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons
key4fdd739516954d69c2364a9b3e16924e,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model
key1c0240b74b213430b8c24ca0c83a4b75,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM
key79454198809b225c6029f36a1bb73be8,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor
key4f102208ee167c484eb3e2c442cb0e51,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor
key2b5320b8b6797d9e7bf712ac8c00cd9f,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand
key9152fd9c8a2f12840c6df26b19aee3e4,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.
key67acf740059624e6a77a0ccd17d2bf6c,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor
key54e9f97339ff4be58c5a1bdfc507088c,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae
key950c8e500400cb2273334fd2c10b332c,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus
key5fbb281b26ad718516ac3f69411b3cca,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity
keya4d577892097d77eb1f6160b5d6ad0d4,lntrinsic activity relative to 5-HT receptor
key810f2df4be4f090cd8f0d3eee176aa25,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay
key7740ca35819fee939673f8b34b59f27a,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.
key68df30eaf7bc2e1f3cb4701301cc8b8d,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay
key5782e2adaf0201af4749b237954691ff,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive
key06e02edf76b20e66cc9174e25ac96d5a,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae
key488eb08487688afe71d69be0d46860c9,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture
keyba1e6f827021583515fbfcbc35883f97,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae
key9cb4e0236719fb8e293f2fac9ec9fa15,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae
keye9488ee6dd364e99ea7eb065dfe434b1,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor
key9b006a5b363b25d1ecc1bb78633b40f0,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae
key3925169812438c587b39450fb17ea315,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.
keyeabd68d76ccd6be756d36f6a78c30e3b,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration
keycd3d4153e50b4630d019f85d0790603e,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum
key1d240c3c4c0c5f71ff36badebe3e9676,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand
keyeeb6d12f64892bf6ede7d7e2c69b3ed7,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested
keya2a72a43dfe84a586d53d999be5e3380,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand
keyf5d072dcc1e8183831f580de2a5fe726,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum
keyf5d072dcc1e8183831f580de2a5fe726,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum
keyadc1fc47595e63a67aeb5a5267506467,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane
key696b9916a885dbd4594945ec533605a5,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.
key7d0f89ddef3fb3c7b5b9417183b92326,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.
keyfe57262320b84f6f5cc7b0ace352a344,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane
keya438e15e128b86ca0ed21ece279bfd2e,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.
key994b4be6a35befd89881a419301e9566,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain
keycb99ff6d0f9584e5ddcc214ec9167216,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat
keyf7618342afec0884a901e2bc11116433,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done
key5d800f5ab418a4e49fa1ad8a06752b8e,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae
keyb88d8c405d37451b8913e8c7594676ec,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested
keycb97266ae6857dea4a09eb1621293897,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae
keyc58cdd26ce4f713d2e0a3b46fde21908,Binding affinity against rat 5-hydroxytryptamine 4 receptor
keyf3e2df8c9d46697a4c8d5b76be7c2a7e,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane
key7a48b0fe0cc8c2f387cfbe7dbbf02bb6,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.
keyf20419c94e4f9e52ccf384ec0f3a9c81,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.
key20558101222a2212ef56e9c171433e7a,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.
key8ca3084976b4d52d42ea40bde580fbcf,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.
key0417e50b8d0cc54cb9d271b96620b9ac,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.
keyb01e0a3a4a42f9acc67ed7b7058bcf8c,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.
keye5fd853425328e659c5a0794de535e89,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.)
key6c00b95f61b240587b33811b6318cbad,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.
key414f2de3cf226ef307f286b42eb3c8e2,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae
keyfba4aebb32df965010d716c0d10bf9c9,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM
key02bd06da25d7ae3d1cc85bb7960aa3c8,Tested for affinity towards 5-hydroxytryptamine 4 receptor
keyde4cb7bb9fc13536af33f14b6128cc0c,Tested for affinity towards 5-hydroxytryptamine 4 receptor.
key15b4837ab4fe1282408384404a6666fe,Compound was tested for 5-hydroxytryptamine 4 binding affinity
key333c04e8bd26e3fa71ea083243f3b1d5,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor
keyc722a06757b587823d70a8487bb45ed3,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
keydea901a0a64c588b05db35b31c35837e,In vitro binding affinity towards 5-HT4 receptor was determined
keyc722a06757b587823d70a8487bb45ed3,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
key7ebc20bd23e3540059bfad635157cfe3,Tested for agonist activity against 5-hydroxytryptamine 4 receptor
key50945425b978f80a8bdb7a781ea3f1d7,Tested for selectivity for 5-hydroxytryptamine 4 receptor
key870c5016e43c3311f6f97d73e26fb069,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride
keyd7b2fe106fd4fd6a22ad49e7d5e4dd5c,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride
keye79f04c90bf98378f4b47e1f237df8d9,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride
keyfc97328ca318d2e77fdea5b2898cfdc1,Binding affinity against 5-Hydroxytryptamine 4 receptor
key51774574cd7e1c871668882037afcc7d,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes
key5f717932a77296c431f9aa828bb245a9,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes
keya49038943a1634af5e18c0b545ba3ab9,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes
key9fbe28f83b5c8dd67ff4d56d401fccfa,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate
key5a3f55d596b252ba8cab4e7c9c66d9ac,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor
key299e6097865ef7d3d035c35d34532ce8,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex
keye54332a6aa2f027c56b030293c8acc1a,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex
key3338221353b0f77ae6b78da73a60d00b,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex
keyac31422b0613d729c757b52402cf15bf,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist
key8bedb5618cfd19bb49103409611c328b,Binding affinity against rat 5-hydroxytryptamine 3 receptor
key303819be181816e0a5744fbaae26fb8b,Binding affinity against 5-Hydroxytryptamine 3 receptor
key3d6969dfc7c1db86323af04c1cfb03c1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex
key47faca25d27a60ee95b680667a1895fb,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.
key60179827c609d0ed95165ebf1a45ce9b,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex
key48cb5b9442f83d184804a8e4b05de3d5,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex
keyb796b261189001baae1173422d3046c4,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex
key22f0b143d5bbad95c9bf69c59e852bab,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand
key514321e015425d15a6e86d44e47d0785,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.
key0ee39a34ce1adfd7358f9471d77f6ecd,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand
key93d7c361037053ea64042ce1b3365aba,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.
key8a261b31636ee65e6297d2cb8d3ffb30,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor
keybe95eeb63122716db8bca0f1680035b5,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding"
key4c201c4697e04450f9eecb9af1c14e74,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.
keyae354e7a2a5bdddc60e05d50a1659d73,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor
keyb46ee3107a42a9cddc6887713e2dea91,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.
keye145ec1f092d13fc7d79603befb5e415,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor
key06856a12ab8efd3bd364e73264789096,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.
key0a15d4a9dca0b57db972eed98d70896e,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor
key34968cb9dd2a3bbcdccf2fc867879bdd,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.
key8df498ac9d1e9e1b071c02452bea5553,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.
key5dccd0aa7307a50a61bf3e77fccabf80,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex"
key19ba54f68c196db88798b70f44547afa,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates
keyec99f63033fb46d274a5a770a5469fd4,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine
key86f8771412fafc828e5a7e2da6ec5aba,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.
key5d2307b33506177690afd8af500825a3,Binding affinity towards 5-hydroxytryptamine 3 receptor
keye48d5868532ad75916c3b34c9757960c,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding
keyd63e84e82a72d2cde8b2348aa9f34383,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells
keyf1c7d5e3450b4b182e14a7835dd4f8d9,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex
key4e9fe4f61b51ed56d942ed279f3040fc,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor
key5d2307b33506177690afd8af500825a3,Binding affinity towards 5-hydroxytryptamine 3 receptor
key7bbda1e8abcebc91fd98f89d67520f6f,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM
key3bfdf7f748fda609c6f43226844cfd40,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM
key96563a747d24f0b0fe4d66d36ba920e8,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM
key28881f85aeedf0fd9a85db168e498393,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor
key3b776594f4ab02c6ac3b2e44a66be2e4,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection
keyf01da476bee8c76f8347b8ff944f5bf0,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand
key02e01250d62257a3069004d87c00313b,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist
key602fa3e5516dcb7ef53170e9fc73f098,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist
key602fa3e5516dcb7ef53170e9fc73f098,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist
key7ad5b296b9c368b599fc97f0fa086476,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available
key45e74a0c837d02f49f236620a1d60e8e,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist
keyd37e651a50796710ed920fe5ee7621cb,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist
key2d2b4377a96115e437b75bab4e1ac5e2,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist
key20c7d7756472fd397eb1a061c9a38979,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active
keyab868d7f12d8455b8c7f92453cca349d,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available
key7c0df2f3b86df923982b6da4e71c805d,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist
keyf9245e3260a843c14baef70e0ceb51c2,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available
key5d2307b33506177690afd8af500825a3,Binding affinity towards 5-hydroxytryptamine 3 receptor
key6d7d1f44dd33d4507bc55ac7021e5b56,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined
keyb590dc236f3b0c9f5e0869b1d3ea2c37,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active
key180145393b0d8bbd7bba58446d66e8ab,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630
keyef9ed3195dea450b9819243300afe59a,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.
key3d2247c79d3b08d8ddce3d108ae05c5e,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand
keyabc2e8c6a69179a1566183e44d88bdac,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity
key80559d2ce3533fe4d3d966410f699395,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity
key00c7f687bb38c487e2c0861e058218f1,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells
key808f1a57e48215a0597288d327eed143,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined
key487d568ad27990a5df64a85e6ea24cfc,Tested for 5-hydroxytryptamine 3 receptor antagonist activity
keyb5543129c972420e25a7ebed1d90236a,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM
key56aa51b0e275b25e76106504fa60cb7c,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM
key976ba2a1e1449680e349465a02bb60ad,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222
key7f223cd89194d9064673ea974899b708,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM
key1392d89e47bbefd37c71cf308dbdedc1,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.
key5d2307b33506177690afd8af500825a3,Binding affinity towards 5-hydroxytryptamine 3 receptor
key77eafb5e093e3f917ee2140639a3bfc9,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay
keyd2b92c8f13938d7c14651751d694031b,Tested against 5-hydroxytryptamine 3 receptor in experiment 1
key3a764aaff121dce14c28288fbf303bed,Tested against 5-hydroxytryptamine 3 receptor in experiment 2
key4d8cd9562ab8cae3aafe3128673633a1,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand
keydf4dda7ef93ba292286e192b2b9023cc,Binding affinity for 5-hydroxytryptamine 2C receptor
key5d2307b33506177690afd8af500825a3,Binding affinity towards 5-hydroxytryptamine 3 receptor
key826d7318c2e415bb49e684294b0b0ede,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor
key28881f85aeedf0fd9a85db168e498393,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor
key64e47e76647e6f8d3ee2fcb74ffe9f30,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor
key9b5a4ef060bc10fa6380560d47d1ff00,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M
keyaa4ad3180f57d87b234a77536565e011,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system
key9b5a4ef060bc10fa6380560d47d1ff00,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M
keyd63e84e82a72d2cde8b2348aa9f34383,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells
keya752e150abfe655bd05ce14080113088,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor
keya752e150abfe655bd05ce14080113088,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor
keyabc2e8c6a69179a1566183e44d88bdac,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity
key556909270f6871dca3ee609d04b34bdb,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor
key90e6f0e5e2fc5678200b479685b63e54,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells
key54ef08bd062cc6841f3f2afc0af61931,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined
keye6d69de1b6f3bd5696b188c01d76640f,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand
key43501f9daae0e053ae49032173dc43d8,Tested for 5-hydroxytryptamine 3 receptor agonist activity
key93d176437e1749789854ff83c2696739,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity
key96ac5834f825415d6d3bfb4badb29911,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes
keyc948ca2cb75f14cedf5488bc0cc1f4d5,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes
key07b5002536714438de5970a8412b9afa,Binding affinity against the 5-hydroxytryptamine 3 receptor
key4ae6957fdd7d00b5e7c5b1430baf956e,Binding affinity against human 5-hydroxytryptamine 3A receptor
key7b8253aab089d54af45be90dd309ecef,Percent efficacy against 5-hydroxytryptamine 3A receptor
key4ae6957fdd7d00b5e7c5b1430baf956e,Binding affinity against human 5-hydroxytryptamine 3A receptor
key428d3ccc961e03db29945ad7acbd922f,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes
keycdda6c5dcb8dcaab9b64d619c567e32c,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes
key72b92865d44783f4b8155d94b1d1f7be,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM
key6b5806563944741533ece17f5dd24030,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum
key9fab0ecb5f77386fc306e4cd0f162d88,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum
key0e8acfdca1604f456cbd49ebc7be10be,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response
key56c4e026799e1a1e46365d7dcd710a16,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum
key45bdb880965a47a020b0e14599774482,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation
key36a522ef292d6b125d04819dec66c9a2,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation
key239dd96d849496ce9effc571c2cecb8d,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization
key338f258cbc01f6f0c5e66d091381e49e,Affinity against 5-hydroxytryptamine 7 receptor
key148537c2087cf0bf69de4f7ce0a2d50f,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand
keyaa1fd64dbdb10aed9abd45d72eaf9ff5,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand
keyb3698d81ce7b8122d2b66fd26ed87373,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect
keyee0b9a20bafc35b4dc663b4eccc09827,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd."
key9f0ee88e6d5d8df886cfe783912ce0b1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd."
keyd43a519c1165c1b208cfe345e4b28af2,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.
keydf47164751e0fab64d9af0c72eb7ff88,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.
key61847e505611131fa1ec328cac34aa96,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes
key45716b287d9f9e037a0dcaee05fb6286,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes
key1451d9872dd56f4546c3fb7ac527bc78,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine"
keybf3df7f507866a70a993cfa6ea732c1e,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes"
key9d3fec4f173545785cef81017dae27e3,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice
key23ed52427debe28b60407da81f765df8,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration
key96f717d8fc2f3f96415f5f2d6628de93,5-hydroxytryptamine receptor binding affinity was determined in rats
key70beef54a35665c6e589c9d3810d8dd7,Binding affinity at rat 5-hydroxytryptamine receptor.
key1a6e2992e9aae48f9c3c210c08504bbc,Affinity against 5-hydroxytryptamine receptors in rat fundus model
keydc5ed847ff1893076ca023b2a91ad1c0,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation
key893e7d781160354fe257590948f76ad3,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined
key8386af42e35cb9942ab76bc2039c2a36,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation
key96422135cec2174bcfa520f5a5e34f45,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).
key31682734f9768a61de25fba8ccf3e6b2,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor
keyfeec0a7160f4d3ef39b3231efd9f49f0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2
key99e0bb2065b29fed9c7b3c4c7c51354b,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot."
keyd5d616e7238bcb030e0cf0a9b2d6ff71,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus
key9628a1bce96b6a08d63567566241349a,Binding affinity for rat 5-hydroxytryptamine transporter.
keyb13812fe87c87042463f3e8dfea3d80f,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.
keyb4f1bb9bfe1a25aad481b8c648920ad6,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT
key00552174f9b24b7a7557a4d9281dc566,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor
key6b36a4f27da75476f351ab82359e7ca4,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum
key039ae3773632ff3e94f6a0e0a15a8758,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.
key3f7d91be6791ba6914f97495f4ca3a4e,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M
keyc4869bd0ade6d93c42d287101266d920,Percent binding affinity against 5-hydroxytryptamine receptor
key64c5bbd5a2e3cb0e76b203ae6537d4c5,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex
key5175fc06284ad3a51906d59ef21b116b,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.
key135a9808978304174948998b918c14e6,Affinity against 5-hydroxytryptamine receptor was determined
key29f043e327a9b3ec763099f999787695,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip
key357c270f23b5e08f27c9a429eb1e6d1f,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
key357c270f23b5e08f27c9a429eb1e6d1f,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
key8799f6f3734496f6a2b63d76d00662e1,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete
key5233caee22e3f83bef2ee281448dc469,Inhibition of 5-hydroxytryptamine reuptake
key82effcfc8fd731ef703eda966c2865c0,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding"
key02506c2c6ec3f5dc3fde7b1839752561,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)"
key1b27dfdb32ea404a3d164a7bbee4dcfa,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)"
key36e396dcf66717bb4ae34ed196c63b40,Tested for 5-hydroxytryptamine receptor uptake
keyed3076a9593bd963e38a5f368446b7c3,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A
keyc019cd4f724e779558cb09f9a5659293,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype
keycab19cd75b0b9ac76b80f43511cb37c6,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.
keye94038e97288438c0e2a78194299137c,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A
keya4a5b29512c04a41384c6020b53c7cd6,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.
keyb43579dd5ba4e6a5acf7a1b2d2524c48,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg
keya8e43af0e6924d431677914c78e58921,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg
keye12d81554238eb9c0e560d61a52bb2bf,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg
keyc9167ca03da4892920ef9ac73156e851,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg
keya41dec92878522f9a8e1d92dbe760f4d,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg
keydf78dca7d86d0d120dd82617bcc9af88,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg
key65041cb4a549f4194d9d5a3e154dc3f1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg
key16126f311836f04c1a5c55c555b40bfc,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg
keyd78acdbc1b27678962d0aa8f3da48bda,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg
key2d3108e77c7d9cef9523595898e274eb,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg
keyf77d011b8c5ee40719e0d9e3f5ec6c17,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg
keyb225ad38e003c2db50604f065624a039,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg
keyf5f868ec90034d3b9e056c4b6637671c,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg
key9ef822a2a6c1b15fd19c900009c040ab,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg
keyd8c4d8bedd3c16694030b2eacc9b3162,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg
key8d7edfeb96485d9833a8f3ea60392281,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg
key76579a195cc3ca73a1f7262ed033027a,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg
key1e72c23c9052479afb55b88951932d36,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg
key3517b611fed5d2d1803fe109a041593d,Binding affinity against 5-hydroxytryptamine 4 receptor
keyc722a06757b587823d70a8487bb45ed3,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
keybe345efe2160a0d1e98fc4165157473c,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration
key37ed96234a8f6cc36db26a4cdbc255a4,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor
key7d6c057400d863c7d930c7bbd768425b,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand
key34f0e64e50ee1be6869bbfb72d7bf2ad,Binding affinity towards 5-hydroxytryptamine 4 receptor
key8614dd68be6f601058dbae295ea262b2,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.
key8614dd68be6f601058dbae295ea262b2,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.
key91ddc2ac72319439512f986c2afd2770,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells
key601ec8d88cf4f2bca78f0c1944f43ad0,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells
key71525349624a4fc3bb93ad8ef6b3adaa,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells
keyd078fe4fc27f36525f567549a0fff2fa,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells
keyb09683d4fd5d353dc8b1c3762cf1258b,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand
key71c3b31f07303159a1498470408cfe66,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand
key6e1a46da8fb59ed74c438dddfaac496d,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808
key646b6604ce82b941b773bba21afb8418,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined
key4c0ddbb595b8e957d6e8304784f1746e,Binding affinity towards 5-hydroxytryptamine 5 receptor
key6e75df02a35416afb8bab7ab26e0ef75,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand
key0072feef6ce89579388f29c99cb941e1,Binding affinity against 5-hydroxytryptamine 5A receptor
keyf1137eea481433f233296459c3ebe1d0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells
keyf040003f737980b9dc90aac8fbf650aa,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor
keyaf18c13cea505eecefe264f3c7cb5a28,Binding affinity towards human 5-hydroxytryptamine 5A receptor
key6ce415d8295340296b314c7c5c7e57a7,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand
key7187107b17aedafb725f6e03685e00a3,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor
key0bcfa67d3917fac0f6faa7662c1d6fee,Binding affinity towards 5-HT5A receptor
key408db5457416a3a5043395d35d858309,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand
key1d133b73fb210ccc04f1441b2aa58bb5,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor
key87b21c546a44145326b50599ac1c6ada,Binding affinity towards cloned human 5-HT5A receptor was determined
key38f9c412df3914330c11c687f6b2e34c,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
keye37ffb0a38419ccc2e00f37268074ccf,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.
key0971316fa5e3638cc8de5731568b3ba9,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand )
keye7442915f7c6ff5b4aed59c590d6e00e,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor
keycc00f35cea882e482876fd5ea5978266,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand
key6095a28b0dd0a5fc9a511ca1140a37c4,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand
keydb4247358606abe4dfd2a167d671c495,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand
key16d2e8dcfe83899b538494934eb33b75,Binding affinity towards murine 5-hydroxytryptamine 5A receptor
key2faad8219cab7122d085238e41479914,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand
key18ec7214a00fcaeced734c01006feab2,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand
key18ec7214a00fcaeced734c01006feab2,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand
keycedef669bab2c7f8d5c207059663fa81,Binding affinity towards 5-HT5a receptor
keyad9bcb34f5be456a79c6f595f1b6d35b,Binding affinity towards 5-hydroxytryptamine 5A receptor
key44f508e0640c942fc87e4d535b0d07c0,Binding affinity for rodent 5-hydroxytryptamine 5A receptor
key35c45e3b4117fd92dc5ac7f98c7cfa27,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand
keycba23ed330908c50985b36e419e3af93,Binding affinities against 5-hydroxytryptamine 5A receptor
key1c405367a4e1564910b42dfabd51d9a1,Binding affinities towards 5-hydroxytryptamine 5A receptor
keyf5b1c1125fb81e5184ed32e30c2a9df5,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity
key0d357042507adc18dd7aa1e600b2c4be,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM
key5805d1af26888eb9cb7c4c2b508de9bb,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell
key73cc7e66c45fb7c8cd8cfd637fed6b78,Inhibition of human 5-hydroxytryptamine 6 receptor
key3e241387f519ab985fcac7a3b7a9ce2c,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand
key6acd0baccc910e5bb908a9aa705b534b,Inhibition against human 5-hydroxytryptamine 6 receptor
keyc5d4423951f61f1641f53fba66f54df6,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor
keycf4426159fb3667f2f100abbbfd0e9e1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.
key5be0f6b8d54b3bf694a35bb8f60769b2,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor
keyebaf4432b9d23df54f571829cbbe7c21,Binding affinity towards human 5-hydroxytryptamine 6 receptor
key9baefc5339d115333d70b20f10b40719,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand
key72d73521bb74a843597546ed806f6d1d,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand
key4dcbed6be973bcb307fe82d0759f1c36,Binding affinity against 5-hydroxytryptamine 6 receptor
keyebaf4432b9d23df54f571829cbbe7c21,Binding affinity towards human 5-hydroxytryptamine 6 receptor
keyebaf4432b9d23df54f571829cbbe7c21,Binding affinity towards human 5-hydroxytryptamine 6 receptor
key94b95e8d71bb131856deceefa88123b4,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand"
keyacba9a5d9883a1ab10ea3f3e1b7a299e,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand
key6578df699af0ef1982b56bb8e82c9dfc,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand
key6e73480eba2b3647bcd3ceb798bcaf67,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor
key1f3daacaa88baa94fa11d1e8e1c5547f,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells
key61860e9efedcc68c16a01af3c9efe471,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD
key4649a03ae471aa05439e4eb15ac90734,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.
keyd97b71059b21bc2ba947c1ff83a9bc1a,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells
keyaf4886eda6fced4c1b1c6ef8046e09b6,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor
keyfe549129c18e2f6998a53777ad448e60,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor
keyed3753de47b54731afa4f31dad6dcf25,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand
key2dc8efd6031eb24b30e2975279510538,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells
keya0d3398fe68783550450f46562e88a08,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase
key7049e50ddfe7a19be9c0c99a117a7672,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor
key3c85240efe1f3e48fb4c06eb1ccaa922,Binding affinity against human 5-hydroxytryptamine 6 receptor
keyd1989fa4db4fa4db14bae4788865885b,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand
keye311897758600cabfce27e1dadf4be08,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand
key070917a85837ae8b5a5e3fc0d6fbda87,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells
keybe97e3b10aa4bc0e8595639d973d5e25,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand
keybe97e3b10aa4bc0e8595639d973d5e25,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand
keycda1311ccd233b2013a258cfa76825e4,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
keyba18abe8baefead56a6009e7c24372e9,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
key9523ef7a3b0197c230636d7d3d09b51f,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.
key2555701c14a1e2a90e26022429caf8bf,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.
keybc78782765b4584e722e242b014adf66,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.
keyebaf4432b9d23df54f571829cbbe7c21,Binding affinity towards human 5-hydroxytryptamine 6 receptor
keyb3db22b856865436bfe1e596b25000b2,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand
key19a4f4cba63cbc56f7ae8fed25897632,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor
key3c85240efe1f3e48fb4c06eb1ccaa922,Binding affinity against human 5-hydroxytryptamine 6 receptor
key4562469bed99205eec9e473eb5366478,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD
key38a9bf20eb3f39d4dd9ba35752989777,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand )
keya9d58d73024e9a5d3da40d61b77f34fb,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand
key8532970d519e0b89efae1245246d1300,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.
key65f99f4d375ba8e857789c31c9cc01ef,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3"
keyb51872b6b7526da3bf8100e39e7b2635,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9"
key477085b05d1a9e5c08301b771750b603,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3"
keyc9350980b645428a313143d80cced939,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells
key2825a92d6dc863eda60a0b04115b32a6,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.
key325ad054b48613fbb633df4a367f09f3,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor
keyb2b3a35acd056e5b99e249e8d8811507,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined
key36bd1df6966ca0cd39520b3d929c87ab,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells
keyebaf4432b9d23df54f571829cbbe7c21,Binding affinity towards human 5-hydroxytryptamine 6 receptor
key7ca12935bb00c1501c2adfed26f5d764,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M
key753b53d1a1ede507343dbd0a04890765,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay
keyfb86e84cac4972089067c0b9654565e7,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration
keyebaf4432b9d23df54f571829cbbe7c21,Binding affinity towards human 5-hydroxytryptamine 6 receptor
key1d519a27a98f7d2d4fb59bfa4dda8687,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM
keyc14ac2d4807cd5c08e4d24fec973522e,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor
keyac3b168e7a6b4fca9021cde19ded792a,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined
key0f3e0a7a9864de7fa031b8cb492c0119,Antagonistic activity towards 5-hydroxytryptamine 6 receptor
key753b53d1a1ede507343dbd0a04890765,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay
key4b811cf1c223b2ae339d72fd8446f7cb,Binding affinity for 5-hydroxytryptamine 6 receptor was determined
key37d23d9c05d88bee76e781e62c8db930,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor
key8278203fd4e1e49c72be5e109892626d,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M
key85d4c6b0d27afa321c5ed08da07b3ee6,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M
key767c86050be3fe408c967ab55d35a366,Binding affinities against 5-hydroxytryptamine 6 receptor
keya482b91d446d396fb55190720d00aa4b,Binding affinities towards 5-hydroxytryptamine 6 receptor
key6861aef153034b3517367f3c3fe85634,Binding affinity towards 5-hydroxytryptamine 6 receptor
keyc88bca3034992257a3003b3e966de088,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity
key4d5212d1b59ac1cad2b22eba99b5d983,Affinity against 5-hydroxytryptamine 6 receptor
key636978b517ae10080533667d62d54d1a,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT]
key0134a79080a4116eda49f718c69ed371,Inhibition of human 5-hydroxytryptamine 7 receptor
key7bc97bc57715b6328d1a439507d44a81,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD
key6f3c024caa9260b94be5f5cc9f20b506,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor
key7fc2a1092c3335ac37c048e540f6833e,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM)
keybab4468b6bb2ebca873360a0d6d0942b,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells
key04d0ef72ac297b4f8b55c905be65333e,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor
keya3b397232d770119a5ffbb0985cc017a,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT
keyd6e35a5e689f29785d15f3ddb47820fe,Binding affinity towards human 5-hydroxytryptamine 7 receptor
key508743183a032db51fd0470b2e2ef008,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor
key6e2137feda3ffce4b19271953747d07e,Binding affinity against 5-hydroxytryptamine 7 receptor
key2457cf66e0043611e30e2a02ec0bfcfb,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells
key75ac89194ac5776d7147131f8b5a648e,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand
key3be93618da10e67a2577d7f962b7a076,Binding affinity towards 5-hydroxytryptamine 7 receptor
key7b972c81e775944675618c5ef7dd8084,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand
key2f2c94d1d7800187e106f803d642392d,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor
keyb7d60131881444b380a7da8afa0884f8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor
key0f662c57800f1139862ce793890893fe,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD
keyc350a7935f1b412796c8968167a46f95,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD
key605257d215502b6f5d39ed14627883d7,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.
key8cf3f76977d9a11a68df2a0fa82ac0be,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor
keyd0ad39bcfaceeb90d2f152e697ff2371,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor
key0d7dcb97d193c3da0a432fe243e036b2,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand
key222a7c19851e2cefab067f2d52f1fa2a,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined
key56f7f4852c7743cbc467e7c53de4b506,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined
keyc29e8d4f0e100814e436c1461f2abc2d,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor
keyc0213e458a3773c1219399b586b8fdd4,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested
keyc4f85acbb14d931c50c0979b1b031a41,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells
key399999c9b77cc924cda149928127c547,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells
key561c9cdb22b54d5aeeb32c302d938521,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand
keyd72851dd5ad93b11f84ac87729726328,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.
key7488375f685be6e4a731dd10dd0cbe90,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand
key9efbc78fd0edc66a908f5918cb7ef192,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand
keybfa8651fa3cfd745ee0387f6570d2732,Binding affinity against 5-hydroxytryptamine 7 human receptors
keye2640d776be5ce0cf40aa85a6bc4a3ee,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand
keyef3116f5178ea608c453f1f9e49c533f,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.
key070f87ccf5e47e02230523689ae8fe5f,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
key3690592919d42298166b1557973926e4,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
key3690592919d42298166b1557973926e4,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
key8af94517f63ef00a3fd1a70dd908cf09,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.
key7599e390d82cec6c6f9473b4369f99d6,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand
key6b9f1ba4bcfebd3c223ca409e2d3b5e5,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3)
keyec065d7fba43b3592b557b2e207f9c43,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells
key759781b1d8179c76bb720481f5514eb8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6)
key99e85bbaf98e919a4c6857372e3dca6f,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells
key7d6e3971963d07781f0a3abaee9e80fb,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand
key284b42e6987e3a931fa2f502fefa6ab6,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.
keydf3af2e61cc4f45fc5fb4b0bba554e73,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT
key6a59f798852f7ed37347adc4932f3fb8,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand
key5c315df1cb6ddd9ae1b51e8abd723c9e,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand )
key78a7ff660b23f8fea87494d0d8bae6c8,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT
key5d6afaf041d10392274f70931145f7f3,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. 
key7ff37685ac170d13b6c1705865bb4314,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.
key126a7454bc9bc4f43a8947705330dcda,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand"
keye326c400e6e4d2bf2f1841cfd8e1ba79,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined
keyad88cdf86f34f55ff7033d93a4a029e4,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand
keyeab6dc111c298a62f0112cf955601fd2,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.
keyd4bfac8f69d373f0db50456883c9ff0c,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells
keyd5a0afdadd0210b4a4cddbbfb7fb7d44,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM
keyd0cb5b5e2063b71b05a89b09f3111c0b,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM
key147d21804cd989359e79be0a1ec06037,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM
keydd7ab4526e768eadf13b119d316a4c21,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.
key69800ff2f0c2e7b83cc30208044e626e,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.
keyff37a9031147a56682f2f631ee624710,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT
key9c9a49ae7fafbd98f50af4730c214280,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM
keyd5c42cd233d979ec45e5d1cacab9e22a,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM
key49025f099adf3b0d21114f8d1afe5b17,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM
keyd48674c35161325a7849cc3e5b67ba5a,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.
key6a1b6803897d453db56d2fd40867ce6a,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.
keydeae2c64888b53eb9d7478d8e9f284e7,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.
keybc3097f9ea5f287ec9402253f5033d83,Binding affinity towards rat 5-hydroxytryptamine 7 receptor
keyb78004ba46604dbdf8e0389efb18ed2d,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand
key39e9ec613643d93f2b3a1a771b472c60,Binding affinity to the rat 5-hydroxytryptamine 7 receptor
key15c1c49f3e0bc0b2a22348be22ecedf9,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.
keycbb786e323d8e52313f39ff869b89934,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT
keybfa60db6c498219e1b6a1879a1fe4a77,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor
keyf1645020c77d8a509d8f7b8bc96e7198,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells
key6b5ae7b14dc1f218611ce8b8a975d1dd,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand
keya2dba537457fa846f3a7d2072420a54b,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor
keyafb8ca7ae8f2bc08451ac699b64c637d,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested"
key34b833543cb537231dc090fea67aaa35,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested"
keydb185078ea6300d7d41a3aae16177471,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested
key475f230cfccaa29363b26488875f2b00,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested
key7bf4e33c6dff9130711a37e08c31b292,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization
key239dd96d849496ce9effc571c2cecb8d,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization
key916aa2958f049d3334685804c67fef53,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization
keye74034f80347476560c6bc1e5537d671,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes
key5b0912ae16b3e6c8a2b28382d06170fa,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined
key4e1e93389406908d33ee6a0a66147cbb,Binding affinity at rat 5-hydroxytryptamine 7 receptor.
key13214a60a48c6c57599a647c9dbda3d1,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.
key70c722c91752cb5bb7fdf79835f41009,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand
key8b2a68cc807304c684507d02185972c3,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes
key3be93618da10e67a2577d7f962b7a076,Binding affinity towards 5-hydroxytryptamine 7 receptor
key391649068a63dfdeb6e8f74eee1c9053,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells
keya70eb014c973f00aca2fa23be5fae7aa,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active
keyfaa7a6a1f588533d25915b98c5716a1a,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active
key3be93618da10e67a2577d7f962b7a076,Binding affinity towards 5-hydroxytryptamine 7 receptor
keyb5b7ebe1e084892cc9f60ba54178062e,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M
keydf2d6c2c418d043d2b4076f831b7dfc0,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration
keyd6e35a5e689f29785d15f3ddb47820fe,Binding affinity towards human 5-hydroxytryptamine 7 receptor
keyeb6107fdaabb25b675e8b6a302a9baf3,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor
key107b74c4ed7eed065978d0852487afb8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM
keyc264814cea92fd7c3f95699c82f0e3b4,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined
key5f55cc82c7dc491da24310f2e6ede0d5,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay
keybdca5c75fd59f0c625c98d384ad5b725,Binding affinity for 5-hydroxytryptamine 7 receptor was determined
keyc264814cea92fd7c3f95699c82f0e3b4,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined
keyab274f0448eba6a530433d26fea3d85f,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor
key0b946971867c4515a420d966de4f9c3a,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor
key7254634d42a88b96c5a72528e19f098f,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M
key8f293dd43a00a5312bd9c9f0eb2ee6fd,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M
key08c3b1cc78f940b18591e2401f0b7225,Binding affinities against 5-hydroxytryptamine 7 receptor
key9c41e796295a5743923120237b29b8d1,Binding affinities towards 5-hydroxytryptamine 7 receptor
key0c37aec4c2fdbf636253433e2ba25be5,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor
key78bfe17ff4d20205c493b33b843bd529,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity
key7bf4e33c6dff9130711a37e08c31b292,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization
key58e4dc61c7ccd44c3b0cfdf86940f43b,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay
key3546036ce767a60834a071d0d168d7e6,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay
key9e2a8554d4e338606b9b30ac3d63b8f4,In vitro inhibition of human recombinant 5-lipoxygenase enzyme
key2e4703d1c3fca4ecfa8f55ea442cc43f,In vitro inhibition of human recombinant lipoxygenase enzyme
keyebc11dadb07ce2719bd3479d8ed5257e,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition
keydc3ac635c74ad17e83c79ec218324985,Inhibition of 5-lipoxygenase in human whole blood.
keydc3ac635c74ad17e83c79ec218324985,Inhibition of 5-lipoxygenase in human whole blood.
key2bfb63a67d6796101d8fe7d8c020e4b1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE
keydbed5f53b815e07a5808dd77043f64fc,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4)
keye487672f98e7345e61afff1f1f704c00,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.
keyfe7c5efd9ae46925376aeb1e146dcd15,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood
keyc3b1ea81013b5f72cdeb78144c184fc4,In vitro inhibition of 5-lipoxygenase from human polymorphs
key3b190d8acdaabbe05e1f83686b6c8c20,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase)
key74ebed1d3856bcfd4bcfb3aeaa4f8ba9,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase
key14c91314e52ef44615de3edca103a76e,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay
key53a0c4ed4eff01de75eeadb4bcea4d50,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB)
keycc815ec9fcc346693fee92a7650c6991,In vitro potency against human 5-Lipoxygenase
key494f439981ca8966bfe29589fe453c16,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay
key061831c74c080c6f3af788f81243d1c1,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data
keyb73cb97488551f2582fda962459d7513,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.
key3af2a05bee5161f7a00c68651f650fd3,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE
keyb598b230858ee098775fe058e21c7706,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active
keyc6f4c25a4fd4caaee95f74b36433bf3d,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4
key879dbcd79c84e6e2a757b85a937d8bf2,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active
key93ef84cfe02631b61e35f49a82224999,Inhibition of human 5-lipoxygenase in human cells
key3dade1aac6353250300e2959a3d69aea,Inhibition of human neutrophil 5-lipoxygenase
key90c3334f861947e5af4ad84147d755d3,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells
key661f806ca4b5c9d5697c1ba8b828a18f,Inhibition of 5-lipoxygenase from human whole blood
key288531c0201e8692afd8c0f9ccf97c58,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils
keyf318c2c82e0719e662a8f9f0b07a0ab9,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils
key3179be983cf1e80d53ea965738cd104f,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase
keyec0639f954bb3bcadf4e0b2e4484cd4f,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
key8bf7c273c1d24a2215452afac6770fa5,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase
key36736350c82fae0795eb35abbbb9aacc,Tested against 5-lipoxygenase
key8f77c54ee5fe1154b68b81d8a2773f47,Tested for activity against 5-Lipoxygenase (5-LO)
keyef00a30af961bd45505271afa2c783ac,Tested for activity against 5-lipoxygenase
key5853e732cd99d39a39018df1928bb6d9,Tested for inhibition of 5-HPETE production by human 5-LO
keyf262bc0954e8e6e3128579e4592275d2,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.
key68573892354906822a4c7f3773ef6bb4,Inhibition of Human 5-lipoxygenase
keyf0c007dd6fe3dcd505c2eb5eb1e7b17a,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells
keydf40fd40e3dc301f550743619f4c4247,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS]
key00e5cdf41880def9b7de4a791473ba0d,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS]
key49eba8743f1ccf2f59fb7691e6441499,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.
keyd93a158890de53132387432ed367da28,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested
key7028f485bf64759d01df662a249aeab6,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL)
key365965499df1651e452dd8f92f5c682f,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils
keyc33f824ef21d39a86743a6c3e0e84130,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
keyf69da6fd31ba4de5a934e9c052156f1d,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells
keyec0639f954bb3bcadf4e0b2e4484cd4f,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
key75fc227b6da5200d16033905459a91e0,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM
keycbe4a32e6b39da07e46f3ff41187b2f8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive
key39b42c7ec6829bb3e69bd9d80b265713,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM
keye9abe7b1c1d454b7e85f3e0db8b5ef57,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive
keya7f3b35de4a9efb241650bbdbf3c4fe6,Inhibitory activity against 5-lipoxygenase at 10 uM concentration
key319bb72a1c0bff8e5904ad1c0c86aefb,Inhibitory activity against 5-lipoxygenase at 1 uM concentration
keyd0c6e542ec49df4d10c8f580fb8ebe91,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration
key288531c0201e8692afd8c0f9ccf97c58,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils
key76ac1139ca867d8b4c7377390660a1d0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM
keyec0639f954bb3bcadf4e0b2e4484cd4f,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
key847ef5fd9fdd36045bc3a54c05391dd9,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive
key5cee21923726d2a4a57582af95935dc4,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90
key1b298db184b1f920f5b62d772b5ca060,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM
keybb7da32bc8fcb322a54073b9e0c8c98b,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM
keybb7da32bc8fcb322a54073b9e0c8c98b,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM
keybbc4374cdf5cf2ec5c03cd2a379f9728,Inhibition of lipoxygenase at the concentration of 0.1 uM
keyfd143c56342825240ada4c65c7faf240,Inhibition of lipoxygenase at the concentration of 1 uM
key7e15f8f5b4dfa365383023aa613c8a1a,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell
key29656db36f0f97ebc72b458a513f2cb7,Inhibition of 5-Lipoxygenase (5-LOX)
keye116b02f329ff068b2073761057c51b8,Inhibition of 5-lipoxygenase in mouse macrophages.
keye116b02f329ff068b2073761057c51b8,Inhibition of 5-lipoxygenase in mouse macrophages.
key4a1b5507c38bdd8030cd21717f47ba6e,Inhibitory activity against lipoxygenase-2 in mice
keyae8b8b7279459d5035330f0fbc341bbc,Inhibitory activity against murine lipoxygenase-2.
key0c0babf4577866832e9174226b72d7a9,Inhibition of 5-lipoxygenase from mouse macrophage
key22d44b879322cdc32ce44ac85804ead4,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages
key5f1341ab470d9b6cc42b985b8a1a30b5,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.
key2b16e23adc9beddc3046d28ce29f4401,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes
key203925ea1d38298443e4547e126605f9,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes
keyc92f99d65f10799638538b0836e17af9,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE
keycccc7ced077c7c6d48d6facbe5187e15,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. "
keye36391bf1c418939af9963f1d3290f8b,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE."
key1935fb904cfa3b29a25386005a407a06,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4."
keybdb87cc85627393e31692b6aaa12461d,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation)
keyba9fd868fc833d4316cda7e2fdb2953a,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM"
keya11f329cf86b57f554c1c7c9c0e21ed8,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE
keyf751e24379d85cce9a5380d981356602,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo)
keya1c693dbfe4839613456e9f127402561,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration
key52897a2223e2c9f05612ba50711ad9b6,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay"
key52897a2223e2c9f05612ba50711ad9b6,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay"
key49f95c6a362a2011455a00d22365be31,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO)
keyb6f6d7b95d704a4bdacdd4e656f276b5,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),"
keyabe36d8a060fbaabcdc5601df26fce36,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),"
key0e9eedcfe0650b82129970e09bf94f2c,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined
keye36391bf1c418939af9963f1d3290f8b,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE."
key2a05ca5d57be75ec5de513665cef4c9b,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. "
keydb46492c7bacf2fcd9d4c0145b2a416f,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells
keyba5d61f74bce814e50619e5e0dccaa61,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined
keyb654f094a9b5809df582acb0b59aaf56,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.
key5a4dc5e0dedecf0408407df5e1b9b3e1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line
key7f26c626f7ac5b2be038c9d1d8ce9c8f,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells
key29d53222fb069cdf05276ed7ddceb411,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase)
keyb4f7effefdd9b68423f6167017050a3a,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay
key3587b750f772a4b7e06d8430bd095604,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase
key0294349faa375d531a8d405e7c48c1aa,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity
key91b617ace44225ceddd1244b050a052e,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase
key18ef0e9050e44afe9ca4abf9124976f3,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase
key515ee07946dcaa8747bc3a42691de2b7,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration"
key67bc3fc1accdafead1304fda8d1e8326,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro
key22d3917c29dc66c577c0ee9877b7ced6,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells
key5df2ee85c29c98332fedcd4f42e8207f,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active
keyb86b5dfbd75f0077abc82c8f77e6b74b,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active
keyb7659d55c589d32291dbd849d3b3ba6f,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data
key198aa0116c0af424f6c5bbf3bd489b6a,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant
key431befd8586c37cb3f62702f39d41418,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells
key4ef0d30e88c32cce49adf8d3e3f94dee,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.
key1771c467f196d7c1be5dea4220db14fb,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data
key848e73c55d5ca9fe279b27bdd332263f,Inhibition of rat basophilic leukemia cell 5-lipoxygenase
keya0ec86870aabeb49397b9aff19140e30,In vitro inhibitory activity against RBL-1 5-LO
key5f9a9c7b5c28de35a218bba5b1c4b43a,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM)
key7159586d8d9e6856b53004f5b21a135b,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent)
keycd9080971fac47f073d67c04f6827bdb,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.
key7c50ee026e21e7c8fe1daa093a193095,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme
keya947169cdfb989b448bda8619a84bf13,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.
keyc4f0031115263d57a2143b7e824ffdaa,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.
key21f9b27a0bab5680f56221607b00dc76,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.
key0d03236c432cfdeb880595667c2ce489,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase
key70ffe59664889ca7c53644fbbe14f42a,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.
key681dd2755be26200485cf098da7cd839,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes
key825a983a205f51b74c792218a57321a1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined
key33e48f0a16398253af7e0690863dcbdb,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay
keybd667a54e8edb698fff61c8f43a6e8a9,In vitro inhibition of 5-lipoxygenase from RBL-1 cells
keydbbb4bbedfd0edbc05dd42df55ae37cb,In vitro inhibition of 5-lipoxygenase in RBL-1 cells
key88e947f62f426dcf2f763425d5f3db1f,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells
keye83e994a57ea48c55ebc01e62e1dc61d,In vitro inhibition of RBL-1 5-lipoxygenase
keyd956dae3bafe079d1276298495a33dad,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31
key6e1c118e4068bc13eacda81a144081e0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6
keyfbe28e5cfc27dad7c4acba18f77a09bd,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2
keyb24c0ddf6029f1c6ba26a44e4dfdb073,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07
keyf96a79189927f5901e48385e73b4eb7d,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0
key0149288d321d941b8269b0d7fa37d165,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5
key5b1d6d13d980c685fc4f00e9c6c8fd57,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7
keyfb6a00456e16e2cc6b3d0e5ac12625d7,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4
key66c59c300811dab4c7427b98525b38c5,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54
keyd92f0d1d5834402592751bb7ad5d4926,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6
keyb187725bd9f549871016dc819802e438,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8
keyd7bf866788c6589b1e6e103f5a72f7d8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2
keyefbca81ff2b4aff71dc55069800f2923,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6
key8037ab15fe5a4f2f06393bde53d85218,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8
key0599d5b7cbf152f62171ffae7547ea74,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7
key4354fb35cfb6e387c8d18ec2aa9a94e3,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4
keybf08972fecdc3dd191c53fa6488915e0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8
key15b19527d5b47b74ef55f0587ea755be,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63
key4134fc16af6f22801bf301fb35237d3f,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5
keya5c4a1b1ba4677b78209015b9231b793,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1
keyb91891efb81c6201731b29b027d05ffd,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4
keyfaf5f61fa81a51de88459867f53b0c77,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6
key1561cf8209c066008df0d0031b3efeea,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8
keya0ffa8dcbaab3fa263967340be8a2e03,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.
keyf18e169b2c802feb8dbfb22453712a63,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay
key93b949aa4603169466cdb66f998c17db,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.
key6d1ce2160757d79af9d57c36263d6efa,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested
key259a5e859cc148f934287d5818ba73a2,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells
keyf44c603b9b42a9fd7a9a7a92e9ea8fa4,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate
key203aa15f0d18a48a832f7f9214f2ff75,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay)
keyd592adcf5871aa3dd37b6ab161c5049a,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells
key89cf18e88884eb015d845a289d56d3b3,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.
key12cea6d150aa04a124fbf2a1afb5a817,In vitro inhibitory activity against 5-lipoxygenase was determined
key97ad86d01a6b116ae2218799e3702b8f,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells
key1c551751515c025730c882f34c2ec1a0,Inhibition of 5-lipoxygenase in intact RBL-1 cell line
key53108d98547b5e1f830e5572bf61bf66,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate
key75cc4997ed88f8bc05232221defbde40,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells
key9ff7fe7dd5644243d49bfe1215d4f354,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells
key7dd5b328687135c0caf35a1f69462d0a,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation
key9371fb4d5400fa0eed68fe21ee110b3c,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration
keyc70f0e318caf174253ce4a0c369a249b,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes
key3ec91b7284267ea6e9665ed89aaf2b84,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells
key788df1e22aa24b32037aa5414c466430,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
key18dbc4497ad6a218b86e1bc7158cce53,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
key484f9ba9adeaf5dc9afdaf984beabcce,Inhibition of 5-lipoxygenase in rat RBL-1 cells
keya96aa7831729cfc408c61db23767ffb3,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
key73412fc53d162b22fe3b705a0ec83170,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg
keyc97347135c3ee150d0516cb047f879b4,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg
key0f5256566eeb9151762e65a0ec1657e1,Approximate dose levels for a half maximal reduction of 5-HTP levels
key1f4cfecb553c04c3983fd1a6ba7ceff5,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
key1f4cfecb553c04c3983fd1a6ba7ceff5,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
keyd6b26655658824e564e10de161288aa2,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.
key4821b4785f9e29577062ef0decfae3b0,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood
keya96d5c6de76e112db44942ca088edc9b,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood
key71fc9e68ec40676000605c0a459ae80a,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS]
keyf1cbec1b6d768ff708c4948c02d65e06,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes
keyaded3f363d6e066bf3e27446317cda9a,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).
key75a33e8969fdea5d7e4fd2f12d9cedf2,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL)
key36d50958b69d8bda5c0dcb239b91b79a,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM
key36d50958b69d8bda5c0dcb239b91b79a,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM
key85fd2f9380a310ba4b969ae5a19ae2df,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.
key0942a7a80bc666829c6b8a581d252ba3,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL
key5f1372ab30c40c5a934a3a8412041b16,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
keyadd83ecf8c36a8884b01099e257c6d4f,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
key94da5a6ae9105a10122468c408e53cba,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
keyf126c97735acf2ef3f99468e3b113ce5,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
keyc1074a0001e10f40d720eacf2d8af178,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
keyd1b80e7a3c798dafdf854a2778176bf8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
key47bdee874fe540952bbce1e7e8b97266,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
key64c5c1da1ec310c30e5f985b7d4dd85a,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
key7e0e780463dae23a2081438265911015,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
key9a1dd1936b7a6d68b85d4225de4deb20,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
keyb708b57440015857ba8d4b47bd0626f0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg"
key9d2acc5be13cdf4c311f3cab6f409abb,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg"
key56bc87933dea2b3b86a8df98d8696749,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg"
key3fc493e3a066a6c21debfe2b8c287951,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
key0e6d9d0baa474ffb80c115347e3aa52d,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg"
key80967c0784651b36e1656aa15c88d13a,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg"
keyfb38fb192e2893c7e7ae7313000690a1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg"
key545c5a45e8cb52b2edaff277bc72c101,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
key70c77013891169c326aa429a25a7a7a6,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg"
keyc7f9032e635003c9dfcfe8b31ff6df38,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg"
keyface8232943084f4dee9c7441017327c,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg"
keya020af00f8bffacecbe754c688f8680e,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
key17887e4bd6300d1f7b531027625d07bc,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg"
key1859bb4b6ceebd6eba9feda9cf42affb,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg"
key7c343982dcac6a74148b80f7551a42b0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg"
keyabb7dc73eced2b78ad58ccfb4a02f48e,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
key404c544a0df2ec8f72a1c75097b69046,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg"
key20ed363cd183ca49e09482b27db6b686,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg"
key93a9abea6c65892c432cb52cd3e51ef8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg"
key9b3b947a8af6a04746fdc940ea5a47ce,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
key7cc76091f9f8afef30b63ac0dfbc81d3,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg"
key13bdd43d6f1c9242c12ba94f92565ccc,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg"
key6c2990b8cd278d2e015bb8e5e23544fa,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg"
keyacf00c30fe7eab261078e3822c601276,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
key89ebba690bbeffd9dd88d0234245b101,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg"
key037d080fd12487f275f3302bc4161478,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg"
key8a4da26132b1854c4a590453f948a0fb,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg"
key7e0e780463dae23a2081438265911015,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
key9a1dd1936b7a6d68b85d4225de4deb20,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
key3fc493e3a066a6c21debfe2b8c287951,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
key545c5a45e8cb52b2edaff277bc72c101,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
keyabb7dc73eced2b78ad58ccfb4a02f48e,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
key3ed5cd7626b2cdf4093063286dbd92be,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg"
key24276ccdbf18f98cfae0b72b66d15fd7,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
keyb7015545246b90ec7eab47997207e434,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
key1d1c3cac508680b06f96a2c571be63b6,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
keyb9bc8d2f057a0c868ae37472255fd82b,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r
key2dbe3f018018207fdf2340696a8c916a,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine
keyc73270cd2f87cd6c73c11bf26b790357,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr
key280bbf432d857a1fa452683bfbcf41cc,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine
keyc69a22137e4eeb8c772bbea13bfbb02f,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr
key48b4db68267bef61266a05c2b51b4979,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine
keyf414c2f8561bc8d9eff47a7b69a730f8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr
key6c1d2fee09661720aef4a01ae0d06e50,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine
key9b01fa25440ac0c90fd6d78a3c5330b6,Ability to inhibit 5-lipoxygenase in guinea pig
key890c3c01ff2ecbf21b336df8b7349e33,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN)
key29575c14d50064861eaa717dbae49644,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.
key23d7875a6b1f7161ca0a2256bba56ba6,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg"
keyde7bd3bf65830911b0f71401ef1de7e7,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production
key531eb12042717cb0a72f7402100b3870,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production
key60f53528b538d2b4e97c5496f7825f4d,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes
keyec4a089fe00e21e7f2fb2c704fa46ae9,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes
keyec4a089fe00e21e7f2fb2c704fa46ae9,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes
key229c2d24888a9d7fc3ce6453122e30b2,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes
keybcc8f54dbc61777723c1b681fdd02537,Inhibitory activity against 5-lipoxygenase
key8f2161f636e4a77e149c08bd0c7ef6a3,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte
key311e834c4483b1e7e78b5dc81fb231c8,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant
keyb4478abd73f5f4ef08d6ef9064818392,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase
key8642a868010ac0789d89203f4a255481,Inhibitory activity uM
key397f010cb31b0509edfce1b8f99964d5,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined
key0536deb4bf6757873d89fcd4504abce6,Inhibitory activity against 5-lipoxygenase at 10 uM
key16771f0cee752e3a0d4ceb1b5c80a8fa,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM
keycff027ace2d95e81572ca6f609309c03,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM
keyfa0c5cdc07b0de6907f2e4c3bfdf851f,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM
key8642a868010ac0789d89203f4a255481,Inhibitory activity uM
keybd8c80e2343b34eb8a947372ec1935f1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM
key8642a868010ac0789d89203f4a255481,Inhibitory activity uM
key8642a868010ac0789d89203f4a255481,Inhibitory activity uM
key59fb424a732ba0f00e7a549c415e0437,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes
key16771f0cee752e3a0d4ceb1b5c80a8fa,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM
keyd4cf5c6e10b6dcb97f497e70f72b4a53,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum
keyc33f824ef21d39a86743a6c3e0e84130,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
keyc33f824ef21d39a86743a6c3e0e84130,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
key4f8208556cbc8885d5300d6fa66aa352,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO)
key7c74166136a4c7379566b8ff9540d430,In vitro inhibition of human 5-Lipoxygenase.
key782619f86d6db37bc03ce19dc0385205,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM
key4787014c46c33fbe731211612c2f5d21,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM
key017160740b1d37ceddb08b2e251f89f9,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM
keyaa86a77d4dd9120073515e7966a787e8,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM
keyfe97a0d738ae37f3a948b72725779c95,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM
keyc513afe548ba9ce5b900298f33fc123b,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
keyc513afe548ba9ce5b900298f33fc123b,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
key9ded60547cba7c9dc0b26deb11a46cc4,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM
key10091903ac2edf36e081a0dc07cc5d85,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM
key3fc5f48dbb198f6f386def091ea40927,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM
key26dc88abb53f2cfbc3d1d6f50ca83e6a,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM
key19916ae8be9fc65c513f47b755bdf4ad,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM
key935ef3315ef39c161aee6814e0879c54,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM
key630bb5558a8f62ca86e38f9ab273070f,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
key5f94867431295a51fa449ea92772fa8a,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM
key16aff8b43d436f7e4e4d5fb3d784a900,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM
key93c78be3144429b145805a9707f23271,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
keyba4e9dabf64c317ce8d7a1856801650c,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats"
key067fa9781e33e216a345315d712e1bf5,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM
key6911a44209e409d01edfa14113e8f26c,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM
key11bf8296a3149ce1162108ae4aa31159,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM
key848870a3ae855dd41e28aa304db0aa61,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM
keyb776f68258a7814d92170b0dc0e7fd1a,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM
key6ba46a0ed3094cb4b946acebe269f855,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM
key2d25734fa5a1f39f89ac67a1bf1924fd,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM
key71552d8b30759e4550e7e231074147e8,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM
key924aafad0cccee98a660026f6ebc5685,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM
keyfa65882be89d9e13478e476c89de2373,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM
keyf5c7a42f749fe5f6d3be1364f9dd6aa2,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM
keyb0470eff442d4d22da6a2a461748c7b3,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM
keybfbe6dc3faa3df186ce7524f79c50a65,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM
key97e4d6af8ad6ddef0da28e17cd86e6c2,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM
key736153bb24bc82e7aed4b2c3311e2653,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM
key38335fcf1b76510c9679e761bf7eb0af,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM
key20b8ef5133f97fc2f410c8fa0d3b2b9a,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
keyc05faccee3fc3d34c88ea20f4e889dc7,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM
key441cfa4988a8d210eb1723208cc0df89,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM
key8b23f4275904ea52453eb033518ab5c0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM
key57f32bb0ccd04d5b8fa7b96a46b60d97,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM
key9d04ddbf8f0e3b75bd04165bbc5f3d4b,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM
keya1e38e08180e34a0891e4f33017af04e,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
keye1daa58a31fac39fd745af1f0e9660e1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM
key40bc88784aa641a99b924613b0b43549,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM
key38c13b4885228e3e80a1975d8e19ea6b,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM
key196d8ac36251f0e08ae33c070fd0e491,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM
key268ec0c363c731268cc237d46b3fd760,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM
key12788e78fec8b5efc34ad5d92128698f,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
key0adce3d7974364d850afef6d68d80a4b,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM
keybe9fc3216f8958d9f5d0437010176fdf,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
key4d1be75ea8c89ebb03b16ebf7e69e379,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats"
key91f69384a431cc30eb1b8e36f5de5344,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition"
key7ca68f4316ad068546aff0fc0fb073d5,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
keydd28cdfc360d9a22e510a4d48457a818,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats"
key332171fcb7406653c1c1df32492b003f,In vitro inhibition of 7226/S myeloma cancer cell line
key0f8e4161699a8222036d49f300771980,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells)
key2e821314f505a653d93eb5cfdd3de3ab,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer
key2e821314f505a653d93eb5cfdd3de3ab,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer
key3f2086f91d04a530e61567ea8719840e,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.
keyf7372faad99dcaa609d63a8b0ef7dfd2,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.
key3736cdddf4e8cf26a63c164be39d189d,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose
key50727a0bfb38c2dd18e5f489d4ea16d2,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose
keyb5d8f9758238c5f2472f662e9556639a,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose
key70119c97333cc3cc07c375f9ec3da347,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose
keyda0e65bb19f73ffa6cabaf237bad518d,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose
keyc1810109019136c80bfcc6b7dbfdaf21,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose
key51d65b58359b05e688255b62c1be842c,In vitro antitumor activity against renal 786-0 tumor cell lines
keyfa54738e2c908adc162d31c1d9efe321,Cytotoxic activity against 786-0 Renal cancer cell line
keye40f3dded2deea988e0652ead4e9940f,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer
key486cfbc86ddefbea257bc22cc317cc75,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer
key98aab0a624c313c32caa7df43e9f2995,In vitro antitumor activity against human renal 786-0 cell line
key7c48193571b7571eb8f5b6ca1ec16ab7,Inhibition of Renal cancer in 786-0 cancer cell lines
key0be9430e6e9fa37e19f721b5ad5a0870,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM
key1989b9757807009992a35bfacfcef67a,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0
keya579064fdb109710038863059d9fb5c1,inhibition of the growth of renal cancer(786-0) cell line
key67a34bbbc15f68722ad10fd942ad0d99,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
keyfd2ea49000cd49ed43c80ea655866267,Compound was tested for the growth inhibition of 786-0 renal tumor cell line
key8d3dc5b45728be6dd649c2db8f249b45,The IC50 value was measured on 786-0 cell line in ovarian tumor
key72b2ef058ca062a90b909582db1bd364,The IC50 value was measured on 786-0 cell line in ovarian tumor t
keya884ed9e6f3e576b5d73b04e89005e48,The IC50 value was measured on 786-0 cell line in renal tumor type.
key054dabf1a83ac0f8f1209573131c4ec8,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM
key11824b7366dc25568d2279f7b9334d7d,Tested for cytotoxic activity against renal cancer 786-0 cell line
keybd8e221bb0d37d34a2ef95b1d90c3d0f,Compound was tested for growth inhibitory activity against 786-0 cell line
key6fc8a0218c76a7f804402bbba8d65860,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM
keyc9f59117f6acc18a30702ba3ab10c05e,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive
keybf1c87c6331fce8549b41e4db234ca74,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells
key788df1e22aa24b32037aa5414c466430,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
key18dbc4497ad6a218b86e1bc7158cce53,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
key9957f40d7fd734909136f4e87e63f090,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase
key557f2a90847f8f3055c247f962705e9e,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes
keyaeabfa3d0321266da9f4b73428be3615,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line
keycf235aa34e212986aff23e7fa1f65828,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated
key8a13e5101add9b21543a01ae108df849,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated"
key729992d30a3fd76acd318ad0e30a8e2e,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.
key2ea18064de8385d7e9471d4407cca881,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase
key8c522f8d0cbfbc315e5a7352c90f67e1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO)
key9f5f6fb8d1bf5703b815fa510fa513e0,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production"
keye501f8f68b56568cc9542b3c37d33446,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells
key4c47a3043c4b8759c44302ef9b1c185a,Inhibitory concentration to inhibit 5-lipoxygenase in the rat
key23226b1b13c9c3798425452f8f6c25d4,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase
key55d149defd57b9a58f7d8381f43ee815,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM
keycf98ea2c856a149ca4f3effbb7bba4fe,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells
key3ae6ffa91dd9f263c4d7e17f9e8d13e2,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1)
key284170e7708abd4efd79345a3ee7ab8c,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells
key1103080dfddf64d1bfc6c5b1465a7538,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells
key2a9b7cddea99004935c585c7f5c61c1e,Tested for its inhibitory activity against 5-lipoxygenase
key01a2e8f3ab900ce0255371498ba74dba,Tested for its inhibitory activity against 5-lipoxygenase; Not determined
key49e90412a1b643442a9bd857dc7f72d3,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)"
key4d6c3b467e63494afaaad6ef491f1a30,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes
keyd15fbd446faf555767141145c468e6dc,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.
keyc9f55cdf90edf00b9657d7d63d62bbbf,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM
key7a3fae42e64c42f358ca0cdf39c6fdaa,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.
key9d3d90e3f64e6f6fc3591dcdd87d20ea,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.
key2daeb72d4d3d4d0b1bf35b08e1fa9f0c,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse
key77a14482318b878ef581bfdf9a2961e7,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1
key5386ca838520dae0aeddad197f831f68,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells
keydc32813befc102179370f295c9648aeb,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS]
key72d50dc773d4396bf32f1a2083903d5c,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro)
key4640945ed44d553aa14f48e80157da62,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo)
key5a73544dff21d4e8503af8ae3a3c46c5,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells
key44639b11f048768316a931ba6c4ce592,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells
keyf559949dd163fb501188e841bda8680c,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS]
key4c09fd529c0d894be0727a81b9fdfe2f,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase
keya95aa32677313b6fdfa4fcd7e5f82eff,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.
key79d8f620af087cc29c5feff67fddff53,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells
keyea0ddd43c5ca7642a4630003aa2a12ef,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells
key363d5ba6eed51a1e495d825e8d2146ee,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells
keyfbf8dbeba5b554b0e2ca48ec9d5df0eb,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL
key2115b7607ae6a17132fae88468083ab0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells
key64ed2ed536f9950703b3014fb03ce3ba,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production
key5b75174eb65cf745ba7b0ff6b525eb05,Compound was evaluated for the inhibition of 5-lipoxygenase
keyad2b9b013309160cb30e63d070200258,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM
key13cc17a9e90082ca32b555ac43a41087,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay
key091aeb7fa9914e6b3a4b2bc2ce92b0f7,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active
keycc641e294ea74ae49b995a3d6db4f964,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM
key839c6e739ed464a28d6e0a29396fae0d,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM
key0294349faa375d531a8d405e7c48c1aa,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity
key585c39294b3e83a258afe59ccf935bbb,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM
keyfdaa7467a2a84e5656b54b2f3e9f2395,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM
keydb40dd1f537a8541ad5e3e83f0d90b91,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM
key607c5f5a0bcf9300081e01b4cacad4ac,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM
keye00f5031bf82258b6116fa6df011be99,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM
key0536deb4bf6757873d89fcd4504abce6,Inhibitory activity against 5-lipoxygenase at 10 uM
key95d467794644980a391de4e410c7272b,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition
key94bb4e7ec56f9627e183b24ebb17278c,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM
keyf6e1bf2cdae76f5278fd6e9b78fd6229,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM
keycdb19b4d9eddbdb24c85bc471f31cd8e,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM
keya36ed9cb4d6ac12b6a22c0314e0eddb7,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M
keye788c782768bee8663dd54188d0a5f59,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM
key11935567b786cb0fbc4fc55a218d159f,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM
key04fc4b86951974ad3d7f4b8fd33b4290,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration
keyb9214c42bf5847148efaec21920dfb8b,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM
keyb9214c42bf5847148efaec21920dfb8b,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM
keybe6749cb10cb602042dcf1225ffc5996,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration
keyfc5a222e162aa59c4535721eec384776,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM
keybe62be94170c1337aafa70c9ed091c2e,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration
key857016d03736eb78d316901e38072862,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM
key318efaed2172c7146557958db612d4bf,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.
keyfebb4fdbb427f7a2e56216df8e2066d7,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
key2245d34a0ffbf62d8017e9a1438b015a,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM
key75c87512cb14e1451d449813e84e5a86,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested
keyfc5a222e162aa59c4535721eec384776,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM
keydfdc35ae944bb6903416d922727a7fb0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM
keyfaec6c1e4458c320494b74d97457bff2,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
key997f3cb84e96e4959040cf78532a5a7b,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
keya403ec963d4c2f44b17399cd142f0a4f,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM
key115da61a36d46a10393919eacd1ad3a6,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM
keya403ec963d4c2f44b17399cd142f0a4f,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM
key7350170d89626a7cde57170d701f8d3b,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM
keyf90cf9ef3cd66efc6d2d2d4b2d187114,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO)
keya8f2d90958ee1f9eb9b6525a9c36bee9,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM
key11b64985682259337616061dea3660d9,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes
key9d3d33ac6283c1a14b985adb850096f3,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM
keya7061e20eb8e83b5f9338cdeb7bd58ee,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM
keya5c5875022bd6ea79c9f06d1dd798eec,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells
key017d2d55681a23b920e0a62b046e565b,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells
key017d2d55681a23b920e0a62b046e565b,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells
keyacf3c649654bdcd231a24a33fa0afd85,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase
key48580898544bfe38c2e0665f24a69ddc,The compound was tested for inhibition of isolated 5-lipoxygenase
keye37fcd4c770aa891c03d405b0b493643,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells
key783311904e513cf6b5b4b2e1907534e8,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM
key650c62ca79a597ba018a667348f7e20b,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM
key2aa2dbed5f4b8dc654fc35871c452942,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM
key0abc99258f2560108ce6c0396b0549c4,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration
keyd715da7efd853287a002661860f17a9c,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration
key1ce8a092e6f984b454865d4ab9a446ef,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM
key301327c09e72f224f3a8a5c1bb6808ca,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM
keyb06787ba438edf30b9cd793872d37c63,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM
key9107ad48a9f1178bb2acb5ba313a0724,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM
key7870ffd00a913ed3c97630868e8cd5d2,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM
keyccc9394f8d03e6c2faa8d532181205ac,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM
key62f9c569cf53cb717009a858edf13ebf,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39
keyad5cc20edc4df5e8f33a28ab2d45a3fa,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM
key05f4350871ae776ec29d104392719565,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM
key923f66d8a96cefa2dfbd59bdd075b515,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM
keye1c8b19cf6115bd23d4221a27b929d0e,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM
key227b21e29504d41fbe8f682ef3b824b1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM
key8a1dff8fbbf7c02765fc61107611d005,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase
key682b7ae021ce584f625dcce1d51556e3,Compound was tested for the percent of inhibition against 5-LO at 10 uM
key854caddbdcd7ce16fe64c8c611a5f242,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration
keybe6749cb10cb602042dcf1225ffc5996,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration
key3418445d9f487d6bfe5cab4895141d21,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line
key8b3c36c14b097fa58df8791024d2221c,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM
key9827d87bf5d65b74d71066fe252578ef,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM
key115da61a36d46a10393919eacd1ad3a6,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM
keyb1932a1988ef6f5fea888b62dac69874,Percent inhibition against RBL-1 5-LO in vitro at 10 uM
key06f2b36c974059487f85974e14db3a91,Percent inhibition against RBL-1 5-LO in vitro at 100 uM
key6486b717445d168abf45552c3e464fca,Percent inhibition against RBL-1 5-LO in vitro at 30 uM
keya8f89bd3ad29513eb30024209e2ecd5b,Percent inhibition against RBL-1 5-LO in vitro at 300 uM
key77efb7e8fa8f6d2cb3ea9b1ea117d077,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM
key2c2be439881793be1c1bfcf2c177e8b6,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration
key118d1bbd21d3aca51f585f91b7154fe1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)
key118d1bbd21d3aca51f585f91b7154fe1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)
keyac35c5e39c06fe1d1bf02a99f334e682,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1)
keybf1c87c6331fce8549b41e4db234ca74,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells
key177ca4dd39193f8802f4651188cfbfe9,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM)
keybe5d6f041288c7715adaf34d2e663ea1,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay"
key05ac83e45613b75bfc9b1f66e4de8597,In vitro inhibition of 5-Lipoxygenase; Inactive.
keycd3460ae54d149bdbbf621f62b7e52d1,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition
key44615c2c72b9a8320d3b01a07bdcb7c0,Inhibitory concentration against 5-lipoxygenase; No inhibition
key983c49769c0d38092ac4e6d1dafd3be7,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig
key9ebb0f6872540bd6dfb8438931ae499d,Inhibitory activity against 5-lipoxygenase.
keyfc7ff03880f6f93332c2f4f66a3724e2,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive
key7523cf3e8656236d5920d0f29c8f3109,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM
keyfea857d97230e72b1f49b3e0dc5398cb,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM
key72199e8447384e1f6818982ea584979b,Inhibitory concentration against arachidonic acid 5-lipoxygenation
key7d4359b7c3aec6beb06643b3c3c3192e,Tested for the inhibitory activity against 5-lipoxygenase
keybf2419ed91c6bf5412c93b9a586b66f2,Compound was tested for its inhibitory activity against 5-lipoxygenase
keye20180cbc129d3836afd04ded9e21be8,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed
key816e01914e945bcec39644f968899782,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active
keyf83b994bcd36d40ed2ad5cc11e9af4a6,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined
key70d91566dcf6f40bd8af70c9c9227325,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase
keyed693942b643371879527df1e555daea,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP)
keye396c0e99b27f02a37dc806a937e8df3,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations
keyaae2e4a15df424724a4b9e65cd2c9ac5,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.
key72d14c55d23909447f12a5125ee6b518,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.
key69f6186fa4f35c66cafe200a8e13ca49,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein
key2653b24b5c58cd773ee0cd510dcdd018,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein"
key8936c7d7a71d1c01ac53f5044eebc231,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)"
key25073e70074d424aea0ede23f2d276f2,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay
key475b0c4f39266eebb6891c4f5fcf209e,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane
key088e0f66f4c858a1967900317abf1120,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant)
key4cdc14b9e56589097a3cab718f016cfb,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate)
key66f490242ac3cbbd24d0265cf7a93e68,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit
keya09348ddb532d850152de402b68623d6,The dark toxicity against 543 human galactophore carcinoma cells
keyeb772e2984b9686e7822154b63d0d9be,Tested in vitro for cytotoxicity against 56 human tumor cell lines
key67219ac3cebb3eb82d7387f09aac88c1,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value
key0624317ba257811127291f7950036c81,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.
key8b65d0e1cd514de2b9ccfabc17065977,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line"
keyeefb3ab32f9f77a036ffe9c69e7d170d,Growth inhibition against human 5637 cell lines
key48d2d52b6e8e4ad3e29ce9c116bff1cd,Antitumor activity against human bladder carcinoma 5637 cells.
key8774254d50cd17055a581e197d17b632,Antitumor activity against human bladder carcinoma 5637 cells
key8774254d50cd17055a581e197d17b632,Antitumor activity against human bladder carcinoma 5637 cells
keyf909e639533c9ff7ba8316b83dff1d22,In vitro inhibition of bovine trypsin(Trp).
key157c6611436c1fc94bcc0148212e02cb,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor
key3188bcbda88ef3b41f1e91f0a8ac1a69,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor
key0af51080683fa971375e14ad909aaeec,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.
key019d8fcaa5fae046ed4f9fc277bc1678,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat
keyfde7e5be8d7554277b77feae2bfd2d0e,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor
key34710e60c0b06e3b8a15c2819d1940ab,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
key34710e60c0b06e3b8a15c2819d1940ab,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
key5f4927db62157f7e8e59829316a24e6e,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive
key5f4927db62157f7e8e59829316a24e6e,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive
keyee8489456aaf3c844f1584d4fd19136a,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli
keyf5a8cab7f3a42c1fa2427c7bf7c903d1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition
key063dc991736685a3e2ddce419e50b965,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver
key549d22ca33fcb0e5262e81997755bd16,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition
key7ff443fb2a5ce6b7e66b9f7588a64a0a,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase
keyb94ab542cc4e990a0d462c7e8c2bf296,Average inhibitory concentration against 60 human cell lines was reported
key98c7a8a565642083dbe53e06fe41ed8f,Inhibition of proliferation in NCI panel of 60 human tumor cell lines
key7a02b6644d5da70f578f7913e3978d8d,Cancer specificity was measured from the +/- value under average log LC50 60-cell line
keyb362a4a6177fcf8a9d236d05104855af,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. 
keyda91523e0d667f1a31f042176dd9efa9,In vitro mean growth inhibitory activity against 60-cell panel
key551a7e189d926e3d127f51e545e44dbc,In vitro mean growth lethal concentration against 60-cell panel
key8e07ef9e4bd7ad9721a9b73e39f744e8,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel
key78520ae2097c8ab24dba5aea1f9d3614,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel
key77e961523fe4100340f2de65df3796aa,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM
key77e961523fe4100340f2de65df3796aa,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM
key8ac18f31c985ba8c74f495960dab050a,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha
key337b49bc5366dc077d5c7265c6315ab8,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase
key5653bf2558c14b6f69f1a937b8203845,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells
keye82691b8b9bdc94cb3531d01487e45f9,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.
key38819b7b7a148e458165c8cae2e1a3b1,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.
key3af18334bb8229d4c42c17c4ed6d91c3,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.
keyd28b8b0eedbc039ac3194df8257728ce,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice
keyad84a9b7b60160bd0496f78cd2579d4a,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice
key2a485e7ce903c78de43e265e091b7407,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice
key56937c0a1b4c2f37e819aad512194336,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice
keyabb6207c82dead2472e33913e496fa21,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice
key51b2c0c2b7663e3da6008f45c924d56a,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice
keyc481eaec3841d69631959e695f14438e,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg
keyb9eb30d15a231ef1f040693211094b13,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg
key5bda2d9d2b0223a70c306cab81f4be77,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days)
key9ba3a9467aa736e1520f423c9394641e,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg
keyc13c0aa59a4b9205254d2bd185de40cb,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg
key8ab3374b46e381475003383ddd900115,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg
keyd6702caf0f581d3fa167050efe124ee4,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg
keyd3557d1765471dbaebea95a4db676fb6,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg"
key832e88689050b8ab256b3f58e664893d,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days)
keycba922f4613418ff3a1ef424060d2c86,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days)
key8444bb1277e21ff74765556351f1e7a4,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg
keyd28b8b0eedbc039ac3194df8257728ce,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice
keyad84a9b7b60160bd0496f78cd2579d4a,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice
key56937c0a1b4c2f37e819aad512194336,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice
keyabb6207c82dead2472e33913e496fa21,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice
key9c7c29642f0bd335cb934de212bde108,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally
key7f857dd0e5a45f1853b036e805afba71,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally
key5b52dbb15d4f211ae121cfa6cdfdc80c,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally
key4d452b2d1b8d9e3e7bf8213ff0bce6c8,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally
key92b91f7e3a92e7a41e601545df05311b,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10
keyfa331cfdef5103b07665d38d3c8760e3,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10
keybb5f775cb72fbbd5de36d59d95cf8c5c,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10
key86f512aaea2ec249d30216b34959bef4,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10
key296e4028afae1e78df381b228eae8315,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg"
key591c3a80d11703468947a381c5dc41dc,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg
keyfce0687819db64c1d7e6bb1fb3472bb3,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10
keyaf79a153c246718d5b15ee17fa099c3b,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line
key94f7cf2110107a12a4e2017f21ea43be,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition
key94cfea9410b677150ecadfec501d9385,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8)
keye7626af72e5c6bc0b53f22716d462c8d,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8)
key729c216df41c9e0b2b267beae5d86b19,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8)
key3b1faba07e80807bc964e31c32665816,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase"
key0164bc158e8e767b334b98a5bc1d3aaf,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM
key8cb22a33868df3daf3955428fc138459,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM
keyf2af2a85718df88233a1a218262fac02,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM
keya50d770bf9b3de897965cd2ab95f91cf,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM
keyea944b505e7dbb4b2ef40b943f65be77,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM
key08f83689796c2c5e0384b3c8cd80205f,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM
keye774231bb3e73b62a2cedfa9bdff80db,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM
key3100982e6516043def75cb4b2a5efd12,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM
keyfe930f42190a113e88e72f92a450fb39,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM
keyf622290077331a1a2b7ad8ffaa9309e7,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM
key731c202721a15a9de31290279c8482ff,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM
key3fa8ef4f66d8bc9a7ef778a9bf5f5b8d,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM
key32643a67ad7ee4c6d5ed7764b1704ce7,The apparent total plasma clearance in monkey
keyb7f618207adb690fdade32e462d21f88,Compound was evaluated for Hepatic clearance in monkey
key7a873212f6d5b49a0a6d011742c4173f,Lower clearance in monkey (i.v.) at 0.5 mpk
key3e72a9568530256f6a71aec93502e8f9,Plasma clearance in rhesus monkey
key1f67114686cf42e69cf83e49d81974ee,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg
key11598c0eb632dfbcff6778dee11be052,Plasma clearance of compound was determined in monkey
key9bd4235f148d4711ed5c6e1a0c376022,Plasma clearance was calculated in rhesus monkey
key3e72a9568530256f6a71aec93502e8f9,Plasma clearance in rhesus monkey
key46edd6a16aa47fcee2eb65b2d3bc08b3,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
key94930f12771757e687e8e0e229eae7bd,Plasma clearance was evaluated in rhesus
key15123083b7f1fbc4af0883d5b406c11d,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose
keyfd6d281032e008ad3912b02eda4a5e7f,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
keyd0643ff8fc7bc4141da1db4463141954,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
key0242e422b5788144cce51600399472bb,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
key5a78638057965b0db34b3db9a29ee31b,Cmax 24 hr after 2 mg/kg oral administration in monkeys
keyebe231a7c4884d9a575c8200f342d909,Cmax in monkey after administration of 1 mg/kg iv
keyea629f769c222af11fd155dab375a7ea,Cmax was determine after peroral administration at 10 mpk in Rhesus
key3728197df15527b80d8b8f2bc5777a20,Cmax in cynomolgus monkey by iv administration
keyd33871b333c8c03cc0bab5d746c7ea25,Cmax in cynomolgus monkey by po administration
key519227627945f1a91c2edd0cac128dd7,Cmax value evaluated in monkey
keyfae0ba3414cd64450ab3d52d3677a493,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey
key1f6e5424beca256d155866dd672eb5ba,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg
key5f9d74f7d5c15d980aadfcb56c01acb9,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg
key41ae815b329c307823bc6e615ae8834a,Maximal plasma concentration in squirrel monkeys
keyf6a1315adc26799d4274eb2b749aec43,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
key98c2cf509a4528bac82857903d81c507,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg
key120622f98b31c0021e9a8f02b629e4fc,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (umol/kg)
keyf17c4a9a64cd314111a23dccb883a566,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable
key5d6f1dfb92fe4ad7a1075ef7243cc0b4,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable
key86362706b5bfc9254908b00cb59c20ee,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable
key532b63dd68afb808baee473686df910b,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys
key791baf1660c723cb654230d15f8107f4,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined
key1531edf0cc829359611c57e7b885a977,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours
keycb02d414830dd6b6e281e813c4a4508a,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours
key820ebcda1607af240b14db0bf409d6ad,Absolute bioavailability was evaluated in monkey
keyb51e15504c4ef7cb51659003bc964a50,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined
keya32c03932125cba28a8a62140bfa34c8,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration
key78c5037429191f40ad98c15b4aea9314,Bioavailability of compound was determined in rhesus monkey
key1fb2a749d3728b3c0fd66b035c451d29,Bioavailability determined after oral administration in marmoset
key2a0ba803648cf25df91c012f838b7b73,Oral bioavailability in cynomolgus monkey
key8b30bedae10978d4f205d8ee6c1b085f,Bioavailability in monkey (p.o.) at 2.0 mpk
keydd0548955b9419c4d954f898e9467521,Bioavailability was evaluated after oral administration in monkey
key71f8ce08e2c457a8f2d6e76313e8e72d,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
keyffc476bc0d56a3175e142b24511c8e61,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
keye3816cad9e84b3fcfeeb21d1ec96d408,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
key85f1b61d91f5905c660d0148c72654a1,Bioavailability of the compound was determined in monkey
keyee6cbc10e6ad668ead18a42899536d39,Bioavailability in squirrel monkey (dose 5 mg/kg)
keyabeee83c55f729715f7339b98e282d40,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg)
key071b413d5349baa62cc8c4855146f516,Oral bioavailability in monkey
key238c925b84d90bf1d1c783a0c8a2fe7d,Compound was tested for bioavailability in squirrel monkey
key9005d004fc2a99b11b6a4a03313bcf58,Oral bioavailability in Rhesus monkey
keyd3ad6a36f06dda693d719274a8706078,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.)
key064c1954238bdbbd75bfb4e404a7e8aa,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable
key7cd3c425e96fabeba3498ac5a371fe09,Oral bioavailability in cynomolgus monkeys was determined; Acceptable
keybdc07d0882f768cc5f2c2b5f452c1bd5,Oral bioavailability in monkey (dose 5 mg/kg)
key6bdd64ab110a00ae6eed78ec17d4d5f9,Oral bioavailability of compound at 5 mg/kg in monkey
key6912e64c305c1a14ea332d61586dbce6,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog
keyd8185c0c1afa65e6b16ebe48f3a46a47,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog
keyf684d6fd827e341ca366ecc1be0dcc5b,Plasma half life determined
key7d2b12d7dc4d7db2246f3f3b41917c36,Plasma half life in dog
key920797fc6691add9ede96f3b907000a2,Plasma half-life in Beagle dogs
keyb7fa71d44ab5f67e249707665c4a17c8,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
keyf51cd45d2f96765f4379cba0022a604f,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male)
keyc37c8ff03bb353168da039f1b3afd699,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog
key887e49d942a782d2f7a541b7b79ff464,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog
key49d73902dd4339ff2830a240752f0a7e,Tested for the half life period in dog
key93243fc10d093882618bda667d975dd6,Tested for the half life period in dog at dosage of 10 mpk
key9286481d7ad7e3c0c09a0250c65ef670,The compound was tested for half life in dog
key3963577eb9fa4d96b20165a5f3b04687,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma."
key4516f981b63d69e71bb2877d8d1b563f,The half life was determined
key73ade0b0bc074fda9954495ca92c5e65,The plasma half-life in dogs
keyea3179b4b39f3748c4d6f966557d2897,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M
key7c544c194b1aa93edd100c9c97ab74ba,Half life in dog
key92c61636c68beea07812d111975abc88,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.
keyd3e5d4f55cf0a8c8a2b0abda3995e0d6,tmax upon peroral administration of 10.0 mg/Kg dose in dog
keyd627dce04312d538e58dd7f62b90e679,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg
keydd80c331e4aed9de2d61de66ccaf6cfa,Cmax in ferrets after 30 mg/kg oral dose
key46abbbd77f98174a53943473e1dbe566,Emesis in ferrets at 30 mg/kg oral dose
key05af41ca143400da2fbe6145d1f83d1f,Bioavailability in cynomolgus monkey
key62cb1094660d662935abbc5cd50c8302,Volume of distribution in cynomolgus
keyc71d250a498c54d8c5e4492f2a583874,AUC tested in guinea pig when 3 mg/kg dose was given perorally
key97baef9aac79d8366fedee9fc021c6b1,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg
key336005b27fcb00a2a98e3e7ebfb8e5f5,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg"
key9ab0bdf9e8ab43a6da8e512fd51f87f6,AUC in guinea pig after 3mg/kg oral dose
keyed18d7d30f852ef1568288ccb89f4e7e,Bioavailability in guinea pig was tested
key8496af903e9bddb0a130fe38fb2788ae,Tested for oral bioavailability in guinea pig at 5 mg/kg
keycfd3c0ec5d38a82da5c1802007a37231,Tested for the oral bioavailability of the compound
key483e7f3d02ac5956e629530d9e8ef755,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported
key4ed2b5b002c24ee9b463267f988c95f1,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally
keye9ea482be4e581c7c2146fc50b43a5ea,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg
key36b58642f08874480a8af58c9fba688d,Cmax in guinea pig after 3mg/kg oral dose
key2d9c4fcff1925fb61b8d634ae9da31d6,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram
key46ef2acdd936f6fa37719b253a47c7a6,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram
key2d8ab826e3b00e95f58e70db4b54ca4f,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram
key4b5197fd8e8e28f90766a94c24631cc9,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram
key56fffa27e71871573c9ff746f7820ad2,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram
keyd81e278c5b78442e44e820274f3b3813,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram
key4a4322a7d680332c00f661e713f43624,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram
key6c61d6bad0c22b438a19cea33a75d0da,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram
key0da6452064dc02badb8f64dbc8c6e350,Elimination T1/2 in Guinea pig (PO dose)
keyf4921011a284c8e72f31c438fa3c09d0,Partition coefficient was measured in octanol/pH7.4 phosphate buffer as -log (counts per min )
key782e9c8746daeabf9173cafbf7e97ee3,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism
key532ee28e0fb2703a54550df2377eaebf,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism
key0da6452064dc02badb8f64dbc8c6e350,Elimination T1/2 in Guinea pig (PO dose)
key65d93d7d1e64b535617106330a9fa275,"Tested for the half life period of the compound, intravenously"
keyb6fcb5e8a539bfe48d4c90daf44db1d7,Half-life was measured
key952172735792b5fd2e5b1d9edb7a285a,The time required for onset of inotropy after addition of a single dose of delta F75
key8932918eb39d226e1825e88f37230e12,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration
key3554ee431fd42fc20d271b8352d8017b,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration
key6d638c22eba500235a48fd76a3b14d67,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration
keyccd2ad2d86625792e4f2fd0437013442,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
keya14c977a7c1aa6dcf15a9e77d1cfe1c9,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
keye786726a1c73494ad0ba8f14d5477a84,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key5306e84e51918c66618863fc4ee00b3f,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
key7660b62c0b4a7e8de85cacc7d0335fbb,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr
key4b71be090a4ce89b8a591772d02c1433,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
key8be5dd4cb536f0a9b84e0f76e4dfeaa6,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
key3ea2c39c796b505b78bb5cb3e71be113,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours
keyfd4f9da5cc9522a11caa929582920876,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours
key3e2a469f68b599a47fbbf2c08d349b7d,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours
key91c67c206b91a511fdc0fe801e0c6f62,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours
keyb9ddf0354aaf37e58636b99089529e25,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours
key82b79a8d3a9b97b5f751227f1c93e402,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours
key2daf868cc7414efa6cdc04d9572ac749,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours
keya916d53cdc895506bb132bcfd065aee9,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours
key05437934c3985e631d0d169d59a9b104,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours
key5d3e8a3737e5a6c865044d31e8e42270,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours
key36533786688c9af61d7f2d7760fadf8f,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours
keycf0177480b032364ebdfdc5344929163,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours
key61f5abf35fab495e23df917444a916b3,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours
keyea534f55276ac7f8d11d51d6dc5132ee,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours
key2ea81131db5b8416d5b1c5b99cb4e28e,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours
key61f7d0138d73002014b842a77129c8dc,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours
key679f8a7e05db81e08f1bba4f0d55951d,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours
key21380ee9893285a72f6798b74eda4a57,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours
key64dc44029faee566e2a3da5da07c42b1,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours
keyc1b65c6451be0465f3a1e73b5a7bb864,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours
keyba825791bed146341991072b58332b2d,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours
keye6c4edccedd9b15b431d5f8bcccc658b,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours
key3af1b2f91f26617f1b014ddc536eb0b8,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours
keyc15bca3195f00fb0d869be96b14d82ef,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours
key3f47cac363f3a58df045f9588c166bbf,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours
key0ff22cea2272225a6615c012611d4b02,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours
keyd6718c029b80cec882ef1bbb739d303d,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours
keyb2f23d68c251a093bf26a99ea200ba4d,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours
key4896cf1638688c21bc8edd2ba50ce962,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours
keya7586ae331cb834778a7a2f5af84cc5f,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours
key8db863fc0915dd8adb5bd08c0f287222,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours
keyc9b4575fbdd82bf1fa6dafd0da5d50fb,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours
key4757bf714acf2e8a594117e87dffeb65,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours
key36e8d8afdbdb2255d2366a91edf87975,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT
key36e8d8afdbdb2255d2366a91edf87975,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT
key224e5662254a431c3a1ff19bffe260c2,MRT value at a dose of 10 mg/kg intravenous administration in mice.
key9912fb90ddebbcfec54e97dbb1a63559,MRT value at a dose of 10 mg/kg peroral administration in mice.
key11e7e569d75b1d9493cba8dc084599a0,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg
key94ab146d70bbf9b1dd997bc0a0142e3a,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg
keyfff01a9ca287ff1b5e0c23657d5f05a4,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr
keydb03de1c357092228040d2c95d1be5bb,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr
key99a12debfce6535491172c43dfe136b7,Compound was evaluated for cytotoxicity against A2780 cell lines.
key691ef34191a823e80da411234b1521d6,Potentiation of growth inhibition of A2780 by compound alone in experiment 1
key561b7beb8ad06239330188ca95ba41ed,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
key3c8d7cdd57fec26985741202c2029b61,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1
keybe336aa1ed1a0004940483fb17fde6eb,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2
key3315467c17eea8fbe659977068cc3e9d,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1
key5059a3fb5abae7d3aa705f4606a18663,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2
key65762afaf67d4cb50d0474b0d92fff18,Compound was evaluated for cytotoxicity against A2780 cell line
keydc0c788f1e19a340484067b0a67783ba,In vitro inhibitory activity against human tumor cell line A2780
keye0e6bec95bdbfd3cc9d1bad816b6b53b,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1
key561b7beb8ad06239330188ca95ba41ed,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
key3c8d7cdd57fec26985741202c2029b61,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1
keybe336aa1ed1a0004940483fb17fde6eb,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2
key698a2d821dcc32d9fa9470733edc77b7,The compound was tested for cytotoxic potency against A2780 human tumor cell lines
key7fb3b3b568fa39015883b5b663af48cb,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.
key413d45312cac96d33d02ca6936b5d4d8,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.
keya4d3a9f4df690edf062bc61aaa7e76b8,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
key3315467c17eea8fbe659977068cc3e9d,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1
key5059a3fb5abae7d3aa705f4606a18663,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2
key1e9aed4ae6634020acaaefafda54155c,Compound was evaluated for cytotoxicity against A2780 cis cell lines.
keye25d7ecb0899d5792461f50f4f9a794b,Relative resistance factor in A2780 cisplatin-resistant line
key4421b7b4ad67bba296b408ba79bb9c96,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells
key0c30dc028beac4abc75c663ec51cac4b,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.
keya4d3a9f4df690edf062bc61aaa7e76b8,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
keya4d3a9f4df690edf062bc61aaa7e76b8,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
key37d9bf2f8ef60160d29cf1c99468ced4,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test
key9fc3ff1e474d96118d2917f2d5bef22c,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen
key16bcfa75a7b23800c528fa6d64669127,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin
key3c5b9460dd66585b1db9b5221ef3ac4c,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1
keyc5d07b521f06708e25a06028cdab81c2,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2
key7e42f18544952b86ebbfe6743da48b00,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3
key471d308b8700693342f07046643b1d9f,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5
key8b7d76d180b9f339470c405bfbc9d600,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8
key17847097a492857c31be3c5161c30bb3,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure
key41bb167d5b4b6af8b3077012183d5f1d,Antiproliferative effect of compound on A2780/DX cell line
key9e0d9532cd7455cbf6d317c0af4916d1,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined
key5f1cc439f6d5e61f138abf38dc543e15,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI)
keyfbc0d3f0a6226cb7b1f4fcee537ee199,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI)
key7bc3b876252829e84b299ba400c72d67,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines
key9c0be4bc0f5256b1ad8117c44eefe38c,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines
key235b29e7c4246ae11747a64ea6bc07c3,In vitro cytotoxicity against A2780ADR cell line
key7eb437e75c8b8b8a96d2b75a380b39af,In vitro cytotoxicity against A2780CIS cell line
key1ce4d7f8a123ee3f77140a8814a60bde,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours
keyc529d6a9d65cb51304b30f9dbec3be8e,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.
keyaba1206559c492c79d14360c2adbb72b,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines"
keyf591b2e790a98ec8acaf11bf7bc3bf7a,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines"
key54d47131c7aaeed1904778c613a15ea1,Oral bioavailability of compound in rhesus macaques
key071b413d5349baa62cc8c4855146f516,Oral bioavailability in monkey
keye22afee14e4c86b17509112a28fb987a,Oral bioavailability evaluated in monkey
key644227a321e20779fa9b6bf345699d1f,Oral bioavailability in monkey (dose 1 mg/kg p.o.)
key9005d004fc2a99b11b6a4a03313bcf58,Oral bioavailability in Rhesus monkey
keyb04455035c8ef0ef454f083538d54519,Oral bioavailability was calculated in rhesus monkey
key2a0ba803648cf25df91c012f838b7b73,Oral bioavailability in cynomolgus monkey
key071b413d5349baa62cc8c4855146f516,Oral bioavailability in monkey
key071b413d5349baa62cc8c4855146f516,Oral bioavailability in monkey
key271de4dc3caad1fa02e57787f7415962,Oral bioavailability in monkey (dose 1 mg/kg)
keybdc07d0882f768cc5f2c2b5f452c1bd5,Oral bioavailability in monkey (dose 5 mg/kg)
key071b413d5349baa62cc8c4855146f516,Oral bioavailability in monkey
key071b413d5349baa62cc8c4855146f516,Oral bioavailability in monkey
key2675426de381f0071800351829aeb0d2,Oral bioavailability in rhesus monkey
keyfb6495c8fba328f85ad84046a785aa2e,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration
keybc6936344b7e10f82ee5d73c3e9c5081,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg
key63e741b4ba925465fd7489159e16efff,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
key9005d004fc2a99b11b6a4a03313bcf58,Oral bioavailability in Rhesus monkey
key25abf1ebd8cee1b04e4cbe568255a342,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.)
key84185b74a7d13d648cb8bfa18738cd59,Oral bioavailability in monkey at 10 mg/kg of the compound
key45f0f0b2eef44e3fa136f55bc0bc3e0d,Bioavailability in Rhesus monkey
keya84f7c9d72abb49be4ff073a2aa7ab8e,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
keycd19d5db516d4b4e4189a396b7e61aaa,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
key79958c8cca51972fe20c80616c946bb5,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg
key26f3d36c6ebdba168f1d095e31e09b2e,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg
key7932bb62efc03459bba242ece6cf23fb,Mean residence time was determined after intravenous administration in cynomolgus monkeys
key3c3c67c81eee64fdb385737dc10579a3,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable
keycd64dcc057073743f1f87984ced742bd,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable
key6ed79f4c8e69e9e44e80c6c94dd0ddee,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
key097d4f30d0d7ef5ae72b8785e19a216a,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg)
key68b8441570159a5c33d5c17a9a2c38e9,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak)
keyd806a18409c07376d6a022aae1f985da,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak)
key5627d706fd8adee7859dc4dc16cfa663,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak)
key033da4a60a03ad7d87622446af34d4bb,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak)
keyed6a60de47c9ad22261e5c2b7a1dd16c,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
keyaae33e64ca67cb04da5cc2805a315d01,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
keya0e2b5b670eb4b8b1e995ef7f3317bb3,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.
key62cc07a2851898c2141a3de16126a2be,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
key533ed27054065d5b0f389fbcb34b464b,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
keyb6868b9124f227b8d6c5cfebe86ac0a5,Elimination Half-life of compound was determined in monkey
key813758aac801e3ab78c1e801cfced364,Half life of compound was determined in rhesus monkey
keyf0f0f5b769c0e7aa1ee7b25be69d972b,Half life in monkey plasma
key13b87e5c394bfd820c42a34f4705e555,Half life in monkey plasma; Not detected
key2891db9f4a441b179878359e80706195,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
key6c997329df01ee3df03c7567de78c0d7,Half-life 24 hr after 2 mg/kg iv administration in monkeys
key35323bd5cf122a91b72ad3a88e336f3c,Terminal half life of the compound.
keybca48a384a2f53bb0e69bb7fab687916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
key3f599698ecb06cb01f1d86563773111c,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg)
key213685ff3440203520f5b5186037adcf,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
key5c5e716a9f2f213614202144b0d35d13,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
keyfffe6cc7b14b169439c3e78e67b83640,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
keycb203f42ea08329b0210cdb72088cb69,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose
key42cad96c22111e4da8ada4457889d52b,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined
key34e35ede48d88eb842b3edc4dcb99414,Volume of distribution was evaluated in rhesus
key6d638c22eba500235a48fd76a3b14d67,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration
keycec03decee812c57f497378f5f8573f7,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration
keyc45204b724fb1c007d848392a70110e1,Bioavailability in hamster was determined
key16ce9af38956ff7a13f02b7daaf38714,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration
key66c0f1fac835f8baa1513ea494971d02,Bioavailability in hamster at a dose of 3 mg/kg by oral administration
key33e643682d0bb07d7353a948df86b69e,Half life of compound was determined in hamster blood
keyafb73f6c111a817ebded2611b983d0d7,Michaelis-Menten constant of the compound.
key03c36f26e3ca60bca54865e97aa80a17,Vmax value was measured at 0 uM concentration of silyl ether.
keydf9ebd72b96b3410e093c72a604aeb17,Vmax value was measured at 10 uM concentration of silyl ether.
key43ff60420f52e4d145a3d8c222b7bc4d,Vmax value was measured at 5 uM concentration of silyl ether.
key6cad3f564d6f8a715b82445b7c30d856,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant
keya715e2bd1745e2d6068256db901a797e,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration
key8a93ccd3dc4e02586dd1bff4a8f6cfc8,Compound was evaluated for area under the curve expressed as (h*ug/ml)
keye6744770460428196767d57ca0ee7d04,Active metabolite of ifosfamide determined in humans; A-Active
key32f5944eb42ce53d4d8164139b5cfe3b,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis
key49975dd7420cb1c40c14af6d4f44aa05,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1
key32bd15045e7569dac3f078e97db096e1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2
key59fa7e0159599fb3f53ec448ed51bb37,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace
key22aa97cf0ebb1ea2e344a8340eb7cffb,Compound was evaluated for oral bioavailability in human
key6a433f0ab253bfe4d707cf6f8c641307,Metabolite of ifosfamide determined in urine; NF-Not found
key96376e3c43a5504ada7841c85901b894,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B)
keye3a1c0725358d7384e11283f64e3f7b0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics
key043ada8363289991802368e983fc9ad2,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose
key1fbf1cef5a814cdfce9d9c330987b07d,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics
keyade02e73dbdce58405cf570a32638869,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose
keyd2c8b9bb9e49d4202719f33ac3ee62cd,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C)
key6923782ecc1b56c52f13524e1467e2a2,Percent of compound in healthy individuals (Group D)
keyc30ac347e972b1235d8b7ce5beec5dc3,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes
key5f26959389ce0cb9805b25c07f49000a,Binding towards human plasma protein at 10 uM
key3ebe4480db796e60ffef346c9cf675c4,Binding towards human plasma protein at 100 uM
keyd59305988c313a782ee324f77e5a2efc,Human plasma protein binding activity was determined
keya8a55a40f184a0131006bc4fdd31716a,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.)
keycb2a5aacc9870ef682da0c7e7b41d548,Percent binding of compound towards human plasma protein was determined
key1b24a95642e29971834d323b8283edfc,Plasma clearance in human liver microsomes
keyd3cca08e31bf750788ae691c5bfe08c3,In vitro intrinsic clearance in human liver microsome
keyd3cca08e31bf750788ae691c5bfe08c3,In vitro intrinsic clearance in human liver microsome
key44818f6d4ee1c941305f262e7583a785,In vitro microsome metabolism clearance in human was determined
key0a70fa52864dd49cf8e8270291622369,In vitro microsome metabolism clearance in human was determined; High
keyfeb99fbba3b899f6f242ea7811e8379e,In vitro microsome metabolism clearance in human was determined; ND denotes no data
key14fee167104b81a246cbf1a985c32ee4,Pharmacokinetic property (clearance) in human liver microsome
key1b24a95642e29971834d323b8283edfc,Plasma clearance in human liver microsomes
key16dfda3790b373e8de61d78675fabb09,In vitro clearance in human liver microsomes
key3c4920c0305db44825df365c853f349d,Intrinsic clearance in human liver microsomes was determined
key3c4920c0305db44825df365c853f349d,Intrinsic clearance in human liver microsomes was determined
key1840288604fa40c058c3cbda422cdecb,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human
key68daefb13c61c5c26f6c166914411d54,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration
key9a32a5b82d2d44d3add65247c1cca6a1,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human
key9c056dee5463e319ecc6e530d4b16092,Stability in human plasma 2 hr after incubation expressed as percent concentration
key69da3a87a9594c523e1da18fb64f1b1f,Stability in human plasma 4 hr after incubation expressed as percent concentration
key277c313ca5fdab9daf18776dd023d907,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
key748f74304f7d41bfa336801ac4f79d33,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
keyd237f49d59265e5f81290851297d7d36,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
keyd80e136485ace78c6b5da36bf982a0ce,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
key636c7cf5d0038a1d747c54b5baf9fa51,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg
keybffe3e0e4a423131f4ddc1e6239446e2,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg
key320a0535c50a4855a1a004105065e1af,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg
key732fd3ca47ea32f22c92f63bf409d4e1,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg
key91177e3ebc70f37413ce2566e40c8d71,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak)
key4f0f1b0129acb5ded050d6c26ef065da,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak)
key9923f628d4c68414c1d305a7726586a0,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak)
key5c79c2838613498895f9f91f1c9f4162,In vitro metabolic potential in mouse liver microsomes
keybdbe5627534553f966b7e66dc1a081e5,Ability of compound to bind to plasma protein was evaluated in HSA cells
key10e7efebe1cccd087370916ce39f842c,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled)
keyc48b4e499330701bfbf8023514218f08,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g
keyfe3b61e9ad79880b4d363c6f3806117e,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g
key0ef8f9807ca8b87ea21440a403d75ebd,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled)
key60cfd6db321450905de9c3b0de2f9539,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled)
key9d6e248355dacd1b724e4ae31e3563b8,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled)
keyc600c61e90cfd2c8a65a2ba5e40d048a,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg
keyd49f4aee93c4ff5380941c02c1109a37,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined
keyde922ae8754c3b333995dacc2787aff1,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined
key1e89441d3850b9eb43338c569f3423a6,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined
keye89b0bdbe3fe5c70f29353aad38c4832,Half life of compound was determined in plasma of mice at 24 mg/Kg
key0304db63244d9b5bae369ad4e339eb6e,Half life of compound was determined in plasma of mice at 40 mg/Kg
keye0c09859328d7830bd2fb91caca23e7a,Half life of compound was determined in plasma of mice at 5 mg/Kg
keyf45d0c3ee8619773bf4f452bad552c67,Half life after intraperitoneal administration in mice at 18 uM/kg
key06359790c4d5286e1c0cedb2f42fe95a,Half life after intraperitoneal administration in mice at 23 uM/kg
keyc4cd57ddfaee13f0395f79d06bb6cf3d,Half life after intraperitoneal administration in mice at 25 uM/kg
key7080b6d3a9cc65261e8bb93f2182d232,Half life after intraperitoneal administration in mice at 26 uM/kg
key3f733b582739a7bd2deb92b3e87d5c63,Half life after intravenous administration in mice at 23 uM/kg
keyc38f010dc9a7bdcf087d602c1ed641c0,Half life after intravenous administration in mice at 24 uM/kg
key3570d7810fa4a31f5c456f8395467a66,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max
keyd83833303c4163e48e2639fec879e6c0,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined
keyb57370c46760a148dce4433c1f6d6a9f,Maximum time required to reach Cp max was evaluated in mice after oral administration
key5c938eb38af82d9ce75192421edf71cf,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2)
keyd3495987929513d8cba5442678581a0f,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period"
key3fa93b175bff90d4fc28304ce91ec809,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg
keye15daa5c46e49ccdbda986b7bbf66786,Half life of compound in mouse blood following i.v. administration of 10 mg/kg
keyb015d6fb153d299de6239e66839c5f53,Half life at a dose of 10 mg/kg intravenous administration in mice.
key81bb0e14da7c60558258036b6aff0674,Half life at a dose of 10 mg/kg peroral administration in mice.
keyc9d953537a7c721aa59a880fbc42229b,Half life in ob/ob mice
keyc77e6a705d8c8b9be2fab00adbede48b,Half-life at a single subcutaneous administration of 40 mg/kg in mice
keyaf3efd97d88a9e45994ef96436b813b6,Half-life was measured in mouse
key805392b3636334630c701e3516b32dbc,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg
keyfd07fb2344e806992a3dd001db2577f0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation
key4cb5188c85e68c63f3933fd3cbb76dfc,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins
keyb66898533d37dcd28a100dbe0a82e1a8,T2 in brain of mice at the oral dose of 50 mg/kg
keya9d40ecefbc451471d6bb1e2061ae252,T2 in kidney of mice at the oral dose of 50 mg/kg
key1cbbc01563946486c5e2da84abd87982,T2 in liver of mice at the oral dose of 50 mg/kg
key006ffb1ec68fbca581ee8a2cc2fac619,T2 in lungs of mice at the oral dose of 50 mg/kg
key3f2d30f7f0928e3dae44f2881782a6d8,T2 in spleen of mice at the oral dose of 50 mg/kg
key3570d7810fa4a31f5c456f8395467a66,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max
key90ced9cb8d650c97764399a7734699f4,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant"
keycd46e012af73b098efa9685de020d60a,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg
keyc399eb7f22c786df1bcad71721dd391a,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined
keyac81b429e4f56e945dff54b4d82f752c,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg
key3f8e9716780e93a49ba11011300001b4,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines"
keyc7ff0d1e809c1b12bf2ecf62753b9ff0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines"
key28d3674288ad8d278ab23c631bfddaa3,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines"
key167f17bed4b293c92c67f2e317e484da,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines"
keyeca6d54544c9cdcdb7898ad033d17562,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines"
keya7bee7a6ec699c4a89a1e24ec8c23d93,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines"
key5fa1f3fb632cbe3cf6ada795c5027635,In vitro cytotoxicity against A2780TAX cell line
key3ec783d75b1bfb20ce28e543daca4565,In vitro inhibitory activity against human tumor cell line A2780cis
key965a11b3835f4521bdd92c2d25d7eae8,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines
key84d222c06c4c0e10b96d2ccff168b224,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line
keyb29b2472b0afa6eb638c3b53f365e7f6,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
key8fc245ffc2f99ead6393e1d29666720a,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C
keyc4592e49e2f1112d607e8f0a424ee272,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR
key972ea1238ca851415ce8611f3611c96e,Cytotoxicity against human ovarian carcinoma A2780cisR cell line
keyb62f34a70ce30bd99d5b4722cf75a559,In vitro antitumor activity against A2780cisR cell line.
key438b8ea2f5aa78e967f9709a63bf5c2e,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin)
key33ae1b32a9790583073dfd960cbce667,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line
key455641d00f69f2d171f3e64c898db825,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay
keyd61d0dd20fdf00da38204698bbf64d1e,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation
keyac63be9d43a4a5b5563a556f77ef0686,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes
key616ad984f985914a40e765cbd85b2459,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity)
key616ad984f985914a40e765cbd85b2459,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity)
key8f2d39c99c27dbef8c8d8aa973051615,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX
key0769ecb7b437f7ed6749e70d6d9c2240,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M
key2ac0c653ce99b73ac4fbc30c388a0e51,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes
keyb45ffdd73b023b1f2e050a16e2dd4915,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity)
keyb45ffdd73b023b1f2e050a16e2dd4915,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity)
keyae3e23c57c4d7bb3e11bbec5b9b4fdcb,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM
key079a0bd1c04a7f01fa08ed7fdbacb04c,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01)
keye92f90ae38148ac2c580c34c13b1e1fd,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active
key15977b0f5bd2e0638345c909e4885762,Compound was evaluated for cytotoxic activity against human melanoma cell line A375
keya5e2b6224483fbc6b77555b76570095c,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.
keyfb8baf7b5b8da75541f769d1df071e39,In vitro antitumor activity against A375cell line extracted form melanoma
key73265dc63631a06cc3460757877a8a8d,Inhibition of cell growth in (A375) melan cell line
key35c1d87b72e1640a913be46282cf981f,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375
keye78196b21cd01bcd14d30e9f823ffbce,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375
key892beed8940e97292b32879df5eb69ab,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.
key346e8f324aef7e84d84f5c2c71eea1fc,Antiproliferative activity measured against A427 human lung carcinoma
key346e8f324aef7e84d84f5c2c71eea1fc,Antiproliferative activity measured against A427 human lung carcinoma
keyd4576c1cbb40f387a0cd6df7b192a672,Cytotoxicity against lung carcinoma A427 tumor cell lines
key0bd789431bb53658c1326069875e8600,Inhibition of large cell lung carcinoma (A427)
key71d62f44b600f16ae9d56748c5dbfc63,Inhibition of large cell lung carcinoma (A427) after 48-h treatment
key3dca1004a7be83aa631d8f644238c4d5,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr
key15e1c7cd573417bed44ab9f46419114c,Inhibitory concentration in human lung carcinoma A427 cell line
keybf71e5faa2d74088acb8eadca1f5cc93,Inhibitory concentration in human lung carcinoma A427/VCR cell line
key46441666b678c92c95b66081d903cc78,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg
keyc03979922a877ae1a932fba6eb3ccfcd,Tested for volume of distribution upon iv administration to african green monkey
key46ee43758cf135963d62f6b0409efb5e,Volume of distribution in monkey
key8a2ef0ae14fec5c8e40024bd466c35cc,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
key5a258529f46f4e02c957a5a236937c67,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.
key7ea0b12c327bbcd3d7c3a31b2bd8dd8a,Pharmacokinetic property(Vdss) in cynomolgus monkey
keybac2c4097fe1db6b7483eb850848ed40,The distribution volume after intravenous administration in cynomolgus monkeys
key407b84e363b59915c87048dda1ae8460,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable
key9362a5f4571ece3de61c654c5fd7a9b9,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable
key801993bb998437555ca854246466eb7c,Volume displacement was calculated in rhesus monkey
keyc0f4c877403f936d3ee2ca4de6ce5b9b,Volume of distribution in steady state was determined in rhesus monkey
key8aa3f736289fd6851803e65c24cbb973,Volume of distribution of compound was determined in monkey
keya41d56bf96cbd27bb52eb745dd28aa04,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
keya63cdbacb29ab8a58ca54f30d5ed6bb1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
key8ebd5a8484471696a3d15e22bb77e7b9,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
key417fd0db9f0e4ac8dab1a51e6a097167,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey
keyb7e2bddea5ec6969e296722884f1f47c,Volume distribution in monkey after administration of 1 mg/kg iv
keyeb7f144865ba9d1661222818955d555c,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
keybb5c03896ad70b80b4fbad83538b0621,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg
key06db66a6997982a9745f89ee9bc348f9,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
keybc488f71f391518c0a99fb7a1412a0ff,Oral systemic bioavailability upon iv administration to african green monkey
key1bd261ef1a7db401acbda762e9cbbc1c,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
key77627e9ec7b928024e9437eba026f284,Baboon plasma free fraction. 
keyf22757d67fc655516f36a5fbb6abd5d6,Area under the curve was calculated in rhesus monkey after iv administration
key916810058ef33a5b31a1aeb1ad4d0075,Area under the curve was calculated in rhesus monkey after peroral administration
keyd21d6954d75ce16514853c9083d979d5,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk
key8ee801913997d3fa28d1ab401b8806d6,Half life period in monkey after 5 mg/kg dose
key31825a09e5f875aca4a297b8b285a723,Half-life was determined in monkey after 3 mg/kg of i.v. dose
key1481ce966b05c750f57f82154a3f5726,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined
key7fb9a1128a75232d5ddfe414d9fc73e7,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey
key9c2f100537d67c7781a58cc075ca85cc,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg
keyb76c5eed2c10240640c0feaa91accf39,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey
key6cc10adb88a716028f44dc007eab8341,Compound was evaluated for terminal half life in monkey
key11960de942ccf00d47caa3b8896d3212,Compound was evaluated for the half life period after iv administration in cynomolgus monkey
key50a974b217a83be0663a3fd8fde8f2ef,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
key22d30d12ff9203ee6429f0354cf43398,Half life of compound was determined in squirrel monkey
keyd69e5146270df1d6339849fea39acd5b,Half life after iv administration in cynomolgus monkey
key581962c69627319f4e833a94d1b905ca,Half life in monkey plasma after administration of 1 mg/kg iv
keya8a42e35c214c01d2904247b9cb90ecf,Half life was calculated in rhesus monkey
keyd385a4a598c8de5dfb299dbb780bc6de,Half life in monkey
key099038937108000b82a5a3c8ed10fe07,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
key59963ad471b006f76fff0fa14109c9a1,Half life was evaluated in rhesus
keyf35f57af439414b83408c0b05a42a181,Half life period after oral administration (2.5 mg/kg) in monkey was determined
keyb0145ff41609b583eca66ffd9a6050d5,Half life period was determine after peroral administration at 10 mpk in Rhesus
key5d0126a5b7248b2852bcb89dc4afbdaa,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
key9b3a68ac30bf833179e442ed42a5081f,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
key6c5d1c822f30bb555a18e884c3861710,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg
key6d581ad5896f68a2ef397f6ff3fed395,Half-life was calculated in monkey
key6e94e1562d301d77abedcc223892b2b1,Half-life in Squirrel monkey
key97952ff446b833c658af2c9c149ca707,Half-life in rhesus monkey
key1df03c2636cfa1695908528794d1579c,Half-life was measured in monkey after an iv dose of 1 mg/kg
keyab7020b66303b3aeb45e384a442a529f,Half-life period after intravenous administration in cynomolgus monkeys
key6032e33bdb29c87e4387554687244017,Half-life period after oral administration in cynomolgus monkeys
keycef1834da1407396dd73a043585e3b59,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined
key520df16b639d1124870b657812722349,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
keyb80ae83ee18fae26662230bdbedfedc4,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
key1c05a5cc42f7582b283f0ef96761391a,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
keyf3f4cc25cfc5dca3546a4d4b775d0f2a,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
key2dbdbb7191f03e40d955b87d02a25044,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined
keyd2f835574b5387d5b44042ad1a12df2c,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined
key0c7c809dc697d09a24ed71ac78241dac,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined
keyb3366478db6475d77881fe4b2ed22f91,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined
key4201c21f9a0967e1b70ce0bec76657b6,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined
key010db949d06471685c8b60b9de287f31,Oral bioavailability in human
key00d3239ef9da8a1ed58f1ab30c636512,Compound was tested for human plasma protein binding
key033633b8fd7cd812064c5b464a1e9a49,Compound was tested for human plasma protein binding; Not determined
key28f23381db2b8ebcfad81557847f47a9,Protein binding activity of compound in human plasma; % Free
key694817ffef3d8915c851d19ac937738d,Unbound fraction (plasma)
key46f1f2354aa66c27dcf5045bd22f5708,Half life for the hydrolysis of compound in human blood serum
key85be897ffd017afbff5860f0da2dec15,Half life period in human plasma using phosphate buffer (0.08 M)
key6ae02b8b6ea1834d28099720c8950213,Half life period in human plasma using phosphate buffer (0.1 M)
key9121c5a1d24e2bc70eb7be11086112b4,Half-life in human plasma was determined
key49c6a5632d279cacf61d6901c3c066b3,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.
key4eb94c0dc25f85ae0d7d37b5d9a9bea7,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT)
key7a2b2890ddf8ba195815e254d484dca7,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma"
keyc1cc02a2ff3c8cb7166bde6915555d11,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)"
key99fc6baff438524237669d35e5dee2f0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)"
key33f1c1dff9cdb0befedbeed38883f949,Partition coefficient (logP)
keyb5fb5c657c96c4aa59970b2e17c0b03a,In vitro metabolic stability in human was measured as pmol/min/mg/protein
keycf6eec5aeb865d4046c996155783e764,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes
key4113f6738b11601e86dbf8b4ee01a3e4,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak)
key054116892e6da4400c67d862aa66a982,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak)
key08ab98ea67db8fad821fb5d71a13a3c7,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak)
key8d94089e1ef6f563fc57873e4f7dd4c1,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak)
key4a531b8631548f7da077cb13c19ca2a2,Metabolism of compound in human microsomes ('++++' indicates largest observed peak)
key56b4c551129c60139e24191c64256cc6,Metabolism of compound in human microsomes; Trace
key715b033c744a69c64997c5c85e35cd31,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes
key9c054b6b9029960996bae1a31a1b697d,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min
keydbb4155a36a0e1008c93fbcc6ea3c362,In vitro metabolic potential in human liver microsomes
key14a971d944f5bafa9fa8e9648413ff0c,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated
keya6a92727df3c5c0e631e3ef02f05828d,Tested for human plasma protein binding of the compound; Not tested
key66a11dd482ae800872c68ef8abaf84c3,Compound was tested for percent protein binding (PB) in human
keya9ccba2c0a4ee1fd26742cab43a2aae6,Protein binding in human plasma
key675510c5bb708bc687553d5352624438,Permeability coefficient (B to A) in Caco-2 cell
keyb47beca9e56c63922a4d28ec2203eeb3,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell
key8cedb936e50ef39fc2d65a3f786fe29b,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3)
key78a96d67fc4288e5e5bc1a2bd96bd592,In vitro rate of absorption observed as Caco-2 permeability in humans
key8ebf1ba0c017dcd9d5375efa48c0e9c6,Cellular permeability of compound was determined in Caco-2 cells; High
key55720ffb88ba8b064af87f52ef70be7f,Permeability in Caco-2 cells of compound
key434f86f283757c301c06953bbf5282eb,Permeability coefficient (A to B) in Caco-2 cell
key675510c5bb708bc687553d5352624438,Permeability coefficient (B to A) in Caco-2 cell
keyc12cb2c91e348131073d4c98af051fb8,Permeability coefficient (Papp) (Caco-2 cell monolayer)
key9b9013455c8e3d931bf1f04d6c7759ef,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL
keyfeb0a6ee6eb39ef7e31242c0b38c3c40,Compound was tested for protein binding in human plasma
keyfe4f9632dfb6120094d41ce3026887f8,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell
keyb57c9d6155a86f5c47d6472a653246aa,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3
keyd712518d2ea502323a232e5396707177,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg
key9d48da17e5cd201199535f800c56eb09,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
key807332b380a56133860e6d065bda230d,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse
keyc1af58596f7ea763c57bdb189aed9c4b,Time taken to reach maximum concentration in plasma upon oral administration in mouse
key5a0cf80d5be1758c64ba49cf5a7ede67,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
key378fdc7f732c8ff72c141a0cc554536f,Tmax after intraperitoneal administration in mice at 23 uM/kg
key251aea75ef0bab13bd0fa5381b526290,Tmax after oral administration at 30 mg/kg in ICR mouse
key904a366b932d7134a998b666490683d5,Tmax after peroral administration in mice at 2.4 uM/kg
key531f9c918bb3c712bb580e01a0ec0b3e,Tmax at a single subcutaneous administration of 40 mg/kg in mice
keyba615b83f08d0349f980cc6f9f2e9092,Tmax in brain of mice at the oral dose of 50 mg/kg
key9054f043f03310e77a88d720a23723c3,Tmax in kidney of mice at the oral dose of 50 mg/kg
key764719b971faedf6e8e01cc05610baed,Tmax in liver of mice at the oral dose of 50 mg/kg
keye7db4e2ab654aedbec89ce4eee75d4f2,Tmax in lungs of mice at the oral dose of 50 mg/kg
key9e8fa1d8f0868b508a4c9576c639b5d0,Tmax in mice at 18 uM/kg i.p. administration
key5cf1ac26947895a137a3f4163da7b846,Tmax in mice at 23 uM/kg i.v. administration
key1bbf229550081c069242c8553b932e1a,Tmax in mice at 25 uM/kg i.p. administration
key33584a38bd686534317530d63c00a660,Tmax in mice at 26 uM/kg i.p. administration
key7b55717113b9b77d2ab1425918efb124,Tmax in spleen of mice at the oral dose of 50 mg/kg
key7326f8ec60d6dc0c8064a6dea3d3343b,Tmax value at a dose of 10 mg/kg intravenous administration in mice.
keyb03279a79b6d7fd10b3b2622c90e8229,Tmax value at a dose of 10 mg/kg peroral administration in mice.
keyc21d19679a231bcdb610134375b5524f,Tmax value in IRC mice
keyc1916d717bac2077d6ceca83fdad5511,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice
key71922efec195832d2bba9cda538b9c24,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice
keyde28b5122b3806b5e2debd56dfe02f8a,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr )
key1ba818ea2ef3b53a40b5641460bd0fcf,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr)
keyd3b8bc7295fc1b2532f70389960b11a1,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h)
key602ea009f721dd428f993fd1a43f0ab3,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice
key9a4018464f21b7e40a293457f56c0369,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice
key4244c6efaa6f6a39b276bc125def1217,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg
keyac98e6de162072c69a5107a4cd302a69,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg
key1a44d66e0196e9b81172d94bbd5b801b,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg
key1ca6fc1eb850743be61f2a31d8f97cd7,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
key578f797ae10f72abffb8d164a00301bc,Vd in mice
keyd3410d4d709731c60bc9fb2000220f54,Volume of distribution in mouse
key014a886ae6941aa4526fc34c54b0ebab,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
key77a02580d3458afd65100dccd63c78f6,Volume of distribution of compound in plasma was determined at 24 mg/Kg
key2269ed30ffcccddba842b0679c9e1c60,Volume of distribution of compound in plasma was determined at 40 mg/Kg
keya9aef7afef7ffc9283398d30bdba869f,Volume of distribution of compound in plasma was determined at 5 mg/Kg
keybcd50e1b7514625b13f7f5df8e3fa788,Pharmacokinetic property (vdss) was measured in mouse
key747ad15bfae352e80246ca1cfe8bfda7,Value distribution upon iv administration in mouse
key4fb4c21eaa0e9716adb9797d8dfad95f,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice
key214c4e3c9f823b03820a3db4530bf2da,Volume of distribution was evaluated in mice after intravenous administration
keye0a42f12de0b896333f14509f699625f,Volume of distribution was evaluated in mice after oral administration
key2b2a374e60a8c3de96dd231a6763a52d,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg
keyc18a803156a8d77e4513339ad19f7afe,Steady state volume of distribution was determined in mice
key5fc4c01e5f2d5e2f7d015ee4a8da582b,Volume distribution (steady state) of compound was determined in mouse
keydbd07808be2bf863587f990c032a5059,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg
keya859666cc73d969d06d93cd54dce6411,Vss value at a dose of 10 mg/kg intravenous administration in mice.
key93dbb3d7ab27b490daedb2c27807154f,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg
keyc003066ce95d35f84d0232f984ef2f89,Biodistribution of compound (oxidized form) in in kidney tissue
keyc0758e490ee87dd6238e2c7ff4332e70,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution
key5cee880d62ef87812ed03ddd2ef56929,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
keyfadfada2935d914a85846ff5b622b8ab,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
key08267064c4e39fbcc3c299186c7578d4,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
key2f49574e159280345427595c046a1867,Inhibition of A431 human squamous cell carcinoma cell proliferation
keye2e46b2ee687c51036c3d0b571796cbd,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay
key0a55966b452e133e520217ef6f5d6cdf,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth
key1ca95ed29bc363455d36a8682970c882,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line
key09a8de63e9f41f7334a61a98f293c731,Inhibition of A431 human carcinoma cell proliferation
keydd372d40291e33dc9c9abcb0f3e33d21,In vitro inhibition of A431 (human carcinoma) cell basal growth.
keyf0cf36d6ef9532300d7c1040e8b283ec,Inhibitory concentration of compound against growth of human A431 cell line; Resistant
keyb39a5b17cae429f7c7fc723ba4da438d,In vitro cytotoxicity against epidermoid carcinoma cell line
key923b284cf974c8aea615daaa62ef04de,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R"
key6a52a8caec6d75adb373444c872e0af6,Antiproliferative activity of compound was measured on human tumor cell line A431.
key5ae2e0be83e5337928cb85b90b03a70e,Antiproliferative effect of compound on A431 cell line expressing mutant p53
key3c9fdc5099504dff5af418875f069b82,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound
keyd446ec2b6e3eac0c6f5e4daba9c327b4,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.
key768bfd7fa6d9ca74867638ac00b1931f,Tested for antiproliferative activity against human A431 cells
key8319076e32e4436ccf96557677c3fecd,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells
key3ce3be53c91bbb3a44e966485bc5439f,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines
key550d167b96828a5b0068cd2bc767e156,Inhibition of A431 cell proliferation
key02d031cea7fb99c0c41c4425db92ece2,Cytotoxic effect on A431 human epidermoid carcinoma cells
keyad568e7a58dec5973a1d9fcab8db6768,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM)
keyb2ce78cfcd5333239436ff5283ac23a5,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line
keycf72aace5cad516b72e53f3d2a27bce3,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested
key5e77ac57ada12b5ee6956c7fb379235c,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line
key4c6dff4ef6055946d4511c3fcc9e96bb,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure
keyc9d17186dd3b352cd8ff21c79df5de54,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R
keyad635d15b5b46e4b539d1d662990bb49,In vivo antiproliferative activity against A431 cell line
keyc084ee579a615d9cc2655ad07635f1e1,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells
keycfb797fb3addac13def0062817aff26b,Inhibition of A431 human epidermoid carcinoma cell proliferation
keyad2c21fbba72dc08b1a54fe508bd65e4,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells
keyd5ae9bbfc2c1fac8e0527aedd747e147,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178)
key9a94fc00fbc91709f0e4bd3a42b8817d,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38)
key691d2266f214f52e25156e20dc2852c7,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21)
key9672a8e39cf64eea296dadeff91b3049,Inhibition of EGFR overexpressing A431 cell proliferation
key550d167b96828a5b0068cd2bc767e156,Inhibition of A431 cell proliferation
keyfb9e4229656592b351c012b75c75b1f3,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor
key9148e10df2cb449eb577ace95f7a47ef,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor"
key1f6bf96f0c6f30e04dcab7466ebe3aca,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor)
key80f30d9d287f58c0540fc0d45dc6291e,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines
key80f30d9d287f58c0540fc0d45dc6291e,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines
keyd4a3719b373cf3f6d67c99cf95341e0b,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability
keyfd9a53c379946cf70a4a8d0f6ee71cdc,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability
keyccfe2bb1ad8695e8e1e5b550cd956c9a,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability
key27ecd3910e71c8ed1feef6cf0a20e99a,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death
key4368c272c2f4d4c3bc8e9a212e3463a4,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death
key3c77c8d0221b0d889f137365a2caaa82,Half-life period in cynomolgus monkey
key5b4b5155a9540e8c8ef9098e85ff5ddb,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma"
keyabf7702cc2758c8c9642fd43e08f84c9,Longer half-life in monkey (i.v.) at 0.5 mpk
keyd6495056cc14ef4c9928036bcd6edae8,Plasma half life in monkey
key52a0f64dcd6bf923f382ac1316a7b1e8,Plasma half-life in rhesus monkey
key5fdd70328da99fa6225eba8269361614,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
keyad7aa0f798176a032155a6ea0a1ca7e7,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
keydd54bad74bc18fbe45610e782444a049,Tested for half life upon iv administration to african green monkey
keyf2dad87267ffa69564a8dc1a5283b2c9,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey
key9c9ed1367a5f40826d24525c4fa5a35d,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable
key198aba3f348fff409f14dc759cffb25b,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable
key72453832c4aab5fe2a3f7e6a1745bc35,The time for peak concentration value after oral administration in cynomolgus monkeys
key11147ecf881a00175077f1c29f5ecf63,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound
key23ea7a380b64e004e76ee11a7dc0ea11,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound
keyfe5804c5080233aac8b5b51fef80ca9d,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound
keybf261139991b013cd645bfbf3a340b08,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound
key91b790b66b3b0ac845b697d58f2b2330,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound
keybe68b5aa1121b88a866edfce0086ecfe,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound
key6715516a3c6c25c31a6c3d0f928751a2,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound
key5b3ba8fbb90ee9621232e6d2ef9ba176,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound
key8b2665cfa96394470540b12417d6f9ba,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound
key204b542ab55b75f040c08bcb6585591b,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound
keyb9c452db345fb2b0d48ac95465dcee87,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound
keya841bb0e6189a4dfce3860676eecccb8,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound
key0b285cfb6875ef288261da8737570054,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound
keyfe4b8ddc0a168802cd2bda9e23ef80b3,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound
key1312f492f9d3b12994aedc59d1c63746,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound
key1a4d95946cb85c3f8b876314a76bc6f5,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound
keyad76032c1cb674efab5391ede26f54c4,Bioavailability in rat (cannulated) (dose 2 mg/kg)
key493db52245f2aec6391a4d0589d0adeb,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration
keyf23adc938ff29d59514028b4c6f3f61a,AUC value in rat after IV administration at a dose of 10 mg/kg
key70dd2219b3e989a6b5c657318a663d2a,AUC value in rat after oral administration at a dose of 10 mg/kg
keycebd8dc707fc0e1be1d753606cc859e4,Cmax value in rat after oral administration at a dose of 10 mg/kg
key7ff16a7ecd44f78719be0a9aa40a6ab5,Bioavailability in rat after oral administration at a dose of 10 mg/kg
key2b6b4a6246091a98013dcc1f674fd1e9,Tmax value in rat after oral administration at a dose of 10 mg/kg
keyf49c0c3ddf8af5a409c19ba8e3ddcb00,Vc value in rat after IV administration at a dose of 10 mg/kg
keyac294d7881b281424d8f6ac8d1b7348e,Half life period in rat after IV administration at a dose of 10 mg/kg
keyfd860d07fd7ed86a76fe8f5adcc416b3,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon
keycd6b80a0cf4d4311abc2e5a5f76812c8,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11)
key96389829f8e143a26d192b4a289cac84,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11)
key104a02ec870b7854a0755b3eed99a044,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound
key18d727c74369c06c344b3a808c3dd558,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound
key76d0c6861de06b5327e2bf0f4c7e84bd,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound
key0c2ce8ea0d7680bdc80a5043e738f7cb,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound
keyfd860d07fd7ed86a76fe8f5adcc416b3,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon
key078d89fbe19b6366f99fdd8346624e78,Area under curve after 1 mpk peroral administration to beagles
keye10056fbe5bd63b4d7bb3f7003d202d2,Area under curve after 2 mpk peroral administration to beagles
key315edd3e84acfbec2dadb3e51a509815,Cmax value after 1 mpk peroral administration to beagles
key9942d838e11c0e6acc2cbcea8d9c069f,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7
keye88a5a1068608a5dc7f775a2ff15418c,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6
keyeaa66d0820d1ebd098b5c6115b8e71d3,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8
keya6636bb5a4262531cccbf14b5b53bddd,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9
keyfa4bdc8e6664f16008d9650b622bacb5,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10
key939ae77bff4c98a7cc37c1137a908f37,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5
key76f368fbf69f83fd67d6cc990c7a9a0b,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4
keyb1f948c9893678dbe898b87f3a2ab584,Metabolic stability observed at 30 min after administration in human liver microsomes
key9da075bd8aca38f8c31d1e73ccb60e99,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients
key3a7a578da3bfa99048182188fa61101c,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients
key1d104940377216aad8061f8d321c7a86,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients
keyd676bc85b0a20cd58e0c285ab5b18b3a,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer"
key563eaa704f15c6ce0cc9b8f94ce7f5e3,Metabolic stability (% remaining at 30 mins) in human S9.
key45ee4a2e445b3e95fe8219a0ba9f8ae1,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined
key2a5d3f83203338f14570d599727f5879,Percent parent compound remaining after 20 min incubation with human liver microsomes
key23eb5fbfd18458983027c23195a799a9,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data
keydbe64b8c18818cdcbad72d73f9e9cebf,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data
keydb84906e362c00b8e63cefa9e08abc6d,First pass metabolism and metabolic bioavailability using human hepatic microsomes
keyc0cc779878990dde143855687b3f813a,Percent compound remaining in human plasma after incubation for 60 min at 37 C.
keya0f1b77c7c2f4b3919fc21b1e9ddda05,Percent remaining in human plasma after incubation for 60 min at 37 C.
keyb70817518903192d5f39980dafa70b22,The percent remaining in human plasma after 30 min was determined
key27ff10418b2c12342290165934aeaab9,Conversion rate of the prodrug in human plasma
keya046473f5ac62436ee311c51e0514c10,Conversion rate of the prodrug in human plasma; ND means no data
key882a3be2aa3747afb6dc93ef31d9f825,Half life of compound was determined in human blood
key042d62347c09daca002f7fc57ebcd324,Half life of compound was determined in man with once daily dosing
key0ae44dc3a980781921fb4d0a6a8d4303,Half life in human microsomes
key7b4c187bdf30090880c385c4ea883457,Half life in human plasma
key89a766bb7da1dc3092f2275c46191b68,Half life in human plasma; Not detected
key3c2566fdc4ba48b8c13cd4f1343d2069,Half life period was evaluated against man at a dose of 10 mg/kg after po administration
key801f5893ec18f3d5a98d685318d9db6a,Half-life for oxidative metabolic stability was determined using rat liver microsomes
keyafc59db5ae9cbaf059dfb31a589f6fe0,Half-life in human plasma
key39a86bfec1d6a6e61810746dac56db75,Half-life of the parent prodrug in plasma
key1c00cc156b4cce307efbeaa9c32d253b,In vitro half life in human plasma was determined
key9fa8caf94afbfbc3d692bada41d306dd,The compound was tested In Vitro for half life in human liver microsomes.
key1487464fa07e800282dd8f082ed18d8e,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration
keyba094ba987074a8e43faa02f2ef673c0,Observed volume of distribution
key010db949d06471685c8b60b9de287f31,Oral bioavailability in human
key89ffe1460b4bf90ef4e5595fd0a3b559,Tested for human plasma protein binding of the compound
key849c641336c8b9479fc8c94a639be403,"First order rate constant, k was determined in human plasma"
key75492e1151f7ac36ff20a8aae1ead976,Observed rate constant in 80% human plasma at 37 degree Centigrade
key75492e1151f7ac36ff20a8aae1ead976,Observed rate constant in 80% human plasma at 37 degree Centigrade
key3533d2975e9f6af1f85b8331bc8dc98c,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes
keye1503a54f9d1110872b2900563968cd7,The compound was tested for the plasma binding in human
keyc36aea605e0ceb05dd6f245cb067affa,Plasma protein binding (human)
key190a94a5d2f11e98ae5748007c4f20a7,Compound was evaluated for half-life in human liver microsomes
key626a1e740b30e8eccb98cd14e6111a1a,Half life measured in vitro for its stability in human blood
keycf2ba075f456dd7d1123f96f802e5159,Half life in human serum
key177b3f219ba51a208d4250d9b3e31292,Half life in human serum; ND=not determined
key04de9e82c8fc1a24408a6e8b3c3e68bc,Half life were determined in CEM-SS cell extract in decomposition step 1
keya945a5a3ef11759c38c8858ad2f54f1f,Half life were determined in CEM-SS cell extract in decomposition step 2
key15a81bf70303840b25020e2ddfe2399b,Half life of the in human plasma
keyd0b308930016da8479c560b3aba5b7ce,Half life period in human hepatic S9 fraction was determined
key4c3978bd0cfe9e431360b61b3e8113f9,Half life period in human liver microsome was determined
key9aa168fba71b8e09ff282a43c13c1f0f,Half life period was determined; 6-7
key942ba0be7c98a2961dc78d834d03f870,Half life period was evaluated in human
keydfb83b799da84c4154ead5a3bf2ee585,Half life time in human plasma
key1c3a6d80f3d54746634b2f8c2cee9e85,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
keya4f691d1f408cd03d5c5fb5c555a9ef6,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol."
key0e2c7723323ae8c5d6e19512d974e2f6,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
key1b51459291d70d48230e71b12dfdd558,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol."
key68d88d126dc1a2879689cafa667e83db,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
keye6f28a3b2253e2e7f6b95411f29c38ea,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
keyb78c07a4830f04faa2410ec2a29e1a9f,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol."
key2989d46f72bda6426876a89d5f8e46a3,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution
keya1774f7764541a36ab5567e61413d6ef,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
key027c4f4cc46c04e4a106402e60b50d7e,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution
keycb01cd587a7f627e8ccb27036b2865bc,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
key2b8b221b686fe2df1d5ee99f6a847306,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
key646f54701f04eda400af16187874f1aa,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key560466ec860cd68a7686ad7651ddf691,Biodistribution of compound (oxidized form) in blood tissue
key84419b35dc4877bee8259622a50b5a5d,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
keydd7783a983424588139429a4cf9afc48,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
keya918c8138cb710a7341d63b6dbae0c3a,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key4c2341bb8c9f351f2494917bf0258910,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
key317ab2ad9c6dbd2c3b8f05ce06d59dc3,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution"
key56e5ed4afce605ff8a374397ee165276,Biodistribution of compound (oxidized form) in brain tissue of mice
key8f506c1406c9afb233ee68126072ad54,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
keye4ff4826d16e5b62fa712df3699801e8,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
key98a9f6254aa08c1d354bef3fdc1adf96,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
keyc24d85b0a37a2d6f9e314860ae661d6f,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
key1dbfb2f76141b024ed206707688202c8,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution"
key7a23d0c197c6a01686f59bbb809e51cd,Biodistribution of compound (oxidized form) in heart tissue of mice
key3af0b9920027f1b7e40862a445d5d061,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
key3af0b9920027f1b7e40862a445d5d061,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
key9bf2bbf53b6e4ee7ff6a767dd6df89ab,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
key8b96f72436db8f71bbafe4fa89843ca3,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
key31633083bf0d69e9fa9446c88ce6ebd6,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
keye26ddc6c2e141f688084c26bdb2c5e74,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
key2471cfa1ca0297990f7d6f632fdc9ace,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
key87d244c330ca8224f1d1c59e3e94974a,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
key489a1f3eb0d57e80bc05979d4e281a04,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
key876da9814118f311528fc48137aa8d90,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
keyf12ab435cb26f2a1549697e2d27e5406,Biodistribution of compound (oxidized form) in liver tissue
keyce3cd198010231dd441bb81d5cbf4952,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
key174ccc7c77c53988082e4443769243eb,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key69bc9943224ebd3c9b32d066663e2b5c,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death
keyfd805131fa45d75c834547067d6937cf,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability
keyd45ac1b27b674c042400f3a8cf87933f,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)"
key223eae485d397545b169a03de2bf51eb,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)"
key686795e2eca2b0bdf21b13774a0f8688,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R
key7b2b6c0a83eaa215aaa26df814d722a7,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. "
key86044baf2759d5133411b3144ce088b9,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells
key47fcbe3e8dcc6e8fa1e6aba0369703d6,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells
key0656fc65605afed1133e155735fbc9b3,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture
key56d86eefad783533d9cb4212b4fd4c8e,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)"
key96830ccbe7dc4eea9c514042a7eb7938,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)"
key96830ccbe7dc4eea9c514042a7eb7938,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)"
key1a590d75dc0a957e302d0a9773aff0a6,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24"
key66a677d69ba1c9f1d324a7374cd4e6bb,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26"
key0e72a7a2a9d429017778ed512d7f19b4,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound"
keybc73d311281b67fe8878905a727a304e,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound
keyc8d573cad7359f8b49316d2e94d719c7,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24"
keyf51b538a89c79cf50ab6f55823069b20,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26"
keyf51b538a89c79cf50ab6f55823069b20,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26"
keyc321456c0f19dbbccb6d1731238d3a04,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration"
key08ee03a956439a0e45c7058e1b9ed174,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration"
key7e068708f1cca7ccabfb3d8b14be6be8,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration"
key41bdaa13aa5340b1db26d5e2bff54971,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration"
key2c0f44405c17e8f11708b758750cdff6,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells
key5fdf2219f585cbe21042dea6ea3bf5fc,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines
key06f6f99a04cb01bf1b29ccacc0ffbdf5,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye
key71d8769d5139ebcac99df994040189db,Dose giving a 50% decrease in the living cell number (A437 cells)
key1602858f9f810739c3c0086cf825d05d,In vitro inhibitory concentration against proliferation of A459 cell line.
key534f41ea24d6aee9d6ed187afb477e64,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined
key6e7866a8c27136344de4ae0655866031,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure
key6b70cc5ad7aade04b50fca4d421dafdc,In vitro antitumor activity against renal A498 tumor cell lines
keyc62711fc8968221698d70f1ae4b4b00c,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors"
key3010d8bff9cb34d273831409e90702c9,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium"
keybee0795f196688eafdd42b609ec507e9,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test
keydebad9552a91082dfe22d78472726b1c,Cytotoxicity concentration against human kidney carcinoma A-498 cell line
key27f29c030b4e0e6bae4c23a11b734304,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested
key1212e252d1cd50c7ebe9a03547e530b3,Cytotoxicity on kidney carcinoma (A-498) cell line
key6d7e296fe901e9b1a420d926efcb8f55,Compound was evaluated against Human cell line renal A498
keye75b66b9101b62320c1614f340fea750,Compound was tested for inhibition of A498 human renal cancer cell line
key591fc644302a3e91f276afa6c63db123,Growth inhibitory activity against A498 human cancer cell line
key0221591151be40e8231c067b6edcbd98,In vitro antitumor activity against human renal A498 cell line
key9a4542d268418499faf2c3e161d991b5,In vitro cytotoxic activity against renal (A498) cell line
keydbef2c0ec2e7ae66c4d99612242d531a,In vitro cytotoxic activity against human renal cancer (A498) cell line
key64e183cb350148d6cd7b6861060fc6a5,Tested for cytostatic activity against renal A498 cell line
keyac03e5cac5c445556177d342114376d9,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.
key7003d1c85da0501fa4284b8103029a30,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M
key51d3234dce7a7db046f809b41834f254,Cmax value after 2 mpk peroral administration to beagles
key226e67caed1ea97a1165ab7afee43ff6,Bioavailability
key40517c3b51b1ab5c3002aafffddf5fc1,Bioavailability after 1 mpk peroral administration to beagles
key907e4b002f093a6b3256f04e87b1f54d,Bioavailability after 2 mpk peroral administration to beagles
keyb0e4fd840a572cbc6093c427fefebb86,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9
key43672278d5221c449425336b24bda226,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat
keyf44a3c5be15c39c14c3ff35201717f87,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound
key1ace810153554fc84cc1201bbbb46ee1,Solubility against bovine alpha-chymotrypsin
keye8805f10917575ee52dd2f8a3d03172d,Rate constant of the bovine serum albumin catalyzed reaction of the compound
keye8805f10917575ee52dd2f8a3d03172d,Rate constant of the bovine serum albumin catalyzed reaction of the compound
keyb7fc1ff8fb2e01bbbed33fce74d30cec,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg
keyd6754df891c06273cf1b57bc1d4464b7,Half life in culture medium containing 10% of heat inactivated foetal calf serum
key7389e9fa6efb2a8ac0900c372dc82c53,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined
keyf06d37cce8fd2236076385c954ea4e63,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2
keyd6c82b41ffa8b256fc06e8052ea0de42,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase
key3e69c0cfde8da1b75ab9b00a67b1534f,Half life in presence of 2 mg/mL BSA at pH 8.8
key0c9664e983ac2531e6857623c83fefff,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1
key5e6bb19eebeb757564ac400b30eebe1b,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2
key6bb734273f5cc84996294fbd2eec0a1f,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined
key38df5447c0f6759d4ffe598410eb902d,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS)
key06e869c3eb325315b170aa4c5e78fbf6,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg
key8ea8f0ff9ebf67b5310716f91f8876c0,AUC after administration at 100 mg/kg/day in dogs
key9f8279eef77a05cceae0892215dc65d8,AUC in dog at 0-24 hr by peroral administration at 3 mpk
key8e16e54a623e4cd5adda0228d966b651,AUC value after 15 mg/kg iv dose in Dogs
key42ed0d69ce9463ee1bca2560abe73f49,AUC value after 30 mg/kg po dose in Dogs
keyd1dfa03a21221a8675ccc9dad4dc5e08,AUC value after administration of 4 mg/Kg oral dose in dog
key9688689edea215152748dcbcdded5f01,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs
key463aab5795155be8308c8be7ba45aa4b,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL
keyfd42f94eff198a0a6fa4d37ec5dcea51,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2
key7cd206f97d9744c3275be79a202317ab,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined
key85fd8e0e6c4b6143e9c4a21cc0e081cd,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined
key80b670175b56b3bb877f090ff19ce3fe,Area under curve determined in dogs after intravenous administration of 3 mg/kg
keyb79f62a97fd5d9296ea9d5e8176cb30a,Area under curve determined in dogs after oral administration of 10 mg/kg
keyff38f5d133a6cce35a5e67133c22423f,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
key6df1dd814bf7ab2f9afeacac5d27c2ca,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg
key9a3cb02c3cc570817129ca92f267a718,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg
key7ca0fc0d4039693057cd514941269b2a,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)
keybaf143f7e25bde92c1f7bd442ad3b098,Area under curve determined in dog at a dose of 10 mg/kg by oral administration
key6f3380251475cc40840cbfb433ab2388,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg)
key35c4a8daafb20cb5cb9e2870d5bb877f,Area under curve determined in dog at a dose of 5 mg/kg by oral administration
keyfea6d84db26adb52c208179049e785f3,Area under curve in dog after administration of 20 mg/kg dose through peroral route
key736752e5b650711c91aa52c0cd006c34,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
keycbb294f9382e88671d4a0a94a91082a9,Area under curve was determine after peroral administration at 10 mpk in dog
key5e9a139db7dcffedf4df618c1157e7c2,Area under curve was determine after peroral administration at 5 mpk in dog
keybd6a08c70e9dc387d342ded0f6b190d8,Area under curve was determined
key120f5f65044d2f9a2e36851a51484afe,Area under curve in dogs
key5f15c4e89a37ec2f81d9f0af4dcd5df2,Area under curve in dogs at 10 mg/kg dose fo oral administration
keydb8793596ba5029bc24e3173c648be9e,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia)
key88453fa57f7a0fc20348175781e39cfb,Area under curve in dogs at 3 mg/kg dose fo intravenous administration
keyc12715b3e913a6344342e0d147818105,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
keyfe8b366c9a418a463f5ef74b321256dd,Area under curve value in dog at a dose of 5 mg/kg
key85212c7a73ca725fc95ce75a5ec7e51e,Area under curve was determined after 0.1 mg/kg iv administration in dog
keyfde79d51fe37480e9758de81a0f4e375,Area under curve was determined after 0.3 mg/kg po administration in dog
keyfb8567bf732429dfa3a0ee2dc16ff476,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg
key9da76d07f9ccdb25135efb880cf09b06,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog
key7317c31528aa83a88362c4b62551fb33,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase
key5f29e1724cdad9ba1b7bc72d88f0c4de,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase
key8ef32f091667d0da4ad45ccc3f50c464,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase
key35701f267320893a405d70bdc4ac0086,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase
key7757a613997ab2ae64907a1afe75957c,Time taken to reduce 50% of the concentration of compound in blood plasma
key6173587bc3cc63c6616f79f524338817,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I)."
key7b4c187bdf30090880c385c4ea883457,Half life in human plasma
key3f1a5f0ea8b6bd661a748d68294833e8,Half life in human plasma was reported
keycf2ba075f456dd7d1123f96f802e5159,Half life in human serum
keye84ee38314de6057d428d38394c14def,Half life upon exposure to human plasma
key46da753999151ea1915559f0ff381de7,t1/2 in human microsomes
keyfc6ed80c100c16dcf57173d35951588b,Half life period in 80% human plasma at 37 degree Centigrade
key8edc3318595fb6d3c18e56407e7677c4,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4)
keyf165746e84f8042862c61048aaf2539d,Half-life measured in in vitro Cathepsin B assay in human plasma
key45be72fdf73ab78bc2ae6e54a75a9b6f,Half-life at initial concentration of 5*10e-5 M in CEM cell extract
key3e202a52be5d4178db2e3aafd5a959c3,Half-life determined by human liver microsome stability assay at a concentration of 5 uM
key1b885e2da59a6b8639b1506e63b352fc,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma"
key5630ce12a4270edf8bcf0d8064bceb11,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)"
key694788e14441b7e0ba2fb0181220b351,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)"
key40d65ff4e64ddeaf965074c574e489d9,Half-life in the CEM cell extracts
key2952b6577ff1702e0651d65e8c21f173,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade
keyd944408955df183e373297f3ef8df296,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed
key8cde0bd8176aa8aa1bf78ad397f60407,Half-life was determined
key7586a4db8f041ccab4e6c3d3e82f8032,Half-life (human blood stability)
key4b21e842e80a59dbfdf70d125e0a1995,Half-life (human blood stability); no data
keyafc59db5ae9cbaf059dfb31a589f6fe0,Half-life in human plasma
key50e8704941d053138dc070a397bafee0,CYP3A4 metabolism half-life (t1/2)
key30f5caed3d50475f903738511096a28c,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability)
key07eb7138c4a4b5c3e50a0aab5828fef2,In vitro half life in human plasma
key17ec0c777366a1c5cdb7872953a4df3c,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma"
keye2531c5a08b794aa9b98f96d8f63e1b2,In vitro hydrolysis in human plasma
keyb13d380b3a0198ac0c7cf9cf994ac1a6,In vitro hydrolysis in human plasma; no data
key7711eeeec622c03416892d4648be1305,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C
key4e523e31a8766cc9f58ea9f1e098c092,Plasma half life in human
keyb3f5a501348367513035608520288b71,Stability after incubation with human plasma (at 37 degree C)
keyfa407f34963a450a9bbd971e63015e6d,T1/2 was evaluated in human plasma
keyf48269e7ba7f041a99146c27b65fb959,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I)."
key92a69fc627cb382dfd2e191b82c42fb2,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined"
key5f29e1724cdad9ba1b7bc72d88f0c4de,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase
key0c1e0e8dfbc62a1bbee813e8de8f8ea4,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase
keyf5b352a9a3ae94a63255ff71ea4af991,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined
key7028cb78b20d12709e301325f8da2d98,The release rate of the free drug from the substrate in human plasma by human plasma stability assay
key6a2624f619d6a43a2202d14323697c19,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed
keya4c208e66dcd8ab8384d969521dda5a7,Time taken for 50% to be consumed by serum PON1 was determined
key0a6dfa98b7d13678ce35eecd4d26987c,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed
keyc30ac347e972b1235d8b7ce5beec5dc3,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes
keye9fa6b9c1cf040009f506ffb1c8eae38,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour
key693a444927579124df54973c883522b6,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour
key680646c3f88b1d27f07bd1f628636df6,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour
key7c89ff386231d20bed9e18a8904297a0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour
keybe12481e5ddce4fab8179c219cbfb617,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour
keybd448cf6200c0560d69a2a2ac0d60639,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour
keyd4027ca8b8e00930a8cdf3d637efa944,Compound tested for growth inhibition of renal cancer cell line 786-0
keybb42b91ed5cca880314df5e2b8402cab,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line
key9dfd4d92639dd4a8c04142f58977899c,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line
key912b06f66df829b11b23c1e307964b96,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration"
key871cf8a9901e358ccb4e707a4dc1628a,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration"
keyc392fc9187592cc186f2ff5d51905a19,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration"
key4a4edc0373dc1c0881602754b77b7089,Tested for cytotoxicity against 786-0 cell lines in renal cancer
keyb6fcfce1d36d5f35e2bfafa62240d88b,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer
key8bdf896ac84769c05a063242b39344cc,Cytotoxic effect on renal cancer line 786-0
key28f830681f95125812f637fdc6186a78,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay
key67a34bbbc15f68722ad10fd942ad0d99,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
key7afbebab39623072e43c440524c53b71,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line"
key5861ab273f94fcf26f4c20e7b715f6b4,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line
keyd962883abe4243b0105749071a6b7c85,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).
key7d43536bda6d6806ba0027f87df1b8b9,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death)
key38fc8c014090ba065a6b4efb648db159,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.
key8462974817e677d7c9ed1f5802c1d87d,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined
key50bea88852a17f9c00a1a4d9e081b1a9,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
key6d888c7b788ef9f40ff2d0d2475062c3,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression
keybd4a88988bc79cf152fdd1fcb418cb81,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL)
key4bf7685b0a77b89fb2d4b6c90ab4bad0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved
key1ebd26e1e1e32c62f7da9735b0da647f,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33)
keyeb87614154c5fb1f1b5819220d1d1e6c,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26)
keyf53082b59158da4c3fee9cfe469649e6,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved
key65b9ec3b7b7668e87c7f4c30a346c8dc,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33)
key5082151bd7bbcc3cc6f6464068939851,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26)
key3c96bf04c3f9809af92671394b86c3a4,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved)
keyce9c04b37574658df35ab65e611c74ab,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved
keyea5c4fff83786f96faffc5790b9ef7af,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line
key2cefc0cb94af8e8c2139fa84e49f12fe,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive
keyf465370f233530e00e1ff014bbefffa7,Inhibition of cell growth in drug resistant 8226 myeloma cell line
keyb2bfc773bf4aec29d28d17600b24ce7f,Inhibition of cell growth in drug sensitive 8226 myeloma cell line
keybcedba658a47174d9565a82e4d251d96,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.
key1ad9fbbe107956a11b3dcef9e78ff9e9,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
key95335bf1fea76e8a1bb9ad75d76f4a1d,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
key85f58b2798d78efe67daca0612b936c2,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
keya10d34437662e41aa18b26e56a8f591a,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
key4ed334db5d0fe5bf8670dafa8912555c,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
keyef72dbd6891ca431d4e06d8d3d19f88b,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
keyef72dbd6891ca431d4e06d8d3d19f88b,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
keyaf555f16eb553fe99853191f8ec1c26a,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
key9e58b69bf61974163bc3c7eb94e74745,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
key24891a9036f444c5693a57254390aab8,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
keyed0f727bfebe5b1ee7f7427b21cb52cc,Compound was tested for the growth inhibition of A498 renal tumor cell line
key1aedf6e207059bc5d10e5859e917a821,In vitro cytotoxicity against human tumor A498 cell line (renal cancer)
key4d988640540848920e372bdfe1bc7ac2,In vitro inhibitory concentration against renal cancer cell line A498
key5a50214c532ef939ef77a4efa55b413c,Cytotoxicity against A 498 tumor cell line
key2eef6d5c7772d724214d3af510eb5bc8,In vitro antitumor activity against A498 human cancer cell line
keyb0b9ddc8c38dac93c36bdfc727e72493,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening)
key1f33093c910cb77f6afa87ecb87701cf,Inhibitory dose required against A498 human tumor cell lines
key08a771a9ba244977679db2de901bc80e,Anticancer activity against one renal cancer (A498 cell line)
key273824befc522e33bea298de0faa5e3e,In vitro cytotoxicity against melanoma A498 cell line
key9ac489314eab7f4fe751ff7b8d615f9d,Compound was tested for growth inhibitory activity against A498 cell line
keyf47f7911d98de5576df1dd654db9d785,Compound tested for growth inhibition of renal cancer cell line A498
keyf06b2125eb59864f2596aa939ffc1a5d,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line
key5835ec4c1d75dda1b41955298ac00fc2,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.
keye31a358e0e89a0632c9c05475589db37,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay
key57b34d5052fc6526fac14778fe936395,Tested for cytotoxicity against A498 cell lines in renal cancer
keyfe842a08e347079e54f7df84df149c2b,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer
key036bfa29dbe2a6fc0739e72802ca6d8f,Cytotoxic effect on renal cancer lines A498
key8b01d71311aad2ad1a14ee94a38724e7,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM
key24891a9036f444c5693a57254390aab8,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
key93f5076caee0b48eadb7f91218d0e781,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line
keycf719f927e3154833bcacc242844a542,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay
key116a5ac9866724e52a9983aa201cf3c2,Cytotoxicity against human kidney carcinoma cell lines A4982LM
key0f92726b30a65dd5d2b93c2e303cd5b3,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
key052a22eb9bbc2d31d7c3155521cfc7d2,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.
keyaf4ff9e24e5cd04e565ec430353d3e8c,Antitumor activity against A549 human lung carcinoma cell line
key1896ef9a390190289c5088b6fbecc61e,Antitumor activity against A549 human lung carcinoma cell line in experiment 1
key872f7ea0cea53ec7ea2bec6e8d766e4d,Antitumor activity against A549 human lung carcinoma cell line in experiment 2
key963319c7f871a9fa23eb89ca959de536,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line"
keycaf3009d6c2e94f3ba37566e86a5a4d9,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay
key16fc4c9aa897895d72ec2179671ee1ae,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
keye2e87b69560524431f6ae64653e31933,In vitro cytotoxic activity against human lung A549 cell line
key6128ed1a19035308355c89281b456d69,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis)
key0fad39b48c80f6963b9cec608c604331,In vitro cytotoxic activity against human lung A549 cell line)
key17539a6f66c6b0240ba562ac5f021316,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested
key06729e0281c1e1f309e36e60b0d5da78,In vitro cytotoxicity against human non small-cell-lung cell line A549.
keyd95a73fdb2c36ead1f8debcb5ee70e47,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors"
keyfb634625c6f2863a4f1eb091be5892a0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium"
key979711b1c618951dd8d080dc5d382727,Inhibition of A549 human lung carcinoma cell proliferation
keybf4b2745413063e932970ab8447142db,Inhibitory activity against A549 lung adenocarcinoma cell line
keya9bc9b081c6b4c180f3a726c9e62119c,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay
keybe9317f1a50e60670959a50f7fc1ebc2,in vitro anticancer activity against cultured A549 human tumor(lung) cell line
keyd93e35f862d225096f671246029e765b,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line
key16fc4c9aa897895d72ec2179671ee1ae,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
key5ad3538f51ecb9fa9cecbe39bd4b9935,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line
keya515f150c7d2b6f3937f89e5ba693e36,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay
key0862334c43bee29ce474e2cde4099fa9,Inhibition of A549 cancer cell proliferation
key1844f8a10fe192efa3c4c51fb46a0abc,Inhibition of A549 cancer cell proliferation (Not tested)
keya515f150c7d2b6f3937f89e5ba693e36,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay
keydd6122ef74c2a26bc6406ba270d58ff1,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation
key4e476fbbfa51738240ead7d191861bb7,Antiproliferative potency determined as inhibitory concentration against A549 cells
keybff0b7d2a0f6621511418cd90c29d6e8,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel
keyde4ca779a0c782b648ac1da20f4d5213,Cytotoxicity against Renal cell lines A549 was determined
keyfbea4afe95daa73b7f940b9825e95ee4,Area under curve was determined in dog after a 3 mg/kg of oral dose
key9418370becfcb520ab35c2702ab00a24,Area under curve was determined in dog after oral administration at 1 mg/kg
key803e79f26fdc6b16c8109c4030ca8cc4,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
keyf34725fdc7dcb71ed891e1cc53a620e3,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
key435ed8759a0f87b8cc3e63fde7e173a4,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins)
keyed6ca9a27da8ad3197e1724713a7591a,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins)
key1593d7d8afba11056bf14c5c36d3e377,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins)
key77927fd8d41422cac4d610ff28b54658,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins)
key59560ca449630f66b90324a3ab300d7c,Area under plasma concentration time curve in dog upon oral administration
key8498d9c0d49a84d46fa9beed88804ebf,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg
keyb2a0f8d952bc93f433f224a2d2de11eb,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.
key97763de482d6a76f228802e26995abdf,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.
keycc2f4c3612ca4753593fd74a3eae65da,Area under the curve for the compound was obtained when tested in dog
keya09f5f072bb922373e08bf3250d8e861,Area under the curve at a dose of 1 mg/kg
keybaadc28ab0f59f2faf3f855e8d3ba92f,Area under the curve at a dose of 1 mg/kg (oral)
key5fd392be1ff6872bbfa8008e4635c74b,Area under the curve at i.v. dose of 0.2 mg/kg
key9e27d4779cb9329aee9d2c3402f95d50,Area under the curve was measured in dog after an iv dose of 1 mg/kg
keyefcf2c4d4e63deb2c4641d98bffbac78,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog
keyf2a434ee9055efba65480e421e446387,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally
key2b68396fcbcfb3d6a83b0d9bdd4f20d0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally
key3855c67ed5b43c67833e47cc3c167ba6,Compound was evaluated for area under the curve in dog blood.
key0bfb8d5981a077da8cc6f7a75ca83a72,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog
keyf13da5b642e7aa9b6796f8f4aeff22a3,AUC in dog after oral dose (1 mg/kg)
keyc347a2145b15e664a2705f379f8a0096,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg
keya88bb5301abacca9306449478f018dde,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported."
key2c42bccd07637096c1e23847c8f21904,Pharmacokinetic parameter AUC after intravenous administration to dogs
keybd5da75c74c228bd2e3072349f7d673c,Pharmacokinetic parameter AUC after oral administration to dogs
key04c029ee0d0ef5ea8c08b7fd255a3f60,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b
key1f9dca2d605d3fe886ff27304449ddd5,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b
key3f1cf64a7fc54132b6af2794e704acda,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.
key7dccf448025a357f85dab7c0a471d9d5,Pharmacokinetic property in dogs after oral administration at 1 mg/kg
key8d4e5c8e45d2f2b742defdc17d9453fc,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog"
key35f75a9a2df83efcb08d0746995c8868,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk"
key15572a2ba564335361c359149068da72,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
keyc4ac33bbbe0bcee28238e1ca15aaa89b,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
key2eb3f8a5dd5db15b660cf3ff21438ebc,Oral AUCN in dog (dosed at 0.5 mpk iv )
key2eb3f8a5dd5db15b660cf3ff21438ebc,Oral AUCN in dog (dosed at 0.5 mpk iv )
key5f3368a751b6f33cc72b6d8b70eb0d09,Compound was evaluated for oral bioavailability in dog; 90-100
keybfa7091ca4cf558a1824e57d4c7af4fe,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay
keya3ec5f090fd58ee0ae7d43a21dbfe567,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined
key62b06b87518d0ae6e3d36b85b1c53b5f,PAPP (membrane permeability) in dog kidney cell monolayer assay
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
keye9ca46096b3304b8ccf8571dc50f6b02,Bioavailability administered orally at a dose of 10 mg/kg to dogs
keyf50292db74945af8f7f4d7a13d4208a8,Plasma protein binding towards dog plasma at 10 uM
key391ea4b3bb42306d9666221467628785,Plasma protein binding towards dog plasma at 100 uM
key975fbe1eb9d369833234cb957756d970,Bioavailability in dog (dose 4 mg/kg p.o.)
key8645b56850c0ac36cba17a6b8b83b893,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog
keybc03aa7d7bb2c6819556379c1a96c3b5,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined
keyfb2a383ba30f6fbdfd8ffeba793744de,Bioavailability in dogs
key226e67caed1ea97a1165ab7afee43ff6,Bioavailability
key4e89e323b5463effa193aeeabfb6eedd,Oral bioavailability in dog (dose 10 mg/kg)
keyc1a9388404e3e696aa9eb5c8c033883f,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined
keyc4fbe9205b7b70dfc13ccd3c35c68ef6,Bioavailability in dog (dose 10.0 mg/kg p.o.)
key401f98f2c69d9f8f30be435d057e0f77,Bioavailability was measured in dogs after an oral dose of 10 uM/kg
key893e04e3e5eef092753edcbbe936582f,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog
key2b7d02e1565471d3a5264ca880e70276,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour
keyad0e667c364e7d1012bf6947206fc201,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour
key3f28a9ed166f10728e566e106d1680c0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour
key5c9e6d9e48b1f78fbf9831e72c697557,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour
key3e8b47b5a443e7a84227dfab22d1b215,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour
key62fd57b33d71888b5ab459e869833809,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour
keyc6bb80f40b469a95a7f9b8edb08309fe,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour
keyeba7b51438201626803550fc4505154f,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour
keydba9fda10566dc7daf40afbcee3e24f3,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour
keyf0062a9ba4db0926e51901cbbdf21d59,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour
keye145e92382c4899f05c9176c32a4708c,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour
key40d4896596a2c4e98258a4b69fdc684d,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour
key73ee1a9738b7cda4a76d442852135371,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour
keyf1b3084726f87b7c806050b851acd982,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour
key80f86efb5e2d7f7af5ae711ce8117bdd,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour
key71e5ba57586f2ac2188a026bc249fa80,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour
key6501a65a9a31353db26d20cb8f6fb91c,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound)
key9a084de89d5b34d2029af5526890146d,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound)
keyeb818e6e339534ec1746a47a68e3f942,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound)
keyff6490442c938306f3c671dded3e430e,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound)
key429effeaf75fca9a9f9818850b7283bd,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound)
keyd619775ccae7e75ffaaa8e39ab4be60a,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound)
key32f16a155b0ab46768dd4e6b096d06d1,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound)
keye38332ca14991297c5c185a39e058124,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound)
keyd701babe5ff37cae562f035b7e1fd2fe,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound)
key0be29786a0a361d56fbb09fa55589478,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound)
key4dcccd2d6c7f72368b27545579ac58a8,Compound was evaluated for oral bioavailability in rats
key2ea268e14527fe1cbcd996914b728fa4,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration
key78dadd9841d8e27e20cdff1a4d11be72,Half life period was evaluated in monkey
keyb8f987dd4050d0c38e1af5323d2c32e5,Half-life in rhesus monkeys by intravenous administration of dose
key27d3b5863b890996d57c3b877cfaccd7,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse
keya6a2af45e3dd32351416f2c4ba720542,AUC after intraperitoneal administration of 100 mg/kg in mice
key33c959ae6b2500b67ee2ce382442a5c9,AUC value was determined after oral administration
keya6b807e95f98aeee43a722ad228bf9ab,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice
keyf38414699ab37a6e490072e9489942d4,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
key6e2bc93e2e472c4fa5a19f14aa2319bf,Area under curve by ioral administration in mouse
keya435cfce3da9b0a358cad4b17a620b8f,Area under curve by iv administration in mouse
key24c0204ee4b510c085dee41051959d02,Area under curve at 0-8 hr in IRC mice after peroral administration
key2b527086374a59c5f1e6d5f370f55183,Area under curve when injected i.p. in mice at a dose of 50 mg/kg
key3ef40489888b67bb46ee0d5f9717e4ae,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg
keycf7c5c4f625859bbad0b456634d82a67,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg
keyef73b0d09eebbbff37045330af5d020a,Area under curve when injected intravenously in mice at a dose of 20 mg/kg
keyb735cf39d8bc7e0361a0dab0e68dd268,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
key0c882bea33e88288b1be3ba4716d7511,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
key02515b10c57de4a58f775bec2e10e6c3,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
key47483823a9c5da67faa4f5cdf3bbe5fc,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
keye483da70b797fa2bd9342ba2c2427b6a,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
keye08c9a6da55c0ba8efcebef905a492ce,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
keybd5a2e820a151d2aad9b377994b23ff7,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
key5a2f4670a6f50f27b447b3fd659c2a83,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
keyfb74900e437b7a20fcbf29fa45acfa37,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
key8239084aa1d86891837daea00afe084f,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
keyca51dc2eb68cd1d7341f8513dbe8e613,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
keyb8aa1e8d5be090c948d99a756c2bf3cd,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
key1002f32280f9067001155cda8ebd7f68,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
keyd0889f02766ff3aac10b5107c39f178b,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
keyeab8734087490fbc38d6c93f6162915a,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
keyb3e9f8a4e9a32ff8897940b3f481be6e,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
keycdfef8b6cae5e9bdcfcd1abb080d4d6a,In vitro inhibition of human 8226 myeloma tumor cell line growth.
keyc819ed06a078805ad39ea678676a9d93,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.
key826d67e79708414bf734b9079db3dcd2,Cytotoxicity of compound against 8226/DOX1V cells
key4394d5dff560bbe77f37ef88dc136ac4,Cytotoxicity of compound against 8226/S cells
keyab555cda86d8eaaa64ee9f8a6f9f14d5,Inhibitory concentration against 8226 myeloma cancer cell line
keya71ea3661229197a1bc822d97bfb94b8,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line
key9ee655ed41f24379d4fe80355ec77d7d,Inhibition of cell growth was studied in human teratocarcinoma (833K).
keye93b827c5d2a1ea37b779bb3bd4b1ef9,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined'
key028882dced842dc23d7996ebab83869e,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells
keyc9acefc64ba009db701014253035933d,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data
key4fdc74de6d85f6daabf9084278c9fe30,Inhibitory activity against caspase-1
key0e9612be0643bb7b3ff410c2f1c70c77,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound
key2fc41f8646a4c8aef3282ee02944bc74,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay
keyd314321c77132ba86f69beb95bb42655,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM
key7e0a4562ce6db27999713660d9616253,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive
keya77d0e33d175ecbfae32975710b515ff,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive
key3f67eb2dcb68b55cf7b91193b9e0f1e9,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive
key5c880d9cc8d86fae82323fbfd5a3e928,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin
key002e14aab9fd0d17fb6b5c4ccd1d8ca5,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB
key002e14aab9fd0d17fb6b5c4ccd1d8ca5,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB
key62914e0375de25afd9d5af348f4ff188,Percent inhibition against Cdc25C phosphatase at 50 uM of compound
key939fb7d363aaa8d113da3beaccd1a3ff,Tested for in vitro cytotoxic potency of compound in 9KB assay
key939fb7d363aaa8d113da3beaccd1a3ff,Tested for in vitro cytotoxic potency of compound in 9KB assay
keyc6853fbccfdf819b12b9a9da38b73c30,In vitro cytotoxicity of compound was tested against 9KB cells.
key0279fb015554ddddd9caf97639e5635a,Cytotoxic concentration against 9L cells was determined on day 3
keyf1d8e38cab13dbd63f6028d23e41bf46,Tested in vitro for anticancer activity against 9L cells
keyb263e1388762e28c5ba232a03e099c96,Tested in vitro for anticancer activity against 9L cells; Not determined
keye3a2b102837a85abc842114a5a71757f,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active
key49b19cf9dc43b6a7a08730cc332fc380,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition
key7f81ba2ad6cda3d763a36032769bbe16,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition
key9465d9edae5abf1538daa4db34854a13,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition
key03e22c1a9cbc9bce77353de83d346fcd,Cytotoxicity against human lung carcinoma A549 cell line
key97f55d8c1d234a88db8696b8eb934419,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.
key63fc7455adba9ff375129455dfc8de68,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%."
keydc7715769f6fce9b5668c1c001d3d1e4,"In vitro growth inhibition of A549, lung carcinoma"
key6ebed24b65d520fa4474c634c050ad37,"In vitro growth inhibition of A549, lung carcinoma."
key452a480beb014900499d814f69362a30,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
key0eb4447c4af364ec852597d5becb27e2,Cytotoxic activity against human lung cancer A549 cell line was determined
keya0ce499142ff9b507b5121ac17997bd5,Cytotoxicity against human solid tumor lung carcinoma A549 cell line
key6c66d276e15ee703b2e38c4e36bc85b4,Cytotoxicity concentration against human lung carcinoma A-549 cell line
key22908c092487cdb72121c9f750cfa100,Cytotoxicity in A549 (human carcinoma) cell line.
key875b5631791986087a33a72ccbb690c6,Cytotoxicity on lung carcinoma (A-549) cell line
key65362a8aea2f3f94532dcaf510c7ac0e,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.
key40b3152c375790d10a35d4aba0540e58,Effective dose of compound against replication of A549 cell line was evaluated
key3805fc5ccf82c8b8ebd2add54c23cfdc,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line
keycd9754b2787b9c8d75ce14d8f4d57778,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line)
keyc1009f71d272be378d9d01f9931f49ac,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active
key16bd6daf6b2ae122b1968db798f58679,The compound was evaluated for antiproliferative activity against A549 cell line
key00f5ff3fbb2dc4fcb71842db7187575a,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.
key30a4a1dd1c522d11d5c21fa2cd45c108,Concentration required for growth inhibition of human lung carcinoma cell line A549
key3b264bbad3fba1d5eff6a83fdb7ff28e,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line
key5104210533a7c7f6418d7e513c20b578,Growth inhibition against A549 cell line was evaluated
key1043fe15e4d4fd3736cbc4f4cbda0441,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay
keyaeea6a4196722a0926b65b03bd292705,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar
key8700a325118dd44ca66ac6c9ecb59034,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs
key2037322803fa931b77ecd5235c244908,Chemosensitivity against DT-diaphorase rich A549 cell lines
key4c7ad893589be39c7e95eb5efbfb0a9b,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.
key4c9ad5bf6222fc136977b9461f0116f3,In vitro cytotoxicity against human A549 (lung cancer) cell line.
keyee3ee67f8b6686dca4fa7f31349c6019,In vitro antitumor activity against A549 (lung) human tumor cell lines.
key008a270ff77299787f44aa44163031eb,In vitro cytotoxic activity against human lung carcinoma A549 cell line
key6c2704d8cc253e40b3d2c3bcd957f0b2,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.
keyb71f75a0069f34e780dbc16d0c6b0c2b,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.
keyfa0c0bc64cbc153819d9651b58973b3e,Tested against A549 lung carcinoma in the sulforhodamine B assay.
keye96bc2566ab288ce982ad75d03469985,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
key434ae785fa515fa675b173606f92ed62,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).
key7f8d28753de77f750d838dd6d1024635,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition
key44bea980319f4b5a70704b4bf126b4e7,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line
key6b7237a5ca6ccdb3300880b432291a98,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line
keyaa9b96bcf2cf19092254935dac1b70bf,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration
keya376fe50321c27376835d462f533a285,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed
keybff7e3d5505d01fd1a5fd7b15da14992,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.
keyd981c14cba47c3d3eb5e3d988f299990,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.
key33c9c9c16a497fb1316ea1c9bf862408,Compound was tested for the growth inhibition of A549 lung tumor cell line
keyb82575767520c15e74e8ed3f6b10b28a,Growth inhibition of human non-small-lung carcinoma (A549) cell line
keyb71f75a0069f34e780dbc16d0c6b0c2b,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.
keyf729143cf9990a1fd34aaedb1c69c82f,Oral bioavailability in dog (conscious)
key0269a5e27675d236179168463baa8e36,Compound was evaluated for the oral bioavailability after oral administration in dog.
keyd76769347db2917d4c0a1552cd275723,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key4ae585eb48d0bd18a312050caedebb0a,Oral bioavailability in dog (fasted)
key62198c22a95f33a2e993faf52d995378,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
keycfe63885b2061c92ffafbb9a67b38c21,Percent bioavailability in dog
keye4604f40f3686e5b2322fa5ac4f54e02,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
keyc212c5018fdf0ad50593255e3210fe61,The compound was evaluated for bioavailability in dogs; 34-44
key975fbe1eb9d369833234cb957756d970,Bioavailability in dog (dose 4 mg/kg p.o.)
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key8051d14305470d5e4fab1c4681a8b18c,8 hour trough Blood level in dog was measured after administration of compound
key690872d8aea8e86d0f729e3cbe51c4ce,The compound was tested for maximum concentration ( Cmax ) in dog plasma.
key536d8d5c6c6d7979ea70b98cc39ea59f,C24 after oral administration at 5 mg/kg
keye743292054c60bd7138d14266298e24d,Clearance after oral and iv dosing in dogs
keybc6aed32dd9d3e8de2e0e1dd51e81129,Clearance of the drug was measured in the plasma of dog
key63e582a0b0ce89cd121d484ecb971faf,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously
keya346d396b483b9faab8eea756b39ab38,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
key8058b04a67e97153643b3b227566dc93,Clearance of compound was determined in dogs
key23e16157d2bb0d7c1969829a2befce69,Clearance on i.v. administration of 2 mg/kg was measured in dog
key46f524461697c464a2245cb21e553a8a,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
keya42b84e3ae415ba88ba40f0a0b10f5d1,Plasma clearance in dog was determined
key10a8901b2b27a170c80ff7e9c41c2d15,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
key5339c828b516987f02f46eb87469e12f,Plasma clearance in dog after administration of 0.25 mg/kg iv
key9a647508f5cf324096206a39ff78a726,Plasma clearance in dog after administration of 1 mg/kg iv
key499efc4a86b4725ba470cccdb89d7722,Plasma clearance in dogs
key15f112a32a2de9d4c37118d544156706,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg
key1b226f10088f74dee86a5ce851ac6f7f,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).
key354282fe6a89c51a0afadc90c405dcbf,Plasma clearance after 15 mg/kg iv dose in Dogs
key48b99af39518dfcd8c61fba407decba1,Plasma clearance after 30 mg/kg po dose in Dogs
key440d8386cc42d28077d783043ac8855f,Plasma administration to dogs
keyab790f636328241402deaf923aa1b628,Plasma clearance was determined
key0b2298fae1af71935f45c5f0d846fb15,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog
key33d2118c8fc12e70626f5bd160a5634e,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog
key1efa535428950b68d9701f5977ab7912,Intrinsic clearance in human liver microsomes
key1efa535428950b68d9701f5977ab7912,Intrinsic clearance in human liver microsomes
key29a6e9f732c60dc90d10e02871234f1a,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
key80ad304ed477404127489101b2264dce,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
keydf231b150f0e28b099fd7fa866fec382,Clearance in dog (dose 1 mg/kg i.v.)
key243823b0a79cb563891b894be42a6580,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined
keycb82bee614098b3825b0177dd82b5bc7,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
key0d335659b859552024ddf9ed8fd1ec18,Plasma clearance after peroral administration at 10 mpk in dog
keydee79797c24b6279c2e879d42b65a775,Plasma clearance after peroral administration at 5 mpk in dog
key78cb6e315dca3961a35252b3f14de57b,Plasma clearance after peroral administration at 5 mg/kg in dog
key1bdaaccb9cf8389b58df0375c9ec0a53,Plasma clearance was measured in dog
key1bdaaccb9cf8389b58df0375c9ec0a53,Plasma clearance was measured in dog
key145ac13224a497fe6c117ccf01791ac1,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.
key5302180d42fc936e25e0f5006bf9b95d,Total clearance was determined after 0.1 mg/kg iv administration in dog
key17298a72202b6abc8dc75064708388e2,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg
key7cd0a2ed926301e08e5199e2fa738558,Clearance after intravenous administration of 0.5 mg/kg in dog was determined
key4966fa5c84b5bfc0e5718fa2b84c3e55,Clearance after intravenous administration of 1.0 mg/kg in dog was determined
keycf70bd0b8c3a613ce6756894c833720b,Clearance after peroral administration of 0.2 mg/kg in dog was determined
key526ef8ceef4cac43a63c574fe1d2620b,Clearance by intravenous administration of 1.2 mg/kg in dog
key5fe9528d577983d4bdbc8405b9d4626e,Clearance by iv administration in dogs at a dose of 1 mg/kg
key720f5c9fa233f5cfa2f1176ea3269978,Clearance value was evaluated in dog plasma
key745ccb15bbdf2e79e14283884e3650f0,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg
key961d7365a71df80d8c27898c95d9807a,Compound was tested for plasma clearance in dog
key13eaff1cf7209b09269630670dc7724a,Pharmacokinetic property (Plasma clearance) was measured in dog
key38ddb75f8d731d0b91b6f3df646c4e97,Area under curve when injected perorally in mice at a dose of 50 mg/kg
keybb129c7d79843645b2bf0e329706a95c,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg
keye93f78584ed38af20c8720d561372db8,Area under curve value in mouse at a dose of 10 mg/kg
key225dd2f43d59b620961e1ff310d9e4fc,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice
key57847b2f0bb06137fa76bef13e028c4f,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice
key966418d110ce3bcdaba3fdd96f596171,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg
keyadf556f513cba634491b1602c003ff20,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg
key7129fd80d064120c5151cef5067dee2c,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg
keyebd63e544803d828113d5cf41305921c,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg
key1e02a9a3662b396b4c314f50f342a00c,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg
keybe5fb63b2745a07e761175614133cfb3,Area under curve was determined for the compound at 24 mg/Kg
key066b9156765e96c1edc397ad4061bf4e,Area under curve was determined for the compound at 40 mg/Kg
key825dd119939040a2b3e9378ae02098b7,Area under curve was determined for the compound at 5 mg/Kg
key3108c2e09727ac5f9527fecba9e9c054,Area under the curve for the compound is obtained at dose 25 mg/kg
keybc91fe5181f779ba63679c4a61bac1c0,Area under the curve for the compound was obtained when tested in mouse
key564877df227a9a0ad710e799ff3c7cf0,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg
key5eb29077e33b3be310f2774b1194f466,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg
key38bc512e189e702f763d9e6dc5764539,Area under the curve was measured in mouse after an iv dose of 1 mg/kg
key07c36967e1c1daabcca2b3294fe2f787,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice
key452a08e49cff74734ae24453ef609e6e,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot)
key7fe107b31a2c21718e8aa4f7805cb385,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice
keydaa0c44469a039c0ea149c18b7bd0171,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice
keyc4dddb58f995e706a3adedc321005db6,"Compound was evaluated for the pharmacokinetic parameter, area under curve"
key1b2e6156dd9864d4e0bc15af07f49aa1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr )
keyfc61306129ff69ebfe5f4dfcff815bdc,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr)
keydc443f94c785e7daac5d30317b03755d,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg
key6e470ada6d7588aa6758c32dafe28177,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg
keybb53a888ee483964ff8c4afb41f42d6b,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
keye149484c9bc068dc44fd0a365bebccc4,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse
keyaa10a80405b62ce1f9ee19c6a9145a0e,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined
key6e5769b4e693240265e3a44ebdcf8e6e,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice
keyc9d419b3f3c0d313391ff6138e3d9252,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined
key5b61fd8ae73df4b98f7156421d196e2c,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice
key36f79ad55a55c54b3db03077f09cfbe4,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice
keyd916531e5de4eb58516d5bc6818aa7ba,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)"
key4c276191c9c299c045932fdfd12dcda6,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)"
keyacf768cd08c02538f00a4f2db46d66de,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice"
key095f41ef6bd00f6a5efcc93238b6b0ce,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice"
keyf5bf1a084477f2fbb101248d90c3124f,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice"
key9eebef108f701b9fdc2e21718a29bdfc,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice"
key4dde69d896efd60627b5faf7e2c303f3,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1
key388bc941828dcc00482a7566a987dfaf,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1
key00a0515fa261a0910a0154b850de442d,Area under the curve was evaluated in mice after intravenous administration
key873bd731de7b6f41b872a69dc52d39d1,Area under the curve was evaluated in mice after oral administration
key58b67694c18afad65cec9549b7c49b03,AUC total value at a dose of 10 mg/kg intravenous administration in mice.
key3af5a84db7bb78d5710f5d854b4f2d59,AUC total value at a dose of 10 mg/kg peroral administration in mice.
key452a08e49cff74734ae24453ef609e6e,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot)
key1cad097c0540523e3c82b1fbc555ba1c,AUMC after intraperitoneal administration of 100 mg/kg in mice
keyb530a9a544dccc57a15501aa77029929,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram
keya6796dfe74bfc6b4ae7365de8e7e3187,The compound was tested in vitro for anticancer activity against 9L cells
keyd751f049404cc5592336d5b1847cce7e,Anti proliferation activity determined; Weak effect
keycefdd37db36f2ac706a46d2017e49e51,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process
key243456fd46f30617b79a92f20f328413,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells
keyf0ec826850dada766f412b3ddd7b4108,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process
key6ee30f65be3580334774ff01dc33a5a8,The cytotoxic activity was in vitro tested by 9PS assay method
keyb0f8b3ffd3145ede5a0aa0944d73a71d,The cytotoxic activity was in vitro tested by 9PS assay method.
keyf3744a73f6aa6de17624a01dc6c8a056,Partition coefficient (logD6.5)
key935a1365010603ad1b57d267dd344a6b,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells
key9e9b510f3992d0bf6731618209c1c298,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM)
key4647db1ad7260ed4ad386eee1008423c,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line
key686795e2eca2b0bdf21b13774a0f8688,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R
keyd32e0ff5837ade5fa350dcc1844be7c0,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line
keyb919ec72dc4decd7471c22039c6701ce,in vitro cytotoxicity against A 498 cancer cell line
key6cc37f2538519c4c307cc1e599697bfc,In vitro cytotoxic activity against renal (A 498) cancer cell line.
key96b01e1295895c0f8a23c4998739cb21,Cytotoxic activity against A 498 renal cancer cell lines.
key9cd8d7a6653b44871c7ac29f51396457,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen
key15b62dbca176baa6c625d894b361b655,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i
key15b62dbca176baa6c625d894b361b655,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i
key718e479bf206266834f72e8ffe529966,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c
key718e479bf206266834f72e8ffe529966,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c
keya36f44a5c6451efbaf159dddb8a3b7ad,Inhibitory concentration required against A 549 lung cancer cell line
key851c73b09719e2d0f1d21f8f91b6d7b6,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
keyf0692f5396b0d1908be6c44204520b91,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
keyb9c864fb3346644196cbe784558f7a1e,In vitro cytotoxicity against lung cancer A 549 cell lines
key6084af1d8c8189dbbb148adcb2e9ab6b,Compound was tested for its cytotoxicity against A 549 cell line
keyd429e1a00c7457b6003a5fb8435152d6,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay."
key4b0da31f72b3681eb10954ad614c9eda,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data"
key2123a901b0906fe9bb12b2019f16a1b9,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay
keydde5e9d5f9a5ccf7224989cb3932c88b,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay
key85d34ebaf9d0ff3897f577d20bd48d58,In vitro inhibition of A549 (human lung cancer) cell growth.
key8c2bada8fe864d86744a0c72f38fac19,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available
keydde5e9d5f9a5ccf7224989cb3932c88b,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay
key1e4f26e07ba99a412935e3041e328201,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM)
keyd898fcc40610c2b7a18b266265c80f20,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h
key70a4ca7bea19efe7ea7719a495cb23f3,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.
keyf2433bef0ecb0a1fc48611f6483112de,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.
key3ac91c63aff0789feedff7db2fb0bbd6,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.
key53342f5ec0efd5afd670e516a1b6ce7e,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.
keyb7b922f6e5013996c843ddeebab36a74,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.
key874ed6b855c34beb6ff0886cf3030db5,Inhibition of A-498 human Renal cell proliferation
keyc253d9a89832b304eb12427ea0eb82ac,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM"
key7b20712dced1aaff63c54b210d49785d,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM"
key6e2cfc994ecb48f3d8217065edd20ece,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM"
keye8b1f4994ec02d391b4bfb16edcfedd4,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay
key550177059d12e5c20afbc6f45af4277b,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5
key550177059d12e5c20afbc6f45af4277b,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5
key2c4f1c8c332040cb0ffb55df8c7c3a27,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.
key5a18b989e79420c6f14ad6ac83751927,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549
key54ea41921531f1bc4b50289108a7ef50,Cytotoxic activity evaluated against A549 tumor cells
key54795359faaef2e8219e0770aa866145,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line
keyf0efef20d11d8e4852812958156fad96,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr
key0d5c0fd6dc7c84f5003c8b5141b11603,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs
key445d3f74dcf64caca8891237d2f0b47e,Cytotoxicity against A549 tumor cell line determined by WST-1 assay
keyd4e31e55c6ae2964a27dd0d10a2ac6ea,Cytotoxicity of compound against A549 cell line
key99285fa3309afa3ffd2731804fb47c12,Cytotoxicity against human lung cell carcinoma A549 cell line
key315138fd437a743d7d975befaf0e5f93,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
key637e00cdd0529ca49eeaeb2ebf859bc2,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines
key5e19d86d8916461b157910d7722e52c9,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum
keyefe2a5d042349ac4ed8abcee6fa4bb45,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined
key249e753be2d64f8bc6a66dbdf030b9a3,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells
key5a88da39bf22b8baa3351d3af0584b10,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line
key452a480beb014900499d814f69362a30,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
keyd63abbad5925b254cf57672d78fb09d8,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549
keyc72fac59bd1e9e8b6a7bd2741e804da8,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure
key080c690fcd0385729b2cc978a701569a,In vitro cytotoxicity against A549 (human lung cancer)
key15ca113f121b180750eee90c0e83ae68,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.
keyd90aa0507ec27ab54e9870c6b0df7859,In vivo antiproliferative activity against A549 cell line
key9a8c2bd00cd975cb3fc16de33ad52794,Inhibition of non-small-cell lung adenocarcinoma (A549)
keyfd6e97e7637f89fd825af26137e4f08a,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment
keye4675e03b38cb6ec22c9513fd674441c,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure
key6cfc0a88978de365d6a41d786a0408fc,Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
key08159a90efc75204fec32189dbb5a15e,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr
keyf132017aa08471940ecbec86121ee7f2,Inhibitory activity of compound against human A549 lung carcinoma cell line.
keye4fec31225552e6447562381e622352e,Inhibitory activity against A549 lung cancer cell line
keydecf53391701eb3d4e78aaf407d58d73,Inhibitory activity against Taxol-resistant A549 lung cancer cell line
key03b16aa0b3877fe201e0cb6694e56998,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined
keybb8f70e2e21fc2d9b462e887df2060a0,Inhibitory concentration against A549 (lung cancer) cell line
key15ca113f121b180750eee90c0e83ae68,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.
keye96c769467a2f07147aabdc96fc9e10b,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line
key3e88e573e9b228b422c3c62f473a95da,Activity against A549 cancer cell line.
key1664faf49bdc42f4c996bb88282cc09c,The compound was evaluated for cytotoxicity against A549 cell line
key54b632e402346d9c7ca8017cbfb36a9e,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA
keyd3b91c8a027858823b73bcfce7401a7d,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line
keyb968e902a4fb84241d8ea64a1a15163c,Growth inhibitory activity was measured for human A549 tumor cell line.
keye4fec31225552e6447562381e622352e,Inhibitory activity against A549 lung cancer cell line
keyd904c886e1718ebd7c4a5ee881081b6d,Inhibitory activity against A549 cell line; inactive
key92a46d83f89c82993af17d0824e8c7e9,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM
key92a46d83f89c82993af17d0824e8c7e9,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM
keyaa9b96bcf2cf19092254935dac1b70bf,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration
keycb59b3377293d3fa6e2079f71ae7ef76,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L)
keycf3d70e7602d1fdafa329e95824a3243,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L)
key9eb9b68419164356a3efa553dff60d80,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L)
key046a1bfff4f7f5ff58c794181eb401b0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L)
key27110626969d31ef7eb3e21fa910308f,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L)
key82625da9c6b6b6076bc6cc339393906b,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL
keycad8db66071a227e2f4db57ac201d95a,Plasma clearance (in vivo) in mongrel dogs was determined
key1bdaaccb9cf8389b58df0375c9ec0a53,Plasma clearance was measured in dog
key1422c7de443fb485eabc0dbce70f6784,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg
key8be0d30850eac7b6e1d1e9cda2c6176c,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg
keyea2dc74c8747c920578137c077b172f5,Tested for plasma clearance in dog
keyefd361c88682f675bbd0ba07a0aa9ee7,The compound was tested for clearance in dog plasma.
keyc0a36528a6d508ff9cbf60ae2f93b0f5,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration"
keyd04af76f30939c2f922db117796ecc72,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog
key5549121bedfaceb38fa180d8ed643bf1,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg)
key36f67b744b2fbfb8446740922d2531ab,In vitro clearance in dog liver microsomes
key31bf0d578da9677b85a8e8910217ed57,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog
key261b2fa9e9615eed8a43b55f6ae42b1b,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog
key3adf949423668986f82bc8d31baa8d9f,Plasma clearance in dog
keya510aba7a95d8287be0ce0392bf67c31,Clearance rate in dog
key96abad887ecbb8c4a595f172e280b144,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose
key382a54b66fb3a03ef56f873133faf1d1,Clearance in dogs
key499efc4a86b4725ba470cccdb89d7722,Plasma clearance in dogs
keyab790f636328241402deaf923aa1b628,Plasma clearance was determined
key3e3d35387d842ba812c23a5d78792ee3,Lower clearance in dog (i.v.) at 0.5 mpk
keydffdabb3075e8a14e201a37dc2d068fd,Plasma clearance in Beagle dogs
keyb1817503222dd72034cff12b3311ab84,Plasma clearance (Clp) in dog
key761ccdc9365b66e5ac1f45c39c59c6ec,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg
key057fab41ae46f6bbc9ceccce46fb6368,Plasma clearance (pharmacokinetic parameter) in dog was determined
key257ed7534c86e0e2fde32ea6908346a7,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg
keye4a0092500bce2bb3263c4cbcc66a9bd,Plasma clearance of compound was determined in dog
key920952c8d3d34251b3dbc4be70de45c7,Plasma clearance after intravenous administration of 1 mg/kg in dog
keyf3f9330b8c156064437113ed179c87d9,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
keya42b84e3ae415ba88ba40f0a0b10f5d1,Plasma clearance in dog was determined
keybb334cde2517b5731b0225d6d2080370,Plasma clearance was calculated in dog
keyf23977168bb71018e300fc1f66a0cd5a,Plasma clearance at the dose of 2 mg/kg in dog
key3adf949423668986f82bc8d31baa8d9f,Plasma clearance in dog
key3adf949423668986f82bc8d31baa8d9f,Plasma clearance in dog
keyff9d98cd3a9c18ecfcb6ffe0b974a4ab,Plasma clearance in dog; Unable to calculate
key3e72a9568530256f6a71aec93502e8f9,Plasma clearance in rhesus monkey
key7b1b3ef97abc13e92609dc546125038d,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
keyd259ff26c81cb1ef24a1aabfb9e766a9,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
keyd259ff26c81cb1ef24a1aabfb9e766a9,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
keyb15bba64688b390a0a77deec85941845,Plasma clearance was evaluated in dog
keya210c8f0322dd943578f10c17a2dd00c,Plasma clearance was evaluated in dog; Not tested
key94930f12771757e687e8e0e229eae7bd,Plasma clearance was evaluated in rhesus
key0fcb39851b9d1d82a654fe3320a3c77b,Plasma clearance was evaluated in rhesus; Not tested
key31eb7887d629ef706911fbc0c3c666ae,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose
keyc69753032523112588ea3b221279bf05,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
key8dcac3d46eb3549e0fb226efec656b72,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration
keye2033d86f4ce46c9c454dd736efe8895,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
key090d2a95d15e2347d8ee3e97f349254f,Clearance value at a dose of 0.2 mg/kg i.v.
keyac269f20765808fd9919c672f5dd4ea7,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg
keyed4bebf015dc60291f12427e52136f23,Cmax after oral dose of compound at 3 mg/kg in dogs
key6d2e4b6763e2473f2b8d17842939b97c,Cmax after single intravenous bolus of 1 mg/kg in dogs
keyd40ba0248976c80605309e921db96453,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
keya980ea77bf5cfa03efa2b012de7c681c,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined
key882dafbcbdc5ebe8c814119b29ebc7ff,Cmax in dog after administration of 1 mg/kg iv
key8bcf25b72ee14eb62d0b02c39e5510bb,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog
keye4bfd5af2513651d482bd44c794b3c30,Cmax on p.o. administration of 10 mg/kg was measured in dog
key2930f866bf4ab159a2440b9ef056349b,Cmax was determine after peroral administration at 10 mpk in dog
keyf23e2b84749dbd12db7df8705c6b6ebd,Cmax was determine after peroral administration at 5 mpk in dog
key3d72ed19c2e11315d25ff455890a48a8,Cmax was determine after peroral administration at 5 mg/kg in dog
key4d19b7292f5d40f8e8e9362d7d3f148f,Cmax after 0.3 mg/kg po administration in dog
key470334e7d07ace0d79588b40fd7c6e57,Cmax after peroral administration in dogs at 1.2 uM/kg
key58561dd14ae9377fa9f31026ca9829c4,Cmax in dog after oral administration at 1 mg/kg
key176604a9ea8f16106be4891fcbcb499e,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation
key97f6b3d325049276958a675062f51ac1,Cmax upon oral administration in male Beagle dog at 10 mg/kg
keyc59ad0c1a3a9a5f5f8fe2299ebb86e57,Cmax value after 15 mg/kg iv dose in Dogs
key880a9cdca6c169e21838c08c70645942,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
keyd3c46586152c5d728e9f660ecb1dc4e6,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key36953e5568b3a54722b4024d6ac0b14f,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
keyd4d13e5033cfc6c8d3b73598a6c7a244,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
key000ea6d3e5349c2412d2e6021eaaf5a7,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key0716391c0c4e251721e0efb1ffde9466,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key765f0a9dc6a0a552947979f9f7ad0404,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
key8e3d87789282316c87a49bec2bd31171,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
keyfcdb2167d4017cbb224f81f30d578d6f,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key347a6f2380a63046b8372a090fa7caa4,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
keyd08c6e1559dc139b575345c91a716aeb,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
keyb0e16a357b10ac4b1a4ce05947725c99,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
keyb762676f7cc5fffa29897cf4ed9e6240,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
key415a247ed25034a26e7db41e88f3d8ef,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key7192615289e3ecdec8984868eb1b7388,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram
keyfce4b8c74c98ecf91e138aaa0acc493e,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key5bfa79fdbfdf23127ae4c682d9104168,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key7e3c1a2e609186958f364e2822d80859,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key63ecf23537a8023a7c8c506b46ad4e67,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
keya56398227a8a11f565e085d2818c0547,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key6b32fc373f4d151e37db88f48d5146a1,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key2d39b079cfdea6f3f70c977f457241cf,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
key685c82ebd820012681e2f82acf82ec07,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key8e2eef5f197468ee6defbce884cd302f,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key465b72715bfb13bd889ab87d1d6b147c,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
key5d79a7807af1a867c595c1df86f6e366,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key45331dbf98e987fd49be1c0cd6f0d90b,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
keyef711e0e01b9a62b2c1616a8ab7de299,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
keye172da62cfcd880ee130608966e1d17f,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key93751378f1a505ab71b3f7e96bbb7ad4,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key57c7c8012bcb91c19a37891803bf9e7c,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
key5ea0d21a81f28c1f2fdf3ee49a1bb4b0,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
keyf23e838fcb4e70c0021fc55d254f86cc,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
keyac2e1cac0be10930fc910778d01fa6d0,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
key02f4e44fb76a9f96ef1ac6b99be174ac,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
keyee6b3e90148d9ff167f4ab7edf6edbfa,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key0cf4fb7e370b5d5f1ec42e57f49188a1,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
keyf74aa65c761237040b7cd979d0c9a0e6,Cytotoxicity against A-172 human tumor cell lines
keydd6a79467d70e371114f8e0e712de7ee,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line
keycfeddb5d3d716af854a0a91549154ffa,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells
key904a8d6ed1312e5d85101a0b309f3c20,Tested for antiproliferative activity against A-2780 tumoral cell line
key6ce5c00f5b1f48624a59851af89fb654,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined
key0e54f48629dd8dddd00b92be8c0106e7,Tested in vitro against A-375 cell line human melanoma
key12aad7f257d89bb46f6c790efdb9ecd8,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay
keyb7f6858235ce5e62e1fc49e3e7bf495f,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
keyf4ce16d8c3d648d57c7c309e85d6072d,In vitro cytotoxicity against human non small-cell-lung cell line A-427.
keyb7f6858235ce5e62e1fc49e3e7bf495f,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
keyc0ec23c21b1167f0b6d723893996f9a3,Antitumor activity on A-427 lung carcinoma cell lines
key85a3bcefe1c145d88147b73ad4b07686,Cytotoxic activity against human A-427 lung tumor cell line
key38541ce927aee2bfcd7de654c65624c2,In vitro antitumor effects against human A-427 cell lines.
key6ef5b932804110759fc7604686c2d1c1,In vitro inhibition of A-427 (human lung cancer) cell growth.
key5878a361b79566d6cfca139dc940fbd4,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available
key6d093c5a3917f328383c501f142a847c,Cytotoxic activity of compound against A-427 lung human tumor cell line
keyb5693f15294f1554e69c780331dedf15,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line
key6d386a674df93bd49c0c7bc0878837e6,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line
keyafb89db6827cf63b5f0c1aa1e721626d,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined
key34fcd213f16f1b89fd81a417278c4209,Cytotoxicity against human kidney carcinoma A-498cell lines
key0a398db3cfe4d43c43bd2fe0b87c7f09,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line
key2d27a0617d88958ed993b10746c54db1,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.
keye16007b6d950648b8a2cfc2dbef77bbf,Antitumor cytotoxic activity against A-498 cell line was determined
key83c1b746e7db3176f6746f62ec76b3e0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.
keyf91c52eb5e205015e1ecabff16a64c82,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data
key4f3f9163cbe5c8bf8419feab3be42f8c,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells
key3e63ba25bb22c0aabc8c6f22f87437f6,In vitro inhibitory activity against A-498 ovarian cancer cell lines
keyb786a57944441f5cecbec6ec41b2d07a,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line"
keyc4319f19b34ba15357819a299282ed5a,Inhibition of growth lung non-small cell carcinoma A-549 cell line
key1f4b851e67d23ebba91aa08e18e34fe6,Inhibition of growth of lung non-small cell carcinoma A-549 cell line
key02ef92f6c1d2265616a813839c718b21,In vitro antiproliferative activity against human A-549 NSCL cell line
key16a928fe10e2270246926fd5bb98f4df,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant
keyece9baf6f3a8ba2588efc601b52d14ce,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay
key957aaa518fec6de13a3613ee4139b6fb,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay
key7217d44b4708d80385060c875f0606c1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data
key899157c07ce1531de268e83421073964,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay
keybc4d268863aa507f1100fd1f28f180fa,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data
keyae20988e768b76beb7c1c3db2ddd3a56,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay
key17ea98a28af29c9a8fc902f9370351ba,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data
key5729a141087bad207910003ef8388041,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation
keyf3a94a124508338cd522bfbea7065520,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation
keye822d414599b32f05d432827bb3f37ee,Cytotoxic activity against A-549 cell line
key5baab40947351fe26ad5c89fdeb2055e,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03
key5faf994dfed657a96afc1972752e53f9,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1
key722a35e2e40890c12d3aab8563c5ad08,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line"
key716054c77ba4382e936f59d375aea951,Compound was tested for cytotoxic activity against human lung carcinoma (A-549)
key92889357f0de84b395169994acb68200,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma)
keybec039679979d34baf6d3180b72f5c23,Cytotoxic activity against human lung carcinoma (A-549) cell line
key93a9310a908c2c5995f81c1c2712207b,Cytotoxic activity towards A-549 cells
key10bfb987d20ad1b616929dd215ee1843,"In vitro percent inhibition of A549, lung carcinoma."
key9ed1f0629772373daa4982a918e7dbf4,"In vitro percent inhibition of A549, lung carcinoma"
key10bfb987d20ad1b616929dd215ee1843,"In vitro percent inhibition of A549, lung carcinoma."
keya683798a8daf838c20bb838f3148dafb,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23"
key20b9c48aa12cc2a47add2751c03a452e,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM
key293bfb304c94b2c901c8fcc48af8ec29,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.
keyb4ae0fa20f994f094f9701b2e2151bab,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay
key8875f1e44dcfcbc9c499f31e878ab707,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
key2b6c7fa6284898debc0fb9062277fc82,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
key321634afca3121782ab6e23a0ffdc567,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
keybe48e07265fad0641e82f5684a8cb70b,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
key1c9822e4a06d0bc92b7f12808fdd7a60,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
key9d3a900696defa9aded31b0b5b55736a,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested"
key4078597f130e7d55479c7c617b361ae6,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3)
key446ae9bf1244c91e0b85b1d9ecbaaf61,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration
keye6078641d7b630e731b42cbf1466b8d6,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined
key2615b63c1a5ab237f48dcff3ae6b30e5,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration
key3ab2e9ad12959d6ff2f7ccebe58b0121,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined
keye0d4af16b22714c694494ede8364d693,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition
key97be477c2729e10b6494bb8b84606b6e,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation"
keyaf693f19b8092db1fed046ab145a5e4c,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L
keyf5eb63428e001b3c141ab08ea7a2efdb,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L
key094fc96adbbbd8d3945cda0f58fba420,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L
key7372a477dee6657fb47f393b566f503a,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L
key24b07bfc1222eb71a834300002477894,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L
key6b8a11796c2459f6af5cf8d0905c18e0,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line
keyac3cbc477647c35ebab8ae31503375a2,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment
key958684467908ffd94361ae82fb8ba7e4,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC
keycdc81e1a4cd1356d05f813cbaaa10e95,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line
keye9fcefedbedd8f4928510e1d9250adb8,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line
key12a9f405940c50db3b167eef056c3f4b,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data
key90c9385282c60ab5c344d1e0693992d2,In vitro antiproliferative activity against A549 cell line
key863a031c396a2b69a7fa90f33601ed2c,Synergism with indomethacin in A549 cells
key92d52cf19cd81615aca3c3b2499a1c8f,Synergism with tolmetin in A549 cells
key47d1149ff1252af7ab85b590953c00fc,Synergism with sulindac in A549 cells
keyc48ac972a6cbd733e647598d97ab42e4,Antagonism of indomethacin in A549 cells
key588826f7ced8a049ebf4453a7e4f6a42,Antagonism of sulindac in A549 cells
key41cf9555ba4a878fd3e9d4f3d2169676,Antagonism of tolmetin in A549 cells
key863a031c396a2b69a7fa90f33601ed2c,Synergism with indomethacin in A549 cells
key47d1149ff1252af7ab85b590953c00fc,Synergism with sulindac in A549 cells
key4f6e8ecee34f8c74c5560551b130d2b2,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available
keyc30962c71d4d30f40da8a650ac223fa6,Cmax value after 30 mg/kg po dose in Dogs
key77d51f6155a0e9071c8577e22b9a02a3,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)
key1915ddfb9eea7ec998c6dd20e6f57f4f,Cmax value determined in dog at a dose of 10 mg/kg by oral administration
key5595865f4b5ca01d64d8945730652d69,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg)
key90002ba44619b5fb300d2872bb764abb,Cmax value determined in dog at a dose of 5 mg/kg by oral administration
key32dd745945a14f63ec7fecd3ba7423f1,Cmax value after administration of 4 mg/Kg oral dose in dog
key339b62736389f5b9a378c233af00e9e8,Cmax value in dog
key0d161c6fdf83eecdcef434fec981ca3d,Cmax value in dogs after oral administration at 1 mg/kg
key24ac42774eeea1a30a68104a3c9dad2f,Bioavailability as Cmax in dogs at 5 mg/kg oral dose
key7c1200308a4682124f598518ee86350a,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs
keyd4629890bd03ae3f65ebb34c3a655d59,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs
key65fb44066bb86c26b631b663bbf8b2a6,Concentration maxima after oral dosing in dogs
key71bc55edad50bffa3ee7f95d4a0842a5,Concentration maxima after oral dosing in dogs; not available
key71bc55edad50bffa3ee7f95d4a0842a5,Concentration maxima after oral dosing in dogs; not available
keyd9d2cb08eb73f58fb83c7bb779dd8d48,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed
key335e44078dadd79fe892490517ab62f8,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed
keyb0deccbab6384441990f737c2b6b36ea,In vivo maximal concentration was calculated at 1 mg/kg in dog
key1653ed560202436185e84e324043e7e6,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed
keyb381fad1de4b0ee8e753e0e5fa0a2dee,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption
key4be3bc237351edcf83260f850d07ab64,Cmax in dog plasma after oral dose (1 mg/kg)
key4542f26e8501676c8af24bf0b0fcc11a,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg
key29b97c0ac51f552cab591c969d858b78,Maximal plasma concentration at a dose of 1 mg/kg
keya107ba64a36724b4e506658ea73a9f51,Maximal plasma concentration at a dose of 1 mg/kg (oral)
keya3e753acac768761b2f5463c847b2714,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally
key112f49fedd622a128f3e912031f7dbf1,Maximum concentration of compound in dog was evaluated.
keyecbb7596087912c327c368a779f11ca0,Maximum concentration by oral administration at a dose of 10 umol/kg in dog was determined
keya33dda6296e7af0388095a1c9e4dc713,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route
key8ee4baf01551d454b9d6ebe0129a863b,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
keydf9cad4773d781dc0fee4ac3e16d5cc4,Maximum concentration obtained in dog plasma was determined
key168abf83391afdadceb99f0de1b0a56c,Maximum concentration was determined
keyf560bedb0277c88d6de6ed5d00a823aa,Maximum concentration at the dose of 2 mg/kg in dog
keye802c043d6d74efec381380d39511e31,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
keyea978b7504294a845276bfdf95e3599b,Maximum concentration was evaluated in dog plasma
key32d7b3eda25e8fe5a084be21fa7d9d43,Maximum concentration was evaluated after 75 min after administration in dog
key21a13ebab771a9cbedcd3061de9d2e32,Maximum plasma concentration determined in dog after oral administration of 17b
keyd05402946f2978d83b7992438663b344,Maximum plasma concentration determined in dog after oral administration of 2b
keya5a5535e8bbd42f3feae20dbbe964c62,Maximum plasma concentration in dog
keyfabde2b7b403d724118816b288915d37,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg
key400b326380a6f1d41f20b15a2668e7cd,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg
key490994c3da2103702a6674673e6ec462,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg
key9ca8e1914afd6f506840b65277445d40,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg
key1692a43a80b6743eaf7799fc0f581344,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
keyaa3be3a494eb9aeb0709c2ff6c77b02a,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg
keyaffb5ffb65bd4226526b5937726cd079,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
keyb7880606a8ba0a874355703779d0fefd,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
key30f67239efda258455e90b7b1489c21a,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.
key017c6ad0ea98338f56abf4b2ac455c06,Maximum plasma concentration was measured in dogs after an oral dose of 10 umol/kg
keyece8cc934d405d074606e0f1a16e9656,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration
key73fa9752a1c8828ef9af41244c3b1a9d,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL
key3f82b38644a0133a2bd9ae38ef57dbdd,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL
key84c79dc76edaecbc1898571b0af2a494,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg
keyd4d36d4aa2907e7f9d518739efb20894,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg
key447ac9b20a00b18fbbdeacd7d05ec238,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg
keyedbb3b2e541d49d9e7685bbb3f08ad02,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg
key6124545581241fa268b7c4129ea3c665,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg
key108b2629da80dadd8e418854d13d70e7,Maximum concentration by intravenous administration of 1.2 mg/kg in dog
keyabb4f0eec3eac457fe7f376da6b1b5ba,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg
key4f9ae1ae24791ff3e8fcd71eb58a48e2,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
key9f58cd962cf34f8e6561d0f172e699f1,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
key2aa7e7c3dc9134c8786780c0599cda18,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data
key4732f17c374c10428732bbe9ffd0e809,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data
key07ed696265b38bc3aff45119b38ac753,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase
key65cd9d1cf3f6d063cc2cb9b19ccebeb5,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase
keyaac26198324849cf2787f1fe7790b3fe,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound)
key63b2383950cd2a87379e43806b2c8249,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound)
key2ea204c77c0f4627bd8424bd9380d9ed,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound)
keyf218520e7f3ce8270456ec006d019ebd,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound)
key8b6542901f9b60d68180eefde4550c53,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound)
keya584b240b8788696257f8682cc85ace9,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound)
key27544a4720fd3834a201e1132ed52588,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound)
keyb1336f3675fc004b23729bef966e7883,Compound was evaluated for washout rate in mice (Radiolabeled compound)
key4d57cbe874821c35c703ea0158e8a6fa,Compound was evaluated for washout rate in mice after radiolabeled ligand injected
key1a91b8ab23a2c28b184bc8afe0ba0ffa,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
key8a34c23283421d7ed3ecfc36b72aea37,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
keyb3465b2d7d59ece76c75f3601d84a2b8,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
key68f3263586057dd4ba553a05c5c2b029,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice
key5e02f58e1bfd63c8c1da504b291896cd,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.
key8d9ee7d931a268926bdea42fe2867fec,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice
key4152a95f3035bbf255c3e516283bce9e,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined
keyfad618e79662c2bf58c4dba37f373623,Time at maximum activity in mice (Radiolabeled compound)
key2b4d864d0ba71fd48723365156ae1f20,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice
keyc8fe9899f0a3cc6c24a9ae3516df9903,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice
key35a6ad6cd710c9566ee64c56a0443d49,Binding towards mouse plasma protein at 10 uM
key4c47682a5deab0e29e7b6fe66a4fb817,Binding towards mouse plasma protein at 100 uM
keyf734f590f04fd3da9d282d85fdf889cc,Bioavailability was evaluated in mice after intravenous administration
key87828598a0f5883d418a5b0e9ecc1751,Bioavailability was evaluated in mice after oral administration
keyb14d3b1260b827f8ce5600ba228b0526,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse
key35ad12bfe0d522d5802dfc2eeea46719,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg
keya9991f8bd5d3b6bf90c25caf3d361d45,Bioavailability at a dose of 10 mg/kg peroral administration in mice.
key671863d2cc610353351d3237988acb88,Oral bioavailability in mouse
keye180e1679e4f330725c574f1cf2ba585,Oral bioavailability after intravenous administration in mice at 24 uM/kg
key23bc3df5345d3feed8be9f036ec0676a,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
key5d2c4110a1908542419dbcbb6d7f1dcf,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
key595aed5889bd4b253c43149e71a7cfb2,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
keyea8c8d2ddef21710a9d356855ade0cb3,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
key65c38876808f76572b396acb2bbf67a0,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
key7937b8b161fe491558f6624a87b19d36,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
keyb7bffa255635c80379151e1fbce05e0c,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
key4078476958185579d55ff4f18ca5b3c2,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
key0c120e52bce9cbec520ad339a0d8e56b,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
key3ebdd3e0f525fdb308d7dd3b6917887c,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
key57cd9e0129d97ccaa274f9bc6c53f109,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma)
key9a105e193809d2b0c79cd313fee1d869,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined
keyb93b163b09bb93601dc648360c9facc8,Cytotoxicity against human lung carcinoma A-549 cell lines
key4577b3335f440332ee38f8d69d84cecc,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line
key6f89adac3cb307ecb089e36a0e41bac9,In vitro cytotoxicity against human lung carcinoma cell line A-549
keyd677d1160c4405747264d83d59cc0aac,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M
key375ed64126c300589bc259b334b9f53b,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M
keycb1534f319cb724959ae8d911813a693,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M
keyc651ec529402d781d2b0708a772674af,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M
keyd45aaa8bba2de845e02a584736af2ae5,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M
key2dfde7218b7492409ff61e2cedaa41b7,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M
keybb7b2c1f835d4eeea15b34bc82cb60d2,In vitro cytotoxicity against A-549 human lung cancer cells
key4c41a74aa90ddf71a60174c5ac173d98,In vitro cytotoxicity against human lung carcinoma (A-549) cell line
key348007b7bc68a2942e7eeb41318b3e85,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines
key38dcdedd70706fed7b77eccd9a509ae6,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line
keydc02485d7ed53306fae2a46a9ac4f273,Tested in vitro for cytotoxicity against A-549 lung cancer cells
key12b7c5445e14214ab104a94c6400a744,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma
key777cc3567e8bd7c13907974e061e26c3,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.
key29f2bb43828cb1ceb8b8099a32fd90cb,Antitumor cytotoxic activity against A-549 cell line was determined
key55e4a27e6ae54f9a9ebb0b0a5e13f376,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported"
key3bc60ecddd107713f25f0dd0d9e38136,Compound was tested for cytotoxicity against A-549 human solid tumor cell line
key5dbe4354aa6882d1347e760ecf8161c6,Antineoplastic activity against A-549 (human lung carcinoma) cell line.
key3b61afcc43b5a2e2d559bfb84b76e568,Antitumoral activity was assayed against A-549 cell line
key9a60805f092522b9ec2604aadacf7b34,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
key3bc60ecddd107713f25f0dd0d9e38136,Compound was tested for cytotoxicity against A-549 human solid tumor cell line
key452a480beb014900499d814f69362a30,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
keyc5fcc79485d9251667237a57bcc5f788,Compound was tested for inhibition of cell growth of A-549 cells
keya7a7a336078c4549a4cc102769167abc,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.
keyca2d1eb8cc5e31666d0d6c0bb8a529ce,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined
keye7c2f2f23abb723d20868a5ca6196dbd,In vitro cytotoxicity against A549-human lung carcinoma cells.
key4858083308b7bf607ff7e9223278429e,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.
key5d2be6b3b79b08262a2020c4428919ee,Cytotoxic activity against A-549 cell lines.
key1d21d9233e0e463dde83cb90d064f4cb,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.
key28ad01aeb15a9d6c64be28fbfa595c51,Cytotoxicity against human A549 non small cell lung cell lines
key3d7cfa0e5e1aa725f9c1cd7279950b36,Inhibition of cell growth in (A-549) lung cell line
key74ad7dc2d48656709da150b4d2995239,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line
keye869efb132fe5455b2d01d64c56bcf1b,In vitro antitumor activity against A-549 tumor cells.
key192255fbe2cbd77f2f2304f8365e9367,In vitro antitumor effects against human A-549 cell lines.
keye9331212aecf0209da08eeb57f0ed8ae,In vitro cytotoxic activity of compound against A-549 cell line
keyb86dd9b6717fd51755cbea051877e94b,In vitro cytotoxicity against human lung carcinoma A-549 cell line
key337effd752cc3db8135f2e82472d91d2,In vitro cytotoxicity against human non-small cell lung carcinoma A549
keyf51912fad3884fc76fe27d60c0d0c3ef,In vitro cytotoxicity against human A-549 cancer cell line was evaluated
key316a2d00d93624e7b6c127199688db77,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line
key8a6e3252607783e3abca0b85b560dba6,Inhibitory concentration of compound against A-549 cell line
key06b18fa26afeecf4957cf854d44317b9,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells
key0bcfcc00ecc1136ddae9e11967206a87,cytotoxic activity against leukemia (A-549) cancer cell line
key38dcdedd70706fed7b77eccd9a509ae6,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line
keye6bb0a00af72e788b160510c2af617ff,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line
key0f74c9762d8500f88521f3a62ddd747b,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml)
key53d1acff3268f5d4a441a4944dad34e9,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml)
key155f3d8bfe92b8aec817301230092f77,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml)
key39dc4b307a3f0d9f08c769f95ab0e742,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)
keyc98fe993c6af629cdbadc8da1a427ef1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available
keyed1f9d8ffb0bf0c7a6720a3cea3fec41,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound
key3551ac418eb17074518cd3462c4d246b,Cytotoxicity against A549 cells; No cytotoxicity
key30d57034424b88f99471e4e74bc9f622,Cytotoxicity against human lung carcinoma (A549) cell lines
key16be6eb5864cfaf74de86d60a8e4b880,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active
key955d8c7c3edba09bf793eccc89929745,In vitro anticancer activity against human lung (A549) cell line
key432ac585ed4584b0df4939e75de1a35a,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells
keyeac431df5c01a05a9dfceea27b1dbc41,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells
keyb0a561c6dce2c3f933c614a934bbc749,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells
keya0d9fa9b377b48b2d9f620cb6025c574,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells
key1b08dbda05611367cb137a3acdf5104e,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells
key34ff6424ffaaf7f3e13d56fb0c77e97a,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells
key8cb9746661a4c4f1f3148a8a3853b1a0,Inhibition of A549 human lung tumor cell proliferation
key725b13b2fe597f151b91481878955074,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. "
keyededbd7e2999b86031b5f037eb286069,In vitro cytotoxicity against human tumor cell line A549
key45aba8fd161ab82d52e290f386db1f46,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. 
keyb14b11ac40762839a69c10e78e6a2672,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line
key9db7eff208e87b87f17ef48a7ca0f192,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells
key5ddabfd33b27f83cda8fb31d746570a6,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells
key6b3403ab68093cee3edcaf6277584c20,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested
key6f2aa612ab0086a38bbaa1b369bd52b8,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL
key5016e19cb5dbccafb21e37b53e0ae2c6,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL
key88b7267ace317136affcd9ecfde81700,% inhibition against A549 cells (lung cancer) at 4 ug/mL
key955d8c7c3edba09bf793eccc89929745,In vitro anticancer activity against human lung (A549) cell line
key080ea4e997ca6d4d24f48f1f0dd91d73,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined
keyd1b7e91c5edb06869d2197f221f94268,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined
keybe29dc75d2f0c209e6bfd51ec600c7ad,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined
key979547a8a5a8cc275f9616f8ef4b8a21,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined
key88d6be615112761c1a8ed3b36d10cef4,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM
key9c8bfc49ddff09eddca6eb8ecefffe2a,Percentage inhibition of human lung carcinoma (A549) cell lines
key141248ebf244afecae3a11a35241f448,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound
keyce99dc8a2d608c293d247460c02b8392,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined"
keycc05dc13a12e5d8f3532cd6cb43a18df,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined
key8440da8e1e75a42ef9d755a1047db29f,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined
keyad9454f5e9c1354bddbef09011b9ca91,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)"
keyd31146a2d3d3a0836bc4d6735c074886,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM"
keyc2b7dfea0630df7760287f42dc92069e,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM"
key48c5d9c100a86b770147712852899364,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM"
keya3feadffdd97d1326f4e388d5938ae07,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM"
key8068bf126bcbb39aef81663d8b47a88d,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells
keyef3ef68d414cd4db6f5651784726852d,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells
keye0d4af16b22714c694494ede8364d693,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition
key36f8187b59d70cf776d6256175efd846,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells
key97b1ff320d15de26838c5a81d8629b5d,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells
keye8a026bf1fcc3799f7413f573f912315,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells
key4175cba9305d6dbf264abe8460620083,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells
keye1543ee682da2fbd027b3ab36278bb4d,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog
key0b11c00eb01bf8282f3d751f37416042,Pharmacokinetic activity (Cmax) in dog
key59520719ad42926584f375ca577d4d78,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (umol/kg)
key90e6653332c303b591a3c8ed38ceb83e,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg
key9d3ef55cfb900ab2233ccd403c4403db,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg
key8404ebc92c7a7ea7835fe5c98ee3a419,Cmax in dog plasma after 30mg/kg oral dose
keycbb4efd6878f34c05f913cf4dad17c8d,Tested for the peak blood level in dog
keyec75ddd4760bb6690da82e5c7ef46610,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog"
key657bd87629375e9d9038d863e4860b06,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk"
key53ea9aa49efe455cdeaf1e9bd9073a56,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined
keyb19894e07dcbc40d198ae1cf33232323,Concentration in the plasma after intravenous administration of 1 mg/kg in dog
keyca7d24f1ee10d9966d2057f3acb88e2c,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours
keyc98f6b7129ca19d9d23bee1c0ff1151d,Final plasma concentration in dogs after oral administration at 1 mg/kg
key1bc57b341e28d35433e0291b0f6acb7c,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min
keye2f1b00bbf2e165a606f82998b109b34,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min
key2f46d35ac1dea60030c55f2fbf927fcb,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min
keyb1396f75147b9361e2c1a0e8939d98c0,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs
key8e28dc0878493a47bb498abcbc3f5f7f,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs
key23177588834b178a7643241d220378e1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data
key23b669d85516e4a60d42e69771bcde0b,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data
key4f7c9ce26c863a937d5d571281cdb21a,Absolute bioavailability was evaluated in dog
key1bcbd6b3d70b5a146fe0ee3050c40116,Bioavailability after oral administration (2.5 mg/kg) in dog was determined
key8462981d4a3cb3b778efd90a7f91b41f,Bioavailability after peroral administration (1 mg/kg) was determined in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
key9d18ad8f7257093a3da71b0c00a709c2,Bioavailability after intravenous administration in dogs
key9f05adc13b01505567b5e456c3aba5db,Bioavailability after peroral administration in dogs
keyb546349e541f2b47bf46a573fc823cba,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.)
key8228c263472cc655aea3572ed08aee90,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr
keyf97e9213ff702a54dde65f2344457d66,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined
key226e67caed1ea97a1165ab7afee43ff6,Bioavailability
key226e67caed1ea97a1165ab7afee43ff6,Bioavailability
key06620ad919355cba04f2d3a392438e0e,Bioavailability by intravenous administration of 1.2 mg/kg in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keyef82e7bc362fe0fa090096495d5000c5,Bioavailability in dog (p.o.) at 2.0 mpk
keydb9349d2d65921c1b3d1f09fcaef8b9c,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.)
key29761b732606eaad69ef5167a1dc083c,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
key15aa8a9af9bb0a064fe5cc6f62fec745,Bioavailability was evaluated after oral administration in dog
keyda32858ca3f475633214ef2fe791098d,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
key906662b6c58de8f768c1be51bfecb183,Bioavailability was evaluated in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keyb93b0b67948169c2dc87a43bfde1f6cd,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
key5f2c90ea954e161f06971a46adbd01bc,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male)
key5cb82cb2137b210bb2b059beb01ac8f6,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
keyd8bb7831dcc440d9a2d0f4d749b917e8,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
key66d19240b153a941cf40f131610e3776,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg
key7149880d4a668c79fed89f1c152fb409,Bioavailability of compound in dog was determined after peroral administration
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key9c9473e848050f8d37c84acf8a51a666,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs
keyf4f7998f5ecf12d06f272f87d94790b2,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs
keyf0b72742f0bb9ac9b142e9f6aaa4d2db,Compound was evaluated for oral bioavailability in dogs; 37-38 %
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keydc99c1e417884dbb71676e1a3859d89e,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.)
keybe984d1ae64137cef29793e341c116c6,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
key53c821f61784a2bb6c047378cae93e53,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
key7990239fc73b6c23758334bb5877358c,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
key4e8dd1b9a3af211f15d0d1fc3685778f,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
key9dfa90bd40439128a1205175fe34aae1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
key59aecce02b40b95c7a1b90bd5fa70e23,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
keyb6ea8c1c3cf0bf59286aea7615b8f8c2,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
key0abbd5ae71bfe7fae0f3cb82f0cbfb2b,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
key8c09bf9a304069e4a4a820f50b69fa6b,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
key1a26721b48221b548423a3acd4319ef7,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
keyd1216711c640e69fc1b6b8fe2ddb4670,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
keyb84f2e8a5d0061d38e0abfef22735bed,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
keya82dd1889b22813d7144004fd0255a56,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
keydcc6792e73c2b93bc3bdd51b75bd7b76,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
key5f870102eba47a12e93542e5f21bcaf1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
key6f901013c98d66c2f18210aae6a35426,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
key916ce909f59fa19a7629dd416cc5b287,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
keyb939dda545394be5bf6a386161f2e985,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
key9c374ee3373539656bd7da5aabf17579,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
key63d5939fc4b3c2fd7b63818b8a0238b7,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
keybf9f1fcfdf37f121f1eeb0643491e5b2,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour
keya775d59e5efec089b0270ef4e41e0abe,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours
key223c4c62865be181533ee3a4d59cbd3b,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes
key19ff9cc3ad6f168637ec8848100b1a25,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours
key456d67658c41bf7d77c45d3676ed88f1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours
keya04354f65c2942c4fea997e73ee32f5b,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour
keyaff497716254c67d96c2a0882277db81,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours
key76c19cd073488c93eba01de95172978c,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes
keyff31ca5c1dca4658bae95959d3403ee2,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours
key65584fd6b575899c1494325e8de88ac1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours
key19618412bc5a349c4ecab294e88cc7a8,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour
keyfa2a158f9088e7497a9925c8e069ed66,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours
key6b69959a0a97531a61bbee51a4add824,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes
key741a4b2aaf88b5a83fb04b3e536c86ee,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours
key9f619ad0ce32c93844fdd02cd87ee1d5,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours
key5f8f575988337bc38d8b20572af5a34c,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour
key3a359082446786bad8c10352c8ee1b36,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours
keyfad7bdc33c37a7e3e6b93fec31070581,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes
key629a17a43873903fea6d668911955c82,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on
keycf93b4022c082c046614ed0e62236a44,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on
key97bcd47ed6ac04c4c781b3379af32618,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)
keycacd10a845c1958ff4a09b449f02719d,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml))
key5dbe4354aa6882d1347e760ecf8161c6,Antineoplastic activity against A-549 (human lung carcinoma) cell line.
key16ea876d5ce75f7737fd7b3e4a712873,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L
keyb9dd399b7ea21584ccd9578fb2873046,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L
key5718c2837d7ababfa8469f120cc02b32,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L
keyb78ae9ed5c2c5fc27a15fea1b6165c10,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L
keyac81c5c216a7b5eb7cea4e2989190f13,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L
keyc8427a61a0334390d7c9d970ac85357a,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM
key95761051533a8b4377d35bf4d3a0425e,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM
key889fcb5e9d4a3fb0ad35340760180481,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM
keyf61aa93f7a9cd158a536afd6dd27f8c0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM
keyf898c26f77e040de7135ba2d3ab3b794,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM
key51e7dac3158c685950a54970abd1369f,The compound was evaluated for its cytotoxic potency against A-549 cell line
keybf3383c98bcc5794d3e509aaadcad016,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines
key70c7f79b8e95141ec80cb3682a8244a3,Cytotoxic activity of compound against A-549 tumor cell line.
key8f0a1ea779991c3219ee0ce6b36a1af0,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.
key313c3d36f0a299a6f0f3ca6600a4080b,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.
key76f2858e3474e57260ae4723be804ea2,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data
key1e362fbcfd764dfc808ce891f8724e22,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL
keyb5ee5258c84ef6de53b65650e1c7f19c,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185)
keydf5d09477785924c78b3f3d5eef419b7,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma
key05f3a62d3edf5cc6e168b303ee9453d0,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells
keye58188c722e9c5112dc75e8447631358,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity
keycbaaefbce0bb571f0b741e9a71895d47,Cytotoxic concentration against A-549 tumor cells.
key4f9b92beef86d8006d983442035f4016,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.
key9cd250c31aea58339fb41bcf01f2ab06,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line"
keycc766b8461ee381d3ab5ccd06d47092b,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A
keyc0e6e5b77b64cca4b6e9b0d18277d452,Activity against Acinetobacter calcoaceticus (AC54)
keyc084df48590c8fd8c987f5ee448c61fc,In vitro antifungal activity against Aspergillus flavus CM74
keyc084df48590c8fd8c987f5ee448c61fc,In vitro antifungal activity against Aspergillus flavus CM74
keyb03e2a51e2be15e584be7d147e059f4b,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration
key7ac60a59046045d451c3cb937f210009,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC)
key9b77a91bf5cf2b23d0dfc415a51e177f,Antimicrobial activity against Aspergillus fumigatus (MIC)
key9b77a91bf5cf2b23d0dfc415a51e177f,Antimicrobial activity against Aspergillus fumigatus (MIC)
keyff4ab29b1ebb2ea78f215a373e4ef9a0,In vitro antimicrobial activity against Aspergillus fumigatus (MIC)
keya922a731f336865c3dd55f9585e2301f,In vitro antifungal activity against Aspergillus fumigatus 48238E
keya922a731f336865c3dd55f9585e2301f,In vitro antifungal activity against Aspergillus fumigatus 48238E
key2af29f1b63af70bd88e211b0b955a43c,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631
keyd4c57d879b507ca7956f0ac2837fd10b,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100
keyb1071896855768b8d4b87c42a12dd2e3,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally)
keyb1071896855768b8d4b87c42a12dd2e3,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally)
key4103c4a514e65887174cabce60cf2ec8,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527
key8b9e752e87c81e6cd701163e22dc2658,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2
keycca7c8b90671f15e8e3738433bb88dc2,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined
key87abbd517d8e3e3a4278de5ea5e68c5c,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells
keye4d5254593eaeec50e8f74410da34c9b,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells
key6f2aa612ab0086a38bbaa1b369bd52b8,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL
key5016e19cb5dbccafb21e37b53e0ae2c6,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL
key88b7267ace317136affcd9ecfde81700,% inhibition against A549 cells (lung cancer) at 4 ug/mL
key62f410c157ca80f4ee6e6be0d2f40cf8,GI values against A549 cells (lung cancer)
keye71ac9ff0409e8cf0d7fdfc363a12e00,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells
key18ca601fa9d82cb13a37cde741db4b2e,Inhibitory activity against A549 human adenocarcinoma
key481abe15f3870b662e2e4b8be63bd307,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg
keyc7fdd47b3e8627d8bdba0b4d1955ef12,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg
keybf4b2745413063e932970ab8447142db,Inhibitory activity against A549 lung adenocarcinoma cell line
keyfdcdbf2772bf417090e83fa623d21225,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined
key17d12e7621612f53f762c845a30a7fa0,Cytotoxicity against human A549 lung cells
keyf4f2730f64c3f2cb9dbb6d3c2807cc8b,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor
key4072945b11b53305f77bda76c65c2068,Growth inhibition of A549 (human lung carcinoma) cell line.
key911207fb374bf45267f8cf199c8a25c9,Effective dose required for inhibitory activity against A549 human tumor cell line.
key994b150073dcb6822af03f0cf42af754,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active
key7064c3f0db009d3e5efbdee8cde34ec5,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive
key6db8e30bad82f3534e10bea9c441c625,Cytotoxicity evaluated against A549 tumor cell lines; significant activity
key4a8b73db0dc32adb55f5416efdeb9ce5,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active
key61a0f985766a7f068bddf1bddec9d784,In vitro inhibitory activity against A549 tumor cell culture
key94e70b261766ca021e4045051dca3873,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive
keyf5405fe5a3666273391adbabe9ac169a,Activity against human lung cancer with mutated beta-tubulin (A549-T2415)
key41e84d5a51b57efe0a97d4afd3583b73,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer
key9fe70ce2462f5ce553d8d4cf4e4f1d21,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line
key8566c88ac5db43641e6119b6e89c0fae,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines
key332d0b5680bf0cec2a981fee29025cec,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells
key7e795a75cd75962b145d4158be7aa9ca,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data
keyd39de4e66f35c3c5448bf8c12cdc0407,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.
key6cb44d78a0d46f610435361c946c1562,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer
key21f2cf4e7ad21dfaf9c593443f2ccbb6,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line
key6cb44d78a0d46f610435361c946c1562,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer
key7596f90318cc795ae7b84de4ae491ca1,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC
key1eea51bfaeb645727fbc1da4f0361137,Tested in vitro for cytotoxicity in A549/ATCC cell lines
keyc795c1e69f7c38fb1ffc3854765c8478,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line
key5aab4fcb420c7e392ef63c555a162f2e,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells )
key5b6c4fa5ba2f620ed00c598d7dca950b,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM
key6a35d40be12ac8ca873ef5504ed92b45,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.
key5a8fa2e76c85e26102f01da371c094e8,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line
keyade573815d882e0d3bf1189e24e282be,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC
keyad3a3567da6811edb4ef23f0d943a4e0,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line
keydc0c1e3df5e785ffb47350550c19db82,Antitumor activity against A549/ATCC cell line
keyd9560cfbe65fa15c683039e9b4752dee,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer
key0a92311ad31f6c21d0550c29d65ff83d,In vitro cytotoxicity against A549/ATCC cell line.
keyad092b86beef058fe869687f900f8430,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer
key0e3a19a61bec13dd8baeee1bd7688e6b,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines
keycccdd60b3cdab9b742b04ddc290cc397,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line
key12269b6f6572923b8a0567222cec9be6,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
key15aab779b6542ad4e11f54ab7c104b4d,Cytotoxicity was evaluated against A649 human mammary carcinoma cells
keyb230c5587e3649535137def6b4cbbce8,Compound was tested for oral bioavailability in dogs
key63cecde1855e3948205adc4f9ce6c687,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr
keya923841ff5b1cff22561a993e01901b0,Compound was tested for orally bioavailable in dogs with a half life of 1.2h
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5215adc335a906fda90dc45d2738a8c5,Compound was tested for the oral bioavailability in dog; No availability
key34d122180cfb77f937c4f5e8e6d0b0ea,Oral bioavailability in dog (dose 5 mg/kg)
key2063c8659be9c0a52db47bce9ca17ee3,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined
key2063c8659be9c0a52db47bce9ca17ee3,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined
keya04bfc3dfd1fc961720a92e226079909,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg)
key34d122180cfb77f937c4f5e8e6d0b0ea,Oral bioavailability in dog (dose 5 mg/kg)
keycc1536d1b4c3aff88792fc147afddbbb,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution)
key86b245d945ccbf955048de73e9a892a8,Oral bioavailability of active FTIs in dogs
keycfb00b4477031b164ee3e154a6ee40ca,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.)
keyb91b33ece2dfc8fc79ecd3b88f264654,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
keyb78ca2af75064b2a741679f90dbfeb18,Oral bioavailability of compound was determined in dog; Not tested
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key1160432618453bf3a7855f1174bb1939,Oral bioavailability (10 mg/kg) was determined in dog
key445c1a24bcba979631e873aa2e10efcd,Oral bioavailability
key44f5216a3cf3e1695af12a5a93629389,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule)
key04c4719c9721fbdd76ba9fb967d18951,Oral bioavailability administered in solution in rats
key60bbe4960bf8c83d96f31205c2c99e06,Oral bioavailability after 30 mg/kg po dose in Dogs
keybc5181b8ee5470738d000beeb41b49fe,Oral bioavailability at a dose of 1 mg/kg in dogs
key1e539c8cf1c8ddebb77ede2140745cf7,Oral bioavailability in dog (dose 1 mg/kg p.o.)
keyee9c0728568577a222a6320c4ac25d9a,Oral bioavailability in Dog; ND = not determined
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
keyf7134a78a0aad41e3cd6c704b1a2ffab,Oral bioavailability in dogs; No data
key769beebaa1a7d9023cf92c9b0f2b3dcf,Oral bioavailability measured in dogs
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5ef866c4732a89ea67483b6c539ea873,Oral bioavailability was calculated in dog
key07e8fbc632465d9629622e0753ed9fbf,Oral bioavailability after 0.3 mg/kg po administration in dog
key4bba53528dd3f71bb1082723e52c84f0,Oral bioavailability in dog (i.v. dosing)
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
keyf940bee9916400b6b8b98908c02cede9,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration
keyf6b42a96bdb42e3cd383dfd72bff2afa,Oral bioavailability in Beagle dogs
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key02430ad8dffebbd45afd25d28675a4fe,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only)
keyff3e8095e86561eac47c766c30221ed4,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.)
keyff3e8095e86561eac47c766c30221ed4,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.)
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key9126ec5762d6c1f6ff5c41b48df6f6cd,Oral bioavailability in dog (dose 0.2 mg/kg i.v.)
key675a1c545a0f9357a3ec2aa6bf44275d,Oral bioavailability in dog (dose 1 mg/kg i.v.)
key214847de8f09d7f57b10752befac9620,Oral bioavailability (F) in dogs
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
key4e89e323b5463effa193aeeabfb6eedd,Oral bioavailability in dog (dose 10 mg/kg)
key05a31b53cbe4330f45d446767486a51e,Oral bioavailability after peroral administration at 5 mpk in Dog
key34d122180cfb77f937c4f5e8e6d0b0ea,Oral bioavailability in dog (dose 5 mg/kg)
key4e89e323b5463effa193aeeabfb6eedd,Oral bioavailability in dog (dose 10 mg/kg)
key43a6abf5cbf62ef4961eaa7a4b1c4f4e,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours
keyd6b5ede2bdc641a03e5dcb8252547daf,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours
key3f05cd33de8002f6acc6207976e628a6,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour
keybcf4573978ddff7c48a6f6433f8a5b53,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours
key7b6b901e3ff5189209181055339f7810,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes
key823df72bb8cfda22264aa329907850f5,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours
key411c90711df1388d705b1319ab307f25,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours
keyf6d5511fa3c75b5b5cd9d15980260f6d,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour
keybd8317578d81ff75d121ede01fb695f6,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours
key3e9e941f9cf28c8de4435dd95a64cb15,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes
key8da3dde3af23a5bdbbf60106534479e6,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours
key7d9436d3f774b7b498fe71194a8b7553,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours
keyf5e9d837cce097e5d71c0f2d1dd52356,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour
key3badf77bae74652e8dbaabafac816ba4,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours
key449e614630bcc7a017147c860d696371,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes
key5bb92ad09ba4b6c59cd2b7e3d8ea3eab,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours
keyf5fc030ddbe92f428933219dd082a4ae,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours
keyfac3a63329fe48615a3c948db4eb0ab1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour
key94d63d7bb2cab4b3df8e71106e2e3fa9,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours
key2bb67f88e675f176d9f73b2c41abbb75,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes
key07d4e2e4eb29acb00d3152f8faf2c104,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours
key1003e94b05b19a367e2fa87ea1848953,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours
key657f29c0395a9528bea30b93bd6760f3,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour
keya7538278e6c04ba8bb6c9eed15e4180c,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours
key90729e1c2bbbaf2c5023ec86531f1776,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes
keyd4bdbebe8b1b4d59f671f5d4a0fd8361,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours
key8182094c0f84e48b5d3c27ae67dd3d38,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours
key227e7d0601f649cd751a47d5f17036a7,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour
key4a5faf1e75ac6699138c8ea8d5c5ebb7,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours
key3b26b721dfe507484f4b0f0a87eceb36,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes
keyc6a2cc4371f4ff2c80d1824732a5b11d,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours
keyfea885693cc61ba6ebb7e7c4de138a24,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours
key1138cb732beb80c72b326b6036809b48,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour
keyffc32520d287892ffb21596d6922ee5e,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours
keycff7df45387146d37390067feb1f8ce2,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes
key1148b7338e52ccb8e03419efb1c21e08,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours
key8005a461c8e1f507656dbc766372e26a,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours
keye9adcaf0f15dbbf9140ac0ed37ddaf0e,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour
keye4d4370f2daff245a1da677f4d55eb9e,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours
keyeeeb5955b64f55c6ecc2c38ed4093a9d,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes
key90f3ea58703625318b81d9fe98ff7c86,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours
keya20f027696aa8903d09783f5fc45eb3e,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours
key10b13d8389827a64b562a0132be77e42,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour
key3b5dbbb2998017672e2f778bb3000425,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours
key6862a57eb6c9e3e3d117a75867d96dea,Compound tested for the antimicrobial activity against Acinetobacter anitratus
key6862a57eb6c9e3e3d117a75867d96dea,Compound tested for the antimicrobial activity against Acinetobacter anitratus
key6862a57eb6c9e3e3d117a75867d96dea,Compound tested for the antimicrobial activity against Acinetobacter anitratus
key6862a57eb6c9e3e3d117a75867d96dea,Compound tested for the antimicrobial activity against Acinetobacter anitratus
keyc0e6e5b77b64cca4b6e9b0d18277d452,Activity against Acinetobacter calcoaceticus (AC54)
key603879424d94c91b04d6886ff0c58e41,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity
key4e0ae7147247afabd3d4a0bb8f95f518,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity
keyf9f6a03f96edc472fb12c6ee87711cfa,Chlorohexidine coefficient for Actinomyces naeslundii 631
keyca8e15b98bf5ef6fa631f7360dbc4201,Chlorohexidine coefficient for Actinomyces naeslundii B74
key66680253e80de8a1c66def863bc6ef07,Chlorohexidine coefficient for Actinomyces naeslundii N/3
keya8aa1f0ac78efae8d84478ec1f4ade45,Chlorohexidine coefficient for Actinomyces naeslundii N/9
key415ac98005b5b2f12c52115b44b5a4ef,Plaque bactericidal index against Actinomyces naeslundii 631
key1f889835eaf59d50edc255220d56c972,Plaque bactericidal index against Actinomyces naeslundii N/9
key82b203c2496893921a9a37b493019cd0,Plaque bactericidal index against Actinomyces naeslundii B74
keyd65103fe20c519e6ad839ad615c27382,Plaque bactericidal index against Actinomyces naeslundii N/3
key1a5eaa63aa86dd0d7ebe60c9cb2c994a,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay
key97e331be5f9c07cecf615478b9a943f3,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity"
keydf7035f691fa95b546ad78fb717060ec,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM
keyb8d6c5b6941a8e56eeb3f1d09e1c5db6,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM
key0ce71851f2bff9df7c22311fc43af1fa,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM
keycefc98bb787e9cf7905f37bb75c3726d,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM
key9c5cf1b058b67a5cfc48a15e724efb51,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM
key3296b7ab1faeb12989d528efd07bcfc8,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.
key0ce2523974bc1b8b6f3b7d013e500d28,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM
keyc6bc111eb36bb48fdcf77fa1961364b9,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM
keyd803af15c0e988454362020c21febfd3,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM
key8113d7c9f85a48dca11f440cda61953e,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM
key8a343016cffcf691e62f524bb2b9f8cc,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM
key5a06bef1356d635b592b2725140be9ed,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM
keyd07388d3bc1dcea1b1f5815339a2b45a,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus
keyd07388d3bc1dcea1b1f5815339a2b45a,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus
key201d1fba22bc3ac9b094627ee535c0c8,Chlorohexidine coefficient for Actinomyces viscosus 8A06
key8604a8c96f4b92b687f6182145ab8c3b,Chlorohexidine coefficient for Actinomyces viscosus M-100
key7b34044ee12029c6a7af78789cf14289,Chlorohexidine coefficient for Actinomyces viscosus M-626
keyb7831ddc77f5a66c6657605af0df5b40,Chlorohexidine coefficient for Actinomyces viscosus T14V
keye929eac7dc4f3dca1954b77ebc1dee45,Plaque bactericidal index against Actinomyces viscosus 8A06
keydcfce5e0e41ade68a786dfacafbc4396,Plaque bactericidal index against Actinomyces viscosus M-100
keye6c1d6218abc44cf64fe67ae2890d2f4,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient
key7cbe780c83becad97ed044c42ef27271,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)"
key4a1cd5ef531318dfb64b52078fe764d4,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)"
key10e377fdaa2e5b2a8b9325b2e0cbf3c1,Plaque bactericidal index against Actinomyces viscosus 626
keyc30dbb4e2523f729177dfb68f6afd8f8,Plaque bactericidal index against Actinomyces viscosus T14V
key243593b22a71ec314ea8e4b70b0866b4,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose
key28f21af58066a27e035f2a61dd57b24f,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose
key54d1ed724cd3fc730011bb2312ac7a0f,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose
key3376d624710dbc72944c5735bdff399f,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose
keyad3ea2a3b860f3cef9108c6931fee843,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose
keyf11d55a83e00b86a1772ac7399f5860d,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay
key33c9c8f0a2c5ae2bbc4092f357d925a5,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay
keya798ede94c2138d49eb4de37d69089b6,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells
keyad6ce4c3e6f1c6f5575b6d14084cad37,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors
key004fab5b803250b12da656f16df5c345,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors
key02f8977334918d39fa4cf28938f7251d,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested
key9b502424744de7298a0283edc69d4d16,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line
key0d75271bcd3b76b6dad699faa4322626,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation
key09de37271b229ce38705389cdb4f350a,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM."
keyaa7937a62f64b10064b3a4e5d0cb2762,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.
keyb9d0fa9263902d96cc2adc88ee44c793,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.
key6d7711d4e972cc4a7547c74c62a07a9d,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined
key49bbefc655318651f03b6041cafe2e22,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive
key108a57e42ea4fef356f7d339881585cd,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar"
key30b61a1555421d0bf32eada653c8bb8b,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined
key5934d214864d24bbaa7a4a185db1df6f,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive
key2aa521724b1e0a5829450a71c1604842,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined
keydf5d1b343c546a3c45bcacd713559c38,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.
key1b1da33b14976e5301671e9c0ebe87e9,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation."
key6443c097ddfdf91f3b9a9b9486c0ed07,Anti -HIV activity was measured against AA5/HIV-1(IIIB)
keya693c182f4c2e8b253762d444c006616,Cytotoxicity was measured against AA5/HIV-1(IIIB)
key8dc7e2b7dbd247c9f47ff11b016c1fa9,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell
keyde3870a02cb5b96d975e6d95a58dce2c,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell
key1d0d17c96f7f150e6ce6d12f97141abc,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines
key2a4dc6ac6fb0d7eaec8dfb7631c2454b,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8"
key1d460deb85289c34ed8fb113d24963ed,Average intracellular compound concentration when the hypoxic SER=1.6
key0aa4b2bd70241a512b1f2c1b5ba49158,Average intracellular compound concentration when the hypoxic SER=1.6.
key2d05d21f59c9cfc5a775555ec1a61573,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6
key7bf47f51f15127c2f19f41c7f2006250,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia
key82714cfcb7056acc957931855071681d,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.
key434e74fd09b035ec4638cf42fc0b5800,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay."
keyf15002ac0e3ec041621e95a8ccf54141,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml"
key222768ed3213e55c510f8940d554807f,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions
key23129fe1f84d9442f470d2156e33ba22,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
key23129fe1f84d9442f470d2156e33ba22,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
keya6d73b22e26b1ee3616042c7f9f74f9f,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.
key10fe4e0aff8a5b179d5aaa21e9744130,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay
key09e3e51872025b2e02948042c5574c67,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit
key847035c032a31ce0a584c6704c5dfdf1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay
keyf6c2c78222d08556d8ca586ab31e1223,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay
keyc17f8e7cfde963bca03ffcc3e39f7819,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8
keyd8451c7ced5ca72ff2f66595e75700c0,Aerobic growth inhibition in Chinese hamster cell line AA8
key7089699c96dc785cb031b04b652d4248,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.
keyb0b44f576552bb48609aebbcde098eb9,Inhibition of growth under aerobic conditions in AA8 cells
key4e89e323b5463effa193aeeabfb6eedd,Oral bioavailability in dog (dose 10 mg/kg)
key6282f97aae42945ab0cc5056413cf355,Oral bioavailability in dog at 10 mg/kg of the compound
keye7ef782e187b53b248070db70ce5b798,Oral bioavailability in dog (dose 5 uM/kg)
keye7ef782e187b53b248070db70ce5b798,Oral bioavailability in dog (dose 5 uM/kg)
key545e70f6628e1b861eb3038ed55a815d,Oral bioavailability in dog (mongrel)
key4e89e323b5463effa193aeeabfb6eedd,Oral bioavailability in dog (dose 10 mg/kg)
key4e89e323b5463effa193aeeabfb6eedd,Oral bioavailability in dog (dose 10 mg/kg)
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
key1f108276ea319e8784a69a20e414cbdf,Bioavailability in dog (dose 1 mg/kg i.v.)
keybee8f8e684b8362b9c6a29a8870682f5,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses)
keyd23d275dd652c356a4af52e5d4f5ee69,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
keyee6d1255f8738be8e557b26fa9bff55b,Bioavailability in dog (dose 3-10 mg/kg)
keyade46b19f9163796c0157e5b3ff431cd,The compound was tested for bioavailability of compound in plasma of dog; Complete
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
keye7f58d0f53288cc2e6ed9485974881f1,Bioavailability in dog
key5030e554c638f9f13fae31286dd357d1,oral bioavailability was measured in dogs
key00a1789cad43f6fa7ee4496ca5524e0a,Compound was tested for plasma protein binding in dog; Not determined
keya7e6d323b5cf32449861ea8fdca83b44,Compound was tested for plasma protein binding of dog
key94ecefc81ffdfd09a76bfe60a959c76f,Compound was tested for plasma protein binding of dog; Not determined
key926bf0fd00ae25b7894ce8cf5cb160e0,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.
key8fe6095c0b36ec0014d313ae75446aa4,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route
key55e2df843666c083dbda843a7f29afc5,Half life was determined
key870a5d21c2ace1f70ea95f9cbbc69553,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg
keyc7129c7b7e854d5d051140309fca3bd3,Half life was evaluated in dog
key55e2df843666c083dbda843a7f29afc5,Half life was determined
keyf7fa3b8dd51a8a38c2946c1674ab8296,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT)
key356d03ad6af9bb38a269639c7d4862d4,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT)
key22fe5d0a80dc2043c6ddedacaad77739,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT)
keya6aa0981177a3470f1fe79e5f5adc485,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT)
key134199e26048ef770166e7920c182ca2,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT)
key57ee055ff3d63976df8c1037ec50499e,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT)
key154b6dd1ea59b55f5551073fc35c409b,Partition coefficient ( LogP) of the compound
key4e7f33290ae99c69fc52689207d04a64,Partition coefficient (logP) of the compound
key4e7f33290ae99c69fc52689207d04a64,Partition coefficient (logP) of the compound
key87e8d495c03c14f71c654794f7df69d5,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg
keyd4a167878de1a006e743c664cb7e0981,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg)
key5ace8b8172896082f2fbfc8ad22a2925,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes
key10d61b4443501ff2d83acda813575c21,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak)
keyc6517fdb4412e5b52aeaf6bf147d62fe,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak)
keyb5f09ab4f6131abac52851cef864fddc,Metabolism of compound in dog S9 microsomes; Trace
keyde784db398d31a09a89ac099477040c6,In vitro metabolic potential in dog liver microsomes
keya331ecde2da1dd7f3944687b2e651dd4,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key8c9d101317e46e09483447699968a7e3,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
keyc6befd9dfd7f973cbc695690b8e9bb4e,The compound was tested for bioavailability in dogs
keyaae5b38fd0dbf4ecc88ad603b1249595,The compound was tested for oral bioavailability in dogs
key5c839bda2149297dfa7b05be4ee54386,Oral bioavailability in dog
key54ad9ae16d45b994bd85b62e110b6884,Compound was tested for percent protein binding (PB) in dog
key12788cba627bd6f5a5f12e37218c039b,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells
key6c5f71b85625893aecc9514b2644f4d9,Compound was evaluated for plasma clearance.
key44dfb3fdf3b7f08f0d06c8ddbe9de638,The compound was tested for plasma clearance in dog
key3ffc68160e38805b3c6615c0a4f1c3a1,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg
key1f349202c2ad75f260d06131cc5cd5da,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog
key7ab39d19ca07a9efedc272d484d9c00c,In vitro relative rate of metabolism was determined in dog liver microsomes
key65daf4906ab5c67bed37438530abef4b,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs
key7817a6fd3051fc59daf104771bef66e4,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally
keybbe471a8dc84f1e943c051f95e7d88a3,Half life after intravenous administration in dogs at 1.2 uM/kg
keyea375147e68e704a761b9a319b4d7670,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes
keya0ef1483bee9fc229f956f599713b526,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours
key9c8346656bbf6bae59dda239c7c533a1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours
key9b1f7ecc8b4899fc920574d251999701,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour
keyde44aded3ea515ee503d20099fad2a56,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours
key1fd49dede954d1329e06db174bae4833,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes
key9016ac6c4e2d48a6259d236a2e03ffbd,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours
key91781a4c55168d7e9cf85da6cbb7258b,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours
key49b6bc121e07d00dd5fa21d3a76cdba7,C2 in brain of mice at the oral dose of 50 mg/kg
keyee966e5b33c604f67d244b4741c74e30,C2 in kidney of mice at the oral dose of 50 mg/kg
key071ac04983596a06c1b9151a6eb08b25,C2 in liver of mice at the oral dose of 50 mg/kg
key9e6d460586e84bd9237175cf18ef9238,C2 in lungs of mice at the oral dose of 50 mg/kg
keyc4adeaa161d30856abb68a1ee16526d6,C2 in spleen of mice at the oral dose of 50 mg/kg
key1fff3cdcf41ce8817085d5ae5e400e9f,Plasma clearance in mouse
keyeb31213ce316c06621fecffc0773d9eb,Clearance of compound after intravenous administration in mice at 24 uM/kg
key2be197436b445e4e7675e3d64b6b9dda,Clearance from mouse blood following i.v. administration of 10 mg/kg
key790b27e5887c816cd42656bc6a2d518d,Clearance was evaluated in mice after intravenous administration
key446e8ee1809d063206fbf503dc2730f0,Clearance was evaluated in mice after oral administration
key4c42f06d5cab2ec0dbc8d44ea5517a67,Pharmacokinetic property (Plasma clearance) was measured in mouse
key5e9f8b7007f3a5aed647cd7671d7beb0,Plasma clearance of compound was determined at 40 mg/Kg
key22011f6287384578c9c410c1a9e051e2,Plasma clearance of at 24 mg/Kg
key8f10e539ba80aa43adf050c1e1655b8e,Plasma clearance at 24 mg/Kg
keyf79ce66b38fa95d8cb4ef8d910bd49ff,Plasma clearance at 5 mg/Kg
key13e5386e6c18f675e920461c4d23cbba,Plasma clearance in mice
key185842fe137655e9573e65d136b8fd47,Plasma clearance value upon iv administration in mouse
key04b3e3de0f9bc5c61af507db9d8591af,Total plasma clearance in mice
key20273f98453f1a844712afcfa2794770,Clearance in mouse
key7d9fa6a5edc4330e6e7f05fb27581240,Clearance value was determined
keyceb4f338372acacc0a8b2127e00aeb26,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.
key1d08ba4fe734c86581eb07f5547d0914,Calculated partition coefficient (clogP)
key75b8c95ca7644a279683c39dc28ef085,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg
key937ce1104d9edd7b88146bcd3da8a6a8,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice
keyac04c96b46bc0b774517323a3f92fed2,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
key9024bad06baef27c081887124c1526b0,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg
key1bc449d9a511b5a95f90870fdd1f5d53,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg
keyecb9b8c3166b325c6ce95eacf4d90426,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
key8d0153a55ded34429c1f014a6828562f,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax
key23f45cc79030e547122930456a7801d7,Cmax after oral administration at 30 mg/kg in ICR mouse
key0fae9cf4121c7566e713cd27c458dc47,Cmax after peroral administration in mice at 24 uM/kg
key5491b76ea7d1583beedf957fa127c182,Cmax in brain of mice at the oral dose of 50 mg/kg
keycf505550346b48bac748e291fe602758,Cmax in kidney of mice at the oral dose of 50 mg/kg
keyd3f3ff455c092cb323f635ffc0a35c22,Cmax in liver of mice at the oral dose of 50 mg/kg
keya6328c141dbd9beee50d9c7b6f3123b8,Cmax in lungs of mice at the oral dose of 50 mg/kg
key7badf8ea65d7366f3eada19fd47dad4e,Cmax in mice at 18 umol/kg i.p. administration
keydb3dfdb64b678dba693a943680f817a8,Cmax in mice at 23 umol/kg i.v. administration
key84ab97d9a133133076bc956133fd9b2d,Cmax in mice at 24 umol/kg i.p. administration
key91a0df06b57ade327f47067180cccd6c,Cmax in mice at 25 umol/kg i.p. administration
key8de0d2829bcafae09705d45bc9b72894,Cmax in mice at 26 umol/kg i.p. administration
keyfdd0eb0eaa5a2b40f3fb44f47b3d991e,Cmax in spleen of mice at the oral dose of 50 mg/kg
key87479acce654eccc49a6e5c0665f2b5a,Cmax value at a dose of 10 mg/kg intravenous administration in mice.
keyca206d57ddd9ef8da86a7f09b2929dcf,Cmax value at a dose of 10 mg/kg peroral administration in mice.
key37eea7befccd59145f6d24df4c98cfc5,Cmax value was determined
keyd08dc0d1d9476b559875d6d7242138a4,Cmax value in IRC mice
keyc4197f5936dd97b2a3ec0f5e8b5b3adb,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice
key3c5273e10c06365ad7eaefb608238fa0,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice
key5c2ead43af1e9fae91d2184962789db7,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice
keydcc2211854893fb42b1e63e966af92c7,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration"
key17addff64be5b35df01075e54038ef75,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg
key81c8f66ecd2457e04103e3627f80366b,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose
key811b51a248ac9a9d47b6929d86115c44,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose
keyf67ad42e701d78674f0fe93fcffc3780,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose
key0de000f66d86a9d9cbc8bff472b0d28c,Inhibitory activity against human tumor cell line A0375 melanoma.
key2c170782dac6b9d9348bec5bb8e3c356,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes
key2ba7c54aef7dbf314d1d843d8fea8f07,Forskolin-induced cAMP production at human A1 adenosine receptor
key9e24de9e536a0f9d7598da06f20bee9b,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.
keyfe1e2fbe516fe001c6c3230fd4136a9e,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells
key102aaed3256d5ea0682e415758103d8d,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM
key9ae302ff932c39d6f5165c9a08701833,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration
keyd143ad20b28fd940066709baddf88f1d,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells
key375d4c38088d9c202902263cf58430fe,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement
keye295b2ca521bae3ebb64bb9020ff3f1e,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.
keybe100c686632a2da1c1ff6fe29c0abe5,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells
keyeb62c07a1d4f2c276d79957455120a8f,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM
key9cf1a41391b60049ba8f884da3094af7,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.
key9a9fe047a398dddf93b70eb52331437e,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration
key3425d161762786b6700b1921ccb05e94,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.
key4d59fcabb16bb2e2676c74a71724be38,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells
key6e8a9187717c6f2d899a0e7d546d600f,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM
keydc7c5ed121b6dc8cf3c9eee840e022fe,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells
keydd5c8f0975fda39c5ee398b629255f9b,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.
keya738022c524b14ecef28d05d43d42e12,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration
key4a3cfc4ef1304597049b5fa090caf4c0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells
key173fec2ebe861376560d640bf4a75d0b,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.
key38a4aec7784bca77f0cd072f29ece35b,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells
keyfdb5fcd0b668e0c2c09b7308b097dbcd,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells
keye19949433ad75374ceeeb3111f64d83a,In vitro potassium channel opening activity in A10 (smooth muscle) cells
keya5bac81fe4bd76d3f1bd91b0a291ee33,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive
key6301bd0b3b0a5e3b00649be264c7bea2,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats
key4494d18d3435d6454facdcd7fedfddea,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats
keybf3df2f59d7598261e9f6845bdfd3de5,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM
key8613711339210c162ab510f321fffb8b,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure
key5661949968143fa11f3f382b18810b60,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay
keyc11e4784d4625ade73be07217772d5c9,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture
keyaddccfd8d1dada32d1297f70ed020e25,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined
keybbcbe300e30a6de484d9c6378f1a6b73,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).
keyb17baaf3836b2e73286d96c2b059cdee,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay."
key57765d8bebd8b3d0158d4bd477c09182,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure)
key8547007fae1ae2155a86681feaf4a677,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure"
key70a96054fca760464d942b32f6812764,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure
key87168a34f5c6d0900bf0052bdd163681,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure
keyc14803d84f762ea896cd72d27d47f86f,Inhibitory activity against aerobic growth of AA8 cells.
key9408f7ceb4eacb382f35bfd367a68fe5,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
key8af54ebff424ed571659d65869fc5006,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
key9408f7ceb4eacb382f35bfd367a68fe5,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
key543fba31efabacdbae7748f910f58f68,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).
key8e49fc825ff7302a4c7adb5ea98f599c,Cytotoxicity against AA8 cell line
keyb94d96b22a7627b7e7424c571f16edb7,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4)
key6cfad3deccd3db30083e3cac9d35da23,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
key6cfad3deccd3db30083e3cac9d35da23,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
key6cfad3deccd3db30083e3cac9d35da23,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
key1751568a516ba9619199422976189f94,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4
key75c95dc748f3683f4b9f603bdd182fe8,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.
key75c95dc748f3683f4b9f603bdd182fe8,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.
keybecf0165f4868b821bcd1e6b0ebe7c5b,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose)
key851ecbc14c049ba315003937ab8c2ccf,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.
key0e2a2c1c80f8ad3b28e63293feb3d9ac,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions
keyc0c9de96ca21f9ff604c5312ec784110,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions
key73775cdfb3ccc1e9e9da169472ac5db6,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions
key45e1667453e094bb249513d8b360fd07,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions
keye2b28f86c28c86071ecaa72f05924ae7,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions
keye5f5579648237f5254c7468fc5962bf0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions
keyc4ac67cdd1e55244b36fefcaba5772a7,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition
key90b88c733cec35e4391ae74b6a16cb05,Concentration required to reduce AA8 cell survival by 10%
key9cee6fb4796d3fe2bca7d268c603a13c,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells"
keya63872607ada639cf66b56f22011ddbc,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay
key1ef5ac4b33728be26de7045f7404f788,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay
keyd80f7e407c8dc0f5e8e7ac408dcc3b46,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5
key12ecbad3ddf4c8d2116661fe82f5691f,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2
key93223af786db802272471f8d50ae2bfd,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air
key7dd538741ab90f2252765834b103cdef,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells
key0154b4a1ba2a5faf5bdff1dc1327cd78,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8"
key12df141a57044ba5b2b34c92211522be,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure
key7bbcdb744f18ff7b5be97eb7c52ff81a,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure
keyc37a5b5733c61294403308a28abbdec3,Half life period after 15 mg/kg iv dose in Dogs
key05bd846395e874aaf89d7bb808ebe734,Half life period after 30 mg/kg po dose in Dogs
key88bccdff55024560f35ba33c55f61dda,Half life was measured after oral 2b administration (tested in 6 dogs)
key757847c163b9dcb5ab6b0406b6490c4c,Half life was measured in dog after oral 17b administration
keybe44ae66b0d0ecd039ed7a7ae8595fd2,Pharmacokinetic parameter T max determined in dog after oral administration of 17b
key791ac6d73289289bcfcd4246490a66f5,Pharmacokinetic parameter T max determined in dog after oral administration of 2b
key0dcfeeebe80d1b12d8f3537504591a29,Tmax value after 15 mg/kg iv dose in Dogs
key30d74faa30bd71e065099fdf8b544bfe,Tmax value after 30 mg/kg po dose in Dogs
keyedcfa1f320240305e67f164abf31c61b,Compound was evaluated for its half life when administered intravenously in dog
key66ec3c28cbf460b7815033eea0105388,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg)
key53008e1b2d21eb554c6f1bafb6421873,Elimination Half-life of compound was determined in dog
key6f9e67ceb6f28dc80d643c3ed7d70ed4,Half life of compound in dog following oral administration
keyf6727d06262dbe8873a7ef021eb01f3c,Half life of compound was determined in dog
key3329c1554a0e6bccb8f9969b5fa3d41f,Half life of compound was determined in dog blood
keyac7c521f7c07e3c0115846d2e1894811,Half life after oral and iv dosing in dogs
key8f44caeb40cd2372c3922b23bb31c1f6,Half life in dogs in hours
key50728ba53ecd0f9e2d0f1aa875d639a2,Half life on i.v. administration of 2 mg/kg was measured in dog
keye8d051f4b7396f0e8dd5eeb2ae033ba3,t1/2 in dog after oral dose (1 mg/kg)
keyc7129c7b7e854d5d051140309fca3bd3,Half life was evaluated in dog
keyb11bc56306d627b7a6c98ed99dde3de5,Half life period of compound was determined after intravenous administration at 2 mg/kg
keyce16e5eea2429f1d46b6654919a99fae,Half life period of compound was determined after peroral administration at 2 mg/kg
key27e703d01bd303b971188db3d49eb181,Half life period (10 mg/kg) was determined in dog
key27e703d01bd303b971188db3d49eb181,Half life period (10 mg/kg) was determined in dog
key005f845fa5dfb372780c0dad3030203b,Half life period by iv administration in dog at a dose of 0.3 mg/kg
keyaa496dac911faf2aa787389145408011,Half life period by po administration in dog at a dose of 0.3 mg/kg
keyfeadafdb6612765f685956b7d35120e6,Half life period in dog
key89580e75db9b666b8dcd11f0bfe04190,Half life period in dogs after oral administration at 1 mg/kg
key3148cb555981dc0b0ee1a84682c2ddcf,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
keyea814dda78f3c5e20742b162e550bbb3,Half-life of compound was determined in dogs
keyaa1e09267f332162da090fbfdd7ab5ce,Half-life in dog plasma
key5d90ab899412de32d116fa000418c4c6,Half-life in mongrel dogs was determined
key0df99f8a006b05c3debfb42c222b7651,Half-life in dog upon oral administration
keyd845bd705044807974223beceee4118f,Half-life in dog upon oral administration; Unable to calculate
keyb9cd40c243076465e0677ebaef291289,Half-life was measured in dog
keyb9cd40c243076465e0677ebaef291289,Half-life was measured in dog
key12e3df6a2a300c6d89b0fb9eafc0a020,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs
keyd61a92dc637e752c2feb018426ed939c,Oral half life was determined
keycd124292c2dc40a1cbaa838b755ff530,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).
keybbdce17a2ac5350c71dd169d90ec0f31,Plasma half life was evaluated
keyb34aed1095abe50357dc115d35ebe2a8,Plasma half life was evaluated in Dog
keyce9b2e72032b3335f9ae22e624a4b535,Plasma half life was evaluated in dog
key4d8dcb26d71f214624593ecb9975a5b2,T1/2 (Half-life) was after oral administration at 5 mg/kg
key269206242464c9a9bbb7fdf1cc2f78cc,Tested for the half life value in dog
key7f4ec4c6da567ca40f0e40882c42b13e,Maximum time at the dose of 2 mg/kg in dog
key18f343d6ee1015de8da4ee94517b84a6,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
keye94074b02d4f01e4ec79e4ffe71f46f4,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
key51e7a135fafaa2dfc6459f7870678a1e,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
key0bb746540e877713886a827e1ed5a608,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg
key58290ddbf958255d2f3cd33b31b6aa51,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
key3df442334132949b1e4cbfdc6c521e29,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.
keydc453392e5b95e5baa9c033676200b38,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog"
key49f7eaa8007e5072e21045b6bdd8b208,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk"
keyabd5792a9e6ddc8f836f675a16a6bffe,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg
key7247e81c00234dbcbaf8f8630488b14c,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.
key97cf939234256fc171ccb654aee280ab,Time taken for maximum plasma concentration in dog
keyafb9c229f3d3753641dab005de214759,Time to reach Cmax after oral administration to dogs
key3c7ff8477c4844ddb58b356cf66e3009,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
keyb7b1ad8c97fec697b1ece1b956312183,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg
key125b6a41071a20531c60f998934d4643,Tmax after peroral administration (1 mg/kg) was determined in dog
keycac449b88a4ce11cbd777883a0bf4495,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg
key8c4b652494d1624cdcaab78e165f0de9,Tmax by oral administration at a dose of 10 uM/kg in dog was determined
key395cb8fcb076aff64e4fb768ff5587d1,Tmax after peroral administration in dogs at 2.4 uM/kg
key73633ca5b370387b178d973bfc3e7f75,In vivo Cmax in mice at dose of 100 mg/kg
keyccdd17671febb8cdfce5af9cc815d73c,In vivo Cmax in mice at dose of 50 mg/kg
key3facbaab426b70bfa3b59cbffb09adbc,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice
key65b69671d17f5264d9ddee38746d2bb6,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
key8e7a6031eb4c960b9170d85e498222dc,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice
key1a53edbc05413ebad4a4639ca0de4d67,Maximum concentration obtained in mouse plasma was determined
keydea2c063013affa2dea788158d4fbec0,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg
keyf631b0c2aee16d2aeacba4c49a4190e5,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
keyeaa88a1a433934c61b29e09d0e9d41f0,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg
keye25b21db97ed7f8dc2940d063fd94035,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg
key39a372b9431df0d1d42230ae6dec5428,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg
keyef1e671e2326a47b5983677310da79cd,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose
key448e0bff467dc06c8c5271c3b41a81d2,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose
key6f8696f00b9433ad1da4a6ee94f319f8,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose
keyb25f0f76a9ef2c86bcf8d9c90a157393,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice
key5d36847e87ba19726c850a6f1c34dc30,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice
key5e67a0ac3e4fe572f09af1e47bef3267,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice
key4bbbe5992c18c1f6470d9b4528f05255,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice
key500ce388827a4c332601b75ced65b205,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice
key6c32cb2e7269b0ced744eefae1ea4a33,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice
key7bdc6b6c1cb479531863e327abbd9f6e,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice
key62f095280b8d906d63c94feb70a2ed3e,Cmax in male mice after 2 mg/kg oral dose
key49245596d7ab877a5c9792d7dc624814,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine
key4d0926d2ce0439049b51d3044d1b9993,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse
key05b308be4850cb836715f39b0c6f7b69,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr
key41a30aa005a8de94f8bb3e44ec1a8b8c,Concentration in plasma (systemic) following oral dose in mouse at 1 hr
key5db2fe9a4121c4e3dfbdc65d5ce83d5d,Concentration in plasma (systemic) following oral dose in mouse at 24 hr
key2d7eeeb32bfb01a753233507bcde7d4d,Concentration in plasma (systemic) following oral dose in mouse at 2 hr
key9c1ffad615f2cb3d84bb02ea79582fc3,Concentration in plasma (systemic) following oral dose in mouse at 4 hr
keyb9f64201528e8e385b5f4504f10d13f8,Concentration in plasma (systemic) following oral dose in mouse at 6 hr
keye0de41c6faa59f7deae11adbb3edc550,Maximum concentration in plasma upon oral administration in mouse
key3769e9745804c2ee5b24f688681443a9,Maximum plasma concentration was evaluated in mice after oral administration
keyfe83ced5e9a9c27a215fcf7f7d18d21e,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined
key944434e4017494420306d341bcb7da3c,Dose at which the compound induced fecal excretion in mice
keyb416feab7cb94e835d7a802f5a772d3f,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM
key8449575d230e35017cd8ee48bcb0526f,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM
key778a876c5f5ac1ad06bac0946d4fc415,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM
keyb0015cf0908e82b95b025f3b78c756f4,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM
key28b0bfb6cc208307034093c98c207a01,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM)
key26badc7b1b0a30c195efd63f8d1af5e3,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line
keyc6dd982b7f65df9a1e96350ad7e84d47,Anticancer activity against human ovarian carcinoma A121 cells
key57b257d23c6db93b533cfd50f8312a94,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM
keya2027321b2f79f9c5f2a5ceddf87f9b7,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM
keyea6a1d81e0d9ed37680eaa01fbe5a664,Growth inhibition of human ovarian carcinoma (A121) cell line
key06827de991b42c9ac3d00b9197d3ea56,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.
key86a8ce07e0f76a337c4ab8b0af5aead8,Cytotoxicity against human A121 ovarian cells
key209f2e119b743f508ccf64fb3d390206,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines
key721f43fdd26435ed9fa1a52905806eab,In vitro cytotoxicity against human ovarian carcinoma A21
key567b24a8db62b6d3d9a004a5c06cdbfd,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure
keyf7c61fe139bbfc75d01fa41bc879fb5f,Inhibitory activity of compound against human A121 ovarian cell line.
key98b9ba663ecc85a567725e130762f492,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.
keyc207d6ab334014c4e6b73bb955a93399,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure
key06eefbd4e238efc21ee97fdccb5d7a7d,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line
keydc2c67df7f243c2282becb317bd177c6,In vitro cytotoxicity against A172 human tumor cell lines.
keya3b90db6a9760c3b7cf357abf88114cc,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM
key95d0d81d425065d28ef23ef8e2daab79,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line
keyfe788d289405f4080725632935556c7f,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
key70e856d01b766c4878d3181cae615056,Association constant against A2 adenosine receptor
keyb8610d443b12f657005be29915c08347,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma
key67c76f5ecd627c6563d4187c5d339130,Ratio of Ki for adenosine A2 and A1 receptor binding
key008879a99f9816268d331afe3510790b,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line
key6fbe34c4f4912af34f9068a2c70b0ca5,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined
key1a11fc28daee74a80d49222b89504601,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines
keyd4895273a8b85e914c1d12d54f8871d9,Growth inhibition against Human squamous cell line(A 253)
key0367d518bcfe4a5c27cd533075a25a61,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line
key4bdd3138dd7079bcb67cc3c638b3194c,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells
keyb8a2d718f335fe47da08acfe27f7d97d,Growth inhibition of A253 cell lines.
key85c08f4e74971886b9afa1ba04458ef3,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h)
keydbfb69eb302cc72addef1bb6c39ff4ab,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined
keydbfb69eb302cc72addef1bb6c39ff4ab,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined
key5084810a59c0bc8a8fdd5fbc9b3110e3,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line
keyfa3c9c7321dc018642634b534cb53abd,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line
keya77f9567d4ba4d50b76650253250489a,Cytotoxic activity against A2780 human ovarian carcinoma cell line
keyf92d978f43bc3092cc74cfe4dc508748,Cytotoxicity against human cancer cell lines A2780 (ovarian)
key0d06750462a9cec97b9108722877cc4f,Growth and colony formation inhibition of A2780 ovarian cancer cell lines
key2d1c2f3c11ddc5ef6bb71e90cf094b59,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay
keye9891de5d4115f79873ef1be9f780a8c,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
keyb0fd4615956992c8a461f18ccca4ea30,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation
keyc8043b0b7183d59d85496b5ee7e4055b,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation
key85e03a5f85b56e2ba7d5004c063bf459,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation
key67f07c6ebbd6da6596e14819d05bf39b,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2
key8c9d1a9a37a2f2b1cfedd93ab77c73bb,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3
key9eeb9074e0d5c24040a99d9fd7b36795,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5
keybbcbe300e30a6de484d9c6378f1a6b73,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).
key4be8c523291c05292db555f2e427e6ac,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay
key972065da8d4269ea2e86dcf51c717588,Evaluated for growth inhibition of AA8 cells under aerobic conditions
key917c7ffb3f7b8f1d4a828fe80811f4dc,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions
key6febc191e2ad2be4069e4d4888fc1824,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2)
key926e71f3f3032980d033d478fd7e27e4,Growth inhibition against CHO-derived cell line AA8
keybf45a4fb5ec4514fbeb07d8f96e33189,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control]
key934f56787909d025fe94d5c2285891eb,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions
key42325f4e8c90830db9c8e45d48bb6c59,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions
key2b1fac644d474dd40a76128cb88045a3,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay
key89bb9a16bada82328b01b56d69ec1e93,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours
keydbf6257a54bcebd91879dd2197eacacd,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay
keyff552f3f72823cbef865b041def47bd4,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.
keyc82357c75d9c62270cca8ffe0362105c,compound was evaluated for association constant (Ka) of isolated serum protein AAG
keye4358816d76fb2d427e5db94b8ebbf24,Number of binding sites (n) of isolated serum protein AAG
key9452f0875b063bcd4384036896d1b804,Association constant for binding to AATT duplex
key41a70b02f03aee98130fb4837464a49c,Inhibition of ABAE human fibroblast cell proliferation
key33b6ead36f64da348a7237dba14ac027,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg"
keyab57942b0360328c91796f47f388a749,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model
key2e915da0ed0b754ef16bc7d6c5bbcfe0,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay
key24c2d7da0b8cdb4704480f504ee89309,Inhibitory activity against angiotensin-converting enzyme (ACE).
keycb1a9f7c549831a9fe1630bb07282e12,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.
key8b96073f7b066a3eed65907af0053f9e,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells
key7f31abedf543bf44fdf44cf711c869c5,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate)
key850b46a57372f132160f952cef8e05f8,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2
key5f0705007d5efa76a53e23fdc68dc943,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate)
key89a0e85857ae1d6f49778c6eb25d3dbf,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate)
key34e2ab29ec57eca8b2eaf8f623dc0e0a,Inhibition of growth of renal cancer ACHN cell line
key22ecdf424a02f04891b87098e9ddb4dd,Inhibition of growth of ACHN renal cancer cell line
key1944ec769ab22b72db0d94c08371361d,Inhibitory concentration required against ACHN renal cancer cell line
key6c2adede82d4747ff4a1c13834fdf62b,Concentration required to inhibit growth of human renal (ACHN) cell line
key4e57c234a951beed18d71c8ace65179e,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested
keya0534fa0b8625347f0a502ea300ef780,Cytotoxic activity against ACHN Renal cancer cell line
key6f29d9ad72cfbb19fdd93379ce7ec867,Cytotoxicity evaluation against ACHN renal cancer cells
keybb67e13bb6f5ca1e8fa5b21605d6619e,In vitro antitumor activity against human renal ACHN cell line
keyc8c409059c3ba78bf9222df69594a00c,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer
keyc8c409059c3ba78bf9222df69594a00c,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer
key1fb3b53f43fc9cb3a7d01ffa006f221b,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported"
keyc203dd893b148655e48d4ed3e2a47feb,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).
key64b1c831fced008a22c2a0a413bd0857,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).
keybce00a43d377ffc43d47f26d3486ab18,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined
key4211f81739aaaec063336da0a6b57eb7,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.
keyd3766b782e96347b6633310f19095b6f,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
key22d16abfc293a60e933c73ca20732f2a,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma"
keyfd0b363a2b43a112c6a3fce3826fdbb0,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma
key263290847bf3cca05401e73bbe38d22e,Compound was tested for the growth inhibition of ACHN renal tumor cell line
keyf7b5bfc2aa7fa7d96cd7d03ce9444a92,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined
key371e0ee24333eeb3a7719b22df6d6a0b,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line
key87648d3e03892a98d4b7249ed05fd5ed,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line
keyfac6fb17c7325348e1003f579add66d9,Tmax value after administration of 4 mg/Kg oral dose in dog
key0dd86c5ed62bd184ec36c305f825e55b,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously"
keyabff440e73f752f14c2b2b1c37872c5a,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration
keya2306d113a02ca95742b715bd95fbbf5,Volume distribution after 15 mg/kg iv dose in Dogs
keyc1ff763ce4417cf31c4e6be9da717df1,Volume distribution after 30 mg/kg po dose in Dogs
keyc8ba7f4b39a678b497aa8b61bff88a5f,Volume of distribution was determined in dog after a 3 mg/kg of iv dose
key8de933d5a49521a81fe8f8ddc37ece50,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg
keycaafd99914135fc1b4c4263952a5cf38,Volume of distribution was evaluated in dog
key14125f3798587ab10b7480eff30a5264,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg
key379db76fad9ee9461cd9496bb59b6867,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg
key65f48fc831e958fe9385e370a33d2806,The compound was tested for volume of distribution in dog
keyd3a97a5121a307dd3408bf4c46661e11,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg
keya31f33d4e8410c1ed9feb68e35166aa7,Vd (1 mg/kg) was determined in dog (in vivo)
key93bb23282e95822df77661277d24159a,Vd in dog
keyb0db6293786725a399caf9ef4807f312,Volume distribution was determined
key687901205fd9f8bfa314ded2b2068c94,Volume of distribution in dog
key6387f85e08088604b67b7d0e183fc520,Volume of distribution by as 4 fold increase by iv administration in dogs
keyc222ccd96b73df00919b373d823e5a93,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).
key45b33a072b2fac0359161e520ad57407,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
key06e536e7458e14da16038ff6b197eac9,Volume distribution at the dose of 2 mg/kg in dog
key9546dee2e91efb3dbc0693063528e157,Steady state volume of distribution was determined
keybb190b127678560c88b53631b670993f,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose
key29a6e9f732c60dc90d10e02871234f1a,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
key80ad304ed477404127489101b2264dce,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
key1f108276ea319e8784a69a20e414cbdf,Bioavailability in dog (dose 1 mg/kg i.v.)
keyf7d60d99e8091c2d5a9851f190ba11b5,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
key4f103c72f0abc7c8a56d54b0f7171508,Pharmacokinetic property (vdss) was measured in dog
key066b596a56ad6d28509c4e6b511fc565,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog
key3297e301d6affffbe43e32901e990e06,Vdss was determined after iv 0.1 mg/kg administration in dog
keybb49d7134aa25e9ff31bbd5781a09038,Volume displacement was calculated in dog
keya552fa28004d74ddbefe77346449a724,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
key4b06d78eddd640647e5842820291caac,Volume distribution constant was determined
key741279752248a8362156fd15678dceea,Volume distribution at a dose of 1 uM/kg in dog was determined
key6475fb68c1e5c20ce44a12ccded7ec7d,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
key67a6bf58cde3c78905fbb902fd5d9dfb,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
keyf3b0feda145fd48b2c9598fe9c6e1845,Volume distribution (Vdss) was measured in dog
keyf3b0feda145fd48b2c9598fe9c6e1845,Volume distribution (Vdss) was measured in dog
key9a803da8f1f16a65057db01764f788aa,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
key0452d4734edeb027a356fd4d874a172e,Volume of distribution in steady state was determined in dog
key13b8b62f8279f67ed37d85bff94a9a72,Volume of distribution of compound was determined in dog
keydd2e85f9bf979db635348d76085737b4,Volume of distribution after intravenous administration of 1 mg/kg/h in dog
key8502d143d3d276e89cc3f0007af8b120,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male)
key3ad232a70ff62506ee1748bdb4b37033,Volume of distribution (Vdss) was measured in dog
key214f1d96a7390152bfb95670c567e27a,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
keye408a6c32b4959d7741cfc17cc24d6e6,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
keye408a6c32b4959d7741cfc17cc24d6e6,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
keyec5d5c7e6364047c8904bedd185e28c1,Maximum rate of depolarization of the upstroke of the action potential
key649ff6ffe6f3b8bd9b979873c38f79f1,Steady state volume distribution in dog
key92d3a3d59f354ea4720cd47c667fd89f,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.
keyefda59c115e9fee14eff4e2194baffbf,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog
key91c7b1815c8e69493e278049de48974d,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined
key917abfa5464113903102f4ee131a9a88,Volume distribution in dog after administration of 1 mg/kg iv
keyecfbd086f3ff7d9e80b15e0182095a3a,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg
keyaf27df3a6d25f3669f65086f48d57331,Vss after intravenous administration (0.5 mg/kg) was determined in dog
key7156c292c63db43ea423d82f0680730c,Vss on i.v. administration of 2 mg/kg was measured in dog
key0adf9054d89a3a711a06190890db45b5,Vss was determined
key8085ff7532b85de7d616457f30d0c0ac,Vss in dog
keyfa69d387b7f1be5c17ca473fcd6f9153,Volume of distribution was measured in dog after an iv dose of 1 mg/kg
key2a570db703f6a53ef53e8da9e02f4dc6,Volume distribution in dogs
key687901205fd9f8bfa314ded2b2068c94,Volume of distribution in dog
key6a639103cbb9a1cf87cfe921c89e3d32,Tested for the oral bioavailability in dog
key38ca5cba5bbe6eed996dd988112d24ae,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg
keyfcc9de4fd2d15ab0989422e57d285d93,Bioavailability after i.p. administration of 50 mg/kg of dose in mice
key42046b9fbb94ae0f21ea940884aa8760,Bioavailability after peroral administration of 50 mg/kg of dose in mice
key5a70078cfb53fd17a7b153acae28c069,Bioavailability was measured in mouse
keyd7c695fc0ed8c178afb7cf3a2a5a75e0,Bioavailability in mouse
keyf148d5df9eb9fd23202a3eb244a389a6,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
keyd7c695fc0ed8c178afb7cf3a2a5a75e0,Bioavailability in mouse
key3a35ac91ed3edddaa74ab3e613f4f3c1,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg
key671863d2cc610353351d3237988acb88,Oral bioavailability in mouse
key8b959b2458c64c387eea76308bb74d66,Oral availability at 50 mg/kg po in male mice
keyc0162f7d0cc71c7efd7ee04b7eefafd7,Oral bioavailability in mouse (dose 10 mg/kg)
key1d3cdb3379c94312996e4fe8059983aa,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg
keydbe692bc83187f79f9fe3e2e2836ab3d,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose"
key671863d2cc610353351d3237988acb88,Oral bioavailability in mouse
key1032649eaa61d2b61b9825822ee24623,Oral bioavailability in vivo in mice;ND=Not determined
key11a0573401b612115a9773b3ae43cb0d,Oral bioavailability in mouse at 10 mg/kg of the compound
keyd497f85f4e9e35d6615191c84bc8e215,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.)
key3811b5b3a477981b8cd8d6eae7e2dc92,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.)
keye1de55c2eeff02e7c611b3c8d7b2e8a0,Tested for bioavailability of the compound
key209b72ed015735dca5f4175c31a8c98f,Tested for half life at the dose of 10 mg/kg when administered intravenously
keyc09a82d77311904eff713cc0ea6dfc14,The plasma half life of compound was determined on EDTA prepared by mouse plasma. 
keya6a8f88c33cb3cafb57c95f42670d626,The plasma half life of compound was determined on heparin prepared by human plasma. 
key893612373040f5aa835f423a2da5f283,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded
keyaea43af1384c8e30b8403d8062d7a054,The plasma half life of compound was determined on heparin prepared by mouse plasma. 
key16262b13cc562ede95bee2f1133d8d34,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded
keycad3a27dca0613a2ff3b3905bea4510b,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg
key5351892b0dd91c47c08c8da04318c79b,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg
key0dc1d31f0c43751581bcbf918432a032,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg
keye2ab43990fa6dd2dad93e3179ed72f09,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key323cf36a82d0c7b62e74774fbcd65635,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
keyfe7e12406fee8f55b7ad894dba09a6cc,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key1d1a6a430bdf71a6889be4bb290fc93d,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
key2fe8e456c9f45766bd11f58183ff5046,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
keyc95470290d70011739394a64b65222e1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
keyff975ff7e8d1ae2dec095b1d35a6e85e,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
key05a997cc6af9170cb506eff001e3f0a7,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key3f7964edd2af316ecb7981411056095c,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
keyf6b54e12544d8bbf747b7bd3a6f902da,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8
keyfdd71b531bdced6b45a64ce46be52698,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay
key65762afaf67d4cb50d0474b0d92fff18,Compound was evaluated for cytotoxicity against A2780 cell line
key6a98c096bb128e9200fb6fb93805a919,Inhibition of A2780 cell clonogenic assay
key5e1e0f27a6d8d9201d2c6f4e0f375d6f,Cytotoxic effect on ovarian cancer cell line (A2780)
key546c4e8494f8ad006409f38954087445,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C
key25e8025d1c803676368c0d611739dc90,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL"
keyc6d6ff46b41e4300d4de64c7f59bdfc4,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells
keyd93a98cb74f182769f14c98abd666f5a,Antiproliferative activity against human A2780 cells
keyc40580739c4504e28c7c0301b2c00f6a,Inhibition of human A2780 cell proliferation
keyb9145f2a83ab0bf426a218a88384eb07,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay
key9f051134f3a355cf3cfe9a5f2c3ec929,Inhibition of human A2780 cell proliferation (No data)
keyb51fafdec273d6a3c76e6026a4d69bc5,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line
keyd3e09d00748391b066a2ada112820e87,Compound was evaluated against human Ovarian carcinoma cell line A2780
key19b7e9206d8f7cc155fe795dfaec7586,Growth inhibition against A2780 wild-type ovarian cell lines
key30d13f793901f268a48fd56ca1c740ea,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data
keyee59821e204ad678c1d1eadf926e018b,Inhibition of tubulin polymerization in human ovarian cancer cell lines
key1dfbee823079231153b249449ff7bfb8,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780
key5238110e894be927825fb2cd41f340a1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R
key1dfbee823079231153b249449ff7bfb8,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780
key5238110e894be927825fb2cd41f340a1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R
keyb0990fc3a2ab32311ad4f0739602a740,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values
keya05567cf9d6c28acb24b86ea1d3043cd,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values
key614043a3f84df285bf7ae0f96ba18d5f,In vitro inhibition of human ovarian cell line A2780
key0344adf89fd8c759eabb1b1ff703df39,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR)."
keya1d8faf1f07cb8421f8fc122d7fe36db,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro)
key4992016f1989bcc6e722aa8ca149977f,Concentration required to inhibit A2780-cell growth by 50%
key6568cc02ee79cbdb6dad19112ab4e601,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.
key780703bf7156f2b46a4417eea51601f1,Cytotoxic effect on human ovarian (A2780) cancer cell line
key96fa130085b9c60e7322ddb452322e18,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure
keyfdfbebaea8d9760b67066bd6a34020eb,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs
keyae206b1794dd18a1533dd57349f9f4d8,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay
key9546529be40537a3be8908bfd980c792,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay
key279300becf477b7da16cd31f1a4f5bd7,Cytotoxicity against human ovarian carcinoma A2780 cell line
key5c0ae3f7808a097cc6a50f7150b25bd4,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line"
key27a1b0240fd52acd34c587d08c88ac7f,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line"
key2389be86db2983d0297df5abec6d4830,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line"
keyb1d27d794ccc971ea430ea4a0755e047,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line"
keycd052e660c124d989120be7bd30826b4,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines
keycb8d04bfa3637b15b214f07d23871ce3,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay
key272f0b37dadd1827af8d24ac6f9bbec8,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay
keyd1a4260fbeebf818dfbe7c0a9323061a,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay"
key9bef05f3b7c3c415d24b0e343e22e5b1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780
key9d4d779c0f1a1b6080a2a010fb036cc1,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line
keyc97bb43c0e3e360d61dc09ef81c3a72c,In vitro antitumor activity against A2780 cell line.
keybb99f215dffac0810c6331197b705ac4,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours
key22dfdc83d7fa3ddb4742f127b4d670c6,In vitro cytotoxicity against A2780 human ovarian cancer cell line
keyb7e71e131cb411d22b9676756262afa5,Inhibitory activity against kidney A-CHN tumor cell growth in culture
keycd23c2e0607900ec8aee5f07cf30ca74,The IC50 value was measured on ACHN cell line in renal tumor type.
key90c4a2dc0a61f786502da6ae3e3d6b02,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro
keyfabb24ea20da15bfae68acb2b19e1bc7,In vitro lethal concentration against most sensitive ACHN cell line
key872ae771f4ee1ee62cc23b09128bd663,Tested for cytotoxic activity against renal cancer ACHN cell line
keyc314b55d089bcce4c1edadb5ce213fee,Compound tested for growth inhibition of renal cancer cell line ACHN
key6bd752382db8df4b162f66fddfeae900,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line
keybb0a69cd76ccd0aab7ebfdebcfab941e,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.
key9432b8f4440fc4e122f110dbe8427fc5,In vitro anticancer activity against ACHN renal cancer cell line
key09eee36e3d3fe58c7d27eb30c664846d,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay
key31508c59a11bc6c4b22f9f783f00b9b0,Percent selectivity was evaluated in renal ACHN cell lines
key4ff25c62fc8d636e3f609e989a9d2a75,In vitro inhibitory activity against renal ACHN cancer cell line
key7f05e3f0fde50f62a6628aa15771f3a8,Tested for cytotoxicity against ACHN cell lines in renal cancer
key6338bd442957e11db72b24a3ee9ebff8,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line
key8462974817e677d7c9ed1f5802c1d87d,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined
key94e1413aeec47f333dc7f946ac1c4e7f,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer
key5915db485382b40df432090f4181ee4e,Cytotoxic effect on renal cancer line ACHN
keya4465b46f748f1802e78522bca66d2cf,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line
key6f68f1c7d1f65c6ced4bed8fc595566b,In vitro inhibition of Renal Cancer ACHN cell lines
key4cbb4ef6a5c8a1e2b5889b77c2fb1898,Antitumor activity against human renal adenocarcinoma ACHN cells
key6a4e96049bb5bb7246a6a27a7c5d32ab,Antitumor activity against human renal adenocarcinoma ACHN cells.
key0a3cafcedb59d4081c4abf467ea048a8,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN
keyd3766b782e96347b6633310f19095b6f,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
keyfbcdc3ac6887ea273ed6c3351d89125e,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line"
key4fcd3a8425248ff51769d47f392fd7ea,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line
keyb0a1635c3477f852980e3aec26e33d00,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).
keyaa983853bfad0e6014098560fef6ac61,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).
keyad64fd82562a02c95c7588cef6176c78,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.
key07e6ae56c83c26ff506050716fe4fc24,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade
keyd6fd1ba6b0f274bb478ddf7746c22cd2,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.
key277d0ffebcdd3f34d14cef06eb8a887b,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.
key7682900678884b5fa1a4d9c0a3c3c8d3,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data
key5bd67ac949e466d253b817ce68dce4e7,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA)
key59c3f99055328858ded1edbb261a22b4,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA)
key535c1158a3ece895362cf0d534424b42,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound
key9c87cc74e3134d83a1d1c5865b33984a,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells
key6e6933aa94b0b876de0c63652b92af11,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells
keyda930fb2d14b040ee815808bc74bfaf2,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor"
key142f6d3c08515db85ea8f3a2dceef509,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg
key12aaeb6d88c916e30de5ea35e5d3d8bf,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group
key2f0aa76668c012f31a2e44b3f8bf49a1,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells
key480092afee1ed269c54975b44a3ef239,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma
key887bd082f18f8a34958eca90fe10765f,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined
key61f35573a6db06414f2c15781ab7f1ad,Tested for cytotoxicity against ADJ/PC6 plasmacytoma
key68efbe15573bb970d42acd39a859c5b5,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)
keydb74063765defcba9c19b9849445f6c0,AUC value in dog after IV administration at a dose of 5 mg/kg
key09ec63fcd9a9e7241bca574ae763caba,AUC value in dog after oral administration at a dose of 5 mg/kg
key32ca007a61f2e7d1560517fdf8740dfd,Cmax value in dog after oral administration at a dose of 5 mg/kg
key74cf20563963b92e6d1d7dfb9cd59efe,Bioavailability in dog after oral administration at a dose of 5 mg/kg
key0dd4908702dc2484e5707d4f763fb068,Tmax value in dog after oral administration at a dose of 5 mg/kg
key6e73e0111404e405f17051276eaa7f6c,Compound was evaluated for its clearance when administered intravenously in dog
key690c8c210df8ddf111eb7603f667156a,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg
key88726e6937c06aca477890df904ff721,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg)
key1d08ba4fe734c86581eb07f5547d0914,Calculated partition coefficient (clogP)
key7c544c194b1aa93edd100c9c97ab74ba,Half life in dog
key3a04b3d4232f1935207d019d04ea28e9,Time taken for EC90 was determined when tested in dog
key10e238d089379cb54c712ee5aa262fc2,Half life (iv) was determined
key3533d2975e9f6af1f85b8331bc8dc98c,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes
key43bbb385e5386e81ba852bdcab6b7bda,Area under the curve was calculated in dog after iv administration
keye74db1d5de09a2c60b866bb3e457d035,Area under the curve was calculated in dog after peroral administration
keyf123f5db0d5accc9a2e45ddeff790cfe,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk
key087f76ead3e22d3bde207af63806f393,pKa was evaluated
key5f8825092d1f596ba56c2114e87b4f8c,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound
key6883d8b5454910375ee6570212e02b48,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg
key693454ef941d8a13935283b63d9680d3,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg
key7817a6fd3051fc59daf104771bef66e4,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally
key1b22998d39e16de00b6a40cf2747f841,Compound was evaluated for the half-life (t 1/2) in hours
key928b757001cf6e482be5452331a790c3,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
keyc5315b47ae06ff4452017378ce115e94,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
key525f3542c92f350d94609f7fa7f468fc,Half life after intravenous administration of 1 mg/kg in dog
key2233a14822d332e124fe7e724b9a34a2,Half life was measured in dog
key4078dda6e4c750226bb57d0ebfdcec70,Half life period in dog after 5 mg/kg dose
key9af697b841eee5d75f1571055b76c0a9,Half life period was evaluated in dog; 4-4.8
key222187d5396db338d613fc525fe394ad,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
key73e42971d844a13a4b052f0bef1ee40f,Half-life was determined in dog after a3 mg/kg of iv dose
key8cde0bd8176aa8aa1bf78ad397f60407,Half-life was determined
key8a809d6ea19db13ef4bfa9398649a744,Half life in dogs
key3bd9e020cc6419e4aabe1ec568f41643,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog
keyd843145ce49d63c32458a8730afc5cb1,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs
keydb6937f298b8dee01c0d800090fb14dc,Compound was evaluated for the half life period after iv administration in Beagle dog.
key9375de7550d0bcbbeb01a1f37b85da78,Compound was evaluated for the half life period after oral administration in conscious dog.
keycdefe8ff8329afd845e7c0cba257b219,Compound was tested for half life in dog
key32727621a9ef0464f1c81969767323cd,Compound was tested for its half life in dog
key04e129f3ac7f902e404b987f95bca7b7,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
key084756bf811967c2166a1c3388e9f76e,Half life of compound in dog was determined
key10e238d089379cb54c712ee5aa262fc2,Half life (iv) was determined
keyafc096bc810807ef4a27e3e15e251d10,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity)
keybba2f48e09c8026d25742a913ca943bf,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration
keybba2f48e09c8026d25742a913ca943bf,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration
key7c544c194b1aa93edd100c9c97ab74ba,Half life in dog
key0b7ba9ed918ba3f218a92f73a595a21b,Half life in dog plasma
key22dbac0c79134421aa2fcb65a5056b24,Half life in dog plasma after administration of 0.25 mg/kg iv
keyd6de1c15210417f2679fdafbe9d65f08,Half life in dog plasma after administration of 1 mg/kg iv
key2f3cefd02c5214cc4bd3c7dae5dde5e4,Half life in dog plasma was determined at dose 10 mg/kg
keya91f7aa98c781a13e9106acf1c6290d9,Half life in dog was determined
key44ee14dcace601328acb18738b0c39fa,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
keye84ee38314de6057d428d38394c14def,Half life upon exposure to human plasma
key20ac07916f71a83893fc2256f4c00ed0,Half life was calculated in dog
key55e2df843666c083dbda843a7f29afc5,Half life was determined
key55e2df843666c083dbda843a7f29afc5,Half life was determined
key5d8c50fcac6ae7f3ecee554edbaf1af6,Half life by intravenous administration of 1.2 mg/kg in dog
key7c544c194b1aa93edd100c9c97ab74ba,Half life in dog
keyf9d338efc0c890c4178dd0120dfe18ce,Half life in dog after intra venous administration of the compound
key95a35258446fcf2e9da29778cedfa933,Half life in dog after intra venous administration of the compound; ND means Not determined
key9ed7a2a1c747eb6776da7fe0daaf0fd6,Half life in dog after po administration of the compound
key315c5daa434f910fda1627169bbb3dac,Half life in dog after po administration of the compound; ND means Not determined
keyd005c4358e6ebdee5d50d9ce5c02ab8a,Half life in dog at the single oral dose of 1 mg/kg
key8a809d6ea19db13ef4bfa9398649a744,Half life in dogs
key053e613efc2fd7f3096b3d64b458fb51,Half life in dogs at 1 mg/kg oral dosing; 35-100 min
key03882c26e3160207d6903d4e1f9caaa0,Half life in rat
key74c08ee82ebddc6009c37b3f17fb48f3,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
keydcd7eae625e8d2f973a3a13ffd83afee,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key88a908e7990c01579dbbf0f7ea86fe93,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
key45dcb456c1068b542a45b825e31b2072,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
key20bc58948fc8cbe66ae237e292126b55,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
keydb16a3dd67a1b0c0ade0dc45a4e00152,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
keyb692c43f9f91339e5d5c103042a87c69,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key51a29a8d2babc743cfb8fd2c008193e5,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
keya3b89fdb421d114e1548a86717fa2ac2,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key0e0bd048c2267c62a7b49170d848eb6b,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
key76b833325fe771e14027a97bec95edea,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
key22ba6e6841c7336b58614ddec6203417,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
key90cfb66e452aff70baf516472eabe462,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
key870fd4c4a01f92f82ac81248b87587e8,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key62360b672ea3652f82ef7a679be2e737,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
key80283c391e4a727055f5155a85d7c591,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key2e8d6ceda6aff7ba3a3fcded896dcc95,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
keye347f23835c3f72feffd8e0342ed348a,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
keya4e8e8d7eb575ba352d7730a17749587,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
keyd596b212a5cac87691f1bb8d5e5fd860,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
key062ca54eea2e83e5a3bed23102a1406d,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key7378b7ddd98eb52940886a98e7d2f9a5,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
key993126735c198ddd26e8f48e6cce5366,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
keyd907cc9b4821122956a86d0092cff9c9,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
keyfad0845088c1803717b6442287194676,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
key07dec17796733c136ee0fad5f523ac3d,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
keyfeb16d8d320b4472a1e5987eabe0ae10,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
keyb830ceea023968a2f0d095ccdf7edb0f,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key9022bc28ee9dfce07d1cd8c95346dc14,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
key356f45b7f86fe5399a5e22ad3484753d,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key2d9a07a4150dcdac911bf39c9c52dac3,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
keyd4c6758e9c06c909f495c1398bb4f5de,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
key1da213c0f4b19c7640877a886cf3766c,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
key3534e94ca7b3da37e2d7e1cb458abbbb,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
keya5b84318603e136d947c62bbe2ec9900,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key745847baec21a8f702083c5c3a993116,In vitro cytotoxicity against A2780 (human ovarian cancer)
keyb451cef26cbca3b791b4edd3709040b8,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780
key37ed09925998932ff5751f485c9aad55,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.
key4b59af794e1706d03e2ae875bd9c2ca2,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).
key00802fbd49dafd80554fb8319d8a29aa,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line
key6a9b48e415e93eb7e0406de3962d55ec,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line
keyc86c2a91a7c46f306990a9a0858c2974,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.
keya79371e3be6e4d47c69f3b6f86c6c0a0,In vitro cytotoxicity against A2780 cell line
key5b410fefb2885115b8ac0f9195ca0818,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined
key75157884d34e984933a30cde43a73c79,In vitro inhibitory activity against human ovarian cancer A2780 cell line
key4ed4704d5e3471dd9ab7f1020497d7e8,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure
key4c9922cc0fd4604b32b501a103862be6,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay"
key2192e4786b0510f6605f32173b2a5593,Inhibition of tubulin polymerization in analogy of ca.
key3fa70658c0fcca2647a1700cc8c85f87,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound
keyc770227479b6ef41c207f360f9c15cf2,Cytotoxic effect in ovarian cancer cell line (A2780)
key070462fbe091fc300cd98e5f57263d13,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene
keya24160bef3ec70761a7668dcb96e7ebe,Tested for the cytotoxicity in A2780 ovarian cell line
keye9891de5d4115f79873ef1be9f780a8c,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
key91d1208cd077a9b614d3b7e89e91451a,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma
key47772e2a4c57de1d5434a2e18f5e33d2,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma
keyb29b2472b0afa6eb638c3b53f365e7f6,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
key6297d5b5be6105bf01037bc00582f0b0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data
key193a6a30118b388d2cbb54bf285072a1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma)
keye431a6aa2c0bc7ed81d4d8cef1790415,In vivo log of cells killed after administration of compound in A2780 cell line
key3afb1a4954b4b7912571edccc42e9d56,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line
keyd47a0d5dbcd0510f19bff1b3b6068759,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active
keyd7bfbfa429c0e6e276f576db84625790,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active
key028ba7f83cb2926baf041efe659d5c37,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data
key58d93a3094943e941c9baad8cf614474,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data
keya5e55894159a49fdab435ff57e38c2e3,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2)
key173b0c1044cb5f776a25bc6f834ee9ab,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line
key5e8da626a965ecd452c83f66666dd5a6,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line
keyac3cbc477647c35ebab8ae31503375a2,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment
keyd1eb5bd464305f520ef1b28ac91c861c,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.
keyebb95d76674466898af6219022d4006b,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.
key5e1de8615fe528760dbfcc3da142c662,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM
keyf85499ce4d06817ed841013ddf5971a6,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)"
key1b7eeb45cece9cec29e92b782f3de8a8,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM )
key697dd61d0f0ece7a5ddcf4dfc565aa5a,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )"
key2f49f1461fee124a1a833bf74515513b,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM )
keyae6aaf7789a74d6617109cc6f19a2167,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM )
key4f2aae6dd51a18338f5f115b1a5543e8,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM )
key1bcf7a8cae08151011d1d23fc39c6ffb,In vitro antiproliferative activity against A2780 cell line
key054a45ea6a03d6025161320847116eef,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days
key4bcbb11ad8f5b2ba3b16ac95a0fbc9bb,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr
keycb9e3e8a2f76dd4fd123ab095ae54149,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr
key462d47d15dafe3aecbb5683da327e512,Vc value in dog after IV administration at a dose of 5 mg/kg
key3e9a401fb1251f40c3e6efc85f547021,Half life period in dog after IV administration at a dose of 5 mg/kg
key56ba99ef613cea9cc73e5362a2b89a77,Area under curve was determine after peroral administration at 10 mpk in Rhesus
keya83f7cd7433dd91d31756a471cde2b31,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
keyf277f01bfe086b2cb8b01fcba0310021,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
key51d7d0b2ea71580e28a56213427d3c5d,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey
keyf262907df917eee23c2c858cb9c94452,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey
key9b5d80252e0f4137bde7aa95fd405ff4,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey
key8c72cde28e328893459b8721973df7ae,Oral Bioavailability in rat
keyfd945d6de9454d0b4168a7e6ee447246,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
key90541fd2d3c1144b7b03ec54b89fc7dc,Area under curve value in monkey at a dose of 5 mg/kg
key042ef5489ffb062d21c14f86d4eec880,Area under curve was determined in monkey after a 3 mg/kg of oral dose
keyf15f129e523edf11df3f056bfd92b651,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys
key76cff0112a76f5ef1e83cab8430e29d5,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys
key1df494339ca61912216e9b1cc23c5e34,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined
key5ce5b25073d10e50fe530f829a729bcb,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey
keyfbd6e592ab5646a2c49f1807f542cf44,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey
keye57af3ce9ba6b8ee8d1732764de0f476,Area under the curve was measured in monkey after an iv dose of 1 mg/kg
keye2871542f580451b84e7b26862585b06,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey
key5d8b4b6f88ad2302ca43fc841c69c549,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey
keyecb5cb05d047be4d21d433a705010a4e,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg
key0e6aedfd2cb024026cb80b46168a2ed6,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.
keybbcd7e9ef844659d13fecbf78ecb7ee7,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys
keyf9b062edf396ebb3d5118c3c7ceb7d33,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys
key50005c07370487d4e4b97ed59682fb1d,Oral AUCN in monkey (dosed at 0.5 mpk iv )
keyfb224158712b33a7d4edae7a8e6d36aa,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration)
keye0c12d66688c681d518fee0412e97acc,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
key06db66a6997982a9745f89ee9bc348f9,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
key0ce202d4f7b2e0a148a84aff84a3caa2,Binding towards monkey plasma protein at 10 uM
key7221cb5a65f35f0fe860f0e097342c19,Binding towards monkey plasma protein at 100 uM
key8cc0a84edc046a2d1be7a7e56c21c481,Apparent bioavailability in squirrel monkey was determined
keya41404c258728eda961a9bf5a3cd9c19,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey
key516d2a919a571407233a0715c645864e,Bioavailability in monkey (dose 2 mg/kg)
keyaa816632d51d0d793367c5fd0ba442bc,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg
key65cd29911001d2350c4b458ea9509ffe,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey
keyfd25b25980aab0dbf29d58bda577496c,Bioavailability in monkey (i.d. dosing)
key2ea5bb8aba13257ee4e1510326edf0f9,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined
keyde2e4eca2d4a536a6d9af2132336fdd0,Clearance of the drug was measured in cynomolgus
keybdbfd82c9ced3d9db9b20e0577195c06,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg
key3cdbfc8840fea8ebe210c0c271dc73c1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey
key395a33455bbd9d58d30edd6d73040f03,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
key29b79307875e15f690bed9dfb81fb870,Plasma clearance in rhesus monkey was determined
keyabff001f928b0d0b71613c49c8bc2ba3,Plasma clearance in monkey after administration of 1 mg/kg iv
key0e874786b44300e02e5a62bf6cbb4f14,Plasma clearance in cynomolgus monkey
key9b753f418ac63eb053db8913daf2cc0d,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined
key36d4b4294ec4c156eda7ef9a5e5608f5,Plasma clearance after peroral administration at 10 mpk in Rhesus
keyc2d76dbea95bdea2f57cb9d7f17f00ea,The total clearance was determined after intravenous administration in cynomolgus monkeys
key72096c9a24ca6c7de2c284fad468345d,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable
keyc1795168c031cea68d722598ef2515ea,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable
key9c255112f8c3b99e335419fb89e787d4,Tested for Clearance upon iv administration to african green monkey
keyc59a0cc69f84d6104566e802df4d18a8,Clearance in monkey
key7d9cd14f26080c112663915eb3855924,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
key7d9cd14f26080c112663915eb3855924,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
key218fbea25df0510b45102b59b9d6d20c,Half life was evaluated after intravenous administration to dogs
keyc7129c7b7e854d5d051140309fca3bd3,Half life was evaluated in dog
keyc7129c7b7e854d5d051140309fca3bd3,Half life was evaluated in dog
keya288276f77c7de02dd0f00087f85d9c7,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
keyb3ee5bc1948a499eb450a9d54fb5beb8,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo)
key42afaa067664fdb9348b37d2eacecad4,Half life period after intravenous administration in dog
keyec314c6204ee2c91ca3b05914f614b6f,Half life period after oral administration (2.5 mg/kg) in dog was determined
key55183113c2bbfd0508175898300ebbad,Half life period at a dose of 1 uM/kg in dog was determined
keyd7f79a2216592c9138689df5ed76c386,Half life period was determine after peroral administration at 10 mpk in dog
key394db5e64b0cf57d4a504c9d249d131e,Half life period was determine after peroral administration at 5 mpk in dog
key3e0d2c07e16ea42ca2a2bd92e4bb64b1,Half life period was determined
key3e0d2c07e16ea42ca2a2bd92e4bb64b1,Half life period was determined
keyd8128a916a308ea9bbd020980320a8f5,Half life period by iv administration in dog at a dose of 6 mg/kg
key31be830ee7eaf1c37a45797c1bee0d14,Half life period was evaluated in dog
keyf0ad67627b6f009ac96e9a18475de021,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration
keye6e927a1014985d6599903bdc8665713,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg)
key66c3cced422d88110529c35d0e279504,Half life time after intravenous administration (0.5 mg/kg) was determined in dog
keye3be0dda036bb366f424f89001537030,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined
keycc72fbe8591864706a389fecaf8b8669,Half-life after oral dose of compound at 3 mg/kg in dogs
key5b5eb901fd08c3a3b45c4b515635b01f,Half-life of compound in dog following p.o. administration of 0.5 mg/kg
keyee9fc2f308a03f62b9e13ebca714705a,Half-life of compound in dog following p.o. administration of 0.9 mg/kg
keye877cbfbf654d828eca5c2568c4fe365,Half-life of compound in dog following p.o. administration of 0.95 mg/kg
key016c728107a265fed8d106d6eb047a48,Half-life of compound in dog following p.o. administration of 1 mg/kg
key121ee4d897e83d1a1c21e4186b7c02c8,Half-life of compound in plasma of dog was determined
keyea814dda78f3c5e20742b162e550bbb3,Half-life of compound was determined in dogs
key1e1687c2f213444f5cfdb7f005c49bf0,Half-life after administration of 4 mg/Kg oral dose in dog
keye9af1ae65c541df93709722baf17917b,Half-life after intravenous administration of 1 mg/kg/h in dog
key51201fa9c9ae02a384d2ebc435a30c43,Half-life in Dog
key51201fa9c9ae02a384d2ebc435a30c43,Half-life in Dog
key283e8457c3ac2a55027a8493dad05d9c,Half-life in dog
keybaab340bbc46984506d6bce6811935d9,Half-life in dog after oral administration at 1 mg/kg
key47160effc5e513fb66b562854ed07c7a,Half-life in dog after oral administration at 1 mg/kg; nd is not determined
keyfcd9b7962533d573ebf2330cfea114f1,Half-life in dogs
key1cd25c2d42d5312696875a73d587689a,Half-life in dogs; ND indicates not determined
key473ab7e75fd52866fea6d151e74c64d7,Half-life in plasma of dog
key70d5b196f3e1c61c555f594462b6fabb,Half-life in plasma of dog at dose of 3-10 mgkg
keyc3354d48826228bbc369fba1079d0a12,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg
key5de0b0c883e6ad9d2375717799f34666,Half-life was measured in dog after an iv dose of 1 mg/kg
keyef4f6c76616c36a10ea46a1221fde651,Half-life was measured in dogs after an oral dose of 10 uM/kg
key2af307a2e8d51a193c7a89653180b329,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg
key3da1f3a504b90b9f4ed8e17ea4cc90e1,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg
key35842b01de47841a00b5f81fa9fd9ad6,Half-life of the compound after 0.3 mg/kg po administration in dog
key45a69713e60c39c56b1b790ed9eb725a,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined
key42a56ca22bc55efe3f36b9a93de595f3,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined
key138b4c97687f7f707d95d219c0267b61,Half-life period after peroral administration of 0.2 mg/kg in dog was determined
key705be1b2f2e88d70af7092a13d857e94,t1/2 in dog
key39c555abe125fa5b424c2a243b4f4841,Half-life period measured in dogs
key1aa1a7caedf9df39cf6dbe7600aa3ecc,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
key1fd1e613f3b36ced9f48868bdbf33ede,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
key4f38e8abe951e8773e796afce59adb42,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
keye0f7601d1743a3e6bccde02b284e95c7,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma"
keyd88e5fef8ad7229fc3c066f7456c6a9d,In vivo half life period was calculated at 1 mg/kg in dog
keyf918b40c73f44625a8ff824ecb2d44a5,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined
key4a8c2065f67b9865a3945d1018e72cdb,Longer half-life in dog (i.v.) at 0.5 mpk
keye7ef782e187b53b248070db70ce5b798,Oral bioavailability in dog (dose 5 uM/kg)
key29a6e9f732c60dc90d10e02871234f1a,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
key80ad304ed477404127489101b2264dce,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
key1f108276ea319e8784a69a20e414cbdf,Bioavailability in dog (dose 1 mg/kg i.v.)
key1c43428bc8a3fad9f03ff3f9651a66d4,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
keyaa343c5ae1bd59d1a9b8b5cbc73ea89a,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key5a8710dd79bc5461573e2c992fe6b7ed,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
key625a6b7fced1aacce0c416e1f718e508,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
keyb28c58cef4f52f2ddaaa80af01033bf1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
key9e10ffcadd6da568703a10bc6103a116,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
keyeb93118300460db99898d2ba3b92babd,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key15567c53bba99f61a573c1567153a972,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
key7849cfcff8f94191a6b506a17498a0ca,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
keyd9950a8786b41c722771fc81246e38bd,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
key6d96a6222b13ad1934cf40189df7be94,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
key5ef841c7e6a4ce1157aa789234c4efcb,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
key5a52f2aed0eef4d1b35d25c6fbe07995,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
key70336a95c77f81985e6c0fd6c7fb1314,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key9d02a188acfb811e243cb4e5a777a7d8,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
key550e50adf304986120bd854cc4e43d3c,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key1c8754e9fb2288f2b82743082b97dfa8,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
keya71d22bf731e1f49431d9c01c4ec9d63,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
key359bf567be180250b0d9724121f70e3c,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
key3fb26ee29a53b8c3a359d04fec13bf91,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
keyfe05ba2dfeba0790f6c3f1e8d5e0b7f2,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
key816d9e5c09184ef38bfbcd1ac205f23a,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
keycce80286e3f48cfcde8a50eaa09d79f6,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
key9406c0d0da7c80e5dbecae0f1ad43471,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
key8005b09561f3aaae77b1af754be63299,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
keyeab1e24f4649342c4d107fffa5614706,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
key985288c9443e97b767276839c4fb2743,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
keyb435389333b9a4bf677b2fd07124af38,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
keya56973b234639b709269db17c062cd1a,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
keyfa702e50579db363c9f7086523ea73e3,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
keye133e2c4f582f55cd10e3e63306deedf,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
key6d1708067322eb04c778be8bdc204937,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
keyb0585d6e33f9f1b3da02c229b8f51f30,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
keyf4897b67f5f4540969843c00c383e2a9,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
key14134f04d4f9c1bde015f7bf746fbd4d,Oral bioavailability in rat
key0584290fc28f26eca41e6fd3bd3345c7,Tested for the bioavailability in rat
keye9e8389e84decf75c5e04790b66856e5,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.)
key3efbc7a9f0ba45f4881c2ecdfe687267,Bioavailability in rat
key3efbc7a9f0ba45f4881c2ecdfe687267,Bioavailability in rat
keyba757a56328750ac57288903991fb750,Bioavailability in rat (dose 3-10 mg/kg)
key3efbc7a9f0ba45f4881c2ecdfe687267,Bioavailability in rat
key46a1ea03e381d1f1aef15dd18779aa9a,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
key51297861469e86de1debc66251ea94ee,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route
key4d0b7f2befc1b5b21183ed1004c944c2,Half life after oral administration was determined in rats at 6 mg/kg
key55e2df843666c083dbda843a7f29afc5,Half life was determined
key8a2ac0a0f1a0599755ce4b75694984ae,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg
key7e50a7431eafaea94d78ca1197b3a4f3,Plasma half life in rat at oral dose 2.8 mg/mk body weight
key082d0d80378e724bcd211f1b369e4032,Half life in rats
keya8916bb6df298bf1113e181ddbde9715,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration
key572e0c1ead4867f543766900a8ab6e52,Hill coefficient of the compound
key7abbe4d081ea5c586ef2b7f56e86948e,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min
key1272a05ce523a22fffcdbc16160091d6,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min
key1125cfc3a50579d1d0fe185ed40334d3,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min
keyb7ecc657186d1fa5bbb36a833531766a,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min
keyc38f829cc90d2f49665f913c94fb78fb,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min
keya10ed02a26f49ccdc73515b5471d0f58,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min
keye0ed035f32894641b0a8120719cde30c,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min"
key60c447fb2d52dac0798d41b55f4f0c11,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS
key76211022041745d7464ae1b644b1517c,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ
key904fdf7cc820e21dc2d39a35d4517202,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ
keyddf957652d3607e7dd0e1bfb6647c41f,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ
key0e4d673e28c9a47746bad08dde672c9c,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ
keyf9421339adab4779d4376da5946324f8,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ
key605be47d9f43c043d934f5f336fd7506,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ
key1650db172862137dce8f4ef7886380ea,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ
keye0b02884167ca480193bc2a92b6ea58b,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ
keyede3aca8dbfab93aa99e2acc65a6b6e3,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ
keyc9a46cae9cad2c433147b01862515b3f,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ
key5661e1980336afaa18ef0535c80089dc,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr
key4133f23af8649e8e55a0ec4e2f771c66,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig
keya1e41dc1d0bfb75f4bc1a477232dcfbe,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr
key4b6415c1b1d6eef581c33c0867f9eb64,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr
key432101b740090e3442f35906241da006,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig
key76aea011225286824533786cd6fe41d4,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr
keya33c5dc3a97658c3947fa7b621b5d0d4,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr
key2a851367fbbe582a51e46fb870e5d55b,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig
key6c9913c8864abbad218c42521315a90b,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr
key73439ef00fe0d0bdf38dd5d3025e7711,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr
key5bdbf3098adf4eec0a9bf250b6e41dbf,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig
key7a0cd4827060fccb335d00cc040b6852,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr
key98afc8b913f510f3c499ae5efcfda444,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr
key3825e8c35959cbe6de18247d0fe4b2be,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig
key80db72b27ba3bc4706ee22de22a0f9b0,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr
keya37d9a99c8deed1424795694a92911c0,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr
keyfc65e6e244d05b17007f26f97980c399,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig
key35188ed3b1db7832c42eb1f2feae03e4,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr
keyf6df9c8aec71ad13853139650cb32347,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested
keyad76ff170e11fe839ce42f566712ca08,Compound was tested for solubility in water
key6bcc273bd2f9d9f69d6910346d28a6f8,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration)
key0fcdd3783462a8e63b54bd271572cd47,Solubility was determined
key9ddc24404f0faca6228cac85a63bd1a9,solubility in water (ug/mL) at 37 degree C.
key05193a2d18b46e1e65ef3b94b79c39c6,First pass metabolism and metabolic bioavailability using rat hepatic microsomes
key6e48a6efaf170d6117a5e7cf76734908,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay
key082d0d80378e724bcd211f1b369e4032,Half life in rats
keybd15407f711b27eb6dbf5f90aa0febfc,Half life in Dawley rat
key7e5ff1780e997901674538d59274a40a,Half life period after 3 mg/kg iv administration
keya61c869f73aa31c2136286c6a3ada1aa,Half life period after 3 mg/kg iv administration in rat
key9e1fe4b4f5e0df7515e62111f88e3b84,Half life period after 3 mg/kg iv administration in the rat
key5e88a6abc1e846b6888890987a2c5b0c,Half life period in female Sprague-Dawley rats
key7bb1832bcf2f83efe4c8d27b67d1b5c5,Half life period in rat
keya4adeebca50ed5dc187a937833013134,Half-life in rats was determined
key4759aaab39a0371b397d3aae0badf23d,Half-life in rats with metabolic oxidation
keyd57efd80cd29b322928a8965154295ee,Half-life in rats
key6614a460348471fcb7ceb17ebc93958f,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
key586f11ca6d6f22b62eb8c9e4369cc888,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
keyf1afdb81cb435957db14ad92d8486329,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
keyca4c890b390dfa3a903f84a4990c00eb,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
key888adfc7828b28437d0e6c83f5876e73,Biological half-life measured in plasma of rat
keydef19afd3feee4b77c5547bf5a686c2c,Biological half-life measured in plasma of rat; 22-25
key3310b64fc777a647c572b22003ade70c,Biological half-life measured in plasma of rat; 9-16
keye385b7d1a9bcd574ea7df223a5f1ea00,Compound was evaluated for its half life when administered intravenously in rat
keya57bee3fbcb54c448473dd0dcd23ac2f,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h
key112d1e343f455d24d9834bfee18a3f74,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg
key73780b5d699f29be57065a76983c651f,Half life (T1/2) after oral administration in rat
keyae443f2f14e467cff7d979ad675ce0bc,Half life of compound after iv administration of 20 mg/kg dose in rat
key1ab975efd16c05cd31f958d212e8e8c0,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg
key94d2013623b4fce641198bc2e919dc9d,Half life of compound was determined in rat
key98bcfc11a74be0cc7b73695b09fda7e5,Half life of compound was determined in rat blood
keyc2f81200ea3d6e4edbfa9b296ca850ee,Half life at 1 mg/kg was determined in rat
keyf8bafa66243e38fde2d491f8b3ee82f6,Half life at 10 mg/kg was determined in rat
key082d0d80378e724bcd211f1b369e4032,Half life in rats
keybe7a1ff8936150c54553de56e51c8635,Half life in rats in hours
key1cfbd33d08d55b49e8dc246dd3a2fb59,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined
keyad91ebd64887af4df0f9e8553967720a,Half life was calculated at a single intravenous administration of 20 mg/kg in rat
key55e2df843666c083dbda843a7f29afc5,Half life was determined
keyf55bfa7523492bdf70e14d3452b95ba7,Half life after i.v. administration
key92c98ba1713a201b02ad1aecd65f3328,Half life in rat after intravenous administration at a concentration 0.5 mg/kg
keye99c6196bf27dd07dee3d36b0aa4f6be,Half life in rat plasma
key6f973206adf1169686a4031522ca61fd,Half life in rat plasma; Not detected
key082d0d80378e724bcd211f1b369e4032,Half life in rats
keya1b38c5ef9b2a4934867c550c2c3e7b8,Half life period of compound was determined after peroral administration
keyff3ccaecb6ede174fedf7aa787972fac,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration
key7bb1832bcf2f83efe4c8d27b67d1b5c5,Half life period in rat
keyf5b16120b03d96a0a4be26193b5be99e,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration
key5a23969268032d2e0038ccb51b56573d,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration
key7fb0fa56d735213362fcfd2ad875e3cc,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available
keyf14cc33f3a303d8c6f5dfdf1f274a37d,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats
keyd7328f6ae0cca14bf38910366f44de46,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg
key80996738efed5cead2d4df501ab7c362,Half life time in rat the dose of 2 mg/kg
key3274620b99b37dd6b6f4d3ba9c54b114,Half-life 24 hr after 10 mg/kg iv administration in rats
key257e383562618c2d60732f8e8e1cb850,Half-life 24 hr after 2 mg/kg iv administration in rats
key536288be56d7c3f4fdba924eba1833d6,Half-life consistent with the observed metabolic steady state in rats
key57f95a3a3d7b365f2fd1bb840cc0f41e,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined
key29ae6616931a5e55b90da3151b4eb968,Half-life for oxidative metabolic stability was determined using male human
key0db20b421e58b959f4fa6a85bcaef894,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously"
keyfb9321f3ce2a73c766ff114753fdf5de,Half-life in rat plasma
key05b87eb00511bab26cb9ebb77bb4198b,Half-life in rat plasma was determined
keya4adeebca50ed5dc187a937833013134,Half-life in rats was determined
key44fb29e2c1dd35f88429fbdaef88db0f,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog
key76be22c0e17fb35d064087f1f8caaa0e,Area under curve after oral dose of 0.1 mg//kg
key9d17d9c845209b4227f9c0177e09bc31,Area under curve after oral dose of 0.3 mg/kg
key21f0d28fef41fd532d38d2b7fefffac5,Area under curve after oral dose of 1 mg/kg
key156da0671fb01af1d22e91bc86a7311a,Area under curve after oral dose of 10 mg/kg
keyc0e26155f45822069b12347c6a0d7949,Area under curve after oral dose of 23.4 mg/kg
key1192266341fe9526b6adea6c32e6cf18,Area under curve after oral dose of 3 mg/kg
key657aa0d6d614137c17af9960153a82f0,Area under curve after oral dose of 3.87 mg/kg
keybd6a08c70e9dc387d342ded0f6b190d8,Area under curve was determined
keyfd9081d37db067212ed08df0048f1820,Area under curve at a dose of 10 mg/kg
key93daf24e67a75f48b28039921fc918b4,Area under curve was determined; ND=No data
key7da5ad31913d722ecfe6432a61fa33cc,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours
keycc3d5158c4214a50d3121282b6967dcf,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours
key44828a98a1d5718b6e3da473f1cd25c7,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours
key30030fbfdbbe6945d34add84432694e6,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours
key25a6ea5303a4d8676480712b7e68987d,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours
key0da7e1d3e107bff5e3d6258a00840d2f,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated
key4ee731820fff26fe89d1d258b0512f08,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours
key792852d3c2b83b6871daa1d2c905337d,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated
key8bfe562a6c81f1383d005545a4d730a0,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours
key20bde9e1452d3938504f17fb7f0ac00c,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours
key187caffa75ffa5e6cd4a70d767a8ee73,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours
keyb957d5825c6dc9b0909540dbda96ad55,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours
key769fb17acc20cdb01560c2950bda51f9,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours
keyf983afd1b724e03322b5d6e6407b455d,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours
keydb8d698249b24b38fd69e8aa49669911,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours
key1156b8c860472a2da58246f5fe3b575d,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours
keyeae7d611b35c7f298142c631a31e83c4,AUC in mice
key096d19d659737c7cc65bf50f444b22f6,Area under curve was measured from the graph obtained from concentration Vs time
keya2fabf091feb0d6d987559505b926f15,Area under curve value of compound per hour after oral administration
key2a5a6fedb663ad102b58d6e41f67dc6b,Area under curve was determined after oral administration in rats
keyc307b8c9739584169153fe62f10b38dd,Area under curve was determined after oral administration in rats; No data
key376b0b93aceef7d6e478801209347462,Area under curve was determined after oral administration in rats;No data
keyf585942fe7f262772dd9c53d8c1c6ffd,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog
key0923ce400203e2f1ba40db536a1de494,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats
key4b052ad785a999f8229afa6368a64877,Area under curve was determined for the compound after iv dose of 5.06 in rats
keye7c8a2b318661b4edf7acd46d26b3181,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats
keyc4a9aebd65e6a09ada9e3d3d9de65d67,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats
key87d861c2c81c268c27ec6eab8e168f7f,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats
key470b4768e271cab010c0219ab3491b4d,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats
key7380d3ef0e9e30b1aeeeef9bef3c43ca,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats
key51c424fc77514b06e3b5ad6d91fa9500,Area under curve was determined in Dogs after peroral administration
key15e8b0cca4504a186e5c0d7b3e92a802,Area under curve was determined in Rats after peroral administration
key13af833828ffb13bceb6160c177f43f7,Area under curve was determined in carotid blood of rat when administered intradermally
key0025a8d715d7bdeededcac9fc044155f,Area under curve was determined in portal blood of rat when administered intradermally
keye290ba0a28813584b4da29fd20059869,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg
key3af02aa6c763975e8dcd371609288c1f,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg
keyeb936ad5e823c68a1958bf5a33d30b77,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample)
key73d7d1b0f59e64ede7fb5a20270dcf67,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg
keyf54140802506040871a9321fe0cdee2a,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr)
key861cca23e6f97ca0a803e43c67815a3e,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg
key2ad8ab44aa1460235fa8115f7d169af9,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr)
key68c34f9f7ebe8d7f2d4b0f56fe7528de,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration
keya1663ebba7842210469dfc6c754df39f,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ
keya7eab5bffb1917f9bab0d626d2cc7d02,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ
key35d45a83e00de21b3269e1c07e0800a7,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ
key2d7b3ec9b50b73f523eaef495a87aaa3,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ
key97b787a94b520452478e94c193258ed5,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ
key05bb324581bcf1e0f212d6dca93a4074,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ
key36b84c57eaf1227d6ea4a9b1dcbfacd0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ
key745e51bcbb5e34159f717c79cdb1d8ad,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ
key2514139b5037a4975dbb01ca364d1730,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ
key11b1f3ffc9581b2acf03e284d201480c,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ
key66e1f1d914215ef3f0f35601706b2366,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ
key531319dd2b70fd161bdb259531de86ba,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ
keydf5857dcf1546c88db1b4530c6f0fc0e,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ
keyc668f76f45e618d90bf6ad8ab59d06bc,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ
key0d9465d63393251ccdac381039c81452,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ
key7e97b84f0cf148630907cfb8f6d6d259,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ
key73394ca24ca250577b79b603157ccd25,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ
keycf05a8da0db15730d3030305b9c51233,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ
key8d52c81f73eccff52295703adb892466,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ
keyad87b3530b1ed941b7704750e99ab08a,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ
key34a6aa9f16f54eb1292c57458ff4defc,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ
keyd72bcc5aac9e8b2cc41ecc47762389fb,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ
keyd95d89e82e911f852122f8f6fb7197b4,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ
key35f3f51fd7e78a13b66150dd876c70e1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ
key67a97bc18ae19f1f6168eb2bb9d73af8,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ
keyc733c51df6005cd76751a61901f33f89,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ
key929c44032484b8066f1a9d2ef531a8b6,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ
key0b46cc2867e0d0aa1d79b4f072393954,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ
key601e465a12c823d8c0a809555c9eb914,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ
key6ebca654f0e20448d8596060754e4884,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ
keya63782cd74bbc174f72d0d9dc6a5e8f1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg
keya63782cd74bbc174f72d0d9dc6a5e8f1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg
key7e35da042084caff432ae911d2ad3144,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit
keyb3c9584c06499e2e689b973bb6bfc7e9,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg
keyb3c9584c06499e2e689b973bb6bfc7e9,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg
key8ef80d78976c52e0546a980ce7c959eb,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
keya3039c21052138111fe55081f07237a8,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
key4c219c4bccfdaed3535d224c0bf4389f,C24h in rat p.o. at 20 mg/kg concentration
key3a4234fd1ffbe7f305b8b051573eac04,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr
keyc024d1e4c704aa1916d6e63fa501cd49,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig
keyce5d65b6fde5e6114b780abfcf114c7f,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr
keybe30c3d004d0fbef5fd618c5dc9cc7be,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr
keyd9a7229efeda1aecb701a83e826f4a47,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig
key8a1dca3335bec5162317afee33df53c4,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr
key0a60e3003918504ddb0c0f9c73052843,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP
keyea3be480fd0da69304ca25551e54f72d,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP
key9c912ac6505dd6fab783b57dacf45389,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP
key443486d6f7e9adabe977c74ea03f1f1b,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig
key04da95f4e54a7a8af0d225beef92d2ff,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP
key8c58790bad209578843418dc13333d80,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP
keyd99223014e89bde1109be9c116bbad3d,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP
key59a72155932b269055e85c53eff1077f,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP
keydcef5de9c2410ec8dd84e4a68534d957,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP
keyfff115c2ddf0bfd8e92c685417abb211,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min
key1b61d10bdbef58317ff997946f5703d0,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr
key175c8279eefe4a8525a31cfcca3d26c4,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr
key3b55bb0cf41277b1fe74880bcd7c8d3a,Biodistribution in rat blood in the presence of GdDTPA at 15 min
key91987defd6753ea0db9e97b421c3b9a7,Biodistribution in rat blood in the presence of GdDTPA at 1 hr
key2377ec92f9f2f5d06fde5493c64807d7,Biodistribution in rat blood in the presence of GdDTPA at 30 min
keydc04ed9b136eb48710779cf2460283b6,Biodistribution in rat blood in the presence of GdDTPA at 4 hr
keya6740c873661f3fe4e110452f6766dbb,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min
keyf8759b5c2d0d89841d9b96b3fcd5e4e1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min
keyd6747149b2ed819de364bfd762769078,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr
keya7ac22eb68535a172f5eb87c5567227b,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr
keyf16a1329c8a94c122ddf3fb328f600fc,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min
key0cda4570f6f58c8a3f99a1c3f7a1fb15,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min
key151d4bc0befd623709f4d62f35272d6a,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr
key784752b4eb643f4664615893759b3b42,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr
keycde62e7f9f4cd6ce57c8cf48c47f55f1,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP
keyd5bd8420afc5d73804dfa7fcfd395677,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip
key820e0b0c6e675ae4b6e7098b718b8cb9,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig
keya2f4bc400b6eece4c7adb8092b92f587,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP
key94cc18c10b208a085c0e1cb2679ba8aa,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP
key0bb4114eec1a0d60425422f7a6b02b6d,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP
key28303d81328b8d1de79b402af20220a7,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig
key0b057843843acca4035c1f06408e3278,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP
keydece3dad0d17022f581faacd0dbd3757,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP
keye29093e94678075e7c22cf6607ad9931,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP
key6066023f94f7d5dae7cd116ae7912ef2,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP
key0f7ab883678427bfbc33c91c62ec24c5,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP
keybfd789c2e42cb82ee512af2d4019d2ca,Biodistribution in rat bone in the presence of GdDTPA at 15 min
key4f58f7e72a37bfc3170bf1830cd30e7c,Biodistribution in rat bone in the presence of GdDTPA at 1 hr
key3ad8ed5cc9a6f1ef8568cfa4cd161609,Biodistribution in rat bone in the presence of GdDTPA at 30 min
key11f8e68276028215ca342dc70b8f88b4,Biodistribution in rat bone in the presence of GdDTPA at 4 hr
key866b91e0f79c0e0a505e5ff965007d6a,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min
key504f26e3718cc61aa06bc76a38b22087,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr
keye973f3baaee57206aa5bef4bd6b0eeba,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min
key19476272c884fd4f6cd76df3bc506986,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr
keyf8e5c17e12465efbbe6e43b88e42d6c4,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min
key3b0e0c3c2c68ba09770d0c286d3c54da,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr
key8798822accd1ef117249debbbbe5da21,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min
keydf7f2c7e2a2e3ab5a962ec07a31c49e5,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr
key84ade5ef48b33d493b8f92e711a2ad75,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP
keye16336295cd7ab121f61079e42f712c0,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip
keyba56899abb6cd5c61f21dcd04588b01b,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig
keyf366f9d06e0b6b6c485a8d6ff9a0f754,Half-life from rat plasma at a single oral dose of 25 mg/kg
key0b7a9a06512cf606f31055db278511b5,Half-life in male rat
key8b6bb217a222d58498bb6e5cf177c133,Half-life in rat after peroral administration at 10 mg/kg concentration
key8e6e963767ae247d319cb2884428da9b,Half-life in rat after peroral administration at 5 mg/kg concentration
keya371d654f2a8f5a37e07130a56ccb3d8,Half-life in rat at a dose of 3 mg/kg
keyccc43c7846730bc070e20ff64d5edb46,Half-life was evaluated in rats
keyeacf8248d4753f881c86492ca3f0d348,Half-life was measured in rat
key0e6be1e050e9e81014e84ce991836195,Half-life period for the compound was determined in rats at 50 mg/kg dose
keybda356f45864a52f9336df5a252bead0,Half-life period in rats after intravenous administration at 5 mg/kg
key2f8fe950e3a3fcb120d0b2970e2678b8,Half-life period in rat at 10 mg/kg
key93787e976ca8c516ce6d8b8c346b993c,"Half-life period was determined in rats at 10 mg/kg, p.o. dose"
keyecbbff50672fa726b88f366e1e677907,"Half-life period was determined in rats at 20 mg/kg, i.p. dose"
keyb9bf16101db2258e4b98707ea4b82899,"Half-life period was determined in rats at 2 mg/kg, i.v. dose"
key44135cffa717da6343170369bbce0bd7,Half-life time in rat the dose of 2 mg/kg
key3694989e13052ec224d6d40659906a1c,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats
key656255b144fc04de675c54424f2c6ffe,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg
key5ae315c9dc5973122d2e8dc55e0705b8,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)"
keyd61a92dc637e752c2feb018426ed939c,Oral half life was determined
key91975c11a881fe706273ec41827e1d48,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration"
key453e13a4b6a7315a43589dfee9bf6644,Pharmacokinetic property (t1/2) in rat
keya980e0236cb506435dbb381006b6f5cb,Plasma elimination half-life was determined
key5b44613e7b0d18f0e9c44d959da5b137,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).
key00b1103ecab05229e684e4bbd0970b9e,Plasma half life was observed after intravenous administration in rat
key0aa3fb3fab1db8a734fda67464531207,Plasma half-life was determined
key86ede1f9efe18abc9fd91e8df5448413,Plasma half-life following oral administration in Fisher rats
key2ffa748522c641367628e1c7e48daade,Plasma half-life in rat
key6440adb1e05e53de36ff678606395382,Plasmatic Half-life after intravenous administration to rat
key3dd2bf10aba4585e63e9295f184a8291,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat
keyc9b1bbefb05d138e53fed87165feb5ea,Terminal half life after intravenous administration (1 mg/kg) in rat
key74ebe402300fa8c2727edbd704f621a5,Terminal half life in Rat at a oral dose of 5 mg/kg
key3f9f1c000b8f0df4b36ec5321c0356d6,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration
key476b3438897c2307378217a9ffd6ccc5,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat
key56fb7b8637b63ffc992181accc771f30,Tested for half life value after oral administration at dosage of 4 mg/kg in rat
keyd4452930f1f575b5308871cc57698956,plasma half life was observed after intravenous administration in rat
key1ab975efd16c05cd31f958d212e8e8c0,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg
key3817ee6c8011c9711a2e20305483316c,Half life of compound determined in rat
keye485d73117855f66bd555abb3d58822b,Mean residence time determined in rat
keyb7ffd31820aa8d7a8ee489ec46f84f00,Plasma half life determined in rat
key0e6f27f520b404dd7059f55fd76d82f2,Compound was evaluated for Tmax in brain after intravenous administration in male rats
keycf9f3c1edd0d7488b07b1a8efe34c73e,Compound was evaluated for pharmacokinetic parameter maximum time period
key8b5ffe157c1217ed8ea626cc2b08d1fa,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg
keycc64120d643bd395e39955e69067e72b,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
keye28a5367280a47fd419d28421343d52c,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
keye44b48b3bbfb14b81882663f0b888687,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
keyc2b3da32e5e3bbd90b0187f0adb16829,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
key367faec7387b7d6258d9c625c296f5ac,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats
keyb46ec767ec2f55589caf1d43dada430e,Maximum time (Tmax) required to reach Cmax in rats
key2a4a852513065f2ca557c927775666fe,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats
keyd539d7f5513443a82f5f0cad1dcb98ca,Maximum time of clearance of compound in rats after peroral administration
keycfc0fc6abb5742d74e668a77b88ed6be,Maximum time at the dose of 2 mg/kg in rat
keya2760fe38643363799a3470d64cce141,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg
keyb51842bfbaa1486257184c35ccfde8bd,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg
key03439bb3c07403df431001ca043a49f6,Tmax in Guinea pig (PO dose)
key0579a72a402df6f4869793de5db03ebc,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration"
keyb6a311f6778c5fa12f13c847d0b78304,Pharmacokinetic parameter (Tmax) in rat
keyf597fd1ae067dc8590e70218bf4fb4b1,Pharmacokinetic parameter (Tmax) was estimated
key3c2f1a5c6395f9b763f6c8fee1e25c8b,Pharmacokinetic property (Tmax) in rat
key1be100dfdfdc3fded2e9bc2fbafb86ba,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.
key2c25597957c5d0aebddfb7cdf58fdac3,T max in Rat at a oral dose of 5 mg/kg
key0598c1b2d508a24e7d078226374c0b9b,T max was determined at 10 mg/kg po dose in rats
key425d812e8ba9d4f2ed006b4e1d6c4b0f,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr)
key6f4b33f0e1675b344159e1987e5755e3,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs
key0eca6581248d0c882aafcb4f2f46e0aa,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats
keya230ac3591e3c928058be8cbfff0b489,Area under curve was measured after i.v. administration into Beagle dog.
key273fd96970b75d8037dd25d4849a1d84,Area under curve was measured after iv administration into Beagle dog
key98e40e2ced501867a72e65cb5780d825,Area under curve was measured after po administration into Beagle dog
key63dd323d39179e3e8f8e72781b80fc24,Area under curve was measured after po administration into Beagle dog.
keyb74f06b108f408653861cac2910e08ce,Area under curve was measured at peroral dose of 3 mg/kg
key99d4e02529db4c414eb6bb5f1604b9a9,Area under curve was measured by using concentration Vs time
key2f6467e7d44abc10bbb1fb67dbc07b15,Area under curve was measured by using concentration Vs time; not tested
keyeef634074e93d366ad35a38049890aff,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg)
keyb521d2df8e769c978f72d9ce4f0e37ab,Area under curve(AUC) was measured in mice after oral administration.
key8ef05e2d823a5e7c83d9e4a06c9edf7d,Area under curve(AUC) value of the compound
key2fee2b57a28864d4d705348d7aececf9,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration
keyc4b8f3535b7cf041c46bd402acd3e677,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration
key851301b8f48ac8e862e178cfd699564b,Area under curve(carotid artery) was determined by the availability in blood
keyc2852d91ab1d34bdc2f46fb2ebce6681,Area under curve(carotid artery) was determined by the availability in blood; ND means no data
key23ce4321813f9832a2cc267e9434e3a0,Area under curve(carotid artery) was determined by the availability in blood; No data
keyfbaa158c459ba4b98b4ced852ff0b87d,Area under curve(portal vein) was determined by the availability in blood
key0c7e670b7141086dd3e456a5bca104ce,Area under curve(portal vein) was determined by the availability in blood; ND means no data
keyd5e1aff6db6031f8416d6f294a3e04e3,Area under curve(portal vein) was determined by the availability in blood; No data
key27e87dd630d8489286f056629dc1f566,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose"
key27e87dd630d8489286f056629dc1f566,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose"
key44d48d48da6b03fe60c312eff84d1863,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose
key4e61560345cbbb54461699935f7bc1d0,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose"
key58c14ad862ea616ad2e7b219552d2e50,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose"
key0452778a8f4b73a664839c1082ae5cef,Area under plasma concentration vs time curve observed in rats for 0-3 h
key57ded2c9d7cda620c8792b189a347b2e,Area under plasma time curve determined in male rat
keyc26268cdf175b352b5d4e21ba7951d9e,Area under the MAP curve measured over 5 min.
key90a474b059b1bace6059a42c24d72a0f,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice
key16f1c7ffce35db5dda6f3c8f44cd903e,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice
keyfacf752ae2443eeb5064f2032b3d34fe,Area under the concentration vs time curve in dog at 10 mg/kg oral dose
keybf3c819bbfcf67851cc92a7d50c5a2c3,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose
keyd9dd0ebdb6f22a30fd3660ec2137c4ff,Area under the concentration vs time curve in rat at 10 mg/kg oral dose
key99dac0654e24f8d4ef820cd792b083d4,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs
key3bf76c3e4153c2dfbc380d518fc2d245,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs
key947c7e2279d0dcd3ca0f46a0cbedbe2b,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs
key70ff8c79920efdd4870dbd065e2cae2a,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)
key55b4d24ed766ebcddb7efe8af01f2e06,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg)
key63ea4fe63e885fd2204a301c12d39822,Serum AUC in marmosets (IV dose)
key878c59d4ccd2b1419737e284a8e272b9,Area under the curve after intravenous administration at a dose of 10 umol/kg
key86edf0e4d859712101903baeb1a15661,Area under the curve after intravenous administration at a dose of 2 umol/kg
key8e55dde6421299e16144f5229e610dea,Area under the curve after intravenous administration at a dose of 4 umol/kg
key8287bdefdf89870e2f0696708b4ffc30,Area under the curve after intravenous administration at a dose of 40 umol/kg
keyce9819ec3349362517e9ef9ea0a953c8,Area under the curve after intravenous administration at a dose of 5 umol/kg
key4d13dad6a3de83ba84d6aed18eca4c62,Area under the curve for fumarate salt was evaluated in F344 Rats.
key2c1652e06a62136e14afd2a030097631,Area under the curve for the compound was calculated.
key7484094093488500135ce1c863127693,Area under the curve in concentration/ time
key52c770f6730acfa231eb72e3c0e3a958,Area under the curve administered intraintestinal in rats.
key62b939372a7fbde19dcf1d41342b7794,Area under the curve administered intravenously in rats.
key82d06f516fabad911278fde5f2207748,Area under the curve during intravenous administration
keyd4f4f20ad993155cc022245a11887d95,Area under the curve during intravenous administration; Not determined
key13dc5974ec561de0c79a9f8c3b007521,Area under the curve during systemic administration
key5e79741219294746964a4966190d8f6b,Area under the curve during systemic administration; Not determined
key4b133eaa43696626f87b227c8539bba1,Area under the curve was calculated for the compound.
key03a19ace37670da0c2ac5cbe682212b6,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs
keye2d4f1960b5132d9bc2e0c516af45a5d,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs
keyea579776102c24d480fd98183a561e09,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats
keyb1b502c62b1edb82a6854166ab08e371,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats
key64722dbef97406f1e43866cece5b58df,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats
keyaf2ddf7390fbb1d4352c371718577a3b,Clearance of the drug was measured in the plasma of rat; No data
keyd825e8482cb098a64a09b2b05222e92c,The pharmacokinetic parameter plasma clearance in vivo in rats
keyb912f2140e8ff9357fb8ae651aade8be,Plasma clearance at the dose of 2 mg/kg in rat
key3f54949299f67b8546d9ec7a15b446f2,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration
key45503afe98f0367048732e0498f2973e,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration
key8f38a48324033c0148c0aaa6e8ae8336,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
key1d624851664ac0a39697030933841db1,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats
keybf7c8a43cf62da73fdc40d369b9ffb16,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
keyafe77effc9e43e4e0ca971b4766fe68c,Clearance rate in rat
keyafe77effc9e43e4e0ca971b4766fe68c,Clearance rate in rat
key214f2c070b5b5b64a5e7e4be65fe66ab,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat
key33c82c907b72e00a745c851af772e5a4,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat
key9db7277dc660c6c6f4830dc56a3fc8ff,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat
key72dd22244e1b794472ffab338ec910ca,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat
keyec1fb00869ed1ccbf5c44a56fb587094,Clearance of compound after iv administration of 20 mg/kg dose in rat
key64e3611be65b93a2ad12ab66502ea1ea,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats
key658ee4037ac6d540cdce51472838471b,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats
key395a33455bbd9d58d30edd6d73040f03,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
key344470104016cdfdbf7578d3cd8ff82b,Compound was tested for its plasma clearance rate in Sprague Dawley rats
key5984aa25879505a989838e1934110e1d,Mean (%CV) PK parameters for CL(mL/min/kg).
keyce1d77579f5c4098a671c989e8672ccd,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat
key867f9c7c7c5bb51b365a87f7e90e8b04,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered
key78e7c6336aa139357f78e80a852d3dd0,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats
keye63f111ceb5df31df1dc798f0e64f595,Plasma clearance in rat was determined
keyfd292aa660ec6ebe7f50f931ad018602,Plasma clearance in rat after administration of 2 mg/kg iv
keyfd292aa660ec6ebe7f50f931ad018602,Plasma clearance in rat after administration of 2 mg/kg iv
keyab790f636328241402deaf923aa1b628,Plasma clearance was determined
keyb2123b80b8f53c7116f2a2819efe24ac,Plasma clearance in rat
keyf5a883cf95069ab34590c785649f2632,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg
key9cc20f63a4f9a634b1614e17034ee26a,Plasma clearance in rat by iv administration
keyfe47ba6580be71851db96141c69bf36b,Plasma clearance in rat by iv administration at a dose of 3 mg/kg
key74f9f54a44d089bafaf23a013ec0be8a,Plasma clearance in rat p.o.
keye13db2e90d8970645dd9acaed15bcef6,Plasma clearance in rats
keyfb3dfb39d48ca7d87f1d44ac663e6a95,Plasma clearance was determined; ND denotes no data
key9dab20fd5093f83091c3d22827bb4dcf,Plasma clearance was determined; ND denotes not determined
key2f67166b0b8ba7e8b18a94f4b8254a35,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration
key502fcfb7473464d04f5f36778d7b4fe4,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).
keyd51c739d01d221f902f6e982b38a26aa,Plasma administration to rats
keyda282563d9f040fd5bbca080379a536a,Plasma clearance of the compound in female Sprague-Dawley rats
key928fe8a600613e939172eb5b4a4837fa,Plasma clearance was observed after intravenous administration in rat
key3ce1c0b5152fb365a51b9fd77483cfb6,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat
key2e12c9cfcfff7f3309a2677c0860647b,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat
keya3f9447ecbd1525d86dc26064b69b15c,plasma clearance was observed after intravenous administration in rat
key4d9069b5b83d07e20bb920f35c9220ae,In vivo CL/F determined
keya0a46abe0f6aba31539082eeb079b6b8,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats
key77123e529438b7d55fa7fa558c3b8d80,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats
key54fd415be368fde9fd0d3da377a1a9fe,Compound was tested for the lower blood clearance in rat
key16c1c672573920db905c5367c9ad5017,Evaluated for the low clearance in rat (in vivo)
key953d1951cbb6b9d0d3267d314b45c126,Pharmacokinetic property (CLb)of the compound was determined in rat
key203f685b759ae570db9ea02f82da3415,Rapid clearance after intravenous administration in rat was determined
keybcf62593cca4982a73d625ae1e48083c,Clearance measured in rat
key53e46beeeefac51d6072b0a480eb8bfc,Compound was evaluated for plasma clearance in rat
key30edd11b4a0f90feb5bd039818aff76b,Low plasma clearance was calculated in rat
keya6baccef29815c1e31b55e36e6ccdb1d,Pharmacokinetic property (Clp) in rat
key233deeaa8113ae700178cbedb5ea90bb,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined
key9757f916518b3b93bd3fc324352918fc,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined
key81409092d6fa16c8add1d25711687da8,Plasma clearance after IV dosing at 0.5 mg/kg in rat
key2993ec5555558394cfde742bdb44806c,Plasma clearance after IV dosing at 1 mg/kg in rat
keyc525c8c37ab9a82053c59c5b62821df5,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP
keye7541851be1ecde729eca1cbcd31e161,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP
keyd8549cdcbd082ec845465377e71ca993,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP
key24c06724708c5a4a95e93a84078f412f,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP
key0055c3b5a589c5c8f4f901180b2b8d98,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig
key8aac0808d1e317886ae54d88a5b491be,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP
key876a1a2f0aa40435734b6b58546df305,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP
key15e74ed77bb8866232f903286c5304c5,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP
key67707732dc3862d592246f7308aff53e,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP
keydb3a8151ece1a8ab158107ef86634bee,Biodistribution in rat heart in the presence of GdDTPA at 15 min
key3a10715290bcbd6404b0facdd6ebed5b,Biodistribution in rat heart in the presence of GdDTPA at 1 hr
keyf9c21b55b0980624aad38860375ce2c2,Biodistribution in rat heart in the presence of GdDTPA at 30 min
key76a84a390a0921b393937d3074996baf,Biodistribution in rat heart in the presence of GdDTPA at 4 hr
keyd83f2262455609774224aeb438ad13f1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr
keycf2d9ddbe3c6ea32ed94bf3e022e8b82,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min
key38b1381687dcbb3ca2741389e08ba9d1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr
keyc0666172248b281e5996b6336f32dd37,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min
keyb5cd7d05767213dc674a1139518d5ba0,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr
key8a92cc095c60cc5f5396c0b63edb3611,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min
key95ec02b000280c0c3ff54e116d1ac152,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr
key459cfc28d482f274ef3c18a88488b860,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min
key3bfb7c84844094aed07350dc3b7d579a,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP
keyddac54426036dae0572b999cf2238648,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip
key21949208960c20fe6c055f288ad52dfa,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig
key979c2b0c05dac8e5e2d3fcf412a3c19c,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP
key37e57b29c73d097a1d925d3cc7244641,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP
key7e7d797934848542717d9d8f24371070,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP
key323afc9e13c09df8e37815c2af68a542,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig
key95f35722910f2a623a4b4a2ddbc93463,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data
key70bfdb2c8a71ab24a94c9078699e18d6,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP
keyb94fcedb708da17ddb46903363774ad4,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP
key723c4addac3d3d0ab55def17197ac75b,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP
key47ddcb1365ae767b69cd1c8c37c6848d,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data
key2ea810217a6bf93e160d95227ff50206,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP
key65aba92496c8a9dc5fda616089f46d89,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip
key751713fe18be8209e7ed44ef7e5d159c,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig
key2b37fd39d4779d596b524cda02792d3d,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr
key74f5b0dbca4db9171132f993bdd25208,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr
keye5ae9e5f534235fe8eb86f5678e17325,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr
key5afe6925374c0303986dd6c0bcaa6841,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min
key9e2d3c4cd19962673a0533bd5b8ded64,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig
keyc8cbd0a7509d483f39f4d0c175c4b613,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig
keyb754f56c151e857733861b1363e5c003,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP
key2e9cf976a1395f5983dad272f30a11a3,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP
keyd1c90f2e0a8274cf8495e7343b4fa8fc,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP
key059490e3eeadc30bd2e07fd142866531,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP
key8e477e2143fdd385c70a5d03a047ef0b,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP
key089f53bd857543e9e3671bd7ac1c2734,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP
key28909ed2f8f61e7d7dc75c4465988c8c,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP
key0855562662c3043958e327cdbb75f9e3,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data
key1c6848cac01a7756276f9204894f613b,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr
keyf29dc58183bf23720f4793ef336d8d2a,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr
key6bc77f1efcb63d166b99e81002beb20d,Biodistribution in rat liver in the presence of GdDTPA at 15 min
key4e6c48a9d7de9273c85d26243f19a2da,Biodistribution in rat liver in the presence of GdDTPA at 1 hr
key0c9d48f53cfc5415133c79685823da1b,Biodistribution in rat liver in the presence of GdDTPA at 30 min
keyafb7cf3049af11aeb20973e3990d6720,Biodistribution in rat liver in the presence of GdDTPA at 4 hr
key3bab0850c6cc4bbd86694f0a7dc251d6,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min
key567b2ac34550c2064406296b9ad9ee95,T max was determined at 3 mg/kg po dose in rats
keye15545b6fde86e41857915e3b8377fde,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose"
key0100848838380d6960c106e14efdad16,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose"
keyadf0d26f2fb6534e11ee8ee43836b976,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg
key9d64afa32488b86bc1eee6d1933d724d,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg
key2ba951d4c687476c04d27eeabc8f16a8,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg
key6d6a314bfa5ed505712e0b2c7b5da331,Time for maximum plasma concentration determined in rat
key5006cf077be75a5c36ac93520cc4aa8c,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose
keycc9cd66e1b87ed9f573c490b7dd24471,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat
key7cd72560f8ae5209fa144d601f7b1630,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat
keyc9165d927521a3c4da85c534121b8709,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg
key2812638850cb2f2462139915e6331d07,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat
key3fe1af2e6f8634536d2ce13b59687e92,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg
key6d6a94ff114d8bc20b34292ced1b0ab6,Time of maximum plasma concentration in rat
key7be421cf2558123d3dfd671934aaf374,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose"
key40772b25aa94e5f0bd24cedfc5895ff0,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose"
keybf78762754acd5e39b6e417a52665383,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable"
key69cbba74ba3364043a2e2df14b6a676f,Time required to reach maximum concentration (Cmax) after oral administration in rat
key9e7852f00ff6f6bb9097c87589685e4f,Time required to reach maximum concentration in rat plasma
key992b6fca5512d049b83ca259d28cbaec,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.
key43ea909160964cb3a3bc645749bf2fec,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats
key0a20e144e9cc70fe395249b28c0b047b,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg
key705222382adcfc27616b1636c1fff7c4,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg
key8a2187728c171843abc6ab5fad234678,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration
key8fd9c9fcf75a8d4fe3e53fc117cbe93f,Time to reach Cmax after oral administration to rats
key074f7a71598e148504bd6aa5fe184f56,Time to reach Cmax when a dose of 1 mg/kg is administered orally
key3ada568bf28a0bd24e38736893ec078a,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4
key4500806cfafeaccf1fae15117c1e8e2a,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable
keyb4f5223e6b2936fcfd05c9e751a9cd84,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg
keyd34fccb0e021347cc3789d8c01f1d989,Tmax after peroral administration (10 mg/kg) was determined in rat
key0b944045200d262ef71a3eec5833f9f4,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg
keya48dc08f54d74b6afe209489d854fe23,Tmax by oral administration at a dose of 100 uM/kg in rat was determined
key7d04e7ea00539127df08f40c0f1c8e60,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously"
key09affa57ca61a95ee58f63ee28bdab17,Tmax was determined
key09affa57ca61a95ee58f63ee28bdab17,Tmax was determined
key64672d20a450b7848a3830547bf5e3ce,Tmax after oral administration in rat
key3e41f39cd5c1a718678da89694202eb1,Tmax after peroral administration in rats at 2.4 uM/kg
key1d5511e682c799162661ffd8a686a0a7,Tmax in male rat
key9c950db003ae78ce73d437799b1a5724,Tmax in rat at 10 mg/kg
key614e709f0bce8c40e14e25538d038d60,Tmax in rat by po administration at a dose of 40 mg/kg
keydc2906573b52309e643d32700654abf7,Tmax in rats
keyd6a7e8a5223396a00f6bfb0b3b6620da,Tmax was measured in rats after peroral administration at 5 mg/kg
key4a51f8c76931825f8910eb9741108175,Tmax value after oral dose at a dose of 10 mg/kg in rats.
key6c6ef99b79da2b048fe26fb90d77530d,Tmax value after administration of 20 mg/Kg oral dose in rat
keye87933333d23221b514b348a6f5f8a86,Tmax value at a dose of 10 mg/kg in male SD rats
key6f78d690c6d8869da37c124d18fb6d28,Tmax value at a dose of 100 mg/kg in male SD rats
key8aeb51e83a8c772cd02c29f1d6190558,Tmax value at a dose of 50 mg/kg in male SD rats
key5e04dba2f00398923099b57adabc0b8b,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
key41aa395b1460f29ecb4231843181aeec,time required to reach maximum concentration (Cmax) after oral administration in rat
key6ad97be496427b53eb8243262423ec6b,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr )
key2550a7271b3e3206198c831335d2af40,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr)
keye8cf1cc12b6a6935380de13aa79addda,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration
keye7c1641d9f88ce2fdd2f41c692fb6e06,Amount of urine output was measured in rat at a dose of 1 mg/kg/po
key2c195e6718ca1458b4fd7c9024762aa0,Amount of urine output was measured in rat at a dose of 10 mg/kg/po
keyb06e3917d87864a9a3610bde7ee901ae,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested
key6a54709b1a17e93a8d4df9fa97d8b1a4,Volume of distribution was determined in rat after a 3 mg/kg of iv dose
keyc55a2ac17fc51b80fc403185455e5c8d,Compound distribution in rat tissues was determined
keya92f6bac254bff22cdd97a96084ad993,Volume of distribution was evaluated in rat
key26dd667447041df3034fb545a769fe01,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats
key334a02b11f4e42d16e07d4e344e600ed,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats
key1c593393e3ccff85879489bc00f55dd0,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs
key37e8e4516b85e69c857c73818bfb27dd,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats
key0b85f06b3e7365cf5f5edd73d9d87fdc,Area under the curve was determined after oral administration (300 uM/Kg)
key60d1f2a5ee758d958da971dff059ff00,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats
keyd43bec36e813928ea256b68f747435e3,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats
key582c2b366a42ab32a2cdeb4f0fbf8d12,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats
key31c050631fc2c1b711d8f789a7dd70f6,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats
key34f840024f383ae5e067e9018e4ac406,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats
keye2070e585d33ce2bc9f5e73606498ffd,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats
keyc751ccfd4ad8a2f54265a4d66c458380,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg
key13225f4e6cc46ee8d88899e85faad2e0,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg
key60fd1544b46601b288a69a84f8d4d39d,Plasma drug AUC in rat (PO dose)
key1602ee3c69e062bedbda592c465deea0,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.
keyb10eebf800adfacf4437d389616833af,Area under was determined at a dose of 30 mg/kg
key613159c2d6ef00d84d4d4f31225888c0,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret
key34a41fd93641325275011b62f69ba0b5,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat
key0914732201cbad5eb4f3428fe580ca09,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat
keyd4013f38ca7604e6c9e5bfb4a71c6823,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret
key733bfd098d1cc6973d308ef7c2305756,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog
key81233cd78a2e87a5a9dd6097fce7f935,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog
keye395ebf8515b2a7ab3941508395ffa2b,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)"
key1e555578235f182cb6732af24f14ac44,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)"
key8dd055db66c3cb769e744e960b8bcc29,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)"
key694ed665b06de7ffe9e86db3b0d5e0d4,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)"
keyae811f1114480bd4b98b6fea1f06d277,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)"
keyf777ce00cc1c9c520137f48df171aa9b,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)"
keye47f6d847becd39c883dbdf8d0632ac4,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)"
keyc75773f1e1a563549cfaddd5b99815aa,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)"
keyc26f896594a660a8cd52ef5c3cd0235e,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose
keyc960e24caa833dad60779978c158d91d,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP)
key91d06bc67e7af030206a4ba681bb287c,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose
key1adcc271b846995e4112fd8fcbff1571,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP)
key4264e6570fb46cec66584bc8a9491e54,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose
key9d8dfbd90c81cfda52699fe8a2f8afdf,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP)
key31ce4973de8c0465b2f27b150a3f68ff,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose
key8e8b8519cbcb18b43132eea8b5827968,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP)
key7028b6a123badabd6c0a4653f42f51d0,AUC in mice after oral dose (50 mg/kg)
key66e518d11cd6fb905b00f33bd0257a91,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum
key18d3eae3327675ea160a171b3d4ac92a,AUC (0-4 hr) ug/ml/h
key15369b435e99995b00e129a7848423f9,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported
key65de5c8cffd3c49871e569dab5a7c21e,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration
keya19c31dbdc96ddc78e359aa9f93b9a7e,Compound was evaluated for Area under curve in mice
key8f06bb1e89ade60a38ec152f25483c57,Compound was evaluated for area under curve doses in rat at 100 mg/kg po
key8f06bb1e89ade60a38ec152f25483c57,Compound was evaluated for area under curve doses in rat at 100 mg/kg po
key03570ad87e829d4105b52d08a00094f1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po
key350b85b2c5c4b7e81c7eed6765cc2522,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1
keyebbc721d513e00031ee47afdf8f4cf2b,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4
key52ecde48d5dfb0c931d700db63a22509,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1
keyb9563bf28ff8e4fb25b1350e37d412ab,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4
key97be239cc3599fd52e142fda8f5819ec,Compound was evaluated for area under curve when administered through oral route in mouse
keya55077919e8d5766efc96c736dfb4e4e,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data
keyfba315e38f113d61252210f8383e6ac3,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data
keyb2123b80b8f53c7116f2a2819efe24ac,Plasma clearance in rat
key64731cc0c61cf675f7da81f9f3ae0d5d,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration
keyb5dfd3cb0ff981c1b99e370cc49a4043,Plasma clearance rate in Sprague-Dawley rats
key8ac895312e9329d5d4a2d30693d3309a,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration
key5d7bf4ee8115dbe52576d7ee3cec291b,Pharmacokinetic property (total body clearance) in rat
key6aba12b18ccf26c5298aadff8aa9c0bd,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.
keyb9370938499475db50b99532453cdf34,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg
keyb9370938499475db50b99532453cdf34,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg
key8242feee9601885772841e2cface6465,Cl in rat i.v. at 2 mg/kg concentration
key58bf27e33f79a9fee6679909ece0bb4e,Clearance of compound after intravenous administration in rats at 24 uM/kg
key09ac68c8ed6d199fe98e73639a3e8993,Clearance was determined
key647e84109d5c86c0e2e142ff093b4dcf,Clearance by intravenous administration of 3.4 mg/kg in rat
key9fc7bda287722f5e85c7d68ea16a9fd6,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg
key367c6ebecdaa5edc6f8ac747abf83803,Clearance rate after i.v. administration in rats
keybb8e851326559edb29c1790b806ca2ad,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats
key40a1c52fa3d80d8f77d3fa2bbb6577e8,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat
keya79a352d756ae13f95b282957a3390eb,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat
key2db69d9eefba3273619e24237b7aa0af,Clearance (Cl) after oral administration in rat
key45d49e9e3673c5dec62ba6fbb0cc4a7b,Compound clearance in rats was measured after intravenous administration at 3 mg/kg
keyc4d17e70a25bcf1b8221aa9c0f460161,Compound was tested for plasma clearance in rat
key5a53a011bb0ff46cf6b9a55d7536fae7,In vitro microsome metabolism clearance in rat was determined
keyd469a05bd083d1a987cc1ff0aa54ffa5,In vitro microsome metabolism clearance in rat was determined; ND denotes no data
key4679e4d7749047fa8cd0575f53fc9933,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
key58aabc7c16b5b937a3fbc1ff805b90cc,In vivo plasma clearance was determined
key6ebe5acca4eaf4d88f5d4a9d757f87f0,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats
keyb59debab1cfc0cf71b51c59d5c118cbd,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.
keyca052a287c1ce74e05ba616881fa3948,Pharmacokinetic property (Plasma clearance) was measured in rat
key61c24075e54029fbea3e46240b286312,Pharmacokinetic property (clearance) in rat i.v.
key44780805ea5a1a6949297078e9b9964f,"Plasma Clearance was evaluated in rats, iv"
keya34a90e44d5cacb1da8088b3a1ce049a,Plasma clearance (in vivo) in rats was determined
key0b5e6cf7a4610bb34506895a5c732b9c,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat
keyab790f636328241402deaf923aa1b628,Plasma clearance was determined
keya8f3d9d61f4ccf534772a22747340c03,Plasma clearance in rat after peroral administration at 10 mg/kg concentration
key52f98aac22dbd5df6fcadcb97b0a7e30,Plasma clearance in rat after peroral administration at 5 mg/kg concentration
keye13db2e90d8970645dd9acaed15bcef6,Plasma clearance in rats
key6e63df6dfc82887ba6298259c1ee5893,Plasma clearance rate determined in rat
keyccdfb286956e2a3d77db65ecdd65c9b9,Plasma clearance was determined in rat
keyab790f636328241402deaf923aa1b628,Plasma clearance was determined
key0443bb14bf8d2ea7e9f85dfd3f9021f2,Plasma clearance value in rat
key29b390cd16f512d52f89202ce5519e09,Clearance rate constant using isolated perfused rat liver (IPRL) assay
key18bdced87b8c98f7b493c61c8b04457c,Clearance in rat
keyd89fb0b0355246e0ed5271927195a410,Total body clearance in rat i.v. at 2 mg/kg concentration
key83feff95e6ba3ae662b3dac35b1404f6,Clearance of compound in rats after intravenous administration
keya39c91b34a61c86e6d6c6ed6ccc5e08f,Clearance after iv administration to rats
keye6b79c8080e1fcc23c817733be0e1293,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg
keye392cd0098bca79b4d24a616e7aba3ca,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg
keya878430948a09a38a3abb20c70f4ca35,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg
key65af835c4e73938a9fa6d70738853641,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg
key9e612de282e07f448d6b7aa7b02288db,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg
key66f69311ecee3fa892809ae8abdb0c79,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg
keyb4e5d00c553410da1a615e7e7f49694f,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg
keyad807d0c07419605fd8e0c211fe306db,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously"
key18bdced87b8c98f7b493c61c8b04457c,Clearance in rat
key97a7484c8c3f4ed5c9348211bed43426,Clearance in rat after oral administration at 10 mg/kg
key04c8935b970ce3c4863f10c95182e1b7,Clearance in rat.
key6c1b4efe63f77854755ec3785d55eb4e,Clearance rate following an oral dose of 20 mg/kg in rats
keye1514eb0ffcb6d82130696e8b14e636f,Compound was evaluated for the rate of clearance in rat upon intravenous administration.
keya16b121748e4cbe485a63358c34dedf2,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing
key9d176d96460b9a73d91d5eb081b33c39,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr
key53a140b6c67b8fc730d6c2fcbf8a192c,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min
key5e997e4814db059f33b1a6e17a64986e,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr
keyebb3ce76912f4c2b133bfc1fb0a12032,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min
key5b8c75af8fe58c1f6f5a5208262f217b,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr
key00d9ae2eb0bb5e8fe8d3b43cba5330da,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min
key4650fab3ed6c02e81823d0b2ccaf5de1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr
key5a8f1299dbea800ed8b0f753eb0e1697,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP
key576957a15dc940020d3508ebfebb5506,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip
keya61eebc5633250e554c6f3ff6e88fc41,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP
key36debb972cbcf6826b3119526700444b,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig
key3bf80383f76bdec7a9e4461cf3a706d5,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP
key4408d6604030733d48b2b30cfc092430,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP
keyc1736e76cc0568763142284b95987583,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr
key71a4fe16d7287ebd1a3e3f620c3b0db9,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr
keyf88939fe4d8d9a21e226207c367f1d9e,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min
keyb3a67088f63bc1592492ae28c302421f,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min
key818b635b130ad67c97e07cc59b78652f,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr
key171da17e7bea008054c71a0250a3c620,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr
key9df3dd797e51a719aa1f438a6edee2a6,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min
key1f94955a2ca10677a909ad71f5aadb8f,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min
keyce299cbd4228817a42332ab660f27c3b,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip
key6941df5065c4740daf20de88b69e3952,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig
key7505648f1bfc8e5424c90537e8bdcfd9,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr
key24beb930f357590a38844b991ddf8fbc,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr
key4b2edca0f934302c28d0b02b600b0749,Biodistribution in rat s. intestine in the presence of NCA (No carrier added)
key6ba2ccd5655c262744cdd0e2ebf35d7a,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP
key5ad1e6c72db451db95589c7fc0a56f5b,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data
key5b6e36b23cac3a29b4475d3071cd8f1b,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data
key67ff80d45ba2490aa1ca5821a1c20a7f,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP
key231b7e081f07b7bf51c5f6669107a6f1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min
keyede64b8961d65e667fe4df9842e5c305,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr
keye38e4f02d5a9538b512a76fcd984e635,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr
key48cbefc66a6f50cab8763c9366af97fc,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip
keyafecb382aa0cbd8877751aa49ef589eb,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig
key5ee92e60af44ef0b31565bbba80ca5bf,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min
keyaa68de18778013f94c794fc02c69c790,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr
key57ea1f4148f411bfabaefd6530e6d837,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data
key397f15fc2c8af70818b9199e7abc372f,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
key56fd0cc1d841e74c1471ad48ecde96e3,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue
keye66fbfe489b4e2bae38a6dae15c6c20f,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue
key0a1498ef591fd8be96e6812c13e09556,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue
keya7c07fe7273c4b841034186741606e85,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue
key3db48c2f8adb3acc3f490b1a587ef4c3,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
keya24dbcefe60ff4a427d14b589c61abd8,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue
key72d4ed418d1c0212066b8320b4b4e45b,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue
keyc496a1157d4a16488dfdd8eb8db72829,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue
keyb0f4a79c9a6942bbdaf83ac836c2f0f8,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue
key9ea39ac51f2dd867706ae6f63c98207d,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
key3c7c9fed6726ffc367c322072d085f46,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue
key6331bf3b93bc978c5a0ad33879f61d30,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue
keye033f27e9ea2b199e5099a12d94f19f4,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg
keyef1b310b9576dd0c1d5c013e1b39384a,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg
key5e8aa8daa8b7a48ab54f4520b66505ac,Vc value after IV dose at a dose of 5 mg/kg in rats.
keya38c0bd1d3ab18577c69813469f23a6a,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration
key70c292eaabb3b4ee7b1bccda93348322,Compound was evaluated for pharmacokinetic parameter volume of distribution
keydd8caf25555a92f54674e1f0fcde4911,Compound was evaluated for volume of distribution in rat
key5f7c64981d6675971f15a6f14fd97277,Steady state volume distribution was determined; steady state(ss)
key7616b83d46adf101565dba0db9c9f4a8,Steady state volume of distribution after iv administration to rats
key65228c9a486260d5fc6297256fde7ad6,Steady state volume of distribution dosing at 3 mg/kg iv
key39a9a07a38b83566f37663b4409a63a9,The compound was evaluated for volume of distribution in rat
keyc1a0a277095b4ffb0f659781eb020a98,The compound was tested for volume of distribution in rat
keyac8328dc1d415ba837875865d2c95a3c,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg
key1691d7c81fc38fbada3d0f22d7ae787b,Volume distribution (VD) after oral administration in rat
key5dca0b17eb9cd474dda8199468b57049,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
keyf36904a6dfbc8287694720832ca1cf41,Volume distribution in rat
keyf36904a6dfbc8287694720832ca1cf41,Volume distribution in rat
keya0dc979a25420bed2cd27cdf6d866528,Volume distribution in rat after peroral administration at 10 mg/kg
key46ec5caefa3039381d0c934062995e8f,Volume distribution in rat after peroral administration at 5 mg/kg
key8a16996fe9836d796af45fdf37c01312,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg
key2dfb861eb918d6e5d3fec80fc8dbfb68,Volume of distribution in rat.
key76fb69b8621ad1c81bee5c5fde47b808,Volume of distribution in rat
key76fb69b8621ad1c81bee5c5fde47b808,Volume of distribution in rat
keyd9d3430304dfa2285f985c9abe41651c,Volume of distribution in rat by iv administration
key18c8777efdcf30edad87896e76f45f49,Volume of distribution in rats
keyfa567ed4fb9c70be7c635745fb9a7324,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).
key832c99622c1695c5a49cbdd77a1cd894,Volume distribution at the dose of 2 mg/kg in rat
key9546dee2e91efb3dbc0693063528e157,Steady state volume of distribution was determined
key8a2ef0ae14fec5c8e40024bd466c35cc,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
key5477d4821cbd88ef6924b0cc5fffc07c,Compound was tested for its plasma volume distribution in Sprague Dawley rats
keyf6ba08ee4b43e42bce5c7e29be8b06b0,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined
key1cfa4234b29d22c602f3fe74662006a5,Mean (%CV) PK parameters for Vdss(mL/kg).
keyddb442b83bbedb1e78ba3dd4d7853b89,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats
keye488a7d9dd2214bb487b661f5016ca4d,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats
key13565b50a90bfba6350b08c5177c06e6,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat
keyde672b5c58e95f6af4c30fad482852bc,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined
key29b39922ecc110aa4937af06eaa5fa13,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats
key0b8c773139baeb705eff1a8ca1e0c987,Pharmacokinetic property (Vdss) in rat
key29b0f19d189bce6b247d1900c8488d96,Pharmacokinetic property (vdss) was measured in rat
key0fc713222c7a98f4a937822cc07dc2d6,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat
key76fb69b8621ad1c81bee5c5fde47b808,Volume of distribution in rat
key0c5164ad143ac265dd039e670109ec61,The pharmacokinetic parameter volume of distribution in vivo in rats
keyf1b02dce5190f2cf34005d51b7531adb,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration
key7304353ec0429cdc1dcb1789b462ad59,Vdss in rat i.v. at 2 mg/kg concentration
key7e1c3edac28213be8dd87878acbfe56a,Volume distribution after intravenous administration (1 mg/kg) in rat
key653719ff1654e2031097048934f67ba7,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration
key3d8f8af4092b126ac35e0e3ff3e507a0,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration
keyfb602501f11b23ecf8865e809e125903,Volume distribution at a dose of 10 uM/kg in rat was determined
key40a957d1b3725c7c731ef85331acf2d8,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration
key5195c5e1fd41dbcbcdaef663ec4c3545,Volume distribution was calculated in rat
keyb0db6293786725a399caf9ef4807f312,Volume distribution was determined
keyd668f334d28fded75b0d502e36ee3a43,Volume of distribution after intravenous administration was evaluated in rat
key9a803da8f1f16a65057db01764f788aa,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
key1a24102080ffe414df3e2f7deabe6cf8,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable"
key1195836a0ba37ca949a4c1ad2652e1cd,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable"
keye870665d7ef09e70510c6cea02a9d1c0,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose"
key55b97c2b02ddc8440d062a880406c4fc,Volume of distribution in steady state was determined in rat
keyaf43a43775a50ce5777ce4f501b77863,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration
key6e5d43d1a18c477975c197f6145c626c,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined
keyc744cc0bf63b8e7233e5dad341d1814f,Compound was evaluated for area under curve when administered through oral route to mouse
key8f06bb1e89ade60a38ec152f25483c57,Compound was evaluated for area under curve doses in rat at 100 mg/kg po
key03570ad87e829d4105b52d08a00094f1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po
key939a27d48c84f03cb52b5064eb99da20,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs
key2ac150136300daf07f5bf705235696f3,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs
key7fe107b31a2c21718e8aa4f7805cb385,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice
keydaa0c44469a039c0ea149c18b7bd0171,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice
keye0479aadb760423e801aaef42e9aa294,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice
keya98890a1a48e32a9231958eb186a7a6e,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice
key2e69f28a636c88301e05b93839086339,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.
key2ac42290ec66a6df44597a8689e86eca,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose
keydc6fba354992cc05ac04271b0c32ec34,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. 
keyb68036f6fb770cd0c7e9a8a6bcbc8318,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose
keyfb0fef5cec62902821be305dc85bfeaf,Concentration of compound in Central nervous system
key122cbc48ac562a75f6611e53a9257f54,Concentration of compound in Central nervous system; Not detectable
keyd039d247178642c352faa1c03416125d,"Concentration of diester in the blood, following oral administration in mice"
key5967f20e97107c4572082a6f10a50c95,"Concentration of monoester in the blood, following oral administration in mice"
keyccd7d3f39e4a7658510e87ad1a5caf29,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice
key307074b0a247dacde4dd82e03dcb8ca0,Evaluated for Pharmacokinetic property: Area under the curve
keyf7b33fd13403d9221441c83144b84028,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice
key08b59f517e377b74cca11e641d504ab8,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice
key89e0686dfd9fa753c24f287fa69f66ec,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve
key9433eb58327a8c5c0e7ff475dfc5269d,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve
keyac2c30f7e2130231ecdf41529665256b,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve
keyb642887d84fd6a325f2413d34d163bef,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve
key93974db8e5f9583dd0340185c56dbb54,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)"
key04e4dfe5032f3414d72a1cd7dca534a1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)"
keyd4ab5975a69c5249e0a416e88fdfe755,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)"
keyac4d848d9dc204d10201dea545c774cf,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)"
key0bc4d087a7eb69c2fb6189681c4a312c,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)"
key3ca7ed6f3214e69e42dcf78eb1906095,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)"
key3592ca150f77c5d394cf0a3b845cd457,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)"
keyecd0640cada174289910a7bd564a5b82,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve
key9e41b408387485cb7c5b8bdf0000cea3,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve
key232f6c48453e32ad57f428e7820d2f24,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve
key65ff549a4a953b243abc4d25e9b72a86,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve
key7d314e6ef373b6b221a9a566056deb06,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve
keydb39ceecfaa652e3744a4e91601938ff,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve
keye960cd75e5d626f81dfadafc83c16c08,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined."
keyedaf9e4d3cc72c564e9a1b673cc54cd3,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)"
key5705f400c370b0249f1a4b49380052d3,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)"
key8a891a99160f090fc49bd691e683a17a,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined"
key944f0e67176c8b8a5e70828d7d6a4d7b,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)"
key7204643bc7310c76bd6ec63ef082ed74,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)"
key3081e8e26ead18e3549031ea05aa798f,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats
keybbaf1dd98e9ec51b30f2f6c7da850ea1,High i.v. clearance in Dawley rats
key9039544c629e98293f878e93efd2d173,In vitro clearance in rat liver microsomes
keyefd2bbc8d5972bb30aba6664e6ec6ce6,Intrinsic clearance in rat liver microsomes was determined
key478cd3e6f3feba38683b4708c9bb69fe,Intrinsic clearance in rat hepatocytes was determined
key16cb15a8019d9e547ad669fb24063387,Plasma Clearance was determined
keyf45e60c54e6fc5eee10cb29ed0267d81,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined
key23b41cc35c38e86d17a43e4f6aeb5c44,Plasma clearance in rat.
keye13db2e90d8970645dd9acaed15bcef6,Plasma clearance in rats
keybf1390acaf92eb3ef948b521f64d9e04,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats
keyce192d541b01880bdb9404a067882f21,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration
key3ee172c2948283765faa4a75f78284e1,Plasma clearance was measured in rat
keye200fa416085c11f0ae66a27509bc37d,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg
keyba78427b098f3acc9293f62da8ac4a20,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally"
key5a9726a32467c3a2fec326dd2b062cf1,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg
key7087e88c12e84fba02e63a39c253bff3,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats
key9388014de708982edf1bcfd650682265,Total clearance at 1 mg/kg was determined in rat
key5a42712131e5c140308e66e7af6c57fe,Total clearance at 10 mg/kg was determined in rat
key18bdced87b8c98f7b493c61c8b04457c,Clearance in rat
keyb113de544626fcfa70383cef7f31d4e5,Plasma clearance rate determined in rats
key1df1c215c8bbe903cb90e3c6c50a5b56,Clearance of compound in rat was evaluated
key7ddd069c1a53afdc780d435eebd7dd9b,Plasma concentration in rats after 7 hr at 30mg/kg oral dose
keyafc63fa6b651aeb53480022df7b6e2a0,Pharmacokinetic property (blood clearance) in rat
keyb2123b80b8f53c7116f2a2819efe24ac,Plasma clearance in rat
keye13db2e90d8970645dd9acaed15bcef6,Plasma clearance in rats
key3c90afab0824b97f9502c5e91e43d57f,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes
keyd24af239b1b179a5b628195057e38395,Clearance in Dawley rat
key9a01025cb5dbe229f1374da81b6477d7,Clearance rat
key4cfc5c76c8834b368979e7be6950919a,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.)
key421e1f8fcab3499a7c1f94185fb4b97d,Clearance rat; Not determined
keycecb0b4aa9cd25119a7fb1035f8406ac,Clearance rate was determined in rat at a dose of 1 mpk i.v.
keya4ff0d59d2c5e4e35ec95a16f4f43702,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined
key86ebc2fd26d3f84f755841a9636b153e,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined
key58431d7f094fde2dec00531a99137c75,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats
key43f6b6e8d98476eff70bffead08955f2,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv"
key3b34a06c7caceaaf2451bcb0470e131c,Clearance of compound in rat after 1 mg/kg i.v. administration
keybfaa779c8068dbb16ea3e5c65ddea1f0,Compound was evaluated for Hepatic clearance in rat
key2437f02fae2b9e6aed451e623c8c3959,In vivo clearance after 5 mg/kg dose
key930deedc612be2d56d95f99b0e56888c,Compound was tested for plasma clearance in rats
key17513f4ef311128f1bd27c77fb9e27e4,Hepatic clearance after intravenous administration was evaluated in rat
keyabc617edece8394702ab83ab4820c5e7,Lower clearance in rat (i.v.) at 0.5 mpk
keya44366f033d8d17a2f9a2125014a25a5,Pharmacokinetic parameter expressed as plasma clearance in rat
keya6baccef29815c1e31b55e36e6ccdb1d,Pharmacokinetic property (Clp) in rat
key6ced68f7d8ba5f67f976503544709fe1,Plasma clearance in Sprague-Dawley rats
keyec1c4e1e2b01a45799ed0c00e9718483,Plasma clearance (Clp) in rat
keyd4a681c55f50b56d995c4a41f99162a2,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg
key66346d5f941cc2a9d1b9625810953a78,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound
key93980a4bef9efaf7a590e02dc18d05ab,Plasma clearance after intravenous administration of 1 mg/kg in rat
keyc2f18e1c976d193cf3d55fb2b08a0c20,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration
keye63f111ceb5df31df1dc798f0e64f595,Plasma clearance in rat was determined
key411169c71a03b1f3f3b4757c980bf64d,Plasma clearance measured in rat
keyf347a30697919244c0e445cc4c9f6d5e,Plasma clearance was calculated in rat
keyb2123b80b8f53c7116f2a2819efe24ac,Plasma clearance in rat
keyb2123b80b8f53c7116f2a2819efe24ac,Plasma clearance in rat
keyb2123b80b8f53c7116f2a2819efe24ac,Plasma clearance in rat
keyb2123b80b8f53c7116f2a2819efe24ac,Plasma clearance in rat
keye13db2e90d8970645dd9acaed15bcef6,Plasma clearance in rats
keyb2123b80b8f53c7116f2a2819efe24ac,Plasma clearance in rat
key27a0c8a09a4cc4ae4d2b7f5960acad36,Plasma clearance was evaluated in rat
key962411bf265755b99c357affd6a6e128,Plasma clearance was evaluated in rat; Not tested
keyc5bdb3970580c663ace33fe2afb28508,Plasma clearance rate was determined for the compound in rat
key35dc491cc36d48e37518e5e01b2abcfb,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable"
keyd5c342b0f6f662b898d830b7064871f2,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable"
key23c833b80e908ab3e32d73160230e9a7,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose"
keyb9c72f255be93391f16778af18ab7bea,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue
key96428c378d9eae38a8dacbdea871aa2a,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue
keyda151a46ad3b285b18086fc0e747d19a,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
key32c7b346d782e14b814a59b88408cbff,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue
keyfef85b9106d1b70b3731f3771f5a2bd9,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue
keyfd2a4257b7e1f735643e182889907b2b,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue
keyc42cdb7bbaec9c7f626f32286bb89b4c,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue
keyd10b47c426ebf5f56f70eac3933ef220,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
key39d674fc5782f4d8caf67d3d8e8ae5a9,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue
keyb6c3c274428bf5124bc707252dc4879a,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue
key7f92b7cc93513f8e8135f64ef902a4eb,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue
keyabbc38ea0d7c3665ce066f208260292b,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue
key68a59b055c8fba89b0b7e66e93c891f5,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
keyb02c71019577b982732a3a8e4e3f8069,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue
keybd3210942c37bba7c18abff61ee34934,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue
key393f54460402f86cdec40277d9798601,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue
keyb1449330b93b54461afcd9f3e8eccdc5,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue
key594e31ea703f38a3538eed233e624565,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
keyb67e7ce6b77fe40acc3f9a63a3ac57b6,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue
key6226a14e9307646b44f4b73a4f0c416f,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue
key9ac7f22ef6761cd02720d825e9819f98,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue
keyaa4a132f66a99f61afa08eba228d95aa,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue
keyef8dbb2091d05b20f09fe729c1c11f6f,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
key0472c6affad4d088b4addffd88f7295f,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue
keyc049b694e366457cf77659addf768e5c,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue
key40307ee07a6ef2416f39c03324be2057,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue
key7c69c1bfa862716a550f0992ffb629cf,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue
key19e55c57dc1bb6e3d54cb2cf326793b4,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
keyed863e196b98f84f91f92f3c3cf3a367,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue
key56be7ed1b412321e3468fc5d9329434f,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue
keyd8c57fbe210f2b57f364372f9afcdd82,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue
keyaa50820fe606c3a422d3f978d6178bc0,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue
keyc242edd700a4323aa1d536369c18986b,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue
key2948f94a4d03e94b7d6e1c1450408e1c,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue
keyf942d232b7f2b76fe4e5d1a465a6fe2e,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue
key13c3fe9aff6baea855189a9fbb143d33,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue
key8a2b6a6a60ab016b30d7a78ed2f3a73d,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue
key814a7bce11d560a17cc31c3fe7e02759,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue
key10de1bfb5ee4e84e0ab111ea0659b816,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue
key7791f3fd04d61c2ae8c027469bbc759f,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue
key8126b110fe47e299668cf84f84186d12,Volume of distribution of compound in rat after 1 mg/kg i.v. administration
key642fc4698b7fa81ab7268f7eaa777031,Volume of distribution of compound in rats after intravenous administration
key76fb69b8621ad1c81bee5c5fde47b808,Volume of distribution in rat
keybcc0f91a6cb81abaf4bd7e62b79ec8d9,Volume of distribution was determined in rat at a dose of 1 mpk i.v.
key34e51ffbb4809598318c5217f096afff,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined
key9d4c4604e175465943b095b0bbf11d2e,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined
keye1f3b508421294bfe3bf7a1264f950e8,Volume of distribution was determined in Dawley rat
key54e4c09106354602cc3a489b946f26b0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat
key4aea94ca0bcaa1673b33d55f2f4df2e1,Volume of distribution was reported in Sprague-Dawley rat
keyfdd192d2ff869d17f138b6b59ecc1ed6,Volumes of distribution in rat after peroral administration
key66009ebc649b9afc0534544e3e2f98cd,Volumes of distribution in rat after po administration
key843920d15e70f8ecafe709eaa65f80ff,Volumes of distribution in rat after po administration; Not determined
keyd81cdd66e757b9b103c5a8a76339d5d5,Pharmacokinetic property (Volume) in rat i.v.
key24b13456fa8b92e4ebbe709f1b49462f,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously
key4435901b1561073458463c640ff3ca0e,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously"
key292e74e8b4865a24cf5e717d81a18a24,Volume distribution in rat after oral administration at 10 mg/kg
key45eac9a36ca98169dc5c2b129ae0f388,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats
key18986c1fc43a36e8dc62ce3acfa03ce8,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg
key29cd8c0dfed58b1aca5e04d70866d301,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined
key18c8777efdcf30edad87896e76f45f49,Volume of distribution in rats
key5e99280e426e5077519a077b999ae6df,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats
key6e1aa741d1d32b6686abb0454508b89f,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats
keydbbe5d9838271bcc0c226f6d63f41def,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
key9902c79a75152ecc25f67e5f819a891f,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
key375d1237b5d5927fe4f7cd01f513069b,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value
keyfb60a9707211f7100d6ec7c80db34ce8,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
key9566741c4b901fc59278da6369b4aa75,Pharmacokinetic parameter (Vss) in rat
keyd81cdd66e757b9b103c5a8a76339d5d5,Pharmacokinetic property (Volume) in rat i.v.
keyfe34aece95b58ec3d5737b5ce4578d59,Pharmacokinetic property (Vss) in rat
key48e3a32389e4380badee2be83421126a,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat
keyc03f4d353e15320163a87eb831f5fcef,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat
key497bebc5eae90a50f69dfe91e29d98c6,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat
key3d2252c25a68798a5d35feaa0f476101,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat
key15dd687ad4ace4d380edbfd71dba790f,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat
key41ec1e3871541890872b6a05be26f848,Steady state volume distribution in rat
keyf9a12bdc1fe96a19069216a4d61bdbc8,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv."
keyd427e4f66c299fb2366f97d23930dfb6,Steady state volume of distribution determined in rat
key856755c729145961fe97f4b1ec59df88,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats
keyac341d08bd15b836f1107cf21daf0286,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat
keyf4ddbce02940e76624491063dfef545b,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined
key38f73066b467c244f7dd76abd0a38cf1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated
key23f5024750d9a3d2f2e1722adc65b859,Volume distribution in rat after administration of 2 mg/kg iv
key23f5024750d9a3d2f2e1722adc65b859,Volume distribution in rat after administration of 2 mg/kg iv
keyd45406678678e7945a4e6163ac805bbd,Volume in steady state distribution value was determined
keyefb822a6017c11ff2632e016c8433a13,Volume in steady state distribution value was determined; ND denotes no data
key46f3652c97ceb1ce8d591dd96e13e01e,Volume in steady state distribution value was determined; ND denotes not determined
keyeffa241310c98ddea1154282ecb90976,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats
key3dd70ef03547e51c7c75e0f586b7dcf5,Volume of distribution at steady state was evaluated in rats
keye411852bc7a98722a141c7212b5381d4,Volume of distribution at steady state was observed after intravenous administration in rat
key55b97c2b02ddc8440d062a880406c4fc,Volume of distribution in steady state was determined in rat
key55b97c2b02ddc8440d062a880406c4fc,Volume of distribution in steady state was determined in rat
key3468331fd9edd71a79fdca5df0cb86f2,Volume of distribution after i.v. administration
keyee7221ffa4c18093790f89b8055c6936,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration
key32ef5d96d80a27603e70cfc1f0380fc4,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution"
keyf1b68915d2f39c4bf279f3495138a1ef,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
keyf949b469d9a9ecfcff9d6386a3747d01,Biodistribution of compound (oxidized form) in spleen tissue
key7cb69b11d5b30211a35e27585b994f55,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
key4853c0c3fbc538da4a5a106eab73fdf7,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
key6ffb86bf9c1df042094c111749b8656b,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key38fdd0f16e2cb64b5fe1d7f3ebc0de2b,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
key8214ec453e28958ef241f46d231f105b,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution"
keyf84057abb7377ca81efaafb6c7904aa5,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood
keyf5695922a386d1e82d949142c78b3cec,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key629db5c4e43a8c03ac10f9217eefb4eb,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues
key90c2cd0e8c761976bfcabbdddd8e7fff,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO"
key46e23713ad785e86e6c3ecc98ca5475a,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key17a27ca90bb16a527b0be5efe586c01f,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues
key1cd50137a497212fd1243853f85181a4,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO"
keyc66c6bf1a8963d94635175403455ae57,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key84afe7e8d6607008423ae5f3b2743c22,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney
key1e454b7098d7095eff0f869c464ca634,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO"
key2cef58a703f78f81d7f7777397461efe,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key1454933318fb7bf841c14615dc3d5507,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver
keyda5361eceb92e6a777dc0d5b45ebb091,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key923a22f6978787404e2efd40692221e5,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen
key6a87828d56ecbba0e640afb605ac16c0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO"
keyba9e44742ddc3cebdf44eeb3092d8799,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
key6944c395346329e9ede89e896f67fe37,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells
key1be67e319b1f83eedbdc822ca0b9afe1,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY)
key7ae528a7d0cdadb9c791ffdcb85b761f,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY)
key0b7690629eb3532d467f179818f81e60,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY)
key04d01d22fade178cba930994f80192ea,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY)
key621a8cf4bc43969968737ecf174ecf31,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY)
key7e99c58de6b56559f0094e451a6d2ac4,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY)
keyecc56eb3cd79a568ae169ac14f6eff3b,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY)
key30353afe4ac8a9c7d3b524f1081b2f77,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY)
keydb0d5381979ff9d86b5b24928efee793,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY)
keya013c55ef373fe54ef16e192500fc1b8,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY)
key87dc8d70ac7b22f52dc65c2fdb0801ea,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY)
keycb2d8f8535f9505ab7b32aa74dca7208,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY)
keyae2fbcc3cae872b41babcf21c702425d,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY)
keydf212efa994dc690da594f4f97dffc2f,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY)
key7ec4ee071cef3664798e6b90146664af,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY)
key6c3223185f9ca2a705cfcac1eb9ab89c,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY)
key24fddf040ca4bf0c92251ec14dc18cac,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat
key9a8222bff028a80ee3418771f4a4af2f,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat
key89ff32cb3153a119af513c30c5382e48,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose
keyc69753032523112588ea3b221279bf05,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
keye7c45afce195e339117765e1966f19bc,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration
key6903899309f6afb5a4340a33c52b1338,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats
key0f1e5142e266ac5e213ee6ee1fcd6356,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat
keyfc7ddfca70e1d60007774416d1f75c13,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat
key8ce5b87a4c4de75cec7290136650db8c,Plasma clearance was reported in Sprague-Dawley rat
key4fe57c243aba01e4d60421025f010be1,Plasma clearance after intravenous administration (1 mg/kg) in rat
keyd4acd3e7e4554892f146e93b5e277133,Plasma clearance of compound in rats was evaluated
key9dd1c63dff1d40ee095b3dc108ff7276,Plasma clearance of compound in rats was evaluated; ND indicates not determined
key7305c9c6f4469b7a44a118b187f5ea41,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration
keye7de3a63cf91c7528331753346e1c17c,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined
keyb5dfd3cb0ff981c1b99e370cc49a4043,Plasma clearance rate in Sprague-Dawley rats
keyd5a46d947529ca13c2cd62f830194f0f,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg)
keya073b8ffbf6731e1ff567d8b93ad1961,The compound was evaluated for plasma clearance in rat
key6a6a84824953ffb0607c34c911c08a34,Total plasma clearance in rat
keyd7dcf6dc597075ae6d003ad1826c70df,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.
key11ebae235abdc999268444615922184a,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined
keybeec1cedcae64d7d203e0297626fcbb6,C max was determined at 10 mg/kg po dose in rats
key65ad4344422b4bc8c018375d29be2566,C max was determined at 3 mg/kg po dose in rats
key1bc2b0f4322a534399167348956c8075,Cmax after repeated oral dose of compound at 1 mg/kg in rats
key84633b17808a5f7d58b81a31ffeaa321,Cmax after single intravenous bolus of 1 mg/kg in rats
key9027492039a2c7eeffffdac0479c19db,Cmax of compound at 5 mg/kg after po administration was determined in rat
key041b1b437ee766aa268297ae073e0304,Cmax 24 hr after 10 mg/kg oral administration in rats
keyeeda53c57a18d0ed7145d93e83e784b5,Cmax 24 hr after 2 mg/kg oral administration in rats
keyc643d808bc9db346f35742777a5a1fa8,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat
key00b62fb2442bb0c7490ba1ed11598681,Cmax in rat after administration of 2 mg/kg iv
key00b62fb2442bb0c7490ba1ed11598681,Cmax in rat after administration of 2 mg/kg iv
keyf0665c581e44298f04d0f0b1e3eb92f8,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg
key2c2afff7b18c633172c146b8dbcfd4d9,Cmax wa determined in rat plasma at 30 mg/kg after po administration
key3c84df7545337fc10615fc148b3791f9,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats
key2319c8d1afc94f2bfed021a6c0124142,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats
keyd9b79a7310d6ee9cf60a2340826fecc0,Cmax after 10 mg/kg oral administration in rat
keybc5374860ea53a479e36acdabec0167a,Cmax after IV dosing at 0.5 mg/kg in rat; no data
key5d524a22ec069c8b130185b8fb619fbf,Cmax after IV dosing at 1 mg/kg in rat; no data
keydd8c343fda0dccf35d05292b5ca18be2,Cmax after oral administration at 20 mpk in rats
key2f2eedcdc36ca4d30fd545146f8e5142,Cmax after oral administration at 20 mpk in rats; Not performed.
key8fa79f275f4084cd732d11370b6ce854,Cmax after oral administration at 20 mpk in rats d; Not performed.
key9353d576bee8179ac4240c1423785297,Cmax after oral administration in rat
keyaca3ed4314359e662ac2ace10c26320f,Cmax after oral administration at a dose of 2 mg/kg in rat
keyfa70d6770a42c563330938a6b984ea4e,Cmax after oral administration at a dose of 4 mg/kg in rat
key2b0a666b85f7b8709bcd338b8430dae6,Cmax in rats after 20 mg/kg oral dose
keyee204f63d8f2878d975504efa1639828,Cmax after peroral administration in rats at 24 uM/kg
key1f15cec151db9e0780ddf46e4001ab1b,Cmax at the dose of 2 mg/Kg administered perorally in rats
keyc6935171fbb685ff4603f6a4ca87b299,Cmax at the dose of 5 mg/Kg administered perorally in rats
keyd0609c55186187edc467f20025a3823a,Cmax by administering at 20 mg/kg p.o. in rats
keyef5cea5e16ba79aaa2d8bbed0067b8e4,Cmax in male rat
key38722ae08eb65f2d34fd5dfc7ac7f213,Cmax in rat
key38722ae08eb65f2d34fd5dfc7ac7f213,Cmax in rat
key38722ae08eb65f2d34fd5dfc7ac7f213,Cmax in rat
key382fcfcddfd13b6d0e7677f601cb3378,Cmax in rat at 10 mg/kg
keyeb818c1e448f223609b33765e6e155fd,Cmax in rat at the dose of 1 mg/kg i.v.
keyf3227537cc5a86adc1e4d33a67952efd,Cmax in rat by po administration at a dose of 40 mg/kg
keye0b8a6a58a40ecf232720f58b8d3dd2e,Cmax in rat p.o. at 20 mg/kg concentration
key2a486e37d1985f4c9ad40a5b2b210904,Cmax in rats
key2a486e37d1985f4c9ad40a5b2b210904,Cmax in rats
key18d0602aba1c350d79b35409898e3b37,Cmax was evaluated after 20 umol/kg of peroral administration
key513ab0c19ac8be89b9027981e77eeefb,Cmax was measured in rats after peroral administration at 3 mg/kg
keyc4ebff94363d6b86dda05bbae9108ab8,Cmax value after oral dose at a dose of 10 mg/kg in rats.
key81dc02816ade59d9449b44916ce48050,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue
key847715ab57eda44110351f1df20cabda,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue
key8e84ee5fd4d95a2eb8c4e6b0657e7834,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue
keyb7905484e3842b6c384329d1f69ec94e,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue
key666ce483be0870dcc72593f6e74bc177,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue
key03413fbe6a9407b07e288af0341c9e25,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue
key9be6f5b1d15937ab623e774461bced19,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue
key91b51d7f92be2e43b1f4d83c3882a763,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue
keycc72e7dfc04a8a5b862e31fe1d0cf543,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue
keyaa5365cf06c63a639719c33d157ac3f9,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue
keyf79ba89084c90cc31c70ce74fd7b7490,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue
key11563a163ac554ad868aa5cc01c6d02c,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue
key8c790a6c4421b02a60c140ead801c52c,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue
keya5c0f9425023d13ca54e7a6a446a4086,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key0b9a5bb391ad34385b97cdc2c7fdee93,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
keybc4006fd339be837c91e3cd2e4c0eb00,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
keyca87a933dcdaa8611081684b73cb1162,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
keya506340589c38ab05702e203f8bb7d18,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
keyd1cc87750131ee9f2bc4399f1d4a3fc9,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
keyb185f1793e84cf568be81ad3fb3deed7,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
keyc720b40a65041226450ce11e3f1be352,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
key45a18832a2f366001cdfcb5f9132a199,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
keyf852fe55fe26f8dbbed00d4cf8ef72bd,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
keyd7692c8e5bada48f914e7ddcadf13ee7,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
key073ce0e07ce4a3a6530d03ce1bfdf8f1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
key2cbeb24636f411dd1239981bb6a3bb8a,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
key3d5507a28fb76890f97cec83f166988d,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key1d9d47573ee6b3a7071b308f22a943d7,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
keya432a972daa1e73807babb5568a6179a,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
key86b52f1928f9b43a2f29072cd3bca08c,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
key76aacd0a3f0aad1bec57af5b078ca693,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
keyb8532bea85655e85da304210155cb655,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key55a9d96a2622e8b5b33306225f707ec9,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
key1cc301a47d964f4a5a3c85ceeea5ef4b,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
key9240959ab713002cc8ea6c980f19c55a,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key24162fd8a0bee52ec9e43578cddc983e,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
keyebafd29ea5672b59fe1f68950f03a800,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
key10c8407841a5917e536e4dea4361de39,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
key9dd9a8d450f1941da55da37363e03314,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key0b46747bdb296e6d9ba02dae8388e111,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
keyfbced851b29431eb10089f42caad964f,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
keyf9fdce0a626aa314dc125dc88ac3f67e,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
key598962ad09727ae510225210b4937324,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg
keyd59eb70c9492de852d61b05c7fbb79ba,Volume of steady state distribution after i.v. administration in rats
key6763c9f12364e4e24200128360e71c3c,Vss after intravenous administration (5.0 mg/kg) was determined in rat
key99b79a48ae186aa835e84578576fe45a,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
key0adf9054d89a3a711a06190890db45b5,Vss was determined
key306fe74773ca5beb5b70e08364cc26fc,Vss in rat
key0dee80e4f69bcec9f1b8687a5543b04d,Vss was evaluated after 10 uM/kg of intra arterial administration
keyc4aed943b5004b9b9365805357030f37,volume of distribution at steady state was observed after intravenous administration in rat
keyb1a0c199939de91638f8ebc5b1818a77,Volume of distribution was measured in rat after an iv dose of 1 mg/kg
key2ecad00143b45f1c0ce77dbcd4969fcf,Pharmacokinetic (PK) parameter Vz in rat
keyb625a4cf542b5fc8a75b67f38c5c7d15,Volume distribution in rats
key5290fe9da6fda4f59a5b5374a561e81f,Volume of distribution in rat; No data
keyd43adb416a564cc61d012daaed36fc83,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats
key713d1a5b5bc9be08f283c113caf55dbb,% absorption predicted from in vitro rat ileum transport studies
key626a2bb0cbbaba60d5d7ae250a814437,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg
keyeb1e73f35d66b71860220f30c0e41a74,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg
keyac670e345135b27fb100012fd2f06d68,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg
keyf7dd5f2489d05560b077ad029e68998e,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.)
keyc45fae1f5f55b90859f62f9a5376bc37,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg
key2ca95656390e62fc5495fb59fb4b526b,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg
key88793bc8bffd673880845a7a1a879563,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg
keyc0681bcb380a80d70c2377cf0240e10f,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg
key14134f04d4f9c1bde015f7bf746fbd4d,Oral bioavailability in rat
key9dc4f88c7143a547ae8ef12d85de7779,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations
key14134f04d4f9c1bde015f7bf746fbd4d,Oral bioavailability in rat
key14134f04d4f9c1bde015f7bf746fbd4d,Oral bioavailability in rat
key14134f04d4f9c1bde015f7bf746fbd4d,Oral bioavailability in rat
key3efbc7a9f0ba45f4881c2ecdfe687267,Bioavailability in rat
keyefa50278bceb928c912208d16eb85b12,Oral bioavailability in rat (dose 30 mg/kg)
keyd2b53d70e7d50174af536b39800837fc,Partition coefficient  (cLogP) of the compound
key3fd3e8c3d1454854103262b0bc61404d,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally
key3c94900223cce92530f5bd010075547e,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally
key04c8935b970ce3c4863f10c95182e1b7,Clearance in rat.
key9603ed343d6ddceaac36db359a8fd33f,Compound was evaluated for its clearance when administered intravenously in rat
keyaffc9294796d68da54746aefe8e809b6,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg
key0e0f234b573fab680a614001f6ac9d12,Blood: Brain distribution ratio is determined in rat
keyc5c083b1012f55f15b2616617213a140,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable
key69a03f8dbec1030b89437a8ff025a6e5,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable
key07f5931305703c622822638f7bc1878a,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key6508425846d31c3b238d768b1ddfdfa1,Percent dose excreted in 0-48 hours administered ip to male rat
key6fcd351fe70dda408c8afe18875a6849,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
key994db29142b0d4a36fbda71ea1948592,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
keye3508d9ece6605da5d2f52e302b6cd8e,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats)
key5022da5deb6e39abec46915bf89bc413,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key0044e831afcfec0636cf2fe810821912,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
keyb105a0d559aa71fc2ed31fe4c02dd504,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
key4abdb52fa6495472caa6f9aa588e82f3,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
key49532310c5014377fe003bb58cc9100f,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats)
key1088863398afb874a3df9758c71c0e93,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats)
keya714305969421aac241cb2ca713097f6,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key38917904522fa9358e81dfdd5e7e0571,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
key7d94a37fc7280fd49e7bc462bbacee80,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
key8944b9b00adc8a7258a01dcf29332dd5,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY)
key74da89a6b8bc623770eecf91fad16c48,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY)
keyecef4e4b7fc9e3292330ae20ecafe53b,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY)
key9cef20a5ee5cf664d015edccae62d4b6,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY)
keyd032f2feace8f3f06fafe399ddeec4de,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY)
keyaa913341e1b3a9132f04f695d3b2c207,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY)
key771544c08e567b2483bfba35204055c4,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY)
key39d5b609868239421e420f769ad570f4,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY)
key8bb342aa341322a0595dab9a5338c4c1,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY)
keydb4b4cbb0bac6cf4df6ba5f5dd32d628,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY)
key9a851c6907c67a5966170a1706b1e141,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY)
key3338990e30f4bccb3feb7d0be5207e70,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY)
key68bdc751f3201dcd861389920e297bdb,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY)
keyf73344a33f70f0807870476f2a9e5ae5,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY)
key3a9b8995a46d8d94b7b0e5b788581810,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY)
keyd49b082b884405fad3a18b121b929394,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY)
keyd43e4f5981bf74b7b447bd293819c7eb,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY)
key5ad1590c2b786eb99f5dc57fb6889dbf,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY)
keyc8b28c216e488f805bee11a67ed936d0,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY)
key07b6c5882f636710b9f6f7e284a3ddd2,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY)
key4ef661f95113625dd9c64ec45ea72f33,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY)
key599289bd24b4aa01cafff8dd3d278c5f,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY)
keyc4e9403768652d23705ee8c5d52373df,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY)
key82247b5d60c8a032aad94963d1c04c45,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY)
keyda4540c81875175df9805243b68d9905,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY)
keyd966a5779fb61ab2b2aa41b09ce8c5da,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY)
key110b17cff9f177bdac63786aa2e3c985,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY)
key8b2ca3ed70c540a4477f0c125fc41619,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY)
key7782f7769f562223842fb39f7240f2e0,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY)
key2405c1f5e553f72bd696935c5383136d,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY)
keya2dface2d8f32439ebb50d5016c0b622,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY)
key864f201d75206bf623000ecf596c8d87,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY)
key1a19c7c731765b96c89f208a0a6e67d6,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY)
keyde98490ccfb32d8ca51dc58f14f3ec0c,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY)
key51d9fd2cada58b1e0be4bcb079afb3cb,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY)
keyb229cdde544d19f2b8b5eeaea2c4ca4b,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY)
key23efc52ddf42a610cde5633e4e5c2c41,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY)
key73e0a3faea5508cc10e099c144c396bc,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY)
key0b3d21677ba377ff6180f9851728ab79,Time taken for EC90 was determined when tested in mouse
key528a1141cab30db17f6daa791edd54cc,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg
key5c938eb38af82d9ce75192421edf71cf,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2)
keyec3728caeae5495d70ec322e636e9508,Half life in mice
key3050ebd228b27b8ad14459e945cc51f6,Half life period in mouse after 10 mg/Kg dose
key7f5825fac3b8611bf5d9041095f94cab,Half life period in mouse after 10 mg/kg dose
key34d5a8f185e8a15381d7975fe54be18c,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
key8fc22e439d7f194c322cd335801afc11,Cmax value at 5 mg/kg po was determined in rat
key7f6095428aa60e6d9757e3f0c8fa3fa6,Cmax value evaluated in rat
keyc8eae8522ec74b29eb6ba222438350fe,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain
keya4dfd9e959f21f26c96af278d2a9465b,Cmax value after administration of 20 mg/Kg oral dose in rat
keyfa6680a21b9e0cdcde5ef1308285a728,Cmax value at 1 mg/kg po in rat
key1f21139662c16ca2b268f2cdf125009a,Cmax value at 5 mg/kg po in rat
key0f8df4c9466216d36902cdb4e9391aac,Cmax value at a dose of 10 mg/kg in male SD rats
keyc7d0c72a40ddce1ff4fe610107caa416,Cmax value at a dose of 100 mg/kg in male SD rats
keyf5352c4369b5c0f6f57f7ca55a414af8,Cmax value at a dose of 50 mg/kg in male SD rats
key3e9c7b1a7f313f46bd587a9cf0cff485,Cmax value in rats at 10 mg/kg
key4157873b93878a57265eb387d88cf21e,Cmax value was evaluated in rats at a dose of 20 mg/kg
keyb3f8147e898aa1693fdbb586986b1254,Cmax value was determined after peroral administration of 20 mg/kg in rat
key75e78dca487f21a09669e2f72dc86299,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500
keya1940ccdb4d933cbcfeae4c7fcfc2c83,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats
key1a2b9da881e477a799174d3df15f1414,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration
key64ae263394c191835f3ed150e50babce,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats
keye5db8cf7eeb220a81bb1c04d8e4b95b3,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats
key9264ab6de26a6cc4eafb9c7e485233a9,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration
key387a7286c0b36a274f620d4ec4f08b5b,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr
keyaf76632a590e68cf7ba191b0c1d3e597,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr
key5c9f2707dc91266b4174f0e0edf2a1c0,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr
keyde3d7c220ae77a312f519549aeb6094e,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg
key145b638de76b0d8d7a927e328a15e2ef,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr
key769c3bd297b86193920f9d3e0086de65,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr
keye641d697ded067e9e609ca9ddf352cc3,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg
key878c0e01e766f117b624796303681c25,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
key88ba1acc4bc58d2e4209859d53666f5b,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
key012c70a0dd7cd7fbda1bc7ffeb739fc3,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
key00a2c18bd83d187ea3ba83a75a8d98a4,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
key29fa5604f75e91525a7e4c5d0a2c7488,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose
key8810ebbc5f6aa57c4957a040628e4246,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose
keya33e9ebd89c1d47805f34d84a5f382ee,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)"
keyae7165e068703871c6ea9ed2f93d01df,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg
key4592172bf7fceeda673b0e36746e7dc3,Maximal concentration in rat was determined
key24970265c569667b6f2f5161ef8e7642,Maximal concentration after i.v. administration
keyf952abbd9433179d6f70c440401a2efa,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg
key101debf46e3c4a5ee5420e853b57ddf6,Maximal plasma concentration in rat after oral administration at 50 mg/kg
key856ac3b0db47d885567dce2766aa57c2,Cmax in rat plasma after oral dose (50 mg/Kg)
keye089ce2e4aa0329bb11c1893a3a03d84,Maximal plasma concentration was determined.
key5548019b0c6cf793ad4cd390eec11f58,Maximal plasma drug concentration was determined
key8fef34817ae6efc1f5b2e45ba344cd53,Maximal concentration in rats after peroral administration
key91d157b30bad7c0a4b8de05553a5a04a,Maximum concentration in rat after 2 mg/kg peroral administration
key8ad8f14366caec6a76feb9c76dadddd4,Maximum concentration in rat plasma after 5 mg/kg oral gavage
keyc4d71387edd24da2b920b52d3174143b,Maximum concentration of compound in rat was evaluated.
keyf9d2eb294baee737ee65b86a8eb7b950,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats
keyc19754b7baed7d6785d9a412b23dc948,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats
key23f972bdcf29e6936e53fcab21753e95,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat
keye86d4d379ed75072d1290937476d29dc,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats
key441d293a2bb8c20e9018276fefbcde7c,Maximum concentration by oral administration at a dose of 100 umol/kg in rat was determined
key0cd62cbf9b2e9cf2b557442b816ad38d,Maximum concentration was evaluated in rats
keycd94f11a2e32cb1b6d53309cfe42fc3d,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats
keye19790a64105163442e05015ce491f85,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats
key25b710b1eef3eb12e5f404a12db59e9a,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration
key849aacd5c63d52a1bf233df37471c5cd,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats
key0141437b17c1c3a7d114302ee9c9b66b,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats
keyc1084a541db49ab47758c133fde849f0,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
keybe56b513af3fc7256844b4b5f541baaf,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
keyebdaa0497f5b7e90cff56eab9cdf388e,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.
key8480a949a015e05daabf9a90fa55896e,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
key935de9eeec6d1c3c0fc727fa0a2ff3cc,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
key88ee5ef04817e97a108b24c6514b2211,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
key74a424e673764aa3d2c5d344ae06c44f,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
key078802abdfb6c3a81e16c2f5999ac1ae,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
keyc3ada00ecfddc06a5dbb8bd0963d2563,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
key5d7dcbb877584d8e66eccc2506b9d0ae,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
key9f9fd74085041b56e0124768dec98052,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
keya9138a37e0c2aaa9803d3989173500a2,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
keyee3dc4afae377496918e00120ef98e40,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
key5077f270a1c4d1f422fd26d988eb254a,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
key91faaf7373bfa4fbf129c9b9f24e8688,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
key76325a1a2175ebfdde50a81b341131e6,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key00f4096ed65ca9816ff6a7d2ddaf1ee4,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
key95be7fd04c447ddf060d7456d3e11992,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
key6f3d94a678bdd92f9764e6c898349578,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key574210888e018e8814aaa14eb00d5570,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
key1c672030c88180af5b949f47b00b66d3,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
keyb70644043b7d3189e3f98d16a873314d,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
keybee218161c458a43741b19a5d53f840e,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key707be9ec103d8b999b56ad564061cf87,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
keyb0b4c69356cd8c3705cbeaebf265660a,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
key5516163033f89769ff54e21fb7fd401a,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
key0088aad233008c280b8374f5807d6485,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
key1288c0c355555e96e304becfaab3d1e3,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
key9542f203fb3cce36fb3cec83fc4babc3,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
key1c3a8f9300a494f7d9a4591753e65c9c,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
keyad5f51afc5a092a07a67b7230df5296b,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
keyc124151250b1122e8ede80a644c05a45,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
key6d7904431a4f3be346295a1fc32c850b,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
key3c1048dd07876a246ba757c9e7f474eb,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
key2c8feddda60e5e5411989ecf728e8f1b,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
keybe1aaf11b626e8607d641afbff062a6f,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key9b51e6762c47463be5ae92ca42a1ce26,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
keyba3a922c5c0c350ddd0c9f0d0a1a2999,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
key1332fd9dc56d3f85c40833b3f0fc1301,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
keyc0a154b19f592be69c05e1715c0b4276,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
key0c0fa3ef8ce38b4f3e8f9199a7e621da,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key452cba5bc7b03df5bc77c553a356661c,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
key31e3ac78a7d69025df9be3b03a7d7bb9,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
keyd1f54f3414b03888c5c4df5012fd7f51,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key8f85c2fdb44fe0b4fd27d4c4cbc669f8,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
keya807be1cf6e13a90ae9e461560bb7fa1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
key342580104bc6b929fcb71e3be93f4042,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
keyc75a9dec10178034b68044b510cb03dc,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats)
keycc319b165942c3d6ad31ae4757bea777,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key5e61bb03bc27186f6c98aba15e7463af,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
key011749cac438db3ec6be359ba366c158,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
keye93a84db41386e09b4e8cc76b7a6682b,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key0fac7711d8b890508e8406038653a89d,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key2396af80d8932309892715ef32a23ab8,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats)
keya0f6d3b758ce129acc26dd6aa7c99c66,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats)
keya2f4b0fbeba2bd93b8840830a15bb148,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats)
keyc8f8b2087ca36e467b76d905dace2eb2,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key6654cedd51db256b94f6c3e21d44604b,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key59c68d398ed050ba420d0f1270420e4c,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
key32040f5f169aa1c87ec517bb72296340,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
keyf1d76e79baa097d9df8a211cdff01bfd,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key54f4d2eefc882eb0761f0994ba048668,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
keydab7c0dea8fab9270cbf78814f6f6737,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
keye86d0d86daa6bd9f1a91749aca2c3929,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
key8a2a205c1478623d217094ac3f976786,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
key0b8f5b79ab0a519e2a5fe922becd9273,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key33a1275b6d8595debaad5c0142a35796,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
keyaee883a926da58e0ea28470933df9078,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
key610e16eb04d84be708ba896b75dd2057,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
keyd91d53d4daeab37be5e285a2094e07d5,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
key32763fefa3acc588af97d3caad0841fe,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
keyd19c1a56c3352b62af7122e43b5b5d03,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key18ca4ce8c982fba7fd349e6e913a555c,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
keyeb401aac3d9d3c3bf6a7a98dfacccc79,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
key2bde0114ab905dd5cca2a437e8360db8,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key223dcf64af82f5c6fa72a7064a260e0f,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key732faf0898426d25d1d50c64d844d5c5,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
key573b5272a358ec99ca0dbdfef60612a5,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
keyfde8f63e3fb8c3613e8d85b895f48693,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
keyaba75616096429facd9c006b25d5379e,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key6eb9cad6d90f5b61cdcb58742785fedc,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key08a4731307a61425cf798eb4860bf3f4,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
keyc7fd82bb1699accb862d18c2985f3d67,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
keyb7b2379a9c672f93de9408c51a5f2f9d,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
key05c810a40250216fd369817c58172974,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
keye7738c4516231859c0e5be6b5ce5eb81,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key42b1b766050d0296efde9077915814dd,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats)
keybb96c1c22b85d8d0b4b7f5b6a7c38b50,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice
key173e7c6648e832ff781bf98b17d129d9,Half life in mouse plasma was determined at dose 25 mg/kg
key55e2df843666c083dbda843a7f29afc5,Half life was determined
key46f67b22eb1ec22c077dc1e6efdf845e,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration
key13168a1f44fd0f71b2f46c20929b197c,Half-life in male mice after 1 mg/kg intravenous dose
key58847cea8ddd7464786da9a285451a1f,Half life in mice plasma
key7df763c8a7652228f0f1669fe1f67729,Half life in mouse
key51255d03042cc23ea35249482d675016,Half life in mouse plasma at dose 25 mg/kg
keyfb14c6386d3a08d07d23939d4ecc4fdc,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined
keyecf6f6ffba1c35e58ad89b574758d3ac,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined
key315212ceaec41a1e9bd90140efce26b3,Half life when injected perorally in mice at a dose of 50 mg/kg was determined
key495ad868db1cdc366e3ca45f4eacdfce,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
key9168311c213edd10601c496fbfca3ace,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice"
keye09063db1db57957b89df6e9969ded4d,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice"
key05ff1b8b8b5798729758ece41f90e490,Half-life by iv administration in mouse
keyb2adf5416e1b427194f103611bcd067c,Half-life by oral administration in mouse
key653f907b68c39d66f4d659278b6dad8e,Half-life in mice
keyf85ad1fe2db92e78ca3debb45cc6d1af,Half-life using mouse brain homogenate
key42f91903ebf6b3988f75d9b129a9994d,Half-life was measured in mice
key70543f2572ddbe66f4de48bbe0a06449,Half-life was measured in mouse after an iv dose of 1 mg/kg
key44e9c2ab47e21ce68af80f1d390b912f,Half-life period was determined in mouse blood
key576ce5e5562c9cd55b283dd1914882c6,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain"
key516e88f2e0c0fdb4ce206122c23d0d23,Plasma half life in mouse
key54d7b4d4d225be0c8a297bff7e654d79,Stability of the peptide in the presence of mouse serum
keyf7b2b7308302527264d7332a76110dab,Terminal half life of compound was determined in mouse
key73bca3de9b57af5c5c0d7d070340fc6f,Terminal half life was evaluated in mice after intravenous administration
keyc9de592511ba91d150589bd429c7b233,Terminal half life was evaluated in mice after oral administration
key397d75643940a5ebab41a990d1d68edf,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.
keyb2c324ec7cf1a9d6085d3847bf508202,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.
key45f87ab8d56bdce3612245c588e6b0ac,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data
key5fa2e937b1afd5edb67227f4dcf09623,half life period is evaluated by administering intravenously at 25 mg/kg in mice
keyd22f977c9e2ba9ec0788db2327d95b2d,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice"
key2cb50821379ddd84f94197b1fd5e504e,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable"
keye4788252d04cc473de5fda53ba679a7b,Half life after intraperitoneal administration of 100 mg/kg in mice
keyff44831c5099b8c4c041a27bbcb76653,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration
key46f67b22eb1ec22c077dc1e6efdf845e,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration
key23bd21141854b36e2959a3ecb72d473f,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration
keybf8242350b4b89c01eeab908fe41f642,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration
keyf97d2180c95adc5df243b71a03c14390,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration
key71fdeffc1b48bdcb4bfafbf17909e8e7,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak)
key1e35fc0eab896ee5424645095c81381d,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak)
keya8682fcc0fdc4fb99accbec360b2fc81,Stability to porcine renal DHP-I
key5dfe904e783bc1fe7fec8117cb0b4a33,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg
key3c7849224e31c098ebe980bd57ba7f65,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg
key253ddfe20bfea34b29bb690bee705b73,Half-life of the parent prodrug in porcine esterase solution
keyff84bf7a126333b2ac5ed47b66ae05e8,"First order rate constant, k was determined in in pig liver Esterase"
key88ceb5f97dfa3426aa805f2a054f22da,Half life of the in pig liver Esterase
keycfb7d0d6163d4be2c723e8f4b933e2ad,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase
key7132d9a51e23d69d0758a1e8688c7a07,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase
keydc251c2eed85beaee27c28ad7f13ec4a,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase
key0b9de85fd40bcdf4547f5eb3bb158db3,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay
key09053c0c6e8dfdf34f1543d4e4a8a341,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined
key9b33531368767b52c605d4ace11d546b,Half-life in the presence of pig liver esterase(PLE) was evaluated.
keya9572ddab5ef3d38a9f8c53a56715e92,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable
key4fa14cb64488a57e0eb4cff020d03895,Half-life in vitro in pig liver
keyf584cdb11a54a71fd42d332153fecc2e,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase
keyc17ce904d2fcdc7ea58740d4bc57ce39,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route
keyd59b87390c525f9466c938f75c719a8c,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.
key445905a4b908d1d44bfeec0b5d0be953,Maximum concentration in rat plasma was determined
key0f3201dbfa737fec3cead76ee1913fee,Maximum concentration in rats
key6bc3050978b922e455a0f2d4aeb7728b,Maximum concentration in rats at 1-2 hours
key09e8988f7b9dac6db4668c1696b33acb,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally
key7aec5ec3e5ee8201564a2a9b45826467,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats
key3e245dfe057ffaee311225047c1d3779,Maximum concentration at the dose of 2 mg/kg in rat
key0cd62cbf9b2e9cf2b557442b816ad38d,Maximum concentration was evaluated in rats
key958ce3efb08b11c74937cc53e327238f,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat
keya1482bd332b0c97101d489ef20f2489a,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat
key8cb0e829468f9d8b5cad3832c4f3bc10,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg
key7d7ef432d46497b93df4720cf3d6dae7,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg
key855d9275c24af5008341e4da1122c149,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat
keyeb5c9618d429f4acf75a3d1441491950,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration
key84fec2cd474aaf01f8822b35196d8f8e,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration
key397f9993a5270c229b421f243f8bdaf5,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration
key5d9a91c9a19189e243bc388de30f2435,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat
key8c5a0bbb2b9b0806b8ea6479376e6f2a,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat
keyd9b3c3dd75eecffc15b49b18da44ca42,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat
keyd6a7129d24f97426f180401137754dda,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat
key2108c45cfba21a534055895ee32ead55,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat
key1e49546f0a05c0aa9002611371da3685,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat
key0200b88cdfb2205cb20a5432ed2d2620,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat
keyca286bb7e6a95686eb0a802136158ada,Cmax in rat (PO dose)
keyf8c43498c97e39bb3ccfdcfd767a5e66,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
keybacc53b31fc71e7a582d621189f7338c,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats
key3b782f62cb6cd8408db122bacfbb1737,Maximum plasma concentration determined in rat
key9544ad7bac1837b62cedc16063fdcc3f,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg
key4f750329412aafd4980e417d84c99aae,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg
key3b345c535d904d93e82369b2dfa6889c,Maximum plasma concentration in rat
keyb9999453b89ab708d012bb4556ed08a2,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats
key178a765ed4f1c7204e48c1d9d0809b93,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min
key32c88b49a8c09c95ec027331f2981655,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min
key98cd851cf3028d47f77d59a95c69ec8b,Maximum plasma concentration of compound was measured in rat
key5a8db3071918ae32cc9244d5402c6d7a,Maximum plasma concentration after 20 mg/kg oral administration in rat
keyd395311f6d334996ab0459243520cc05,Maximum plasma concentration after oral administration to rats
key3b2ebe28a2a4577eb579404c4631ece2,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11
key43a2ffee744a0d35a96d8a65950d225a,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously"
keyb149eb862657b195e4265730c9829df3,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11
keyf1d20a3e93fca8e861dcb1bf787c5dcd,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control
keye6a9a4f957a433009d7f0f720f2804fa,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration
keyaa99af823f85a5a06479ad8b1499449a,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration
keyb2de5af290e2831e7b84b599939ea393,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration
keycc32df2425cf6eeaf81276aaaa05f522,Maximum plasma concentration dosed orally in rats
keybd52d3cec8b4df18e328c55981c322d6,Maximum plasma concentration dosed orally in rats after 6 hours
keyd738a6823791b45518c765934ed17bc2,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected
keyce3b05ca1d3ec81adbb3578debeaaa1f,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats
key7673f5b566165e7aecd25dd65c8f8873,Maximum plasma concentration in rat after po administration
key0c298f102233397c25742a0e55ceac3c,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose"
key501b70314d6c76b938eb337f44540620,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose"
key19b11fbf670f6f05f3cb80ac9f41c4a0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
keyab86614114221408efb4bb38553468ae,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
keyd48be8ffadcbd0e4039e1fc8f3575e42,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
keyb00cf0d4b56f2c0f97f4f0ec4b3b8577,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
key5080068d2f778e2074aba4cbb68ef95b,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
key8bfd4f152820018917939a5629cf1742,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
key9dc341d0ab619bab94406780dc451610,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
key8bf83ea25b6508c0b95f4193e4c0b979,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.
key3795a17d3c86975ad0a9533c2da44250,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
key288f470a809c39b4200f912812cf22ec,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
key9b608fd022147194e0fcad6f3fb1e315,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
key598bb672753a5f02133ef9017f529470,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
key228ff2278661adf7eda3852bd869a15d,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
keyc005a5a4b9dce2bdecf6c69dd5caaabc,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
key9995456aa1ea12de0e93be659400c886,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
keya97ff97e40fc1399814bdb17d92b85aa,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
key68d8988edfc734dd0901dcffa6fea215,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
key6ec72e50c3004fb990525cc61310889d,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key1185097d32d4ab48f5e986f0080bc8d3,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
key2b51f78d8b2c5ac6d255ee4f17adf3ad,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
key38286f01d1d1d712c7bc0f1f71e73f0f,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
key113116299791c923a8459f0351f460b6,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
keye906c7a25c7b261f990d7d5480061d4c,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key9800a76ae225e39b0ccb3d34a978a91d,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
key6952b96862a09651ba121dd7387abbb7,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
keydf2476aba57cb493680dd1470cc42504,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key99cc539d29ead193a143f9efae7df7aa,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
key4b7f87f6ab704958e85c9ba8bac8e45b,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
key2f3b53239632a6d2008fdce3279e72ae,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
keyf425ae15ceb508d2c2034a1190f2992c,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
key035a6dd7cf891065fd68a3e0649254e8,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
keyfe5f3c231974dd6f39430324b8c20181,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
key4d7dd721ffc956bc7186c203e0a94b5a,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
key104a8640343ebbb476ebb885d511114d,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
key8431f4d02d2aa81c2330ed17dd32ca81,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
keycc665ed3e9a7c7d99267150811065464,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
key4aa6a1d864eb72dbdbbc62025091583e,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
keyaf0b162bad7c58e3afd20e7346445bbd,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
key83c0836be7fda8457193fb8eebff99b5,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key5add4ebc41282b261dc76f5b2cfb7c31,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
keyb8065da8a935d27a07eefb7f975faa0e,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
keycf23b7a6b227ffb286eef51ab8721474,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
key96510f0c4ae816d65aa792b80f32a1bb,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
key50e273ddf08f713dc401fde0530ae5ac,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key0c87995e43900146672dbdeb4e820841,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
keya5fdeec8da55539525b10e3dfd777ea5,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
key791741778ac50792bad3ec4f3bbb5f11,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
key356f4ca75729b0084b932cbaa661802b,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
key87341298004043102ac6cd80a64ee0b8,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key01d456262ef771182b3428c4377beff2,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
keyab7fcade4cafc4af64c26a28207a0824,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
keyed6284bd9bf6dc7bb4a9a79a7aa88834,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
key4b22d17784a6b152d225286f29a35b7d,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
key18148c012b15c15fcc96db4683ddfa38,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key16ca28981b8f0d1853c667c7c181794c,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key6599caf65315075bf8837efe3a6909cd,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
keyb718e2f9a0394874aae4a24b1966ab4d,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
keyd4522f868edb9c0b66241b00b22478f4,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
keya50ec54cd663d83d93bebd58c7c93ad6,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key51b53ab02c4e0f5e6c36ad46d5ce6399,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
keye03832aa9181661976a004368e4e0120,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats)
keybc97d118884ffb9a9abae5892c7558f2,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
key3156f46889a096629ef2c2347419770b,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats)
key37f73206317a0278768c555600b0b9b3,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats)
key5025ddc4577a8624cc1dfb6381af561d,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats)
key573b5272a358ec99ca0dbdfef60612a5,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats)
key082d0d80378e724bcd211f1b369e4032,Half life in rats
keyf91e0d38aafe6ca2212aa559cdfd080c,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily
keyb42396fea75aa5b37f04142feb59f412,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver)
keybcc2907af00342587d0d6e0be9f9f78d,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined
key584544700428f371b1493cd6c6857923,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver)
key88df15ef15a2925113e241cc51236811,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined
keye4f54ea2f15fa1dbe1a857c2c42938ac,Rate constant (k) of clearance from isolated perfused rat liver (IPRL)
key136a7e3792f80e62173a238883a14410,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined
keyeaba62d4fc622fbe5e744d6f1468c094,Maximal blood concentration after oral administration of a 30 umol/kg dose of compound
keyc7cc072b24d6449e30ff02deb647c8de,Stability (%) in rat liver microsomes
keye697be2046b50518f546665f210311a3,Area under curve was calculated after intravenous administration
keyed8cc6b50ed11c61b9bc89be652f862c,Area under the curve was calculated after iv administration in rat
keye0a4517c52b25d1e0074648d208ba0a4,Area under the curve was calculated in rat after peroral administration
keya2d3327b863a4555197058269769e0a5,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats
key791b70d55806a6ee00f021d3d7e444b9,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg
key56f1060ae2bda7542551f1e53101c74a,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg
key796525b267fcff1dddc6a5d41b457b6e,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk
keyffcf1a8651364ab534879feb02d76216,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk
key317df7cffe75349df90023ecd76c8344,p value of the compound
key317df7cffe75349df90023ecd76c8344,p value of the compound
key317df7cffe75349df90023ecd76c8344,p value of the compound
key10780124b0b4ca22e5dece7e8728336f,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
keye54890bb89e0839f4eafe81a43ef5d56,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
keyc7f790248f561c951ff6783fc3617880,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
key902b5bcd4b28add3a8a0022c4f5fa86c,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic)
key70d8a02a1e97020969dc2c26dd1a321f,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr )
key12bb7a390b5f48e58a13ec6a0a9f5ced,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr )
key0d9ec960030d1d742b3257032be11dd6,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample
keyde64b6daa28165d768bab638956a5a2c,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample
key35bb1c37f3835d0466bd66669344c6df,Clearance rate in rabbits
keyf5712bf690a2d16fafba5435a767addc,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.
key8083fbbc2e7c9bc4a1b76f5ee507cd52,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg
keyb2759aa3cb4b34f7c41f3160efcebed2,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg
key8bb0847af7a068419c1d73a49e2a0a19,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg
keyf4363efd7b6fd860e3979f7d4beef10f,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg
key7d0c5c4b3ab12df5de5411c974588f87,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.
keycd446bf6e85fff9a0cf6aaba513d9c56,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2
key183f8fff09f309812885cab64efc2969,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide
key1e66b9e88d4d006549dd281c0dc380b0,Dose at which bioavailability of intravenously administered compound was tested in rabbit
keyaacdccb6403ae028201cc6849550fa75,Dose at which bioavailability of perorally administered compound was tested in rabbit
key3a46c2ef39200ba6deae732b4ff95861,The compound was tested for its bioavailability in rabbit (by oral dosage).
key5f3a749e495a68596bf86d95583cb8b9,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg
keyc2c73e75afa592d00e8877767ba56554,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg
key170a60c1e90c5dfe846bf88032937640,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg
keyb30e0412cb7cbe228a4cf9a2814e2f78,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak)
keyd1a22f4545a36281a1a45f1bc1a97631,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak)
keyaf16fa76d4f670cb8dc179e80c048b8f,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg
keya6638813202017ee8e0399d513b020d7,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg
keyec1f51c0e96c6d0233cd66961e5a961a,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg
keya307b544c90b2a320341441aea0c01ae,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg
key0a8eb86374d1c602cc0fbe43972eb01b,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg
key5d81930cbf7a2bdcadfbf2a05233c64a,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr )
keyab2ee3e8d399b2e0f0b2af628584ebd9,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr)
key92634b64dd33db73dd6fae76c1b9129e,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.
keydd2e85f9bf979db635348d76085737b4,Volume of distribution after intravenous administration of 1 mg/kg/h in dog
key25ad23213f4c8993fba6d89aa7b4e907,In vitro Biological half-life in crude homogenate of rabbit renal cortex
key59a4898b08b1a2c5a57119dac7a6f96c,Time within which only 10% of the drug was degraded
keyb4e18744be3edf548835612d53255d36,Half life period in rabbit liver homogenate
keybc63e3b6b27e49013ca66d513b1eb674,Half life value in rabbits
keya03289f5fb92addda13459b372150583,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample
keycd94453db48c3c40502102477275aab2,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample
key93addd6a8bb07dce43be1d10b3377f67,Half-life period in rabbits following intravenous administration at 2 mg/kg
keyb362d79c7a812b7f91f0d43973ca3bfa,AUC 0-8 hr value in rats at 10 mg/kg
key0478bd52482a2fe9b35bc8f40549b6dd,AUC after administration at 2000 mg/kg/day in rats
keye3c040fd9d4b8788d674d7f644959cd2,AUC of compound for a 2 mpk po dose of the sodium salt in rats.
key6a217eeacd7bc09dcf35cb1362eb0cca,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat
key7c3366fba9f62388dd74d3dc6f5dc143,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat
key3362dbfc454341bd8d28c031b4833540,AUC in rat after oral administration at 10.5 mg/kg dose
key64b4272b8aef826722c83b9b795751ab,AUC in rat after oral administration at 11.2 mg/kg dose
key69e6657797ef76b8bd5bc504507c42da,AUC in rat after oral administration at 9.7 mg/kg dose
key31bc4eb2a646c7c69161152a42e04e53,AUC in rat brain after oral administration at 10 mg/kg
key3cfd30047f24c9d1d750d975bb156736,AUC in rat p.o.
key067de3f004938127ee22fe2004e2d3be,AUC in rat p.o. at 20 mg/kg concentration
key63d254324c59cc7b8195572ab28cbaff,AUC in rat plasma after oral administration at 10 mg/kg
keyf266005d7e82667c6b8231160c689b6c,AUC in rats
keya146f34e41c6925ad789ed27d4ae81b8,AUC value after IV dose at a dose of 5 mg/kg in rats.
key56f5e54a4cf834ac659f2c7260023189,AUC value after oral dose at a dose of 10 mg/kg in rats.
keyb8a1ded87853b3a0dd7e1a4d0eab9821,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable"
keyebf3ec51d2d2408d4f502b713adb184c,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given
keyb60fc9d85481f772a089c29b0600e383,Maximum plasma concentration was evaluated in rat
key57c07614da44e2ee6275d804cfc8a386,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration
keyece8cc934d405d074606e0f1a16e9656,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration
keyd7098ec7d2e18fda2010eacde8991b9d,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose
keyb80ba58d3d39442619d8e002f5275a65,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats
key72a4316db7dc82210819353d845094a6,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg
key5a372dc820c4911dfa14ceaf769d3eb4,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg
keyde12da08378972439f94b44600b42424,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally
keyfa902eeea974bfc4ebaef69473c797a7,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg
key73516d8e0fc5dcf3544de81766055b9b,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg
key82900330d5d2d908c55f9ac725ca23ec,Maximum plasma drug concentration was determined
key848560bbddbe10b37f87045596da84d8,Maximum concentration by intravenous administration of 3.4 mg/kg in rat
key39024b76b9ac69b5ccf69ee86984a35e,Mean peak plasma concentration was observed after intravenous administration in rat
key20ba2bdddb896aa3725b26a53ee5cdb4,Mean peak plasma concentration was observed after oral administration in rat
key410b13643282bf2a3aab282d4d72ccce,Peak concentration (Cmax) at a dose of 10 mg/kg in rats
key4555bf39d8a813d036d93b507f882bc7,Peak concentration (Cmax) at a dose of 20 mg/kg in rats
key80298819fc15e442e83d6aa958d64e0d,Peak oral plasma concentration was determined in rats by oral administration
keyd1fdcb57157e5a8a0be94c6ce3d05e84,Peak plasma concentration (Cmax) was determined
key309150d7a257904aefcc7a66ec587b2b,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats
key97b5161144d62f6de32d72f62f51b994,Peak plasma concentration (Cmax) in rats
key86e6e7e795bace4123c20b4e0d96bc0e,Peak plasma concentration at 1 mg/kg peroral administration
keyfaeba9775da4338da571cc6bfc45bd95,Peak plasma concentration in rat
key3a8807f1a0558ce15f3439744045ce82,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration"
key078161d3e66ef06799593fa8fdf6504c,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg
key3856299d72bf83959ffa3c173d208903,Pharmacokinetic property (Cmax) in rat
keyd96f92a28d95d3f94d1a69bc4ba6ba3f,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.
key18dd500e3d376c8ef15e8b5d46f56a0b,Cmax in rat after 3mg/kg oral dose
key3d9cd2a34f7bda991d64456bd7af343e,Clearance in Sprague-Dawley rats after 2mg/kg oral dose
key2b0a666b85f7b8709bcd338b8430dae6,Cmax in rats after 20 mg/kg oral dose
key7f3ea912161bc3e98dcbdab25777d9be,Cmax in rat plasma after 30mg/kg oral dose
keyf98e912f02e02e6f732dc5c856ae7b4a,Plasma concentration after oral administration of 100 mg/kg to rats
keyf40346a3df083ba0f800e2ae60cd4c89,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats
key6fa2895b43b0dd96aa6bdeb3887188eb,Tested for the Cmax in rat at 10 mg/kg per orally
keyad519b85abd834522b464956061445e1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose"
key7a6191b139288179a2cc915a70121138,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose"
keye38bf76f50abf7dd9a95703509f47111,Bioavailability as oral Cmax in rats at 30 mins
key1936716707dedfe6604640b21f2b9158,Bioavailability as oral Cmax in rats at 6hr
keyb002e13271ad2b7c18bb2ab49340dda5,The maximum concentration of compound was measured at the dose of 100 umol/kg
keye696cfc3de94849c5c0b8546330e9847,The maximum concentration of compound was measured at the dose of 300 umol/kg
key37c2f5590dabf6f980466acb09a2541d,The maximum concentration of compound was measured at the dose of 30 umol/kg
keyf63ecd9addbe48331cf4d9427e7c7ee0,The maximum plasma levels for the compounds were determined by LC-MS.
keya517dcc8de03a042bb094e304e3bb423,mean peak plasma concentration was observed after intravenous administration in rat
keycbb8d697d1f9e38bd2cf6c5c0025aa4e,mean peak plasma concentration was observed after oral administration in rat
key113044f99766f9b388f737d073638e97,Concentration in the plasma after intravenous administration of 1 mg/kg in rat
key41d729bf5b216a020e53ccaf6c616fa4,Concentration in plasma (portal) following oral dose in rats at 0.25 hr
key1d6c920c700c401ce94f4d31a078f1e3,Concentration in plasma (portal) following oral dose in rats at 1 hr
key34651314b2585e9270477e3fd8dbbcb6,Concentration in plasma (portal) following oral dose in rats at 2 hr
key8180f5b93b681a2327eaf07baf2cb0df,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr
keya1e1e15d3609aff1e9ad295b9606026a,Concentration in plasma (systemic) following oral dose in rats at 1 hr
key7fcc8140495473a1599c89b87997de00,Concentration in plasma (systemic) following oral dose in rats at 2 hr
key51f0ccb462e53356c9cb7b8224b64b1a,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo
keyad00227d7a74556078b563645e8cad71,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours"
key3d4c9247fb99a5f0a145013b1a38d990,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours"
keyd2d8e44dbe2edea7280e4beb12c817a2,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours"
key3fccf1faa07d9addbe90c9f0b85af072,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours"
key66d6c35bff87aa826a793eedfb08c490,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg
keycc0d21fea0374af2830ebc139d8d894a,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
key75cc9c58972580f4e1a834745e65bbfb,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
keyf087b47f2b274b9f8dea4981d10cb955,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
key17d10bb7e04562b8e3af52615679a9ab,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
key80409ca4dec6e22c8e4169de237e6753,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
keyc61b12edc66d501d4e78ca43f8ba7655,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key59efa7673eca31db50e30a764520fbac,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
keydb9720886134cac38bd9d6fbb2cabbba,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
key54d4368ebdc912a8cc19a52591170b43,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
key903a180e74330d85b780c8be295ae8ae,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.
key45993b422404ef504173dd637485aa80,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
keycf13a8d875aa96dde0e5b5db011e80e2,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
keyd5478237232ca6e15f314b8e517215cb,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
key79d98ee6e47251d119cd997526a5e20f,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
key0cb21f5876706606b88f101952f88bb4,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
keye635ad3223030f8e1c5ef1d999a862cf,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
keyb90dbcb3fd3c83b117b0ece3ad9762ce,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
key8aede9c3f07323a7b45dbb95128e0626,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
keya556c5b84e5092bf418436ffd92b6bf0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
keyb759dcb0680156a7ab0664d00b621d5e,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
keyd61afc9bac27573ba01633bebc38deaa,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
keya06efc35c66894f0494d921c0b7aa3ad,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
key985468f8b4ce934f0f43896aafc01ecc,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
key9e7769aff09580980b466c193357d57f,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
keye8048ba2c99d83cb78482dc5d61c72dd,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
keycbfc7af422af1ab9d6385c329ab92b24,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
key1167d363bcae48338f51412c6f72b6e8,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
keybe64b90460e8819a1c04466a2026e8c3,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
key09a7a1389edb1334a200957e88c062f8,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
keydd083206fdc31d2f48f2e20fb0467eae,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
keyd2a4649273a0e999639d20ab0dc6fb87,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key4a861abc481580f1ccac7fcc6d707a41,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
keyc37491f41147b8641a6324b2024bfd0c,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
key5e0c369fcbaca96006de58219cf8c073,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
key1dd81cc01cd91458cc2b6033b531f026,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
keyd82c55e5c22de35d864829466ef125f8,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
keyc32d1fbddd20f0a505a3aa9a75002afb,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
key0af7ec1b2c9b9f20a8aa4815e20d5229,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.
key94c073db0864d92dcaf2abdcfd0134b3,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
key8b1586d79d31273aa5946c6bd12491da,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
key115bec3d6d957b18b75adba2fade54b9,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
keyd5908bc978b8e9a9b07189fbd85fcad0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
key09ca06d205fda7b1011d51839b6f88e8,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
key13fc48416a3db623230683cef45854a1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
keye7e10731805fd2822035a110d682310c,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min
keyb032534c1441404d53ba8a2ac99469e5,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
keydae240a706a461fe1ba42d7487a70e15,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
key17c5f22690521ac0cb8c726792084e0d,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
keybc6ef0e5953303b6829a5d47a7d93d4d,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation)
key669d6f6e7936afc68abd91861abaa238,The compound was tested for the plasma binding in rat
key85bc98f19cd15cef182878c1893022be,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)"
key6ea53e7dd6337a4929061acf696c3a78,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)"
key3c2c0576341fda7d8fda6cecd06f6103,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)"
key387306d2cce12261b9ac390b277bfd30,Plasma concentration after oral aministration at 1 hr. (10 mg/kg)
key0e6498bca9fbe321885152961150526c,Plasma concentration after oral aministration at 2 hr. (10 mg/kg)
key92ee526ad876451008c5f882ef9c8d7c,Plasma concentration after oral aministration at 4 hr. (10 mg/kg)
keya8d9ffbb8e809ab8dd740d5932a24815,Plasma level at 2 hr after administration of the compound
key36f9837919984b1ba9a09c3a4ab56e07,plasma level at 2 hr after administration of the compound
keyb865f5770dc1964814bb95c4cf0ee8fc,Stability in rat serum measured as % recovery at 1 min
key9147ca4778569846e0db0e1b631e5df4,Stability in rat serum measured as % recovery at 10 min
key16dff2ef52e3d1860b3cb25c70ad90ce,Stability in rat serum measured as % recovery at 10 mins
key9e4e16f99a1c7d7289aa37bbcac35269,Stability in rat serum measured as % recovery at 2 hr
key82903c40dee648e00e4f738c2342b592,Stability in rat serum measured as % recovery at 3 min
keye4727df88b1943c945a0c2370881431d,Stability in rat serum measured as % recovery at 3 mins
keybb750e84e3c0ea317cccbaa4583f6480,Stability in rat serum measured as % recovery at 5 min
key04f8ae2e6ac5b3ac09daa9f337a09203,Stability in rat serum measured as % recovery at 5 mins
keyb71701af144654c7451551d7a747e78e,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg
key51f45707d4e92fe3bb65c7c24d3dc827,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg
key63ec3df076c01e686ff18d1e5c7fdc74,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma
key5a9b605f2e1acc3313f60426f44e4856,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.
keye385038592e9a2dc4cdbbed8967c34e1,Half life tested in mature male rat at a dose of 30 mg/kg
keye67009a319dd2fd71066f99d41ca372e,Half life after intravenous administration of 1 mg/kg in rat
key3329777a95da333f131a371da3362456,Half life period after administration (30 mg/kg) in rat
keya1ce44191d859b5363157e640ff094ff,Half life period in rat after 5 mg/Kg dose
keyfa7b1239b8eeb2a29bbd87e710c7fe8c,Half life period in rat after 5 mg/kg dose
key3e0d2c07e16ea42ca2a2bd92e4bb64b1,Half life period was determined
key8b7243bc30b67184ddde98c0a1fc7140,Half life period was evaluated in rat
key3b9d29984ba8449927a04fc69e7d2c7b,Half life period was evaluated in rat; 0.5-1.0
key05d4e57406ff17d53ee143d86adc0351,Half life period was evaluated in rat; 5.9-7.5
keyfb9321f3ce2a73c766ff114753fdf5de,Half-life in rat plasma
keyab2aa11fa2040c2b2cb59df58772cacf,Half-life time in rat was determined
keyb83f2e45ed9120bf960fdad479eef3b4,Terminal half-life after iv administration to rats
keybf2fd65bd8cd7f2a668633dc80901201,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats
keya2654bc44474241b1b48dce587a3242d,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg
keyccf20b4aff396bf94abe0f0a9a963bf4,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv)
keyc3b8947907cf8cf9dca005aa547bafb0,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv)
key5062a9aee2b2e754ddb1d87a27fb4349,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats
keyc6d4f01da8e786a0a84fae7e2dc6f9ca,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats
key082d0d80378e724bcd211f1b369e4032,Half life in rats
keyb9f2d93db905d15c259831a37a81383a,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat
key9ce8f5af7427062fc887cf5b4ae7ae88,Apparent half-life after single intravenous bolus of 1 mg/kg in rats
key46a1ea03e381d1f1aef15dd18779aa9a,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
key932d356b27f25682d2d7a1052a0a1bc8,Biological half-life was measured in plasma of rats
key37bf1b46e44a3ce23d6396a62d6e8ded,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats
key3abe549a6cd41900c4afdaee7d31b29c,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.
key7c681fabb2cce2cc2f19434a05a0c00a,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats
keya067142def5e3011cf6c9fc7e25666e0,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats
keyfbf07b2e64ae44993f49573f203d50b8,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats
key676cb5186f314ee870528305682ed757,Compound was evaluated for plasma half life in rat
key1cde634fa2bd9e66fca57acadff3ebad,AUC value at a dose of 5 mg/kg (p.o.) in rats
key8eb699da7b6163968a3325f3256ef303,AUC value after administration of 20 mg/Kg oral dose in rat
key051de4303f7d97f0ce099ff0fa41bde4,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats
key6439c1c5667dc9e2c469c2551b19c05f,AUC0-96 after administration at 50 mg/kg
key0cb05dc7e6f55b78216e6ffac9543640,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats
keyebcfa4fe1fe57190b38de3e4ec5ac5f2,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats."
key993f271e0c4349ef4b9d3b514ffcac4b,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats
keyb72f68c58b3c93563a002ba846717057,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats
key5d8ce1209a9f6b9e1b8c6bf89a197c95,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats
keya9cd0cdc394f584add3929419549ef6c,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney
key51ea88a371b8bfe330e149ef3befead0,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver
keyeada36bf464666186e2462c16d171dc9,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung
key5f5244a1ada6b8f1bf7de93ed2208c47,Area under curve (AUC) at a dose of 30 mg/kg in rats
key4030f3d784ec5048737c8e41d0983815,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats
keycc8caa528d14e798564745f26fc0643b,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats
key4030f3d784ec5048737c8e41d0983815,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats
key2340b9e4f1e36918e82c545e0c2b6d79,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat
key8c97daba1041fe2a2cf2f12aa2f710ab,Area under curve (Pharmacokinetic property) was determined
key2770ee715b318357744695d051405435,Area under curve (Pharmacokinetic property) of the compound; Not determined
key7e3cfabea8d72ca1431dfe131ee7f64f,Area under curve after intravenous administration (1 mg/kg) in rat
keyca42aed8040e50a49df1cdeddb49278c,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined
key4bece5f3775e7b8c0362de14f404930b,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined
key0fb553b9ba9d691285fc5cd21afd3766,Area under curve in male SD rats was observed after oral administration in rat
keybb01206b1ee3a92f0890658c288a2467,Area under curve of compound after iv administration of 20 mg/kg dose in rat
key43e45ff3de6c099dba43926bad2b5d9a,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg
key07efea7d019e62ddb9b3cfa992704ec5,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg
keyde595fe6398da4045c048acaa7430d2c,Area under curve at 5 mg/kg po was determined in rat
keyf6c6702f3b4d5a17e71620beaf33703e,Area under curve in Rat at a oral dose of 5 mg/kg
key38ba4a177763e26e0aa24ecb1cf18727,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
keybd6a08c70e9dc387d342ded0f6b190d8,Area under curve was determined
keydea8edba449ab79055bba68ccfc9332e,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr
keycce0f00124cf70781bff47e70ba1704b,Area under curve after intravenous administration at 3 mg/kg
keyfd1073b30baea5022828ef71c28d9a4a,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h
key9bd76b170d45ca33932938210a7ec9ed,Area under curve at 4 hr in rat
key6e6a569402e74417aa2a41231bb1865b,Area under curve at a dose of 30 mg/kg
keye4a78be0dee8e9f2b26141c36fa7c34f,Area under curve at the dose of 2 mg/Kg administered perorally in rats
key2ecff1f88523b3fcf99d3ab1d9a16931,Area under curve at the dose of 5 mg/Kg administered perorally in rats
keyf00ed1e889edc2362aa656439fbc305d,Area under curve for a 2-mpk po dose in SD rats
keyc0e13d82d67e195381d1dc4792e4ffd4,Area under curve in SD rats
key99b9a77a57ba9bedabcc60732b27b166,Area under curve in rat after oral administration at 13 mg/kg dose
keydab7f97e352539372ea3dabb798ec5f9,Area under curve in rat by po administration at 0-24 hr
keyf073ade0456ffac831c920293714bc7d,Area under curve in rat plasma
key92a50a16d577f7dabcd5fa13798668f0,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg
key1149ef89f968346a7e0e0ad3ab782a4b,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg
keye638a8f1357bb8665623982699dd0557,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously
key14728094bf3065f679299e9b480e0528,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats
keya6ca29955eb3e47413b162b4b3e20b06,Area under curve value in rat at a dose of 5 mg/kg
key2a5a6fedb663ad102b58d6e41f67dc6b,Area under curve was determined after oral administration in rats
key58bce2658f544277e18aeb7c39bbabd5,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats
keya86c916d95d7bffcd1214b8b02351420,Area under curve was determined after peroral administration in rat
key788c795931fa2ba040ecf94532da1d39,Area under curve was determined at a dose 30 mpk administered orally.
key48f7b1f5e57206063edb529ead9ffdfd,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg
key001201cba74a285f5b7103a06762edd6,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat
key7080a5c90f7a1ae4492e26e0344f3ba8,Area under curve was determined in male rat
keyb0c0bfe1a5d937f62cd35622978dd4b8,Area under curve was determined in rat after PO administration
key989ec29992e9370705291a49e6c0cfd8,Area under curve was determined in rat after a 3 mg/kg of oral dose
key1be36aaed33e06399a14ac5addff014b,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg
keyd66e8841ce2a186c128715786b6897d7,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg
key4b852fd3c1d8b717a47a5b87778f9819,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active
key8fa60ac3c3f9b423845e256bef4081b8,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg
key0b6cc517fcb6c21f9183a052a57a7188,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg
key18e1d5f3a0e03ac1071f837f36d9fbdb,Peak plasma concentration in rat at a dose of 3 mg/kg
keyd126148a7a50649ef742fdfc2ffc0a34,Plasma concentration at 2 hr in rats was evaluated.
keyeed618483e9119d11b6759ba300d86bd,Plasma concentration at 2 hr in rats was evaluated; Not available
key68e116578011a44ea14d40b805be1ef9,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg
key1ea36ee6435143b014a194afb1a8d33b,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats
keybec60681f913bc8772497130a1066ef4,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats
key020d98198ed7c03c5687b559adf8ed00,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats
key81fe591a24de0e7f08b58df450436e49,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats
key33fc97b04f7a30bcb3ae351a697bc580,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats
key3d6ed5bb73fd8af82f792b209e46d2cd,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats
key7dbdc14792b257ff2f3b1bc4ebb41794,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C
key639d1fb4df1c6920a464e10653990a3b,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound
keye44f312502ffaaab01b350127aca1607,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined
key88e58801d702514d222a4d2c9419a85c,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested
key4da1ace032b79ac521db4879f9b7ee57,PK study was carried to determine the relative absorption ranking in rat.
key1c8fe2b491155a50fb8169e377abd396,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg
keyc26ede31abb808744246726535dd5b8d,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g"
keyd431c94f7f17d239a8556e1e56f340fe,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g"
key3249ab677a5e50c21c4dabbd871b521c,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g"
key321fcee25f3b105c87b53c6a9fbac58d,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g"
key1550ce57140d6952ddcf4734fd09900a,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g"
key6619ee4e94854445fb20152bd66c130c,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g"
keybeabd701916cbfd0138ec3a7fc65fdaa,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g"
key8f91094a909ae2b061b9457785701c7c,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g"
keyb22c4e8d09f5925c7d563ce9f02f0c23,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g"
key41dd98ca1ebe99b268987bea499ad12d,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g"
key030715d81f962c84806ebb53fe3e57e7,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g"
keya882c3b55330328174f37eb456d9a071,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g"
key6841d42faaf592217aad83d6e9b2ead0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g"
key4c3d7a1c070103ed8f35e61a21266484,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g"
keyb9ac13d838bbeab4fed02c8cff094663,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g"
key78cfe9f749449732879680f582b1d4fc,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g"
key93212af747044c56fc8cbe3a422116ea,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g"
key1cc54bc78b1b75e72ed371cef29105cc,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g"
key45ed76fb52477e2d2e3399416c9a70aa,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min
key0c6e242afa46e169f2632f95c64d79c6,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key8c480cf94fb175864ddd6baa3993d4fb,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
keyf225e3d25c52bffa79d2b119c54ea367,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
key5b227322f6b04612943500d87d88b8b4,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key17c38476fe809e262c0043203b5635ad,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
keyd3825e39538c59875c18d592b9124c4f,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
key94aa8bfcc177e16da92c8a4b6c53df2d,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
keyb8e54ad7a52fef19b4a7e8b6249c64cb,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key1e97fae6dc1b8b0fe1f55e2c6f422d23,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
key6deb7997377ff047e4a8e35669b01124,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
keya27db1e86f0be2c2c0576075d1ab9d30,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
key02211caec2fa60cea1cd8965e3ceb25e,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
keyd485fc132fac01bbcaf847696777d229,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
key1dc6d18c73c8a4e808af920e33848477,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
key9bccc0650cdb47e20961cfcee6d50d76,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
keyd13bcf9d36cf923443a4cf98f5b099a5,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.
keya769c7987e93dad70c9266474dbfa7d1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.
key0aa0bf7cdb8a431919a7355a131d63db,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
key65732e7032bdd0ada90b824e07ead5d8,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
key98323e1ea7fb0596759054870714ba31,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
key4fb3cb03ad92960c579ba4bdf9409c13,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
keyb950df1a323a90eff75dccf618141c2c,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
keyec188bc031b6fa57b998a9e5019a2537,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key6b0638e37a4d68aab6b30c6839cb69d5,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
keyf4b78d3b35d5e1f88f1cfd1764618d19,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
key1b5b7baf927891ba438c3e2bfe75dbec,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
key2ba61d3510e9b3767291a91c9f17887c,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min
key288f24379c29089a21a65aec13e59591,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key0b4b103cbfdb00a32d4416ad2ce4f359,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
key1cd8e575bfc1fe0bfa4cc537de373e28,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
keya87316516d9ea8c07aab3aac3acaeedd,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key379182c74a3fbdbcba98c1f8870a1f36,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
keyd3d276900a8e05a6e751cbeef323f06f,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
key190c8abca4b138bcc1195cf1311201ca,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
keybee4ac90c35191c84b196f11c4e62e5c,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key2e4af0bc3a171a04e5b32f4173c1a4ea,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
key579100edaf3a4b1f5bab0e77b905c915,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
key36e96598efe96da7a4de0fc2f57c9c75,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
key52d51c54c7853d3c91ff170fd80645b0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
key44c4415acb0f81e353a4b87f1df694a9,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
key802fb7e54f0820468a253c1c084a6850,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
keyadf360500cb9975aa90dde3071115647,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
keyebd6eb4f83326995e2609d910876f29e,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
key21b62550a060738643b52f1627e7c561,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
key9dec6737cccaf6a3ee150f1bfff296b7,Compound was evaluated for terminal half life in rat
keya3b8e04aaa2d6d6471e4fda745a0f5fd,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve
key6ca7b3dcf584541e5ccb62751beda52a,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve
key9b8ced8d78081b28b5525e7ee079030c,Compound was tested for its half life in rat
keyf3f6a8f01065da49460271d99a23a2fa,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.
key858afbeb77b5022e82c2a6c39dffdd3a,Compound was tested for its plasma half life in Sprague Dawley rats
key10cce77ca758e15d078daca037c5abe2,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined
keycb2e888c6464c8b464ee8e119c1dfac5,Compound was tested for plasma half-life period in rat
key31f510738e70dfe662e97a717cd63b10,Elimination half life after i.v. administration of compound in rats
keyf7647a7c313a185fa00cda0264640f0b,Elimination half-life after IV dosing at 0.5 mg/kg in rat
key2800292370e697b6441f37b86c73e423,Elimination half-life after IV dosing at 1 mg/kg in rat
key808d65aa3e6e2bdc619d2a5e0aa7fbd6,Elimination half-life after oral administration at a dose of 2 mg/kg in rat
key5ff0af98c15271c3cecadf2713d64922,Elimination half-life after oral administration at a dose of 4 mg/kg in rat
key770108215467053dfd54d945dba1ca29,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined
key7f1941badb1bafaab924647a6e018b98,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma
keyd2c64b0e873647d0d9334147dc4992df,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain
key0110808d0569b9be39bc81b67daa1189,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma
keyec3233074dfa9c5607eff6f07f554b6b,Evaluated for the half life in rat (in vivo)
key036e3b16a59ca2dd1029ec8f6ddc8afb,Hafl life in rat
keydebc2cb9e4a9c2fe85859ab7472ecad7,Hafl life rat
keydebc2cb9e4a9c2fe85859ab7472ecad7,Hafl life rat
key487320f6eb29bbafd9189d992b34f7e2,Hafl life rat; Not determined
key487320f6eb29bbafd9189d992b34f7e2,Hafl life rat; Not determined
key89a1e9006a1e69dcc6e230bb9dff3bfb,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg
key010e29243e87e64e4ad988b645c9874c,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg
key4956fd247b359312e316f7387d1e0de9,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg
keye9c826df6971edd5d40684d10e31a42d,Half life in rat after 1 mg/kg i.v. administration
key48219fc0515c00a6bf79dff677220b02,Half life in rat after 2 mg/kg peroral administration
key3fc71fb23eae7c3c77a3d18559987afb,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg
key3d54f15684468154e680543bf5427b4a,Half life of 10 mg/kg oral dose determined in rats
key75ae670388113a803924e2ef3494fa0f,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat
key32fa6f9cef087b2cf00a996275e2cc12,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat
key481a5a9dc268c2393f7b82fe1494e093,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat
key6acce0405c32af3e7786511da62b9cf5,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat
keyf852ac7fc4147c0e5a106574399b028a,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat
keyb2ca90e348798f92b916eb79aad39def,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat
key4962815d1438cd967cd85adaacc7d3ca,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat
key91a83883bfbd2d212f74e6559a8aa5fa,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat
keyc9a8e653e8ace158fd1c53b070d5ce82,Half life of compound at 5 mg/kg after po administration was determined in rat
keyd43d8679f0edf7010553fda89e0c9adb,Half life of compound determined after intravenous administration to rat
key94d2013623b4fce641198bc2e919dc9d,Half life of compound was determined in rat
key493db52245f2aec6391a4d0589d0adeb,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration
key9cc8f7526ddacca8199d424b1e669a3c,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
keyf8d933033d8a0f127060124adc40cec3,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats
key6661335fd443f03547d480c6ce06e137,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey
keyf5d05a0d700ab4534564787b6f2b681f,Half life determined in rat by intravenous administration
keye4ab9b7c9378f17e0594f2b0866dc501,Half life determined in rats after iv administration
key491629b5015b10b887eb4ba6c6af4195,Half life in rat plasma after administration of 2 mg/kg iv
key491629b5015b10b887eb4ba6c6af4195,Half life in rat plasma after administration of 2 mg/kg iv
key961568a235bd58d7d78e1634d50d4423,Half life in rat plasma was determined
key00610943db092b5aab4ad9e0142d14e8,Half life in rat plasma was determined; NA means not applicable
key6355f212e2486ebecb2b9754af6212d6,Half life in rat was tested
key374d823fcc18dadd23a7b467ae58e416,Half life measured in rat plasma
key3bb324e5451ec14a9976d056405e3352,Half life recorded in rats
key17d091b9b0a787f14b9120c22487697d,Half life was calculated
keyf59f554f27ae8c0c75fd18ac0a59a475,Half life was calculated in rat
key55e2df843666c083dbda843a7f29afc5,Half life was determined
key96ba325f2cc99c47b42c52af317189b2,Half life after 10 mg/kg oral administration in rat
key0af5e7e7db7992787280ef6f37e5010f,Half life after administering orally a dose of 10 mg/kg to a fasting rat
keyc17f0466c5ae652097e8060dc0e4b520,Half life after administering orally a dose of 30 mg/kg
key8e6191a872cc31d3b2fe2696c6b67696,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats
keyd843512fa19f9b0ac37a0cb38054d30e,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours
keyf4179eafe388be0986191b884105257e,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat
keye739e21432c20dd08a3dcafb089e5bbe,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat
key794bf3228c58cec2fdc3e81f4fd89a1d,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg
keycf514c2b0e79a894131109bcbcb4b097,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined
key93ccb9b4f80b7d0091cadc313a948a2a,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats
key4385a3954eca4e09668d70f5ebc85d9f,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats
key33d16f44a5b983b54ebe0f24fd3a3e5f,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1)
key888d37dfaa5536e5691fe35c1ec63908,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2)
keyb937f0978135ee2903f1c66c9927f240,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5)
key438f6d6f6746c6bf9a8e95709a7011aa,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10)
key131deec8d430fe54d9f7d63440cca83c,Area under the curve was evaluated after 10 uM/kg of intra arterial administration
keya7f2d12403e19eb074afb4ef9ecb3af1,Area under the curve was evaluated after 20 uM/kg of peroral administration
keyc868a55604badbf2b54d30dbfb8dbaef,Area under the curve was measured in rat after an iv dose of 1 mg/kg
keyb319479c34f11b59a82c1ff80644ca42,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat
key44f1e547c8a1ea79dfb2dfeab15695d5,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat
keybca3e5c15096de2c76c7270be404f7a4,Area under the curve was evaluated at an intravenous dose of 3 mg/kg
key38dd18002a81c1d7d54fbdf3d89cbbf3,Area under the curve was evaluated at an oral dose of 30 mg/kg
key47c61f208cb8034d6e7447bd0a802040,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
key676aa9c00aabea67dcbcec9d7b27ef97,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats
keyf5d898e6f6a4d0232f152699f04d4532,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
key57dc57a9bc8b3988ed52ce68bb8fae4e,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats
key3741611bc7b58ea16a266962aaae995f,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats
key41f7ad7d02cb55e791c2484d6aaa962a,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats
keyda0cf8b4ffab5048ed57c3a8c03fea2b,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration
keyc87d49f46c2897a5dc153afdf47578b0,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat
key9c21b040e1796ea21b469f7fe2679d6b,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined
key9c8d4f174f70297d0aef14728e5bd26e,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured
key33133e1c9bfd87f14a27b9b149cea038,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats
key2bd63e6466a0dd0ed7b3abcfb3117a4e,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats
keya41fcfce592ba7b0bc55351b9d8c0a20,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats
key2a08b1e2f16dcb2f664564c2198eba01,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats
key8a93ccd3dc4e02586dd1bff4a8f6cfc8,Compound was evaluated for area under the curve expressed as (h*ug/ml)
keye658f46364b2b9c47ebc1a5eafd85b0c,Compound was tested for area under curve in rat
key5eea0c398206e2dbe484e8e97fdfa88e,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours
keya2d3327b863a4555197058269769e0a5,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats
key853acf1d2ce739f416d35e24a7fbcda7,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg)
key7e809cffca501fafe88521ed80733478,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined
key99ad48e409917cebc0e536746bcbcb06,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma
key4ce14cfdf1da78efe3fa23b3c1a3f37c,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain
key8ae6264c95a72573284be81986dcba40,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma
key40e1c011f725b4feab3e609619be5e04,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr )
keya30b15632918f1ed5b41bc1512ddc7c7,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr )
keybcea6d5bcc90fccd4e9f3c53bd884100,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr)
keya72426edb51c3b570d2d85a38fa150c8,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats
keyc004b2027bc296aafa4b883982bfca09,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
key562c4b3d6bde51410c1ea646e8faf154,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
key23ed94d41ce18d3187d15287a18490f1,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
key4de005df17f030f0b60788a8b5123828,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g"
key1f121c71a9d28b7d97e2fbafacaa7051,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g"
keybf40ad2bc4955dc6347eca5e56d05bad,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g"
key5e0c9f52a34eaa824aa69dc892e797cc,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g"
key4d1dce1c538a18fbd85255be7c866560,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g"
keyc1c4f852433689f3e71143e31c047df3,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g"
keyeddc1f8da132440b6bb888ffdf4f7238,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g"
key57ca9549ef0786bef0ee8bc2fa8550ba,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g"
key41724672755875ca1360054ffbfb4659,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g"
key0fb566a24c0c0e8a72e016a067de441c,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g"
keyc1594a84d1d229749fa7103fdf056a10,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g"
key5cbbfef775eccfd06dff9ab10bd742fd,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g"
keyaa02bef3f14fd93cbd295a3834d0fa9e,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g"
key87a9c9ada27c2d61c1a3e501cd3cabb3,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g"
key962b6a5847fe23c5ececfb6c12248835,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g"
key9aec6d5af42ab0664e47984d64481197,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g"
keye1cb193e94964cc5c7b00c661fc9b1db,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g"
keyb6699780e5d8cdc4f5eddb71f057dbcd,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g"
key5284223d7c5376fcffbf0d64989ba71a,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g"
key68ee516150813f1478ceaeea07220085,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g"
key6e4441bb8489049648787c491dc85c33,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g"
key343568e8c635ffee175903a8f87b622e,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g"
key7de2f7119628e0443d5cecdc1696d635,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g"
key59dd8c910aa61650370b30cdf72209d2,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g"
keydd6c9fdf211370b31c62fda94ae8f245,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g"
key3032476fface35f5f66773a1e7e68625,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g"
key1b21849db3b73a440fd5f9e0ead76d53,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g"
keybc1b99ab3dbdd6139e502ee0de15962a,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g"
key4dd2367436cc1edc5075d59d171b186f,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
key4df200a3d5bdbf02d203ed46f55e1ca1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
keyc741ae454b2a765a118d4469fbb2576d,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
key82a5a1f98258a0be99ad96289087bac4,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key5190234fbefe369f99bb98df8695f291,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
key6b5aae12c90b9b6daa522ccc47accec7,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
keye03ce7b004ca065391a17d8ae615fb86,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
keya594d350a8ca12fcca51e592e29c6db6,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min
keyb1a6fb43433323264ef093d3da371461,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min
key20aab9126db2361386f59ecb03b30e0e,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
key6379e4dcb9ad9240353267d9504741dc,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
keyf18f18e1a1162f6f1ff04c84283fb13d,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key3205d10a9ac9337608e5b3ea54d0ff74,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
key6b37e4aba4dbafd229672f9eda98bd6d,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
keya9469631e3b1abb0c4f12363cd839586,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
key5fa4d566d6b0c2910541de33eb5fd442,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key16d8457b2e6dd23f961f24455818805e,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
key3f8ac17ff11117d6a2cad011a67c5259,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
keyca1b447b86ed4843002c7557cb9828ed,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
keyd32c56b3e8e18703684a7579ec42b6da,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
key08d86e13eaf17738155e5214b4e352ac,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
key2f126a951208604fa1ff59e54d186352,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
key61ad5f22be92b719a3df698425d5db6e,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
key3a54de6c953e79f88f9a60d95f0c4a26,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
keyeb0f9087619608abf23edb2832f652ad,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
key07341140da513d7167da1f69c910539f,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
key99287c9122223084d8255def98cce692,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
key21365bff49014dd7db9c8710e3ebe137,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
key2b4c2c903c1028a632aad1a9b2168aab,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key3620e0719dc41d53aa7a9fb391b956b4,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
key3610a2035a5d079ccfd3984e60b06b57,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
key5fe508c02b9374dff9952ce036816bb4,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
key11fe786a7b8db7b78700a16e0c074f99,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
key97b9700841615fba20025553ba3ca3f0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key0220728cb205d37cc82a6ef161b4e7c9,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
key4b7f19690503e8c8e072b9ebf8ad909a,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
keycc2bffc4fe4e5f4afa57545f98ef20fb,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key487575a7efaf9689e359e9962b935fbf,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
key2bed6f6416be7723b822809151a3dc09,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
key4ccfa804c1c74180926705e52ce3a3aa,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
key66a4bb7223aa467fdba8fba02a6684cc,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
keye749d413297fb2e29f3afe7c1fea88c1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.
key847df80a08a75237d5769b894b45a6aa,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
key425ecc733b5b29b5cca1af012add2097,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
key04cb264618a93759d850a6b831bc0a36,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.
key733d6bdc00baf52a4189e565234a5cd3,Half life after administering orally a dose of 3 mg/kg
key20306c29b240e7b9945c8ad55740b459,Half life after administering orally a dose of 3 mg/kg to a fasting rat
key5399ed3b990c0f69c67b45aea7e7e445,Half life after administering intravenously a dose of 1 mg/kg
keydae8fbe88147825215802397c657bbd4,Half life after oral dosing in rats
key464eec07327ac73ae43389f6b1d72320,Half life after the administered orally a dose of 1 mg/kg to a fasting rat
keyf36936dbc4b268b2d64ba9f9cec41aa0,Half life by intravenous administration of 3.4 mg/kg in rat
key03882c26e3160207d6903d4e1f9caaa0,Half life in rat
key03882c26e3160207d6903d4e1f9caaa0,Half life in rat
key03882c26e3160207d6903d4e1f9caaa0,Half life in rat
key46b2245a68e00bd6d7ff66bc7a483d46,Half life in rat after intravenous administration of the compound
keybb69b38b401f107b5aa763b1c8a4a0ae,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life
keyb6954e989c81cd57685e2450f733605c,Half life in rat after po administration of the compound
key53ad1fc982beb1d9e422ff9134c11fc8,Half life in rat after po administration of the compound; ND means Not determined
keyfecea1b1fd0faa416a128ac6ccac862e,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life
key4d7f0d16990b509b880289ab4131a383,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life
key864c9665bf76dcc1dfb1963861cafe1d,Half life in rat i.v.
keya6fa7a3e4b919eed3dc0628cd4516222,Half life in rat i.v. at 2 mg/kg concentration
key082d0d80378e724bcd211f1b369e4032,Half life in rats
key60180471f7118a1e1e6cefb6bb361f4d,Half life in rats after intravenous administration
key61a8eda0c984339d1af419dd41a8bab2,Half life in rats at the dose of 1.0 mpk by i.v. administration
key03882c26e3160207d6903d4e1f9caaa0,Half life in rat
keyfd23986310d02d6ecc56450b6bd526e4,Half life was evaluated after intravenous administration to rats
key4a8884074f1d237cb884e3ddf0a9277c,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO)
key3b2013efd8a2206c29f39b8131d329c6,Half life was evaluated in rat
key3b2013efd8a2206c29f39b8131d329c6,Half life was evaluated in rat
key26e575cd75f5cf6f2f265cbed4bc0fc3,Half life was evaluated in rat; Not tested
keyc0bda0687c149ef33262169c69516492,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats
key6979318a1a4571da5d0f2fc9c148a5af,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats
key18537a0fec04dc1716524a55031749a5,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats
keyeb387877228553db97030c9d02c1aa7d,Half life was measured in monkey at dose of 10 mg/kg by po administration
keyeb387877228553db97030c9d02c1aa7d,Half life was measured in monkey at dose of 10 mg/kg by po administration
key6d89b8fa9d3cc9e8d817c295d555c1d9,Half life was measured in rat at dose of 30 mg/kg by iv administration
key54028acf3fac09bd114213e014bb92f5,Half life was measured in rat at dose of 30 mg/kg by po administration
keyf76dee0d73282d4b1e0f2f880bd524cd,Half life (t1/2) was determined
key448139a8411f9823285d756cdedea036,Half life period at a dose of 10 uM/kg in rat was determined
key82f093447506f22edfc8ec4dca142704,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined
key3e0d2c07e16ea42ca2a2bd92e4bb64b1,Half life period was determined
key907695d6e0fe8b9f844518e6b268abce,Half life period after intravenous administration at 20 mpk in rats
keyc7cb5176b5b09048e4c13ca7a524533e,Half life period after intravenous administration at 20 mpk in rats; Not performed.
key171e124b831c53b5249f4fbd5181f9be,Half life period after intravenous administration in rat
key87606815f26dde2ebd6361026f1a0d7d,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration
key9cacc3efbaa9d8efbde9817b8b0d367f,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration
key351a1e00ca9adf6ee09d6d024154fe45,Half life period in 80% rat plasma at 37 degree Centigrade
key927e5ce11ad4527db0ca0f5473385e2c,Half life period in SD rats
keyd4a4302616bf2def5033fee8ab54dfa8,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4)
keya74dc9862b13db16e3dbf0447abbe01e,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4)
key6b3ec62c75f7f79001a594ec6f221936,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data
key6b3ec62c75f7f79001a594ec6f221936,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data
key7bb1832bcf2f83efe4c8d27b67d1b5c5,Half life period in rat
key7bb1832bcf2f83efe4c8d27b67d1b5c5,Half life period in rat
key7bb1832bcf2f83efe4c8d27b67d1b5c5,Half life period in rat
keye133c41768b1857707a6a28cb0b4d4c0,Half life period in rat after oral administration at 10.5 mg/kg dose
key22a09e98e71209928c5eab53a963eca6,Half life period in rat after oral administration at 11.2 mg/kg dose
key5e7843d1d4e21a257a5122b95c91fb28,Half life period in rat after oral administration at 13 mg/kg dose
keye17d5f483c1b1dec80cda5a4a1c6e961,Half life period in rat after oral administration at 9.7 mg/kg dose
keyd33bbafeaf172606f4456b20574b1c6e,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
keyf1fa20c852f97188ffa8fa97af274ce3,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg
keyf1fa20c852f97188ffa8fa97af274ce3,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg
key7f3a6520dc856f339eb6f961a05c3fa8,PK study was carried to determine AUC (area under curve) value in rat
keyd7f4529b914b77422ef52b9d2fdf1ddd,Pharmacokinetic parameter AUC after intravenous administration to rats
key381796531492ac35eee6e92e1deaf6cb,Pharmacokinetic parameter AUC after oral administration to rats
key4954dbfc88110222b60888e73b5bea8a,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg
keyfe331e4b45bd997b342b61457cbe4dad,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat
key68452b774a5cc1672b36cbe23ac92c54,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat
keyc27b3f24115784fc108e1c7974ea1e93,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally
key317010d8c6e84648796788a447b44318,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally
key19ac463b5f21e8626071838c8e2dc298,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat
key5066a2b641c26546ec97bf25864d77be,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg
keyf756ee0bb5ea73cb20ac76abb82284e5,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg
key52b2baed7b82e5c2c4d15f988ac0ddd5,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats
key3beaaad042f69f7f4194532052665995,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats
key88ef6b16f023453df2a1c73fcdb262eb,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats
keyf2226c912af029eda582a8c0a609ccdb,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats
key5febfa4cb6268b69f36113ab410efbc8,Pharmacokinetic parameter area under curve was reported
key97bc7b5126133eae156b6970268f7d3c,Pharmacokinetic property (AUC) in rat
key30a136fcf72715f320f118dcc60f511b,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.
key6fa7d4220a179f9f0b19468c7a616b8a,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.
keyabec68dd7dca5a9203949c1b9bffb860,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested
key7d4d00ded5b63b1c6a4d4a9c5a187d8a,Pharmacokinetic property was determined
key1a7b8a0d753dd996f3856fcb70e3b867,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg
key64ccf3ad41bf0c931ebc76aeeede57fc,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested
key0c52190544251f7e19585e2102734707,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats
key46a6d4fe7c4e03ad2e1d1463c05ecdb5,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats
keyff87ba15589ff5f7ba396782b3d13a95,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats
key4d8b1137a0a16c62983d08961336c355,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h"
key54ed08a55ed4ee135a4ae3a8e68e48f7,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h"
keya1efa7929f48a3822f05b7bc7d7d2295,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h"
key6a2792b0c9f0f942de6aff59a85feecc,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h"
key69ff6e1f8f0b21553edb117dabdb7cda,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously
keyed34a32cc4d532d7d4e9f385acb2aa20,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally
key145f2d6b81e3b2adb4dc92471576bf4c,Plasma concentration expressed as area under curve after intravenous administration was determined in rat
keybeecc555e478f7fd0c6c63472d1cf43f,Plasma concentration for the compound was determined in rats at 50 mg/kg dose
keyc404a4662876dd5b9cbf0d4b8b920c7e,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound)
key1044021c72c3020c7ef44893e3196f2b,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound)
keyb9efaf175e15f186e7f22dfda445a6bb,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose"
keyf305515d45ab4d2d2d0a50e2264d9a50,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose"
key04eabf093a9ea3e4b8b1864e092eee65,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose"
keyefa2106a7a544531c90de7c99f60af79,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)"
key99575891833d158e8ec6c699dfcbfec3,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)"
key9b111fa5aed5f3095bd0a69dc4ee9ebe,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant
key3f6bdf9dee57bc5298f64e3fe9fc7faf,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats
keyf40346a3df083ba0f800e2ae60cd4c89,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats
keyef8d0a2f7f624e21d04f679f1aa632d5,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats
key9dc7be0c514e0686cffe76f97ca19130,Tested for the pharmacokinetic parameter in rat and expressed as area under curve
key6ffce8b258a891a8c80202da565e92d9,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose"
keye8a701b67258eef6fd6eb261a482577a,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose"
key9f0a9556849007e423831a86f88f5dfa,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose"
key26c3413077f78e13e53db482f662261b,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose"
key112b7a2a8fa6fba2037acbeb607c1b1e,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g"
key9f7aa24b002c3b7f6c840df591aaa9a5,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g"
keybf052eb9907ee94d11342ac3831cf57c,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.
keyb0e3727f6e1c3070e69d04a22ef5df29,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg
key82861ca13eaf7b7251b6fdeaefad622a,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg
keya55c46b4e1cec3a84b788e48a66019d0,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key3ed4fc18ee03f395477c71ee86ebfa32,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
keybf1b92ed5c51dec247bb56df2ff36f40,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key0eb38afadd2dbc3c0845a527e0b9f719,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
keya0047fc7628c628ff7d703bc35c72cb6,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key007c40632b6d37c992870a2d7e3fe4bc,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key37ffbc2fa2f2e32a7955d1e0764fff5b,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key385898288fcd5e811c86a994af56c3ba,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key1d5bf5dd1b5bd2ab240a8a9c108990db,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.
key87f208625a54c6fe9e7645e323c70b1c,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key6c6da7ae389e864dfeccc539c311be59,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key7e6409fbdf1b3ecb05f47d8213b08cc6,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key07f5931305703c622822638f7bc1878a,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
keyb8356008d0f4230e143e7b0804261a88,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key4fda2b9ab612c4c42651b1976b90e7d3,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key86462c425a897c2ae9a4c311ff962e43,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
keyca933e591a20f1cba94befdfdbb475da,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
keyb7f6d86c8a2b4ce2b1b77b549f61b5cc,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key630d5aee35f96395d439643b09f7b642,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key0cfc046314045cb0eb370831008b14db,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
keya9fa861f48010ebfbc4f167d7967d4f5,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key8eedef5690aeba1951383aaaf51158e0,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key3e95c2d0da66116888029cb47e73ee2a,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key7f17eaeab82595f6b93e8b32e870f27a,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key8b14ac0f537349e2e19a2b2fdd75c047,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
keyea4132ff2f5675760938e1e8d4d390ff,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
keycee4eac74ba92f4aa41b022ca604d039,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
keyaa4201be4407bc50cddc71dd766dc220,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key2298cd01bb899e4e575ccdfc5c084595,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key843f0fa2a08a9c19c8f7a95ab2461577,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key640655090caec7a5077859e88563d475,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key2825b2f7a12cb223b26d9ec5596720a5,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key82cd7625a22f2c50f6216c677b8ac977,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
keye97de0e0866af535b6d304a543524044,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key56a13b2a9c19c33168063d87b6168a04,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
keye2673c4979b3c690aba77fd6ada5bfee,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
keyb6872c029fbda1ff0e2bc3808a770190,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
keyfce784b0a07be7bdf5b50d4eba8525dd,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
keyc814354a309c042c4496a0078ba6a5f9,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key676307aee553c9e4086b28afdb9fd674,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key1a64c702a379f2757580649aa8b62a36,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.
key4ba245a619a0475cb9b68739ff1127cf,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.
key045f7a485767d0901b57bc0e58bb9e18,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.
key72348bf2ac63ec53430f1bc3ae972de6,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.
keyea9e26df4fdae214d54e31c546aba672,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.
key2eaac5449e17ec116626d6046b4dd481,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.
keyacc86a284ea1b7b84547f6df75857991,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.
keyed5b85a971db5366650774fe5d6b71fc,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.
key048c27430834f2d700bbd0b70a455127,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.
key1512d7fea096c4477217947bf830f2cb,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.
key22bbe2032f8fcc853e6802fb2f9f7560,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.
keyf67863abde4a03a072cdf7afe5255a0f,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
key7cc3ac31f2c55165c8e0cc28e89ec1f9,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
keyd177d230430c2aacd3772ea9586591d1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key7857b8eeff2fae23d3393c0ed2152fd7,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
keyb357b59ecabcd6ce689a4d4d57142ca8,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
key8a2d169ec6af8b629ba8fc1c74cd4555,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key6c683b464081fcf35bd54145f73ad5d7,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
key003de26229c0d184e2eacde1f1ffd21e,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
keyda36a70d6ea443a74943a9cf7d6ee412,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
key5ce56e1a6caf62b5f33ff2dc3950733e,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.
key98ab26844d82652d4986f89052bb22ab,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.
key3f9d5ecca09bb7178482483a13d0c6d3,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.
keye48ee52bce57f14406ce25d8e72d617b,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min
key4af69532d6110a3f862522ce0227017d,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min
keyf28a10361d80ac869c60f6939ac309fd,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min
key8ab006e169aea6e559e02bfd369947a6,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min
key316eb6a04fbc4ff37ad7015352482fad,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min
keycd695c5c5737c9711aec08bcfe323929,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min
key7cdface83b4074e5788d0f715e1fc95c,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min
key1cbe32a3e122f11147c3f633a1b2f2de,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min
keyea82c1f9ed6f04b9d024ff165842ade4,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min
keyba6829bb053d964496d53b08c54dc60a,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval
keyacb89be19dc415d7b64ba87c41468aa3,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval
keyf22491ffe6785fdcdc73e7b1b2487615,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval
key86a20c1cf35b1b850ddbe58fe3fcc949,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval
keyc0c2337e8f82cb9e6f72756f98736632,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval
keya544c51dfc4ea443e9e80c03c51a4468,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval
key3a4b8d67980879bb8e7e45fe9e33ff59,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval
key52f4b3ec0f3e2b9055c2e08cafa200c8,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval
key87427bc0ce3bf43eb8efc2882decb9a9,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval
keyf36435349a74dfba0c60559059ea83c1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval
keyf2d922a5dd56c6f6c4b1e30921aeac72,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval
keycf645a58315b991204559942b3bda95f,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval
key960a82f66979e65c187ee7faf1c2b7ae,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval
key048eb8a1d728880cd3b2f86297359f7d,Half life period in rat by iv administration at a dose of 3 mg/kg
key72aa63452cc5868c7fe60f0c74c467df,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4)
keyac610a9877e838b4a1d85fa1dd55b4be,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4)
keydc9562c4e8c008084186a472abd1508c,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data
keydc9562c4e8c008084186a472abd1508c,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data
keycded2fd2ece6740cb9d6bd2e1e04e3ff,Half life period was evaluated in rat plasma
key8f81838fc52248af50c0cf395d464026,Half life period was evaluated in rat plasma; Not tested
key5a9055f9a7b3dbe26a633a22ca82e247,Half life period was evaluated in rats
keyb8d60a8687c4c0f4e3f43018fd409210,"Half life period was evaluated in rats, iv"
key307aeebeda941221eedfc92313a2282f,Half life period after intravenous administration at 5 mg/kg in rat
key570c5075f588014681f287568876d480,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration
keye7a4cf30f15f0d5d22d3cb2a8dd284f6,Half life period was determined in rat after iv administration at a dose of 5 mg/kg
keya9248e78f821f9fd655da7d066b2a25c,Half life stability of compound was evaluated in rat plasma
key681f1fcc5d1cbbf22774840d77d1e30e,Half life time after intravenous administration (5.0 mg/kg) was determined in rat
keya6b7714cfd45d4ab09a79e21b93c8a20,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats
keyf2baebdc5ed9680d82ffa4c694d8d126,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat
key1ceec87aa424e37d5a8734b7ea4f1236,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated
key2bb5c860e4384c9da0a773e5304fb29b,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.
keye16e4a80565041d6e3ef12452849b88d,Half in rat i.v.
key4ecb99591086b37389a5cc1da6723aeb,Half period in rat after intravenous administration
key1a5cb12397c21546bc08f6a631357697,Half-life after repeated oral dose of compound at 1 mg/kg in rats
keya433b5f78e8aa00c3eaf6bc1ebf838fe,Half-life measured in in vitro Cathepsin B assay in rat liver
key6073b301d79de00d9084cb1498f8671a,Half-life of compound was determined in rats
key5092399c41b12b8871bb0a99462c6934,Half-life at 10 mg/kg in rat upon intravenous administration
key3694a024cc2eb161c43375d0f57bcc3c,Half-life determined in rat
key3694a024cc2eb161c43375d0f57bcc3c,Half-life determined in rat
key04d119862ceb3a4796fa57d6063774f0,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats
keye14a6f076a24297f9b969e25c677678a,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma"
keyc3295af80b0dc232ed14562ea55ae08e,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg
keyb6253193057210b3e26fc8e37dab0666,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats
keyfb9321f3ce2a73c766ff114753fdf5de,Half-life in rat plasma
key05b87eb00511bab26cb9ebb77bb4198b,Half-life in rat plasma was determined
key6114c9cc814495be39227b1c901adf8e,Half-life in rat plasma; Not tested
keya5bd6c3d3ac8ef7b1c6db1f2b18dc664,Half-life in rat serum
keyd97a82a293cc88751387005ad93b95da,Half-life in rat serum; na is not available
key744573bf9f4be20b2de9ed205617cec5,Half-life was calculated in rat
keyf324209e63bff3d4c132d82e219f5277,Half-life was calculated in rat plasma
key8cde0bd8176aa8aa1bf78ad397f60407,Half-life was determined
key8cde0bd8176aa8aa1bf78ad397f60407,Half-life was determined
keyc634c0f6cc61fa0b0f772940d854110b,Half-life after administration of 20 mg/Kg oral dose in rat
key33d69e188189a8d268ef3aecf39f5e96,Half-life after administration of 3.2 mg/kg intravenously in male rat
key761963e2cd2879b0e1786cd5a1d22db6,Half-life after intravenous administration in female rat
keya6c5d1c311389f67abd4d53f3cefc787,Half-life after intravenous administration in male rat
key78629b699b6c7528cbc6c287a1a4468d,Half-life after intravenous dose in rat
keye871808d4fa958f7bf43bfc08344680b,Half-life in a rat liver homogenate preparation
key58a1bce6cea178bc3b2612f9dc03ea26,Half-life in plasma of rat
key72422706a3a236f695e61cfb26663933,Half-life in plasma of rat at dose of 3-10 mgkg
key0fe8f98db8786d2dec5cc0bcb6b19df2,Half-life in rat
key0fe8f98db8786d2dec5cc0bcb6b19df2,Half-life in rat
key0fe8f98db8786d2dec5cc0bcb6b19df2,Half-life in rat
key0fe8f98db8786d2dec5cc0bcb6b19df2,Half-life in rat
key0fe8f98db8786d2dec5cc0bcb6b19df2,Half-life in rat
key0fe8f98db8786d2dec5cc0bcb6b19df2,Half-life in rat
key5b2178c245a27db7a115f14e071ab6ba,Half-life in rat after oral administration at 10 mg/kg
key379d5b47fd3c6c8aa724ed9ed9f61473,Half-life in rat after po administration at a dose of 10 mg/kg
keyf8594d80be99373b4b6d1cf22317c847,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined
keyd9d68d948f43950f3b28af4ccf080c9d,Half-life in rat at 3 mg/kg dose administered intravenously
key0ebf35e016294778ca078cc367f58314,Half-life in rat brain homogenate
keyfb9321f3ce2a73c766ff114753fdf5de,Half-life in rat plasma
keyd57efd80cd29b322928a8965154295ee,Half-life in rats
key9af3c939461a42d00ce44cc88d544fd9,Half-life in Dawley rats
key8718768ce9324defe7c0acf34a581e0b,Half-life in vitro in rat plasma
key4103706d1a50ff5bcf5a9b7ec586293b,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours
keyc9ae8676de30de9fb5c88514dc2ea931,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat"
key108c76acd7f2024b33bbbe3967b04e59,The area under the curve of compound was measured at the dose of 100 umol/kg
key726e07993ada778879531517edb6a3b3,The area under the curve of compound was measured at the dose of 300 umol/kg
key545d70932c02a4d4ef7fe9e11d9faf4e,The area under the curve of compound was measured at the dose of 30 umol/kg
key93e535575868f2524d5ffaf88d0d3b29,Bioavailability as oral AUC in rats
key27288c1f3452aebd16908708a3bd5099,The plasma concentration versus time curve (AUC) was determined
keyfde119e66a95e865e60506dce78faaa9,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg
key11ae5bb8005c3c1f04330e9939603d64,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg
keyafc69e0391724ced164a0db2fecf7c5f,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg
keyda9a837de0b15062812bfc685cd879f9,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours
keyd546b6ea560f6cf6245a31ab1fd149cd,Total concentration in rat after 2 mg/kg peroral administration in 24 hours
keyc5f2ff1c236d74c0d2d64e5ad503cb2b,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg
keyc5e07e27860dc386eae8a113806b192d,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration"
keyf6fd71cd9813b0b67218ba930c0704a2,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration"
key57cc9143706e48b180620549ed3f9bdd,AUC in rat after po administration at a dose of 10 mg/kg
key10fc50d65521eefa45df5e2da770f3fa,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg
key06d26fe7d0be4b9b5864bfe540c51673,Area under curve value 24 hr after 10 mg/kg iv administration in rats
key67c74ba8a04b5c2a10d707b763e6feb4,Area under curve value 24 hr after 10 mg/kg oral administration in rats
key4a318caa130bdd5bd986bcdb08193f6e,Area under curve value 24 hr after 2 mg/kg iv administration in rats
key080bde0e9f39272faa92b6fa272dc5c5,Area under curve value 24 hr after 2 mg/kg oral administration in rats
keye8aa41c183093baf85cbb29799b639be,Area under curve value 6 hr after po administration in rat
keyf6cb80e79a5aab74f4ef7f51c12f9e00,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11
key391d4be3346d67657d4c1e4dad8bca79,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously"
key71921d2106e2de8c8c86abdd27fcd593,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11
keyc5cd18f25a47f255983a239e40117a10,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control
key70f52d5889efb76bf7d46fa423ec58f4,AUC normalized for dose (AUCN) in rat
keyf582046a6b0c1e946e9996c1f5907831,Area under curve in rat after p.o. administration
keyf582046a6b0c1e946e9996c1f5907831,Area under curve in rat after p.o. administration
keyfd33dd5d8c4099aaec013b813ae8b55c,Area under curve in rat after p.o. administration; Not determined
key46afd7ff79763e263dc2f1063af3e449,Area under curve in rat after peroral administration
key57894d92cc0446532f79b01c0155122b,Area under curve (carotid artery) value of the compound
key5d76efb0c62e7e026e155a210f491c67,Bioavailability expressed as the area under curve of rat carotid artery
keyf06849201a8e573e2335308831b13c75,Area under curve in male SD rats was observed after intravenous administration in rat
key6e277fca4e1ce54259c72b922585b69a,Area under curve of the compound was determined
key9156c49d3a93180beeae889826554a63,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax
keyae8b070450ca05dc71e6a0943f2d7adb,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg
key5365b56329037e1f2ad9439bb35dc1e7,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg
key971cda50ffbe86a3ff4cd4c526ab38cc,Area under curve (portal vein) value of the compound
key60161c1de615dd978e7455b836147f4d,Bioavailability expressed as the area under curve of rat portal vein
key9c9b75f0f9db4d6c7e189e0a625b361b,Area Under plasma concentration time curve in rat upon peroral administration
keya45e438ef81e5d5a8a756bf1e15dd01b,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats
keya402e01cf1ab7a85d5617e1f71608be0,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats
key4dcccd2d6c7f72368b27545579ac58a8,Compound was evaluated for oral bioavailability in rats
key52f7eb5019b94e676072e03888d89740,Compound was evaluated for oral bioavailability in rats after iv administration
key5bd9b4f4e94f6ceb7acc0c9b545f294b,Compound was evaluated for oral bioavailability in rats; 30-80
key5ad1b9df2f432e24e4046873a4e9ab4e,Compound was evaluated for oral bioavailability in rats; 50-60
keyfbf81dcb631688bcae19a7ce51f4afb7,Compound was evaluated for oral bioavailability in rats; no data
keyfa7303ac6b99a9e219392921c107f8a3,Compound was evaluated for oral bioavailability in rats; peptide
key3938cf69c8e5562ecb7edc320508087a,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03"
key4f76a2d184da84f8433dd00b7d066fc7,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03"
key76879259d844cc2306c0abef28dce496,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15"
key47fd1426bcfcac0485660970da532b4e,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87"
key80a1afc86daff0bb2474bf118dace744,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
keybb73a0f08476eaa6986c91d7dfd84b16,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
keya67a41cfb4fb47f18d6e3ad0eec44847,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key094b65f98023119366594985e44c4d0f,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key96ecb74e57ad0ef3caf17236de0969f2,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key7fb1879246ca1e4676fb17bff9324840,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key0066a624f12a39ef7fb75a729f22582b,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key32af3d9c1f007809bf5a05bba250d153,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key098c10f786e99dc5310f8cee8d23dd19,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)"
key0788714b00b07dc25f9aee8dc8959cb8,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine
keyc82e671a23a43e6aca3400b31155621a,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available
key9ffcb4d7204004280ff5c0b613dd20e5,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver
keyd93a527f9d0e37d5162e3e6205a09093,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine
keyaa95470e653eeb622ce8e18b1870d529,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available
keyb6d73cd29e9f9fade79b44b4a16c0bff,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)"
key532802a266a4ef16d1ed8ff2bbb37eb0,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney
keyc12a713c014f96e3652ebd2a0ba2f456,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine
key3cfff8ab50fd3f19e869f17d72a4a450,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats
key907852c5c453764c4153d0b30ea823ac,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats
key0806e838101be50710f47b9b6588f62a,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data
key75fb7db55d941c057cda52427ba6aa67,Biodistribution of compound in rat blood after 5 min of administration
key7beb766971a134a6fa8d5bd5db534a1a,Biodistribution of compound in rat blood after 5 min of administration.
keybf435233b77b2fa5a6202c14677835c1,Biodistribution of compound in rat brain after 5 min of administration
key69adb6a33a27b9e290320e609638aa91,Biodistribution of compound in rat heart after 5 min of administration
keyd4b4d422c419b82da5949ee92349a192,Biodistribution of compound in rat heart after 5 min of administration.
keycf09daa502ed46be7813942dec2d0a94,Biodistribution of compound in rat kidney after 5 min of administration
keyef60e5910e06c56f8ab0e3fedebc634a,Biodistribution of compound in rat kidney after 5 min of administration.
keya98ea00cdb76b7018bef354c3032266c,Biodistribution of compound in rat liver after 5 min of administration
key176f805e4e11831f8747c376f73a1407,Biodistribution of compound in rat liver after 5 min of administration.
key4fe195a5a7219810a2ba88a56431d022,Biodistribution of compound in rat lung after 5 min of administration
keycc38cb0ef50287733f09f75c5695cf04,Biodistribution of compound in rat lung after 5 min of administration.
keyc4d80719cb9ecccbfd7223449f95dcf6,Biodistribution of compound in rat muscle after 5 min of administration
key41d038ff0b5bd5a9a494d9a5efd4d511,Biodistribution of compound in rat muscle after 5 min of administration.
keyf095548c02bb1427b7917ef8dee62133,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
key6cd6979b57eacd203728abc28c164a18,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
key6f07c535354e563b0f87947d8f37ec08,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
keyfad27988b255c1dd682ac29fec6250cd,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
key18dfdff6b8bec4ac7f3375a1d6a6f1c6,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
key9aeaf60978702b0f99d0d61d7c66fadc,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
key8023fad3c9d27f0715c1da2809d383a8,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
key133ab35a1f0d68e2be234baf6cdaf859,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
keya0c4594338393ab97fd42d4ac1b6f088,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
keydf67cdd0a0e367d6f3a520841d41ae4a,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells
key785087bbd04f7b1b17b4a043d3c6460c,Compound was tested for the duration that the plasma drug concentrations remained above the IC95
key9cab1043f1cc00f528c757a1aa0703bb,Dose required to lower urine osmolality to 300 mOsm/kg in rat
keybf6cfbe8b437ce2c2e4677852f75c6d6,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested
keyee8c1fbbd37f1cd155e381109a91235a,% Bioavailability after 1 day of the drug administration in rats
keyd6e27cbd165ae8997acba3f63a4c1354,% Bioavailability after 4 day of the drug administration in rats
key487b8eff584bae093cb6fcaa68096691,Absolute bioavailability was evaluated in rat
key6cf55c333306d21a14c549e24f378895,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval
key0ddf54e2f124ee88722b269a33b6c412,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval
keye5828a57c6659460e1289dcd56927067,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval
keya665518189a879cc2aa7f7895f776b33,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval
key02db6cb2337b0842e4a5d8540b7bbb33,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval
key72610ddf1acd638e5aab1dbfeb970e9b,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval
key54cc0803c76b819d9a3b44b3a4bdc05f,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval
keye1cc9425c70c3e62a7932c1b03875b3d,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval
key414a4e5c93579e09b720609c754bb355,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval
key4aee8cb6b5e66b7e5e3ec1baa055a6fb,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval
keye738f191381f16da42407391815a978c,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval
key47b6451b827c5ca62f8a02ce0d153301,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval
key58bbbbcc4169314bd888d9442daa0ffb,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval
keyd18879b83bf803c4a1cc4bfc9de10ffb,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval
key36cf3c2676210de52ccf620a1b83ac8a,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval
key4566ddd9ca62c162e100f0b0816895f6,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval
keyf33c6be8c1fb941f4608ea949ba1d5c1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval
key0d2b0d0df31b884281e30507dc069eb7,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval
key54fa7097c822c6b9ee0a20844821e496,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval
key19ad47c1935391290dc30a4f98e84bce,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval
key335f5ee6864129c176686e15cc4b6fd0,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval
key0f0b9813e6a5bcdceedb7af53f862cda,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval
key9aa28bed16fefeafb77f9361555e3101,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval
keyea0b49d3bdaa76daf1f8770d85140ace,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval
key0d30cb0bd662267cf799940615a0797b,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval
key08f51f38afe3dafd4a254977c8563520,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval
key3be0427f1842179c4b48340052328f3f,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval
keyd6523170b706e2c915ff7a20db857517,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval
key5f4f33da14a55d65644505b273225bc4,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval
key244e7d7df4c20a7efef3b5dbd9df9c74,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval
key534cb6dac4ac216f860de6ca96ad03fb,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval
key67eac42eb36df3ee3b050839bdee02c1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval
keyed1ee4fbac531c9fb0124e5edfdb2414,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval
keyce86678b6b6cdcead7749ceaaa8f2678,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval
key230824fddc643ff84dbce76a73eb72b5,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval
key27131fae230d6a9111ddd988553c42d9,Dissociation constant was determined
key6e842d9d0e3a1ce6ef57de2430ac613d,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration"
key87677b33299e89412f5dc1adc31cf07c,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose"
key7d12683432c272a08881ed60a744e278,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose"
key2c07f78f0b34687b4bfcc408239449f1,Observed rate constant in 80% rat plasma at 37 degree Centigrade
keyf7912963f4a1ca5a8008e6f5186694bf,Partition coefficient (LogP) value was evaluated
keyb1035f6ca4de62ff472270e716171405,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats
keyccccb7031cf12933a546815a64368898,Mean residence time (Pharmacokinetic property) after i.v. administration in rats
keyd618bcd03cca4093a48f94934bd204fa,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg
key312e5171a25a64f1913374fe717a417a,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration
keyf7040d35ea9bd41283bfa8dff0377e9f,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose
keybfbc47a3d53e737041e4e153157cc005,Half-life was evaluated after 10 uM/kg of intra arterial administration
keyf0540cbbf5916f275ebce1e10d7d0ad9,Half-life was evaluated after 20 uM/kg of peroral administration
keydee9ff4845005094e264c73930656d2a,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg
keyd1058c368b388672fc2479f58488ac68,Half-life was evaluated in plasma of rat
key908369869dac8c56533c3a27f9175402,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg
key2a8d309213e9cbfa528b1e1e72717692,Half-life was evaluated in rats at an oral dose of 30 mg/kg
key66aff6f11ca1bc997ffc4caec77f30b5,Half-life was measured in rat after an iv dose of 1 mg/kg
key586299fa7deb603b5c8648001d2d38d2,Half-life period of compound in rats after peroral administration
key687b36cf4b4d89ba87eeba21eaf5339b,Half-life period of compound was measured in rat plasma.
keyfb42abfa0d8b0333ee20c86b1600de01,Half-life period of compound was measured in rat plasma; ND is not determined
key4bdf514a0ca65541e97e2b5631e72625,Half-life period of compound was measured in rat plasma; not determined
key49e98da395216895fc11c42418510361,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration
key38d9d557c9268e7368d8e9e4898ac591,Half-life period in rat by iv administration
key65897f241c399a283858fd1cf98f1a82,Half-life period in rats following intravenous administration at 2 mg/kg
key4f38e8abe951e8773e796afce59adb42,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
keyb0c285b224d58ed02e15452fcfc27d36,Half-life period was determined for the compound in rat
keyb061290944dd6a63532f1bb6081ba022,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously"
keybd0a90e00af843546af455b42e5c4c3d,"Half-life period was evaluated in rat, after administering 10 mg/kg orally"
key184c30af98fb190ccc25578cdcfc06dd,Half-life value after IV dose at a dose of 5 mg/kg in rats.
keyf6afca5e7d09be8ef4b99218dd1ae4bf,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats
key158adb475cf5e5ee73ef2c0855aedb3c,Half-life was determined in rat after intravenous administration (0.5 mg/kg)
keye301118d66099ad0a2c43bcd890fcedb,Half-life was determined in rat at a dose of 1 mpk i.v.
key56d3cda7de3719190498f05c12e66272,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined
key09b5483082eb66212a1fdf121319a34c,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined
key0fe8f98db8786d2dec5cc0bcb6b19df2,Half-life in rat
key6ab8ab70454ae63eeeb1e2a7e72c20b2,In vitro half life in rat plasma
keyd116e5a62bc42ee2c0b51932d7a92bf7,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma"
keye9728a65fa5a2af15925f7b0aef37c86,In vitro half life in rat
keyc2a04890b26690d3de3713987d5c76e4,In vivo half life period after intravenous administration in rat
key6b8dff06efbce76dab571bca0e3724fa,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats
keya2de8c848d67da44bba713725f470e9b,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats
key8a63902c26db1dc12ceed71c84f188fb,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat
keyf05ceaf0365c7684ad0d1b692f48b4a9,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat
keyb718597f096898910072b7dad84ce7e1,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat
key50fb684bc5223217499704f6ecbd2d3d,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat
keyf99591f619b04b4888912619f83e91f1,Longer half-life in rat (i.v.) at 0.5 mpk
key9ee85b1849ec08e3449b0f93af48dae0,Longer half-life in rat (p.o.) at 2.0 mpk
key0e0c9ffe7285a1607afb81d1717ce097,Pharmacokinetic property (half life) in rat
keyaeabbb610a95da94434f12f2a9da53a4,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats
keyf0440dbfc0f8b55961338f485425182e,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats
key2854d6a148aab66959a29087066dc4aa,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats
key5d8e9aa13e92bfef78eab7a83b2f4211,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats
keye6c5f15d2180367a90b496e353110606,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats
key63b080a20fcbb0d7847a0123db495e1c,Pharmacokinetic half time was determined intravenously in rats.
key2da160295fb171e40b965043132e4af2,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours
key74c467674061b6ed28a241eaa223da0f,Plasma half life of hydrolysis of the compound
key67ada9c579049b05b898e0d063f53e8b,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat
key8e68348a13cc4dc0ce8484c7f16821ea,Plasma half life period was calculated in rat
key8579286f894bda9ba74f88a25a281e9e,Plasma half-life in Sprague-Dawley rats
keyaa42757db5f2a975926882260731ba14,Plasma half-life in Sprague-Dawley rats; Not determined
